Comparison	O
of	O
the	O
backbone	O
dynamics	O
of	O
the	O
apo	O
-	O
and	O
holo	O
-	O
carboxy	O
-	O
terminal	O
domain	O
of	O
the	O
biotin	B-Protein
carboxyl	I-Protein
carrier	I-Protein
subunit	I-Protein
of	O
Escherichia	O
coli	O
acetyl	O
-	O
CoA	O
carboxylase	O
.	O

The	O
biotin	B-Protein
carboxyl	I-Protein
carrier	I-Protein
protein	I-Protein
(	O
BCCP	B-Protein
)	O
is	O
a	O
subunit	O
of	O
acetyl	O
-	O
CoA	O
carboxylase	O
,	O
a	O
biotin	O
-	O
dependent	O
enzyme	O
that	O
catalyzes	O
the	O
first	O
committed	O
step	O
of	O
fatty	O
acid	O
biosynthesis	O
.	O

In	O
its	O
functional	O
cycle	O
,	O
this	O
protein	O
engages	O
in	O
heterologous	O
protein	O
-	O
protein	O
interactions	O
with	O
three	O
distinct	O
partners	O
,	O
depending	O
on	O
its	O
state	O
of	O
post	O
-	O
translational	O
modification	O
.	O

Apo	O
-	O
BCCP	B-Protein
interacts	O
specifically	O
with	O
the	O
biotin	O
holoenzyme	O
synthetase	O
,	O
BirA	B-Protein
,	O
which	O
results	O
in	O
the	O
post	O
-	O
translational	O
attachment	O
of	O
biotin	O
to	O
a	O
single	O
lysine	O
residue	O
on	O
BCCP	B-Protein
.	O

Holo	O
-	O
BCCP	B-Protein
then	O
interacts	O
with	O
the	O
biotin	B-Protein
carboxylase	I-Protein
subunit	I-Protein
of	I-Protein
acetyl	I-Protein
-	I-Protein
CoA	I-Protein
carboxylase	I-Protein
,	O
which	O
leads	O
to	O
the	O
addition	O
of	O
the	O
carboxylate	O
group	O
of	O
bicarbonate	O
to	O
biotin	O
.	O

Finally	O
,	O
the	O
carboxy	O
-	O
biotinylated	O
form	O
of	O
BCCP	B-Protein
interacts	O
with	O
transcarboxylase	B-Protein
in	O
the	O
transfer	O
of	O
the	O
carboxylate	O
to	O
acetyl	O
-	O
CoA	O
to	O
form	O
malonyl	O
-	O
CoA	O
.	O

The	O
determinants	O
of	O
protein	O
-	O
protein	O
interaction	O
specificity	O
in	O
this	O
system	O
are	O
unknown	O
.	O

The	O
NMR	O
solution	O
structure	O
of	O
the	O
unbiotinylated	O
form	O
of	O
an	O
87	O
residue	O
C	O
-	O
terminal	O
domain	O
fragment	O
(	O
residue	O
70	O
-	O
156	O
)	O
of	O
BCCP	B-Protein
(	O
holoBCCP87	B-Protein
)	O
and	O
the	O
crystal	O
structure	O
of	O
the	O
biotinylated	O
form	O
of	O
a	O
C	O
-	O
terminal	O
fragment	O
(	O
residue	O
77	O
-	O
156	O
)	O
of	O
BCCP	B-Protein
from	O
Escherichia	O
coli	O
acetyl	O
-	O
CoA	O
carboxylase	O
have	O
previously	O
been	O
determined	O
.	O

Comparative	O
analysis	O
of	O
these	O
structures	O
provided	O
evidence	O
for	O
small	O
,	O
localized	O
conformational	O
changes	O
in	O
the	O
biotin	O
-	O
binding	O
region	O
upon	O
biotinylation	O
of	O
the	O
protein	O
.	O

These	O
structural	O
changes	O
may	O
be	O
important	O
for	O
regulating	O
specific	O
protein	O
-	O
protein	O
interactions	O
.	O

Since	O
the	O
dynamic	O
properties	O
of	O
proteins	O
are	O
correlated	O
with	O
local	O
structural	O
environments	O
,	O
we	O
have	O
determined	O
the	O
relaxation	O
parameters	O
of	O
the	O
backbone	O
15N	O
nuclear	O
spins	O
of	O
holoBCCP87	B-Protein
,	O
and	O
compared	O
these	O
with	O
the	O
data	O
obtained	O
for	O
the	O
apo	O
protein	O
.	O

The	O
results	O
indicate	O
that	O
upon	O
biotinylation	O
,	O
the	O
inherent	O
mobility	O
of	O
the	O
biotin	O
-	O
binding	O
region	O
and	O
the	O
protruding	O
thumb	O
,	O
with	O
which	O
the	O
biotin	O
group	O
interacts	O
in	O
the	O
holo	O
protein	O
,	O
are	O
significantly	O
reduced	O
.	O

Correlation	O
of	O
activity	O
regulation	O
and	O
substrate	O
recognition	O
of	O
the	O
ADP	O
-	O
ribosyltransferase	O
that	O
regulates	O
nitrogenase	O
activity	O
in	O
Rhodospirillum	O
rubrum	O
.	O

In	O
Rhodospirillum	O
rubrum	O
,	O
nitrogenase	O
activity	O
is	O
regulated	O
posttranslationally	O
through	O
the	O
ADP	O
-	O
ribosylation	O
of	O
dinitrogenase	B-Protein
reductase	I-Protein
by	O
dinitrogenase	B-Protein
reductase	I-Protein
ADP	I-Protein
-	I-Protein
ribosyltransferase	I-Protein
(	O
DRAT	B-Protein
)	O
.	O

Several	O
DRAT	B-Protein
variants	O
that	O
are	O
altered	O
both	O
in	O
the	O
posttranslational	O
regulation	O
of	O
DRAT	B-Protein
activity	O
and	O
in	O
the	O
ability	O
to	O
recognize	O
variants	O
of	O
dinitrogenase	B-Protein
reductase	I-Protein
have	O
been	O
found	O
.	O

This	O
correlation	O
suggests	O
that	O
these	O
two	O
properties	O
are	O
biochemically	O
connected	O
.	O

Mass	O
spectral	O
study	O
of	O
polymorphism	O
of	O
the	O
apolipoproteins	O
of	O
very	O
low	O
density	O
lipoprotein	O
.	O

New	O
isoforms	O
of	O
apolipoprotein	B-Protein
(	I-Protein
apo	I-Protein
)	I-Protein
C	I-Protein
-	I-Protein
I	I-Protein
and	O
apoC	B-Protein
-	I-Protein
III	I-Protein
have	O
been	O
detected	O
in	O
delipidated	O
fractions	O
from	O
very	O
low	O
density	O
lipoprotein	O
(	O
VLDL	O
)	O
using	O
matrix	O
-	O
assisted	O
laser	O
desorption	O
(	O
MALDI	O
)	O
and	O
electrospray	O
ionization	O
(	O
ESI	O
)	O
mass	O
spectrometry	O
(	O
MS	O
)	O
.	O

The	O
cleavage	O
sites	O
of	O
truncated	O
apoC	B-Protein
-	I-Protein
III	I-Protein
isoforms	O
have	O
also	O
been	O
identified	O
.	O

The	O
VLDL	O
fractions	O
were	O
isolated	O
by	O
fixed	O
-	O
angle	O
single	O
-	O
spin	O
ultracentrifugation	O
using	O
a	O
self	O
-	O
generating	O
sucrose	O
density	O
gradient	O
and	O
delipidated	O
using	O
a	O
newly	O
developed	O
C18	O
solid	O
phase	O
extraction	O
protocol	O
.	O

Fifteen	O
apoC	O
isoforms	O
and	O
apoE	B-Protein
were	O
identified	O
in	O
the	O
MALDI	O
spectra	O
and	O
the	O
existence	O
of	O
the	O
more	O
abundant	O
species	O
was	O
verified	O
by	O
ESI	O
-	O
MS	O
.	O

The	O
relative	O
intensities	O
of	O
the	O
apoCs	O
are	O
closely	O
correlated	O
in	O
three	O
normolipidemic	O
subjects	O
.	O

A	O
fourth	O
subject	O
with	O
type	O
V	O
hyperlipidemia	O
exhibited	O
an	O
elevated	O
apoC	B-Protein
-	I-Protein
III	I-Protein
level	O
and	O
a	O
suppressed	O
level	O
of	O
the	O
newly	O
discovered	O
truncated	O
apoC	B-Protein
-	I-Protein
I	I-Protein
isoform	O
.	O

ApoC	B-Protein
-	I-Protein
II	I-Protein
was	O
found	O
to	O
be	O
particularly	O
sensitive	O
to	O
in	O
vitro	O
oxidation	O
.	O

The	O
dynamic	O
range	O
and	O
specificity	O
of	O
the	O
MALDI	O
assay	O
shows	O
that	O
the	O
complete	O
apoC	O
isoform	O
profile	O
and	O
apoE	B-Protein
phenotype	O
can	O
be	O
obtained	O
in	O
a	O
single	O
measurement	O
from	O
the	O
delipidated	O
VLDL	O
fraction	O
.	O

Evidence	O
that	O
halogenated	O
furanones	O
from	O
Delisea	O
pulchra	O
inhibit	O
acylated	O
homoserine	O
lactone	O
(	O
AHL	O
)	O
-	O
mediated	O
gene	O
expression	O
by	O
displacing	O
the	O
AHL	O
signal	O
from	O
its	O
receptor	O
protein	O
.	O

Acylated	O
homoserine	O
lactone	O
(	O
AHL	O
)	O
-	O
mediated	O
gene	O
expression	O
controls	O
phenotypes	O
involved	O
in	O
colonization	O
,	O
often	O
specifically	O
of	O
higher	O
organisms	O
,	O
in	O
both	O
marine	O
and	O
terrestrial	O
environments	O
.	O

The	O
marine	O
red	O
alga	O
Delisea	O
pulchra	O
produces	O
halogenated	O
furanones	O
which	O
resemble	O
AHLs	O
structurally	O
and	O
show	O
inhibitory	O
activity	O
at	O
ecologically	O
realistic	O
concentrations	O
in	O
AHL	O
bioassays	O
.	O

Evidence	O
is	O
presented	O
that	O
halogenated	O
furanones	O
displace	O
tritiated	O
OHHL	O
[	O
N	O
-	O
3	O
-	O
(	O
oxohexanoyl	O
)	O
-	O
L	O
-	O
homoserine	O
lactone	O
]	O
from	O
Escherichia	O
coli	O
cells	O
overproducing	O
LuxR	B-Protein
with	O
potencies	O
corresponding	O
to	O
their	O
respective	O
inhibitory	O
activities	O
in	O
an	O
AHL	O
-	O
regulated	O
bioluminescence	O
assay	O
,	O
indicating	O
that	O
this	O
is	O
the	O
mechanism	O
by	O
which	O
furanones	O
inhibit	O
AHL	O
-	O
dependent	O
phenotypes	O
.	O

Alternative	O
mechanisms	O
for	O
this	O
phenomenon	O
are	O
also	O
addressed	O
.	O

General	O
metabolic	O
disruption	O
was	O
assessed	O
with	O
two	O
-	O
dimensional	O
PAGE	O
,	O
revealing	O
limited	O
non	O
-	O
AHL	O
-	O
related	O
effects	O
.	O

A	O
direct	O
chemical	O
interaction	O
between	O
the	O
algal	O
compounds	O
and	O
AHLs	O
,	O
as	O
monitored	O
by	O
1H	O
NMR	O
spectroscopy	O
,	O
was	O
shown	O
not	O
to	O
occur	O
in	O
vitro	O
.	O

These	O
results	O
support	O
the	O
contention	O
that	O
furanones	O
,	O
at	O
the	O
concentrations	O
produced	O
by	O
the	O
alga	O
,	O
can	O
control	O
bacterial	O
colonization	O
of	O
surfaces	O
by	O
specifically	O
interfering	O
with	O
AHL	O
-	O
mediated	O
gene	O
expression	O
at	O
the	O
level	O
of	O
the	O
LuxR	B-Protein
protein	O
.	O

Activation	O
of	O
p38	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
by	O
oxidized	O
LDL	O
in	O
vascular	O
smooth	O
muscle	O
cells	O
:	O
mediation	O
via	O
pertussis	O
toxin	O
-	O
sensitive	O
G	O
proteins	O
and	O
association	O
with	O
oxidized	O
LDL	O
-	O
induced	O
cytotoxicity	O
.	O

Oxidized	O
low	O
-	O
density	O
lipoproteins	O
(	O
oxLDL	O
)	O
have	O
been	O
shown	O
to	O
play	O
a	O
crucial	O
role	O
in	O
atherosclerosis	O
,	O
but	O
the	O
underlying	O
molecular	O
mechanisms	O
have	O
not	O
been	O
fully	O
understood	O
.	O

The	O
present	O
study	O
showed	O
that	O
oxLDL	O
strongly	O
evoked	O
phosphorylation	O
and	O
activation	O
of	O
p38	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
in	O
rat	O
vascular	O
smooth	O
muscle	O
cells	O
(	O
VSMCs	O
)	O
in	O
concentration	O
-	O
and	O
time	O
-	O
dependent	O
manners	O
,	O
reaching	O
the	O
maximal	O
activation	O
at	O
100	O
microg	O
/	O
mL	O
within	O
5	O
minutes	O
.	O

The	O
results	O
from	O
immunofluorescence	O
staining	O
also	O
revealed	O
that	O
p38	O
MAPK	O
was	O
activated	O
by	O
oxLDL	O
in	O
5	O
minutes	O
,	O
and	O
the	O
activated	O
p38	O
MAPK	O
was	O
translocated	O
from	O
cytoplasm	O
to	O
nucleus	O
of	O
VSMCs	O
in	O
15	O
minutes	O
.	O

Activation	O
of	O
p38	O
MAPK	O
by	O
oxLDL	O
was	O
apparently	O
not	O
mediated	O
by	O
their	O
classical	O
scavenger	O
receptors	O
and	O
was	O
not	O
affected	O
by	O
tyrosine	O
kinase	O
inhibitors	O
.	O

However	O
,	O
activation	O
of	O
p38	O
MAPK	O
was	O
effectively	O
blocked	O
by	O
pretreatment	O
with	O
pertussis	O
toxin	O
and	O
was	O
significantly	O
reduced	O
by	O
phospholipase	O
C	O
inhibitor	O
U	O
-	O
73122	O
.	O

OxLDL	O
also	O
inhibited	O
forskolin	O
-	O
stimulated	O
cAMP	O
accumulation	O
and	O
increased	O
inositol	O
phosphate	O
formation	O
.	O

More	O
interestingly	O
,	O
inhibition	O
of	O
p38	O
MAPK	O
by	O
its	O
specific	O
inhibitor	O
SB203580	O
significantly	O
blocked	O
oxLDL	O
-	O
induced	O
cytotoxicity	O
(	O
increased	O
leakage	O
of	O
cytoplasmic	O
lactate	O
dehydrogenase	O
to	O
the	O
culture	O
medium	O
,	O
reduced	O
[	O
3H	O
]	O
thymidine	O
incorporation	O
,	O
and	O
attenuated	O
mitochondrial	O
metabolism	O
of	O
tetrazolium	O
salt	O
,	O
(	O
3	O
-	O
(	O
4	O
,	O
5	O
-	O
dimethylthiazol	O
-	O
2	O
-	O
yl	O
)	O
-	O
5	O
-	O
(	O
3	O
-	O
carboxymethoxyphenyl	O
)	O
-	O
2	O
-	O
(	O
4	O
-	O
s	O
ulfophenyl	O
)	O
-	O
2H	O
-	O
tetrazolium	O
)	O
,	O
MTS	O
)	O
in	O
VSMCs	O
,	O
and	O
pretreatment	O
with	O
pertussis	O
toxin	O
also	O
inhibited	O
oxLDL	O
-	O
induced	O
cytotoxicity	O
.	O

Taken	O
together	O
,	O
our	O
data	O
clearly	O
demonstrated	O
that	O
oxLDL	O
effectively	O
activated	O
p38	O
MAPK	O
in	O
VSMCs	O
,	O
which	O
was	O
likely	O
mediated	O
via	O
pertussis	O
toxin	O
-	O
sensitive	O
G	O
proteins	O
,	O
and	O
the	O
p38	O
activation	O
was	O
functionally	O
associated	O
with	O
oxLDL	O
-	O
induced	O
cytotoxicity	O
in	O
VSMCs	O
.	O

Characterization	O
of	O
residues	O
in	O
human	O
IgE	O
and	O
IgG	O
binding	O
site	O
by	O
chemical	O
modification	O
of	O
ovomucoid	O
third	O
domain	O
.	O

Chemical	O
modification	O
of	O
ovomucoid	O
third	O
domain	O
(	O
DIII	O
)	O
has	O
been	O
conducted	O
to	O
characterize	O
the	O
binding	O
site	O
residues	O
that	O
determine	O
antigenecity	O
and	O
allergenecity	O
of	O
DIII	O
.	O

Nitration	O
of	O
Tyr	O
,	O
ethoxyformylation	O
of	O
His	O
and	O
succinylation	O
of	O
Lys	O
residues	O
led	O
to	O
a	O
decrease	O
of	O
alpha	O
-	O
helix	O
content	O
of	O
DIII	O
.	O

Modification	O
of	O
His	O
,	O
Tyr	O
,	O
Glu	O
,	O
Asp	O
and	O
Lys	O
residues	O
on	O
DIII	O
resulted	O
in	O
a	O
reduction	O
of	O
human	O
IgG	O
binding	O
activity	O
,	O
but	O
little	O
effect	O
on	O
IgE	O
binding	O
activity	O
.	O

These	O
results	O
suggest	O
that	O
hydrophilic	O
residues	O
appear	O
to	O
be	O
more	O
critical	O
for	O
human	O
IgG	O
binding	O
site	O
,	O
whereas	O
hydrophobic	O
residues	O
may	O
be	O
more	O
important	O
for	O
IgG	O
binding	O
site	O
.	O

A	O
new	O
30	O
-	O
kDa	O
ubiquitin	B-Protein
-	O
related	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
hydrolase	O
from	O
bovine	O
brain	O
.	O

SUMO	B-Protein
-	I-Protein
1	I-Protein
is	O
a	O
ubiquitin	B-Protein
-	O
like	O
protein	O
functioning	O
as	O
an	O
important	O
reversible	O
protein	O
modifier	O
.	O

To	O
date	O
there	O
is	O
no	O
report	O
on	O
a	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
hydrolase	O
/	O
isopeptidase	O
catalyzing	O
the	O
release	O
of	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
from	O
its	O
precursor	O
or	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
-	O
ligated	O
proteins	O
in	O
mammalian	O
tissues	O
.	O

Here	O
we	O
found	O
multiple	O
activities	O
that	O
cleave	O
the	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
moiety	O
from	O
two	O
model	O
substrates	O
,	O
(	O
125	O
)	O
I	O
-	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
-	O
alphaNH	O
-	O
HSTVGSMHISPPEPESEEEEEHYC	O
and	O
/	O
or	O
GST	B-Protein
-	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
-	O
(	O
35	O
)	O
S	O
-	O
RanGAP1	B-Protein
conjugate	O
,	O
in	O
bovine	O
brain	O
extracts	O
.	O

Of	O
them	O
,	O
a	O
major	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
C	O
-	O
terminal	O
hydrolase	O
had	O
been	O
partially	O
purified	O
by	O
successive	O
chromatographic	O
operations	O
.	O

The	O
enzyme	O
had	O
the	O
ability	O
to	O
cleave	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
not	O
only	O
from	O
its	O
precursor	O
but	O
also	O
from	O
a	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
-	O
ligated	O
RanGAP1	B-Protein
but	O
did	O
not	O
exhibit	O
any	O
significant	O
cleavage	O
of	O
the	O
ubiquitin	B-Protein
-	O
and	O
NEDD8	B-Protein
-	O
precursor	O
.	O

The	O
activity	O
of	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
hydrolase	O
was	O
almost	O
completely	O
inhibited	O
by	O
N	O
-	O
ethylmaleimide	O
,	O
but	O
not	O
by	O
phenylmethanesulfonyl	O
fluoride	O
,	O
EDTA	O
,	O
and	O
ubiquitin	B-Protein
-	O
aldehyde	O
known	O
as	O
a	O
potent	O
inhibitor	O
of	O
deubiquitinylating	O
enzymes	O
.	O

Intriguingly	O
,	O
the	O
apparent	O
molecular	O
mass	O
of	O
the	O
isolated	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
hydrolase	O
was	O
approximately	O
30	O
kDa	O
,	O
which	O
is	O
significantly	O
smaller	O
than	O
the	O
recently	O
identified	O
yeast	O
Smt3	B-Protein
/	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
specific	O
protease	O
Ulp1	B-Protein
.	O

These	O
results	O
indicate	O
that	O
there	O
are	O
multiple	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
hydrolase	O
/	O
isopeptidases	O
in	O
mammalian	O
cells	O
and	O
that	O
the	O
30	O
-	O
kDa	O
small	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
hydrolase	O
plays	O
a	O
central	O
role	O
in	O
processing	O
of	O
the	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
-	O
precursor	O
.	O

Cell	O
cycle	O
-	O
regulated	O
attachment	O
of	O
the	O
ubiquitin	B-Protein
-	O
related	O
protein	O
SUMO	O
to	O
the	O
yeast	O
septins	O
.	O

SUMO	O
is	O
a	O
ubiquitin	B-Protein
-	O
related	O
protein	O
that	O
functions	O
as	O
a	O
posttranslational	O
modification	O
on	O
other	O
proteins	O
.	O

SUMO	O
conjugation	O
is	O
essential	O
for	O
viability	O
in	O
Saccharomyces	O
cerevisiae	O
and	O
is	O
required	O
for	O
entry	O
into	O
mitosis	O
.	O

We	O
have	O
found	O
that	O
SUMO	O
is	O
attached	O
to	O
the	O
septins	B-Protein
Cdc3	I-Protein
,	O
Cdc11	B-Protein
,	O
and	O
Shs1	B-Protein
/	O
Sep7	B-Protein
specifically	O
during	O
mitosis	O
,	O
with	O
conjugates	O
appearing	O
shortly	O
before	O
anaphase	O
onset	O
and	O
disappearing	O
abruptly	O
at	O
cytokinesis	O
.	O

Septins	O
are	O
components	O
of	O
a	O
belt	O
of	O
10	O
-	O
nm	O
filaments	O
encircling	O
the	O
yeast	O
bud	O
neck	O
.	O

Intriguingly	O
,	O
only	O
septins	O
on	O
the	O
mother	O
cell	O
side	O
of	O
the	O
bud	O
neck	O
are	O
sumoylated	O
.	O

We	O
have	O
identified	O
four	O
major	O
SUMO	O
attachment	O
-	O
site	O
lysine	O
residues	O
in	O
Cdc3	B-Protein
,	O
one	O
in	O
Cdc11	B-Protein
,	O
and	O
two	O
in	O
Shs1	B-Protein
,	O
all	O
within	O
the	O
consensus	O
sequence	O
(	O
IVL	O
)	O
KX	O
(	O
ED	O
)	O
.	O

Mutating	O
these	O
sites	O
eliminated	O
the	O
vast	O
majority	O
of	O
bud	O
neck	O
-	O
associated	O
SUMO	O
,	O
as	O
well	O
as	O
the	O
bulk	O
of	O
total	O
SUMO	O
conjugates	O
in	O
G	O
(	O
2	O
)	O
/	O
M	O
-	O
arrested	O
cells	O
,	O
indicating	O
that	O
sumoylated	O
septins	O
are	O
the	O
most	O
abundant	O
SUMO	O
conjugates	O
at	O
this	O
point	O
in	O
the	O
cell	O
cycle	O
.	O

This	O
mutant	O
has	O
a	O
striking	O
defect	O
in	O
disassembly	O
of	O
septin	O
rings	O
,	O
resulting	O
in	O
accumulation	O
of	O
septin	O
rings	O
marking	O
previous	O
division	O
sites	O
.	O

Thus	O
,	O
SUMO	O
conjugation	O
plays	O
a	O
role	O
in	O
regulating	O
septin	O
ring	O
dynamics	O
during	O
the	O
cell	O
cycle	O
.	O

Expression	O
of	O
a	O
prenylation	O
-	O
deficient	O
Rab4	B-Protein
interferes	O
with	O
propagation	O
of	O
insulin	B-Protein
signaling	O
through	O
insulin	B-Protein
receptor	I-Protein
substrate	I-Protein
-	I-Protein
1	I-Protein
.	O

Rab	O
proteins	O
are	O
small	O
GTP	O
-	O
binding	O
proteins	O
of	O
the	O
Ras	O
superfamily	O
that	O
function	O
in	O
the	O
regulation	O
of	O
vesicle	O
transport	O
processes	O
.	O

The	O
Rab4	B-Protein
isoform	O
has	O
been	O
implicated	O
in	O
insulin	B-Protein
action	O
.	O

For	O
instance	O
,	O
overexpression	O
of	O
a	O
prenylation	O
-	O
deficient	O
form	O
of	O
Rab4	B-Protein
has	O
been	O
shown	O
to	O
inhibit	O
insulin	B-Protein
-	O
dependent	O
GLUT4	B-Protein
translocation	O
.	O

Other	O
steps	O
affected	O
by	O
Rab4	B-Protein
in	O
the	O
cascade	O
of	O
events	O
resulting	O
from	O
insulin	B-Protein
receptor	I-Protein
activation	O
have	O
not	O
been	O
elucidated	O
.	O

In	O
the	O
present	O
studies	O
,	O
we	O
measured	O
effects	O
on	O
insulin	B-Protein
-	O
signaling	O
proteins	O
in	O
3T3	O
-	O
L1	O
adipocytes	O
transiently	O
expressing	O
cytoplasmic	O
forms	O
of	O
Rab4	B-Protein
and	O
Rab5	B-Protein
.	O

Expression	O
of	O
a	O
mutant	O
Rab4	B-Protein
lacking	O
a	O
prenylation	O
site	O
resulted	O
in	O
reduced	O
insulin	B-Protein
-	O
dependent	O
phosphorylation	O
ofcytoplasmic	O
and	O
internal	O
membrane	O
-	O
associated	O
insulin	B-Protein
receptor	I-Protein
substrate	I-Protein
-	I-Protein
1	I-Protein
,	O
leading	O
to	O
decreased	O
insulin	B-Protein
receptor	I-Protein
substrate	I-Protein
-	I-Protein
1	I-Protein
-	O
associated	O
phosphatidylinositol	O
3	O
'	O
-	O
OH	O
kinase	O
activation	O
and	O
decreased	O
Akt	O
activation	O
.	O

These	O
effects	O
were	O
not	O
observed	O
upon	O
introduction	O
of	O
a	O
similar	O
mutant	O
form	O
of	O
Rab5	B-Protein
.	O

These	O
data	O
indicate	O
that	O
Rab4	B-Protein
or	O
a	O
Rab4	B-Protein
-	O
associated	O
protein	O
is	O
involved	O
at	O
one	O
or	O
more	O
steps	O
in	O
propagating	O
the	O
insulin	B-Protein
signal	O
,	O
in	O
addition	O
to	O
any	O
role	O
it	O
may	O
play	O
in	O
the	O
regulation	O
of	O
GLUT4	B-Protein
vesicle	O
translocation	O
.	O

Our	O
results	O
support	O
models	O
of	O
insulin	B-Protein
signaling	O
in	O
which	O
regulation	O
of	O
internal	O
membrane	O
trafficking	O
plays	O
a	O
role	O
in	O
transduction	O
of	O
the	O
insulin	B-Protein
signal	O
.	O

Structural	O
determinants	O
of	O
post	O
-	O
translational	O
modification	O
and	O
catalytic	O
specificity	O
for	O
the	O
lipoyl	O
domains	O
of	O
the	O
pyruvate	O
dehydrogenase	O
multienzyme	O
complex	O
of	O
Escherichia	O
coli	O
.	O

The	O
lipoyl	O
domains	O
of	O
the	O
dihydrolipoyl	O
acyltransferase	O
(	O
E2p	B-Protein
,	O
E2o	B-Protein
)	O
components	O
of	O
the	O
pyruvate	O
and	O
2	O
-	O
oxoglutarate	O
dehydrogenase	O
multienzyme	O
complexes	O
are	O
specifically	O
recognised	O
by	O
their	O
cognate	O
2	O
-	O
oxo	O
acid	O
decarboxylase	O
(	O
E1p	B-Protein
,	O
E1o	B-Protein
)	O
.	O

A	O
prominent	O
surface	O
loop	O
links	O
the	O
first	O
and	O
second	O
beta	O
-	O
strands	O
in	O
all	O
lipoyl	O
domains	O
,	O
close	O
in	O
space	O
to	O
the	O
lipoyl	O
-	O
lysine	O
beta	O
-	O
turn	O
.	O

This	O
loop	O
was	O
subjected	O
to	O
various	O
modifications	O
by	O
directed	O
mutagenesis	O
of	O
a	O
sub	O
-	O
gene	O
encoding	O
a	O
lipoyl	O
domain	O
of	O
Escherichia	O
coli	O
E2p	B-Protein
.	O

Deletion	O
of	O
the	O
loop	O
(	O
four	O
residues	O
)	O
rendered	O
the	O
domain	O
incapable	O
of	O
reductive	O
acetylation	O
by	O
E	O
.	O
coli	O
E1p	B-Protein
in	O
the	O
presence	O
of	O
pyruvate	O
,	O
but	O
insertion	O
of	O
a	O
new	O
loop	O
(	O
six	O
residues	O
)	O
corresponding	O
to	O
that	O
in	O
the	O
E2o	B-Protein
lipoyl	O
domain	O
partly	O
restored	O
this	O
ability	O
,	O
albeit	O
with	O
a	O
much	O
lower	O
rate	O
.	O

However	O
,	O
the	O
modified	O
domain	O
remained	O
unable	O
to	O
undergo	O
reductive	O
succinylation	O
by	O
E1o	B-Protein
in	O
the	O
presence	O
of	O
2	O
-	O
oxoglutarate	O
.	O

Additional	O
exchange	O
of	O
the	O
two	O
residues	O
on	O
the	O
C	O
-	O
terminal	O
side	O
of	O
the	O
loop	O
(	O
V14A	O
,	O
E15T	O
)	O
had	O
no	O
effect	O
.	O

Insertion	O
of	O
a	O
different	O
four	O
-	O
residue	O
loop	O
also	O
restored	O
a	O
limited	O
ability	O
to	O
undergo	O
reductive	O
acetylation	O
,	O
but	O
still	O
significantly	O
less	O
than	O
that	O
of	O
the	O
wild	O
-	O
type	O
domain	O
.	O

Exchanging	O
the	O
residue	O
on	O
the	O
N	O
-	O
terminal	O
side	O
of	O
the	O
lipoyl	O
-	O
lysine	O
beta	O
-	O
turn	O
in	O
the	O
E2p	B-Protein
and	O
E2o	B-Protein
domains	O
(	O
G39T	O
)	O
,	O
both	O
singly	O
and	O
in	O
conjunction	O
with	O
the	O
loop	O
exchange	O
,	O
had	O
no	O
effect	O
on	O
the	O
ability	O
of	O
the	O
E2p	B-Protein
domain	O
to	O
be	O
reductively	O
acetylated	O
but	O
did	O
confer	O
a	O
slight	O
increase	O
in	O
susceptibility	O
to	O
reductive	O
succinylation	O
.	O

All	O
mutant	O
E2p	B-Protein
domains	O
,	O
apart	O
from	O
that	O
with	O
the	O
loop	O
deletion	O
(	O
LD	O
)	O
,	O
were	O
readily	O
lipoylated	O
in	O
vitro	O
by	O
E	O
.	O
coli	O
lipoate	B-Protein
protein	I-Protein
ligase	I-Protein
A	I-Protein
;	O
the	O
E2p	B-Protein
LD	O
mutant	O
could	O
be	O
lipoylated	O
only	O
at	O
a	O
significantly	O
lower	O
rate	O
.	O

Likewise	O
,	O
this	O
domain	O
exhibited	O
1D	O
and	O
2D	O
NMR	O
spectra	O
characteristic	O
of	O
a	O
partially	O
folded	O
protein	O
,	O
whereas	O
the	O
spectra	O
of	O
mutants	O
with	O
modified	O
loops	O
were	O
similar	O
to	O
those	O
of	O
the	O
wild	O
-	O
type	O
domain	O
.	O

The	O
surface	O
loop	O
is	O
evidently	O
important	O
to	O
the	O
structural	O
integrity	O
of	O
the	O
domain	O
and	O
may	O
help	O
to	O
stabilize	O
the	O
thioester	O
bond	O
linking	O
the	O
acyl	O
group	O
to	O
the	O
reduced	O
lipoyl	O
-	O
lysine	O
swinging	O
arm	O
as	O
part	O
of	O
the	O
catalytic	O
mechanism	O
.	O

Recognition	O
of	O
the	O
lipoyl	O
domain	O
by	O
its	O
partner	O
E1	O
appears	O
to	O
be	O
a	O
complex	O
process	O
and	O
not	O
attributable	O
to	O
any	O
single	O
determinant	O
on	O
the	O
domain	O
.	O

Identification	O
of	O
a	O
novel	O
isopeptidase	O
with	O
dual	O
specificity	O
for	O
ubiquitin	B-Protein
-	O
and	O
NEDD8	B-Protein
-	O
conjugated	O
proteins	O
.	O

Covalent	O
conjugation	O
of	O
proteins	O
by	O
ubiquitin	B-Protein
or	O
ubiquitin	B-Protein
-	O
like	O
molecules	O
is	O
an	O
important	O
form	O
of	O
post	O
-	O
translational	O
modification	O
and	O
plays	O
a	O
critical	O
role	O
in	O
many	O
cellular	O
processes	O
.	O

Similar	O
to	O
the	O
concept	O
of	O
phosphorylation	O
and	O
dephosphorylation	O
,	O
these	O
conjugates	O
are	O
regulated	O
by	O
a	O
large	O
number	O
of	O
deconjugating	O
enzymes	O
.	O

Here	O
,	O
we	O
report	O
the	O
cloning	O
of	O
a	O
2	O
,	O
141	O
-	O
base	O
pair	O
DNA	O
fragment	O
from	O
human	O
placenta	O
cDNA	O
library	O
by	O
a	O
strategy	O
that	O
involves	O
expressed	O
sequence	O
tag	O
data	O
base	O
searching	O
,	O
polymerase	O
chain	O
reaction	O
,	O
and	O
rapid	O
amplification	O
of	O
cDNA	O
ends	O
.	O

Nucleotide	O
sequence	O
analysis	O
revealed	O
that	O
the	O
cloned	O
cDNA	O
contains	O
an	O
open	O
reading	O
frame	O
of	O
1	O
,	O
143	O
base	O
pairs	O
encoding	O
a	O
novel	O
protease	O
,	O
USP21	B-Protein
,	O
which	O
is	O
composed	O
of	O
381	O
residues	O
with	O
a	O
calculated	O
molecular	O
mass	O
of	O
43	O
kDa	O
.	O

The	O
human	O
USP21	B-Protein
gene	O
is	O
located	O
on	O
chromosome	O
1q21	O
and	O
encodes	O
a	O
member	O
of	O
the	O
ubiquitin	B-Protein
-	O
specific	O
protease	O
family	O
with	O
highly	O
conserved	O
Cys	O
and	O
His	O
domains	O
.	O

The	O
activity	O
and	O
specificity	O
of	O
USP21	B-Protein
were	O
determined	O
by	O
using	O
a	O
COS	O
cell	O
expression	O
system	O
in	O
vivo	O
.	O

We	O
showed	O
that	O
USP21	B-Protein
is	O
capable	O
of	O
removing	O
ubiquitin	B-Protein
from	O
ubiquitinated	O
proteins	O
as	O
expected	O
.	O

Furthermore	O
,	O
USP21	B-Protein
is	O
capable	O
of	O
removing	O
NEDD8	B-Protein
from	O
NEDD8	B-Protein
conjugates	O
but	O
has	O
no	O
effect	O
on	O
Sentrin	B-Protein
-	I-Protein
1	I-Protein
conjugates	O
.	O

As	O
expected	O
from	O
its	O
biochemical	O
activity	O
,	O
overexpression	O
of	O
USP21	B-Protein
has	O
a	O
profound	O
growth	O
inhibitory	O
effect	O
on	O
U2OS	O
cells	O
.	O

Thus	O
,	O
USP21	B-Protein
is	O
the	O
first	O
ubiquitin	B-Protein
-	O
specific	O
protease	O
shown	O
to	O
have	O
dual	O
specificity	O
for	O
both	O
ubiquitin	B-Protein
and	O
NEDD8	B-Protein
and	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
cell	O
growth	O
.	O

Activation	O
of	O
H	B-Protein
-	I-Protein
ras61L	I-Protein
-	O
specific	O
signaling	O
pathways	O
does	O
not	O
require	O
posttranslational	O
processing	O
of	O
H	B-Protein
-	I-Protein
ras	I-Protein
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
H	B-Protein
-	I-Protein
ras61L	I-Protein
retained	O
transforming	O
activity	O
when	O
lacking	O
C	O
-	O
terminal	O
lipid	O
modifications	O
,	O
provided	O
that	O
plasma	O
membrane	O
localization	O
was	O
restored	O
by	O
an	O
N	O
-	O
terminal	O
transmembrane	O
domain	O
.	O

Since	O
several	O
ras	O
-	O
activated	O
pathways	O
contribute	O
to	O
the	O
transformed	O
phenotype	O
,	O
we	O
utilized	O
a	O
novel	O
set	O
of	O
transmembrane	O
domain	O
-	O
anchored	O
H	B-Protein
-	I-Protein
ras	I-Protein
derivatives	O
to	O
examine	O
if	O
lipids	O
are	O
required	O
for	O
activation	O
of	O
any	O
specific	O
signaling	O
pathways	O
.	O

We	O
demonstrate	O
here	O
that	O
H	B-Protein
-	I-Protein
ras61L	I-Protein
-	O
induced	O
activation	O
of	O
the	O
Raf	B-Protein
/	O
MEK	O
/	O
MAPK	O
pathway	O
,	O
including	O
recruitment	O
of	O
Raf	B-Protein
to	O
the	O
plasma	O
membrane	O
and	O
activation	O
of	O
Raf	B-Protein
and	O
MAPK	O
,	O
does	O
not	O
require	O
C	O
-	O
terminal	O
processing	O
of	O
H	B-Protein
-	I-Protein
ras61L	I-Protein
.	O

Biochemical	O
fractionation	O
experiments	O
confirm	O
the	O
localization	O
of	O
TM	O
-	O
ras	O
derivatives	O
to	O
the	O
plasma	O
membrane	O
,	O
as	O
well	O
as	O
the	O
ras	O
-	O
mediated	O
recruitment	O
of	O
c	B-Protein
-	I-Protein
Raf	I-Protein
-	I-Protein
1	I-Protein
.	O

Changes	O
in	O
the	O
actin	O
cytoskeleton	O
,	O
controlled	O
by	O
H	B-Protein
-	I-Protein
ras61L	I-Protein
-	O
mediated	O
activation	O
of	O
the	O
Rac	O
/	O
Rho	O
pathway	O
,	O
as	O
well	O
as	O
PI	O
3	O
-	O
kinase	O
activation	O
,	O
can	O
also	O
occur	O
in	O
the	O
absence	O
of	O
C	O
-	O
terminal	O
lipid	O
modifications	O
.	O

Finally	O
,	O
downstream	O
events	O
,	O
such	O
as	O
the	O
induction	O
of	O
the	O
immediate	O
-	O
early	O
gene	O
c	B-Protein
-	I-Protein
fos	I-Protein
or	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
,	O
are	O
stimulated	O
by	O
the	O
expression	O
of	O
plasma	O
membrane	O
-	O
anchored	O
,	O
nonlipidated	O
H	B-Protein
-	I-Protein
ras6lL	I-Protein
.	O

These	O
results	O
demonstrate	O
that	O
H	B-Protein
-	I-Protein
ras	I-Protein
can	O
be	O
functionally	O
targeted	O
to	O
the	O
plasma	O
membrane	O
using	O
a	O
transmembrane	O
domain	O
sequence	O
and	O
that	O
several	O
signal	O
transduction	O
pathways	O
downstream	O
of	O
H	B-Protein
-	I-Protein
ras	I-Protein
can	O
be	O
activated	O
without	O
the	O
presence	O
of	O
normal	O
lipid	O
modifications	O
.	O

Membrane	O
pore	O
architecture	O
of	O
a	O
cytolytic	O
toxin	O
from	O
Bacillus	O
thuringiensis	O
.	O

To	O
investigate	O
the	O
membrane	O
pore	O
structure	O
of	O
Cyt2Aa1	B-Protein
toxin	O
from	O
Bacillus	O
thuringiensis	O
,	O
14	O
single	O
-	O
cysteine	O
substitutions	O
of	O
the	O
toxin	O
were	O
constructed	O
.	O

Five	O
of	O
these	O
mutants	O
(	O
L172C	O
,	O
V186C	O
,	O
L189C	O
,	O
E214C	O
and	O
L220C	O
)	O
yielded	O
characteristic	O
products	O
when	O
processed	O
by	O
proteinase	B-Protein
K	I-Protein
;	O
other	O
mutants	O
were	O
degraded	O
by	O
this	O
enzyme	O
.	O

Mutants	O
that	O
yielded	O
characteristic	O
proteolysed	O
products	O
and	O
wild	O
-	O
type	O
toxin	O
were	O
labelled	O
with	O
polarity	O
-	O
sensitive	O
acrylodan	O
(	O
6	O
-	O
acryloyl	O
-	O
2	O
-	O
dimethylaminonaphthalene	O
)	O
at	O
the	O
thiol	O
group	O
of	O
cysteine	O
residues	O
.	O

A	O
green	O
-	O
blue	O
shift	O
in	O
the	O
emission	O
spectra	O
was	O
observed	O
with	O
all	O
labelled	O
toxins	O
on	O
transfer	O
from	O
an	O
aqueous	O
solution	O
into	O
a	O
solution	O
containing	O
membranes	O
or	O
liposomes	O
from	O
red	O
blood	O
cells	O
.	O

These	O
results	O
suggested	O
that	O
the	O
label	O
moved	O
into	O
the	O
hydrophobic	O
environment	O
of	O
the	O
membrane	O
or	O
became	O
buried	O
within	O
hydrophobic	O
regions	O
of	O
the	O
protein	O
oligomers	O
.	O

Digestion	O
of	O
membrane	O
-	O
bound	O
labelled	O
toxin	O
with	O
proteinase	B-Protein
K	I-Protein
did	O
not	O
cause	O
a	O
significant	O
decrease	O
in	O
emission	O
intensity	O
from	O
any	O
of	O
the	O
labelled	O
mutants	O
.	O

This	O
suggests	O
that	O
L172C	O
,	O
V186C	O
,	O
L189C	O
,	O
E214C	O
and	O
L220C	O
are	O
inserted	O
into	O
the	O
membrane	O
and	O
are	O
therefore	O
protected	O
from	O
proteolysis	O
.	O

In	O
contrast	O
,	O
a	O
marked	O
decrease	O
in	O
emission	O
intensity	O
was	O
observed	O
when	O
membrane	O
-	O
bound	O
labelled	O
wild	O
-	O
type	O
toxin	O
was	O
digested	O
with	O
proteinase	B-Protein
K	I-Protein
.	O

This	O
suggests	O
that	O
Cys	O
-	O
19	O
does	O
not	O
insert	O
into	O
the	O
membrane	O
.	O

Fluorimetric	O
analysis	O
of	O
delipidated	O
pore	O
complexes	O
suggests	O
that	O
L172C	O
,	O
V186C	O
,	O
L189C	O
and	O
E214C	O
point	O
towards	O
the	O
lipid	O
in	O
the	O
membrane	O
,	O
whereas	O
L220C	O
is	O
either	O
within	O
the	O
hydrophobic	O
environment	O
of	O
the	O
protein	O
oligomers	O
or	O
exposed	O
to	O
the	O
membrane	O
lipids	O
.	O

Most	O
of	O
the	O
Cys	O
-	O
19	O
from	O
wild	O
-	O
type	O
molecules	O
is	O
enclosed	O
within	O
the	O
hydrophobic	O
pockets	O
of	O
the	O
protein	O
oligomers	O
.	O

Escherichia	O
coli	O
alpha	B-Protein
-	I-Protein
hemolysin	I-Protein
(	O
HlyA	B-Protein
)	O
is	O
heterogeneously	O
acylated	O
in	O
vivo	O
with	O
14	O
-	O
,	O
15	O
-	O
,	O
and	O
17	O
-	O
carbon	O
fatty	O
acids	O
.	O

alpha	B-Protein
-	I-Protein
Hemolysin	I-Protein
(	O
HlyA	B-Protein
)	O
is	O
a	O
secreted	O
protein	O
virulence	O
factor	O
observed	O
in	O
certain	O
uropathogenic	O
strains	O
of	O
Escherichia	O
coli	O
.	O

The	O
active	O
,	O
mature	O
form	O
of	O
HlyA	B-Protein
is	O
produced	O
by	O
posttranslational	O
modification	O
of	O
the	O
protoxin	O
that	O
is	O
mediated	O
by	O
acyl	O
carrier	O
protein	O
and	O
an	O
acyltransferase	O
,	O
HlyC	B-Protein
.	O

We	O
have	O
now	O
shown	O
using	O
mass	O
spectrometry	O
that	O
these	O
modifications	O
,	O
when	O
observed	O
in	O
protein	O
isolated	O
in	O
vivo	O
,	O
consist	O
of	O
acylation	O
at	O
the	O
epsilon	O
-	O
amino	O
groups	O
of	O
two	O
internal	O
lysine	O
residues	O
,	O
at	O
positions	O
564	O
and	O
690	O
,	O
with	O
saturated	O
14	O
-	O
(	O
68	O
%	O
)	O
,	O
15	O
-	O
(	O
26	O
%	O
)	O
,	O
and	O
17	O
-	O
(	O
6	O
%	O
)	O
carbon	O
amide	O
-	O
linked	O
side	O
chains	O
.	O

Thus	O
,	O
HlyA	B-Protein
activated	O
in	O
vivo	O
consists	O
of	O
a	O
heterogeneous	O
family	O
of	O
up	O
to	O
nine	O
different	O
covalent	O
structures	O
,	O
and	O
the	O
substrate	O
specificity	O
of	O
the	O
HlyC	B-Protein
acyltransferase	O
appears	O
to	O
differ	O
from	O
that	O
of	O
the	O
closely	O
related	O
CyaC	B-Protein
acyltransferase	O
expressed	O
by	O
Bordetella	O
pertussis	O
.	O

Association	O
of	O
prenylated	O
proteins	O
with	O
the	O
plasma	O
membrane	O
and	O
the	O
inner	B-Protein
nuclear	I-Protein
membrane	I-Protein
is	O
mediated	O
by	O
the	O
same	O
membrane	O
-	O
targeting	O
motifs	O
.	O

Targeting	O
of	O
nuclear	O
lamins	O
to	O
the	O
inner	O
nuclear	O
envelope	O
membrane	O
requires	O
a	O
nuclear	O
localization	O
signal	O
and	O
CaaX	O
motif	O
-	O
dependent	O
posttranslational	O
modifications	O
,	O
including	O
isoprenylation	O
and	O
carboxyl	O
methylation	O
.	O

These	O
modifications	O
,	O
although	O
necessary	O
for	O
membrane	O
targeting	O
,	O
are	O
not	O
sufficient	O
to	O
mediate	O
stable	O
association	O
with	O
membranes	O
.	O

We	O
show	O
that	O
two	O
variants	O
of	O
lamin	B-Protein
B3	I-Protein
(	O
i	O
.	O
e	O
.	O
,	O
B3a	B-Protein
and	O
B3b	B-Protein
)	O
exist	O
in	O
Xenopus	O
oocytes	O
.	O

They	O
are	O
encoded	O
by	O
two	O
alternatively	O
spliced	O
,	O
developmentally	O
regulated	O
mRNAs	O
.	O

The	O
two	O
lamin	O
variants	O
differ	O
greatly	O
in	O
their	O
membrane	O
association	O
in	O
meiotically	O
matured	O
eggs	O
.	O

The	O
presence	O
of	O
an	O
extra	O
cysteine	O
residue	O
(	O
as	O
a	O
potential	O
palmitoylation	O
site	O
)	O
and	O
a	O
basic	O
cluster	O
in	O
conjunction	O
with	O
the	O
CaaX	O
motif	O
function	O
as	O
secondary	O
targeting	O
signals	O
responsible	O
for	O
the	O
stable	O
membrane	O
association	O
of	O
lamin	B-Protein
B3b	I-Protein
in	O
Xenopus	O
eggs	O
.	O

Moreover	O
,	O
transfection	O
experiments	O
with	O
Green	B-Protein
Fluorescent	I-Protein
Protein	I-Protein
lamin	O
tail	O
chimeras	O
and	O
with	O
a	O
Green	B-Protein
Fluorescent	I-Protein
Protein	I-Protein
N	B-Protein
-	I-Protein
Ras	I-Protein
chimera	O
show	O
that	O
these	O
secondary	O
motifs	O
are	O
sufficient	O
to	O
target	O
proteins	O
to	O
the	O
inner	O
nuclear	O
membrane	O
and	O
/	O
or	O
the	O
plasma	O
membrane	O
.	O

Implications	O
for	O
the	O
intracellular	O
trafficking	O
of	O
doubly	O
lipidated	O
proteins	O
are	O
discussed	O
.	O

TcRho1	B-Protein
,	O
a	O
farnesylated	O
Rho	O
family	O
homologue	O
from	O
Trypanosoma	O
cruzi	O
:	O
cloning	O
,	O
trans	O
-	O
splicing	O
,	O
and	O
prenylation	O
studies	O
.	O

Rho	O
GTPases	O
are	O
members	O
of	O
the	O
Ras	O
superfamily	O
and	O
are	O
involved	O
in	O
signal	O
transduction	O
pathways	O
,	O
including	O
maintenance	O
of	O
cell	O
morphology	O
and	O
motility	O
,	O
cell	O
cycle	O
progression	O
,	O
and	O
transcription	O
activation	O
.	O

We	O
report	O
the	O
molecular	O
identification	O
in	O
trypanosomatids	O
(	O
Trypanosoma	O
cruzi	O
)	O
of	O
the	O
first	O
member	O
of	O
the	O
Rho	O
family	O
.	O

The	O
cloned	O
Rho	O
protein	O
,	O
TcRho1	B-Protein
,	O
shares	O
approximately	O
40	O
%	O
homology	O
with	O
other	O
members	O
of	O
the	O
Rho	O
family	O
.	O

Southern	O
blot	O
analysis	O
revealed	O
that	O
TcRHO1	B-Protein
is	O
a	O
single	O
copy	O
gene	O
per	O
haploid	O
genome	O
,	O
and	O
Northern	O
blot	O
assays	O
showed	O
a	O
transcript	O
of	O
1200	O
nucleotides	O
in	O
length	O
.	O

Mapping	O
the	O
5	O
'	O
-	O
untranslated	O
region	O
of	O
TcRHO1	B-Protein
transcripts	O
revealed	O
at	O
least	O
five	O
different	O
transcripts	O
derived	O
from	O
differential	O
trans	O
-	O
splicing	O
.	O

Three	O
of	O
the	O
five	O
transcripts	O
contain	O
the	O
trans	O
-	O
splicing	O
site	O
within	O
the	O
coding	O
region	O
of	O
the	O
TcRHO1	B-Protein
gene	O
.	O

TcRho1	B-Protein
also	O
contains	O
the	O
C	O
-	O
terminal	O
sequence	O
CQLF	O
(	O
CAAX	O
motif	O
)	O
,	O
which	O
is	O
predicted	O
to	O
direct	O
post	O
-	O
translation	O
prenylation	O
of	O
the	O
cysteine	O
residue	O
.	O

A	O
synthetic	O
peptide	O
containing	O
this	O
C	O
-	O
terminal	O
motif	O
,	O
when	O
tested	O
against	O
Q	O
-	O
Sepharose	O
chromatography	O
fractions	O
from	O
T	O
.	O
cruzi	O
cytosol	O
,	O
was	O
shown	O
to	O
be	O
efficiently	O
farnesylated	O
,	O
but	O
not	O
geranylgeranylated	O
,	O
despite	O
the	O
fact	O
that	O
the	O
CAAX	O
motif	O
with	O
X	O
=	O
Phe	O
specifies	O
geranylgeranylation	O
by	O
mammalian	O
protein	O
geranylgeranyltransferase	O
I	O
.	O

Furthermore	O
,	O
immunoblot	O
analyses	O
of	O
epimastigote	O
protein	O
with	O
anti	O
-	O
S	O
-	O
farnesylcysteine	O
methyl	O
ester	O
and	O
anti	O
-	O
TcRho1	B-Protein
antisera	O
strongly	O
suggested	O
that	O
TcRho1	B-Protein
is	O
farnesylated	O
in	O
vivo	O
.	O

The	O
farnesylation	O
of	O
proteins	O
such	O
as	O
Rho	O
GTPases	O
could	O
be	O
the	O
basis	O
for	O
the	O
selective	O
cytotoxic	O
action	O
of	O
protein	O
farnesyltransferase	O
inhibitors	O
on	O
trypanosomatids	O
versus	O
mammalian	O
cells	O
.	O

Thiopalmitoylation	O
of	O
myelin	B-Protein
proteolipid	I-Protein
protein	I-Protein
epitopes	O
enhances	O
immunogenicity	O
and	O
encephalitogenicity	O
.	O

Proteolipid	B-Protein
protein	I-Protein
(	O
PLP	B-Protein
)	O
is	O
the	O
most	O
abundant	O
protein	O
of	O
CNS	O
myelin	O
,	O
and	O
is	O
posttranslationally	O
acylated	O
by	O
covalent	O
attachment	O
of	O
long	O
chain	O
fatty	O
acids	O
to	O
cysteine	O
residues	O
via	O
a	O
thioester	O
linkage	O
.	O

Two	O
of	O
the	O
acylation	O
sites	O
are	O
within	O
epitopes	O
of	O
PLP	B-Protein
that	O
are	O
encephalitogenic	O
in	O
SJL	O
/	O
J	O
mice	O
(	O
PLP	B-Protein
(	O
104	O
-	O
117	O
)	O
and	O
PLP	B-Protein
(	O
139	O
-	O
151	O
)	O
)	O
and	O
against	O
which	O
increased	O
immune	O
responses	O
have	O
been	O
detected	O
in	O
some	O
multiple	O
sclerosis	O
patients	O
.	O

It	O
is	O
known	O
that	O
attachment	O
of	O
certain	O
types	O
of	O
lipid	O
side	O
chains	O
to	O
peptides	O
can	O
result	O
in	O
their	O
enhanced	O
immunogenicity	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
thioacylated	O
PLP	B-Protein
peptides	O
,	O
as	O
occur	O
in	O
the	O
native	O
protein	O
,	O
are	O
more	O
immunogenic	O
than	O
their	O
nonacylated	O
counterparts	O
,	O
and	O
whether	O
thioacylation	O
influences	O
the	O
development	O
of	O
autoreactivity	O
and	O
experimental	O
autoimmune	O
encephalomyelitis	O
.	O

The	O
results	O
show	O
that	O
in	O
comparison	O
with	O
nonacylated	O
peptides	O
,	O
thioacylated	O
PLP	B-Protein
lipopeptides	O
can	O
induce	O
greater	O
T	O
cell	O
and	O
Ab	O
responses	O
to	O
both	O
the	O
acylated	O
and	O
nonacylated	O
peptides	O
.	O

They	O
also	O
enhanced	O
the	O
development	O
and	O
chronicity	O
of	O
experimental	O
autoimmune	O
encephalomyelitis	O
.	O

Synthetic	O
peptides	O
in	O
which	O
the	O
fatty	O
acid	O
was	O
attached	O
via	O
an	O
amide	O
linkage	O
at	O
the	O
N	O
terminus	O
were	O
not	O
encephalitogenic	O
,	O
and	O
they	O
induced	O
greater	O
proportions	O
of	O
CD8	O
+	O
cells	O
in	O
initial	O
in	O
vitro	O
stimulation	O
.	O

Therefore	O
,	O
the	O
lability	O
and	O
the	O
site	O
of	O
the	O
linkage	O
between	O
the	O
peptide	O
and	O
fatty	O
acid	O
may	O
be	O
important	O
for	O
induction	O
of	O
encephalitogenic	O
CD4	B-Protein
+	O
T	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
immune	O
responses	O
induced	O
by	O
endogenous	O
thioacylated	O
lipopeptides	O
may	O
contribute	O
to	O
the	O
immunopathogenesis	O
of	O
chronic	O
experimental	O
demyelinating	O
diseases	O
and	O
multiple	O
sclerosis	O
.	O

COP9	O
signalosome	O
revisited	O
:	O
a	O
novel	O
mediator	O
of	O
protein	O
degradation	O
.	O

The	O
COP9	O
signalosome	O
is	O
an	O
evolutionarily	O
conserved	O
multiprotein	O
complex	O
that	O
was	O
first	O
identified	O
as	O
an	O
essential	O
complex	O
that	O
represses	O
light	O
-	O
regulated	O
development	O
in	O
Arabidopsis	O
.	O

The	O
COP9	O
signalosome	O
has	O
similarity	O
to	O
the	O
lid	O
of	O
the	O
19S	O
regulatory	O
particle	O
of	O
the	O
26S	O
proteasome	O
and	O
has	O
recently	O
been	O
shown	O
to	O
interact	O
with	O
SCF	O
-	O
type	O
E3	O
ubiquitin	B-Protein
ligases	O
.	O

Although	O
its	O
precise	O
role	O
in	O
the	O
process	O
of	O
protein	O
degradation	O
remains	O
to	O
be	O
established	O
,	O
the	O
COP9	O
signalosome	O
is	O
a	O
positive	O
regulator	O
of	O
E3	O
ubiquitin	B-Protein
ligases	O
that	O
functions	O
at	O
least	O
in	O
part	O
by	O
mediating	O
the	O
deconjugation	O
of	O
the	O
NEDD8	B-Protein
/	O
RUB	O
-	O
modification	O
from	O
the	O
cullin	O
subunit	O
of	O
SCF	O
-	O
type	O
E3	O
complexes	O
.	O

Here	O
,	O
we	O
discuss	O
these	O
recent	O
findings	O
,	O
which	O
add	O
an	O
additional	O
component	O
to	O
the	O
biology	O
of	O
substrate	O
-	O
specific	O
protein	O
degradation	O
.	O

Lovastatin	O
-	O
induced	O
cytoskeletal	O
reorganization	O
in	O
lens	O
epithelial	O
cells	O
:	O
role	O
of	O
Rho	O
GTPases	O
.	O

PURPOSE	O
:	O
To	O
understand	O
the	O
involvement	O
of	O
isoprenylated	O
small	O
guanosine	O
triphosphatases	O
(	O
GTPases	O
)	O
in	O
lovastatin	O
-	O
induced	O
cataractogenesis	O
,	O
Rho	O
-	O
and	O
Rac	O
-	O
mediated	O
cell	O
adhesion	O
and	O
actin	O
cytoskeletal	O
reorganization	O
were	O
investigated	O
in	O
lovastatin	O
-	O
treated	O
lens	O
epithelial	O
cells	O
.	O

METHODS	O
:	O
The	O
effects	O
of	O
lovastatin	O
on	O
F	O
-	O
actin	O
reorganization	O
(	O
phalloidin	O
staining	O
)	O
,	O
focal	O
adhesion	O
formation	O
(	O
paxillin	B-Protein
or	O
vinculin	B-Protein
)	O
,	O
cell	O
-	O
cell	O
adhesions	O
(	O
cadherin	O
and	O
beta	B-Protein
-	I-Protein
catenin	I-Protein
)	O
,	O
and	O
protein	O
tyrosine	O
phosphorylation	O
were	O
evaluated	O
in	O
human	O
and	O
porcine	O
lens	O
epithelial	O
cells	O
by	O
immunocytochemical	O
staining	O
with	O
specific	O
antibodies	O
.	O

To	O
explore	O
the	O
involvement	O
of	O
the	O
Rho	O
and	O
Rac	O
GTPases	O
in	O
lovastatin	O
-	O
mediated	O
effects	O
,	O
changes	O
in	O
distribution	O
of	O
Rho	O
and	O
Rac	O
GTPases	O
were	O
analyzed	O
by	O
Western	O
blot	O
analysis	O
,	O
and	O
the	O
effects	O
of	O
C3	B-Protein
-	I-Protein
exoenzyme	I-Protein
on	O
lovastatin	O
-	O
induced	O
cytoskeletal	O
changes	O
were	O
evaluated	O
by	O
immunocytochemical	O
analysis	O
.	O

RESULTS	O
:	O
Lovastatin	O
induced	O
drastic	O
changes	O
in	O
cell	O
shape	O
in	O
both	O
human	O
and	O
porcine	O
lens	O
epithelial	O
cells	O
,	O
including	O
a	O
profound	O
loss	O
of	O
actin	O
stress	O
fibers	O
,	O
focal	O
adhesions	O
,	O
protein	O
phosphotyrosine	O
,	O
and	O
cell	O
-	O
cell	O
adhesions	O
.	O

Lovastatin	O
treatment	O
also	O
led	O
to	O
the	O
accumulation	O
of	O
nonisoprenylated	O
Rho	O
and	O
Rac	O
GTPases	O
in	O
cytosolic	O
fraction	O
.	O

Supplementation	O
of	O
culture	O
media	O
with	O
geranylgeranyl	O
pyrophosphate	O
dramatically	O
reversed	O
the	O
lovastatin	O
-	O
induced	O
morphologic	O
and	O
cytoskeletal	O
changes	O
,	O
whereas	O
farnesyl	O
pyrophosphate	O
was	O
ineffective	O
.	O

Treatment	O
of	O
cells	O
with	O
C3	B-Protein
-	I-Protein
exoenzyme	I-Protein
(	O
a	O
Rho	O
GTPase	O
-	O
specific	O
inhibitor	O
)	O
,	O
however	O
,	O
abolished	O
the	O
geranylgeranyl	O
-	O
supplementation	O
-	O
induced	O
recovery	O
from	O
the	O
morphologic	O
and	O
cytoskeletal	O
effects	O
of	O
lovastatin	O
.	O

CONCLUSIONS	O
:	O
This	O
study	O
demonstrates	O
that	O
inhibition	O
of	O
protein	O
prenylation	O
by	O
lovastatin	O
leads	O
to	O
disruption	O
of	O
actin	O
cytoskeletal	O
organization	O
,	O
and	O
to	O
loss	O
of	O
integrin	O
-	O
mediated	O
focal	O
adhesions	O
and	O
cadherin	O
-	O
mediated	O
cell	O
-	O
cell	O
adhesions	O
in	O
lens	O
epithelial	O
cells	O
.	O

Based	O
on	O
isoprenoid	O
supplementation	O
studies	O
,	O
it	O
could	O
be	O
concluded	O
that	O
impairment	O
of	O
geranylgeranylated	O
Rho	O
and	O
Rac	O
GTPase	O
function	O
is	O
most	O
likely	O
responsible	O
for	O
lovastatin	O
-	O
induced	O
cytoskeletal	O
changes	O
in	O
lens	O
epithelial	O
cells	O
.	O

Impairment	O
of	O
mineralocorticoid	B-Protein
receptor	I-Protein
(	O
MR	B-Protein
)	O
-	O
dependent	O
biological	O
response	O
by	O
oxidative	O
stress	O
and	O
aging	O
:	O
correlation	O
with	O
post	O
-	O
translational	O
modification	O
of	O
MR	B-Protein
and	O
decreased	O
ADP	O
-	O
ribosylatable	O
level	O
of	O
elongating	B-Protein
factor	I-Protein
2	I-Protein
in	O
kidney	O
cells	O
.	O

Acute	O
and	O
chronic	O
treatments	O
of	O
mice	O
with	O
the	O
glutathione	O
-	O
depleting	O
agent	O
,	O
L	O
-	O
buthionine	O
-	O
(	O
SR	O
)	O
-	O
sulfoximine	O
(	O
BSO	O
)	O
,	O
impaired	O
the	O
mineralocorticoid	B-Protein
receptor	I-Protein
(	O
MR	B-Protein
)	O
-	O
dependent	O
biological	O
response	O
by	O
inhibiting	O
aldosterone	O
binding	O
.	O

This	O
steroid	O
-	O
binding	O
inhibition	O
was	O
fully	O
reversed	O
when	O
reducing	O
agents	O
were	O
added	O
to	O
kidney	O
cytosol	O
obtained	O
from	O
mice	O
treated	O
for	O
5	O
h	O
,	O
but	O
it	O
was	O
only	O
partially	O
reversed	O
in	O
cytosol	O
obtained	O
from	O
mice	O
treated	O
for	O
10	O
days	O
.	O

Although	O
the	O
oligomeric	O
structure	O
of	O
the	O
MR	B-Protein
-	O
hsp90	B-Protein
heterocomplex	O
was	O
always	O
unaffected	O
,	O
a	O
decreased	O
amount	O
of	O
MR	B-Protein
protein	O
was	O
evidenced	O
after	O
the	O
long	O
term	O
treatment	O
.	O

Such	O
a	O
deleterious	O
effect	O
was	O
correlated	O
with	O
a	O
post	O
-	O
translational	O
modification	O
of	O
MR	B-Protein
,	O
as	O
demonstrated	O
by	O
an	O
increased	O
level	O
of	O
receptor	O
carbonylation	O
.	O

In	O
addition	O
,	O
a	O
failure	O
at	O
the	O
elongation	O
/	O
termination	O
step	O
was	O
also	O
observed	O
during	O
the	O
receptor	O
translation	O
process	O
in	O
a	O
reticulocyte	O
lysate	O
system	O
.	O

Thus	O
,	O
a	O
high	O
polyribosomes	O
/	O
monomers	O
ratio	O
and	O
both	O
increased	O
proteolysis	O
and	O
decreased	O
ADP	O
-	O
ribosylatable	O
concentration	O
of	O
elongation	B-Protein
factor	I-Protein
2	I-Protein
(	O
EF	B-Protein
-	I-Protein
2	I-Protein
)	O
were	O
shown	O
.	O

Importantly	O
,	O
similar	O
observations	O
were	O
also	O
performed	O
in	O
vivo	O
after	O
depletion	O
of	O
glutathione	O
.	O

Notwithstanding	O
the	O
EF	B-Protein
-	I-Protein
2	I-Protein
functional	O
disruption	O
,	O
not	O
all	O
renal	O
proteins	O
were	O
equally	O
affected	O
as	O
the	O
MR	B-Protein
.	O

Interestingly	O
,	O
both	O
EF	B-Protein
-	I-Protein
2	I-Protein
and	O
MR	B-Protein
expressed	O
in	O
old	O
mice	O
were	O
similarly	O
affected	O
as	O
in	O
L	O
-	O
buthionine	O
-	O
(	O
SR	O
)	O
-	O
sulfoximine	O
-	O
treated	O
young	O
mice	O
.	O

We	O
therefore	O
propose	O
that	O
a	O
dramatic	O
depletion	O
of	O
glutathione	O
in	O
kidney	O
cells	O
mimics	O
the	O
cumulative	O
effect	O
of	O
aging	O
which	O
,	O
at	O
the	O
end	O
,	O
may	O
lead	O
to	O
a	O
renal	O
mineralocorticoid	O
dysfunction	O
.	O

Time	O
-	O
dependent	O
potentiation	O
of	O
the	O
beta	O
-	O
cell	O
is	O
a	O
Ca2	O
+	O
-	O
independent	O
phenomenon	O
.	O

When	O
isolated	O
rat	O
pancreatic	O
islets	O
are	O
treated	O
with	O
16	O
.	O
7	O
mM	O
glucose	O
,	O
a	O
time	O
-	O
dependent	O
potentiation	O
(	O
TDP	O
)	O
of	O
insulin	B-Protein
release	O
occurs	O
that	O
can	O
be	O
detected	O
by	O
subsequent	O
treatment	O
with	O
50	O
mM	O
KCl	O
.	O

It	O
has	O
been	O
thought	O
that	O
TDP	O
by	O
glucose	O
is	O
a	O
Ca2	O
+	O
-	O
dependent	O
phenomenon	O
and	O
only	O
occurs	O
when	O
exposure	O
to	O
glucose	O
is	O
carried	O
out	O
in	O
the	O
presence	O
of	O
Ca2	O
+	O
.	O

In	O
contrast	O
to	O
this	O
,	O
we	O
now	O
demonstrate	O
TDP	O
under	O
stringent	O
Ca2	O
+	O
-	O
free	O
conditions	O
(	O
Ca2	O
+	O
-	O
free	O
buffer	O
containing	O
1	O
mM	O
EGTA	O
)	O
.	O

In	O
fact	O
,	O
under	O
these	O
Ca2	O
+	O
-	O
free	O
conditions	O
glucose	O
caused	O
an	O
even	O
stronger	O
TDP	O
than	O
in	O
the	O
presence	O
of	O
Ca2	O
+	O
.	O

TDP	O
induced	O
by	O
glucose	O
in	O
the	O
absence	O
of	O
extracellular	O
Ca2	O
+	O
was	O
unaffected	O
by	O
inhibitors	O
of	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
.	O

However	O
,	O
cerulenin	O
or	O
tunicamycin	O
,	O
two	O
inhibitors	O
of	O
protein	O
acylation	O
,	O
eradicated	O
TDP	O
without	O
affecting	O
glucose	O
metabolism	O
.	O

The	O
TDP	O
by	O
glucose	O
was	O
not	O
associated	O
with	O
an	O
increase	O
in	O
the	O
cytosolic	O
free	O
Ca2	O
+	O
concentration	O
(	O
[	O
Ca2	O
+	O
]	O
i	O
)	O
during	O
subsequent	O
treatment	O
with	O
high	O
K	O
+	O
.	O

Exposure	O
of	O
islets	O
to	O
forskolin	O
under	O
Ca	O
(	O
2	O
+	O
)	O
-	O
free	O
conditions	O
did	O
not	O
cause	O
TDP	O
despite	O
a	O
large	O
increase	O
in	O
the	O
cellular	O
cAMP	O
levels	O
.	O

In	O
conclusion	O
,	O
glucose	O
alone	O
induces	O
TDP	O
under	O
stringent	O
Ca2	O
+	O
-	O
free	O
conditions	O
when	O
[	O
Ca2	O
+	O
]	O
i	O
was	O
significantly	O
lowered	O
.	O

Protein	O
acylation	O
is	O
implicated	O
in	O
the	O
underlying	O
mechanism	O
of	O
TDP	O
.	O

Sumoylation	O
of	O
topoisomerase	B-Protein
I	I-Protein
is	O
involved	O
in	O
its	O
partitioning	O
between	O
nucleoli	O
and	O
nucleoplasm	O
and	O
its	O
clearing	O
from	O
nucleoli	O
in	O
response	O
to	O
camptothecin	O
.	O

Previous	O
studies	O
identified	O
a	O
small	O
fraction	O
of	O
putatively	O
sumoylated	O
topoisomerase	B-Protein
I	I-Protein
(	O
TOP1	B-Protein
)	O
under	O
basal	O
conditions	O
(	O
approximately	O
1	O
%	O
)	O
,	O
and	O
anticancer	O
camptothecins	O
that	O
trap	O
the	O
TOP1	B-Protein
-	O
DNA	O
covalent	O
intermediate	O
markedly	O
increase	O
the	O
sumoylation	O
of	O
TOP1	B-Protein
(	O
<	O
or	O
=	O
10	O
%	O
)	O
.	O

To	O
study	O
the	O
role	O
of	O
the	O
sumoylation	O
of	O
TOP1	B-Protein
,	O
we	O
mutated	O
sites	O
on	O
green	B-Protein
fluorescent	I-Protein
protein	I-Protein
(	O
GFP	B-Protein
)	O
-	O
TOP1	B-Protein
corresponding	O
to	O
the	O
consensus	O
sequence	O
for	O
protein	O
sumoylation	O
(	O
PsiKXE	O
,	O
where	O
Psi	O
is	O
a	O
hydrophobic	O
residue	O
)	O
and	O
assayed	O
the	O
mutants	O
for	O
basal	O
and	O
camptothecin	O
-	O
induced	O
sumoylation	O
.	O

Only	O
one	O
of	O
the	O
eight	O
mutants	O
,	O
K117R	O
,	O
located	O
in	O
the	O
highly	O
charged	O
NH2	O
-	O
terminal	O
region	O
,	O
showed	O
a	O
substantial	O
reduction	O
(	O
approximately	O
5	O
-	O
fold	O
)	O
in	O
basal	O
and	O
camptothecin	O
-	O
induced	O
sumoylation	O
;	O
thus	O
,	O
Lys	O
-	O
117	O
appears	O
to	O
be	O
the	O
major	O
sumoylation	O
site	O
.	O

A	O
triple	O
mutant	O
having	O
the	O
PsiKXE	O
sequences	O
flanking	O
K117R	O
additionally	O
mutated	O
(	O
K103R	O
/	O
K117R	O
/	O
K153R	O
)	O
showed	O
little	O
if	O
any	O
sumoylation	O
,	O
but	O
was	O
degraded	O
like	O
wild	O
-	O
type	O
GFP	B-Protein
-	O
TOP1	B-Protein
during	O
camptothecin	O
treatment	O
.	O

However	O
,	O
K103R	O
/	O
K117R	O
/	O
K153R	O
-	O
GFP	B-Protein
-	O
TOP1	B-Protein
was	O
markedly	O
concentrated	O
within	O
nucleoli	O
,	O
depleted	O
from	O
the	O
remainder	O
of	O
nucleus	O
,	O
and	O
failed	O
to	O
be	O
cleared	O
from	O
nucleoli	O
in	O
response	O
to	O
camptothecin	O
treatment	O
.	O

These	O
data	O
are	O
consistent	O
with	O
a	O
model	O
wherein	O
basal	O
transient	O
sumoylation	O
of	O
the	O
NH2	O
-	O
terminal	O
,	O
highly	O
charged	O
,	O
disordered	O
region	O
prevents	O
TOP1	B-Protein
binding	O
to	O
sites	O
in	O
nucleoli	O
,	O
thus	O
driving	O
it	O
to	O
bind	O
in	O
the	O
nucleoplasm	O
;	O
and	O
camptothecin	O
treatment	O
,	O
which	O
increases	O
TOP1	B-Protein
sumoylation	O
,	O
further	O
shifts	O
the	O
binding	O
resulting	O
in	O
delocalization	O
of	O
TOP1	B-Protein
from	O
nucleoli	O
to	O
nucleoplasm	O
.	O

Age	O
-	O
related	O
changes	O
in	O
human	O
bone	O
proteoglycan	O
structure	O
.	O

Impact	O
of	O
osteogenesis	O
imperfecta	O
.	O

Proteoglycans	O
(	O
PGs	O
)	O
are	O
a	O
family	O
of	O
molecules	O
that	O
undergo	O
extensive	O
post	O
-	O
translational	O
modifications	O
that	O
include	O
addition	O
of	O
glycosaminoglycan	O
(	O
GAG	O
)	O
chains	O
as	O
well	O
as	O
N	O
-	O
and	O
O	O
-	O
linked	O
oligosaccharides	O
to	O
the	O
protein	O
core	O
.	O

PG	O
composition	O
and	O
structure	O
have	O
been	O
reported	O
to	O
alter	O
with	O
age	O
.	O

To	O
test	O
whether	O
the	O
post	O
-	O
translational	O
modifications	O
to	O
PGs	O
can	O
serve	O
as	O
in	O
vitro	O
surrogate	O
end	O
point	O
markers	O
for	O
chronological	O
age	O
,	O
the	O
extent	O
of	O
GAG	O
modifications	O
was	O
determined	O
for	O
PGs	O
derived	O
from	O
normal	O
human	O
bone	O
cells	O
of	O
14	O
donors	O
(	O
age	O
range	O
,	O
fetal	O
to	O
60	O
years	O
)	O
.	O

Isolated	O
cells	O
were	O
steady	O
state	O
radiolabeled	O
with	O
(	O
35	O
)	O
SO	O
(	O
4	O
)	O
(	O
2	O
-	O
)	O
and	O
[	O
(	O
3	O
)	O
H	O
]	O
GlcN	O
.	O

For	O
biglycan	B-Protein
and	O
decorin	B-Protein
,	O
iduronate	O
content	O
was	O
linearly	O
correlated	O
with	O
age	O
(	O
increased	O
1	O
.	O
5x	O
between	O
fetal	O
and	O
age	O
60	O
years	O
)	O
.	O

For	O
the	O
syndecan	O
-	O
like	O
heparan	O
sulfate	O
PG	O
,	O
the	O
N	O
-	O
sulfation	O
of	O
post	O
-	O
natal	O
cells	O
increased	O
over	O
3	O
.	O
5	O
-	O
fold	O
until	O
reaching	O
a	O
plateau	O
during	O
the	O
4th	O
decade	O
of	O
life	O
.	O

The	O
amount	O
of	O
O	O
-	O
linked	O
oligosaccharides	O
was	O
also	O
found	O
to	O
decrease	O
as	O
a	O
function	O
of	O
increasing	O
normal	O
donor	O
age	O
,	O
whereas	O
the	O
specific	O
activity	O
of	O
the	O
metabolic	O
precursor	O
pool	O
remained	O
constant	O
regardless	O
of	O
donor	O
age	O
.	O

These	O
age	O
-	O
related	O
changes	O
in	O
post	O
-	O
translational	O
modifications	O
were	O
then	O
used	O
to	O
demonstrate	O
that	O
osteoblasts	O
derived	O
from	O
patients	O
with	O
osteogenesis	O
imperfecta	O
did	O
not	O
exhibit	O
facets	O
of	O
a	O
pre	O
-	O
mature	O
aging	O
,	O
but	O
rather	O
were	O
arrested	O
in	O
a	O
fetal	O
-	O
like	O
phenotypic	O
state	O
.	O

A	O
growth	O
matrix	O
rich	O
in	O
thrombospondin	O
altered	O
PG	O
metabolism	O
in	O
osteoblastic	O
cells	O
,	O
resulting	O
in	O
the	O
production	O
and	O
secretion	O
of	O
the	O
fetal	O
-	O
like	O
(	O
rich	O
in	O
O	O
-	O
linked	O
oligosaccharides	O
)	O
forms	O
of	O
decorin	B-Protein
and	O
biglycan	B-Protein
.	O

This	O
effect	O
was	O
qualitatively	O
different	O
from	O
the	O
effect	O
of	O
transforming	O
growth	O
factor	O
-	O
beta	O
,	O
which	O
predominantly	O
altered	O
GAGs	O
rather	O
than	O
O	O
-	O
linked	O
oligosaccharides	O
.	O

No	O
other	O
Arg	O
-	O
Gly	O
-	O
Asp	O
protein	O
(	O
fibronectin	B-Protein
,	O
vitronectin	B-Protein
,	O
type	O
I	O
collagen	O
,	O
osteopontin	B-Protein
,	O
and	O
bone	O
sialoprotein	O
)	O
showed	O
any	O
detectable	O
effect	O
on	O
PG	O
metabolism	O
in	O
bone	O
cells	O
.	O

These	O
results	O
indicate	O
that	O
a	O
proper	O
matrix	O
stoichiometry	O
is	O
critical	O
for	O
metabolism	O
of	O
PGs	O
.	O

Expression	O
and	O
characterization	O
of	O
recombinant	O
vitamin	B-Protein
K	I-Protein
-	I-Protein
dependent	I-Protein
gamma	I-Protein
-	I-Protein
glutamyl	I-Protein
carboxylase	I-Protein
from	O
an	O
invertebrate	O
,	O
Conus	O
textile	O
.	O

The	O
marine	O
snail	O
Conus	O
is	O
the	O
sole	O
invertebrate	O
wherein	O
both	O
the	O
vitamin	B-Protein
K	I-Protein
-	I-Protein
dependent	I-Protein
carboxylase	I-Protein
and	O
its	O
product	O
,	O
gamma	O
-	O
carboxyglutamic	O
acid	O
,	O
have	O
been	O
identified	O
.	O

To	O
examine	O
its	O
biosynthesis	O
of	O
gamma	O
-	O
carboxyglutamic	O
acid	O
,	O
we	O
studied	O
the	O
carboxylase	B-Protein
from	O
Conus	O
venom	O
ducts	O
.	O

The	O
carboxylase	B-Protein
cDNA	O
from	O
Conus	O
textile	O
has	O
an	O
ORF	O
that	O
encodes	O
a	O
811	O
-	O
amino	O
-	O
acid	O
protein	O
which	O
exhibits	O
sequence	O
similarity	O
to	O
the	O
vertebrate	O
carboxylases	O
,	O
with	O
41	O
%	O
identity	O
and	O
approximately	O
60	O
%	O
sequence	O
similarity	O
to	O
the	O
bovine	O
carboxylase	O
.	O

Expression	O
of	O
this	O
cDNA	O
in	O
COS	O
cells	O
or	O
insect	O
cells	O
yielded	O
vitamin	B-Protein
K	I-Protein
-	I-Protein
dependent	I-Protein
carboxylase	I-Protein
activity	O
and	O
vitamin	O
K	O
-	O
dependent	O
epoxidase	O
activity	O
.	O

The	O
recombinant	O
carboxylase	B-Protein
has	O
a	O
molecular	O
mass	O
of	O
approximately	O
130	O
kDa	O
.	O

The	O
recombinant	O
Conus	O
carboxylase	B-Protein
carboxylated	O
Phe	O
-	O
Leu	O
-	O
Glu	O
-	O
Glu	O
-	O
Leu	O
and	O
the	O
28	O
-	O
residue	O
peptides	O
based	O
on	O
residues	O
-	O
18	O
to	O
+	O
10	O
of	O
human	O
proprothrombin	B-Protein
and	O
proFactor	B-Protein
IX	I-Protein
with	O
Km	O
values	O
of	O
420	O
micro	O
m	O
,	O
1	O
.	O
7	O
micro	O
m	O
and	O
6	O
micro	O
m	O
,	O
respectively	O
;	O
the	O
Km	O
for	O
vitamin	O
K	O
is	O
52	O
micro	O
m	O
.	O

The	O
Km	O
values	O
for	O
peptides	O
based	O
on	O
the	O
sequence	O
of	O
the	O
conotoxin	B-Protein
epsilon	I-Protein
-	I-Protein
TxIX	I-Protein
and	O
two	O
precursor	O
analogs	O
containing	O
12	O
or	O
29	O
amino	O
acids	O
of	O
the	O
propeptide	O
region	O
are	O
565	O
micro	O
m	O
,	O
75	O
micro	O
m	O
and	O
74	O
micro	O
m	O
,	O
respectively	O
.	O

The	O
recombinant	O
Conus	O
carboxylase	B-Protein
,	O
in	O
the	O
absence	O
of	O
endogenous	O
substrates	O
,	O
is	O
stimulated	O
up	O
to	O
fivefold	O
by	O
vertebrate	O
propeptides	O
but	O
not	O
by	O
Conus	O
propeptides	O
.	O

These	O
results	O
suggest	O
two	O
propeptide	O
-	O
binding	O
sites	O
in	O
the	O
carboxylase	B-Protein
,	O
one	O
that	O
binds	O
the	O
Conus	O
and	O
vertebrate	O
propeptides	O
and	O
is	O
required	O
for	O
substrate	O
binding	O
,	O
and	O
the	O
other	O
that	O
binds	O
only	O
the	O
vertebrate	O
propeptide	O
and	O
is	O
required	O
for	O
enzyme	O
stimulation	O
.	O

The	O
marked	O
functional	O
and	O
structural	O
similarities	O
between	O
the	O
Conus	O
carboxylase	B-Protein
and	O
vertebrate	O
vitamin	B-Protein
K	I-Protein
-	I-Protein
dependent	I-Protein
gamma	I-Protein
-	I-Protein
carboxylases	I-Protein
argue	O
for	O
conservation	O
of	O
a	O
vitamin	B-Protein
K	I-Protein
-	I-Protein
dependent	I-Protein
carboxylase	I-Protein
across	O
animal	O
species	O
and	O
the	O
importance	O
of	O
gamma	O
-	O
carboxyglutamic	O
acid	O
synthesis	O
in	O
diverse	O
biological	O
systems	O
.	O

Cholesterol	O
-	O
modulating	O
agents	O
kill	O
acute	O
myeloid	O
leukemia	O
cells	O
and	O
sensitize	O
them	O
to	O
therapeutics	O
by	O
blocking	O
adaptive	O
cholesterol	O
responses	O
.	O

The	O
mevalonate	O
pathway	O
produces	O
many	O
critical	O
substances	O
in	O
cells	O
,	O
including	O
sterols	O
essential	O
for	O
membrane	O
structure	O
and	O
isoprenoids	O
vital	O
to	O
the	O
function	O
of	O
many	O
membrane	O
proteins	O
.	O

3	B-Protein
-	I-Protein
Hydroxy	I-Protein
-	I-Protein
3	I-Protein
-	I-Protein
methylglutaryl	I-Protein
coenzyme	I-Protein
A	I-Protein
(	I-Protein
HMG	I-Protein
-	I-Protein
CoA	I-Protein
)	I-Protein
reductase	I-Protein
is	O
a	O
rate	O
-	O
limiting	O
enzyme	O
in	O
the	O
mevalonate	O
pathway	O
.	O

Because	O
cholesterol	O
is	O
a	O
product	O
of	O
this	O
pathway	O
,	O
HMG	B-Protein
-	I-Protein
CoA	I-Protein
reductase	I-Protein
inhibitors	O
(	O
statins	O
)	O
are	O
used	O
to	O
treat	O
hypercholesterolemia	O
.	O

Statins	O
are	O
also	O
toxic	O
to	O
several	O
malignancies	O
,	O
including	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
.	O

Although	O
this	O
toxicity	O
has	O
been	O
attributed	O
to	O
the	O
inhibition	O
of	O
Ras	O
/	O
Rho	O
isoprenylation	O
,	O
we	O
have	O
previously	O
shown	O
that	O
statin	O
toxicity	O
in	O
primary	O
AML	O
cells	O
(	O
AMLs	O
)	O
does	O
not	O
correlate	O
with	O
Ras	O
isoprenylation	O
or	O
with	O
activating	O
Ras	O
mutations	O
.	O

In	O
other	O
studies	O
,	O
we	O
have	O
shown	O
that	O
hypoxic	O
and	O
oxidant	O
injuries	O
induce	O
cholesterol	O
increments	O
in	O
renal	O
tubule	O
cells	O
and	O
that	O
statins	O
sensitize	O
these	O
cells	O
to	O
injury	O
by	O
blocking	O
protective	O
cholesterol	O
responses	O
.	O

We	O
now	O
demonstrate	O
that	O
exposing	O
particular	O
AMLs	O
to	O
radiochemotherapy	O
induces	O
much	O
greater	O
cellular	O
cholesterol	O
increments	O
than	O
those	O
seen	O
in	O
similarly	O
treated	O
normal	O
bone	O
marrow	O
.	O

Treatment	O
of	O
these	O
AMLs	O
with	O
mevastatin	O
or	O
zaragozic	O
acid	O
(	O
which	O
inhibits	O
cholesterol	O
synthesis	O
but	O
not	O
isoprenoid	O
synthesis	O
)	O
attenuates	O
the	O
cholesterol	O
increments	O
and	O
sensitizes	O
cells	O
to	O
radiochemotherapy	O
.	O

The	O
extent	O
of	O
toxicity	O
is	O
affected	O
by	O
the	O
availability	O
of	O
extracellular	O
lipoproteins	O
,	O
further	O
suggesting	O
that	O
cellular	O
cholesterol	O
is	O
critical	O
to	O
cell	O
survival	O
in	O
particular	O
AMLs	O
.	O

Because	O
zaragozic	O
acid	O
does	O
not	O
inhibit	O
isoprenoid	O
synthesis	O
,	O
these	O
data	O
suggest	O
that	O
cholesterol	O
modulation	O
is	O
an	O
important	O
mechanism	O
whereby	O
statins	O
exert	O
toxic	O
effects	O
on	O
some	O
AMLs	O
and	O
that	O
cholesterol	O
modulators	O
may	O
improve	O
therapeutic	O
ratios	O
in	O
AML	O
by	O
impacting	O
cholesterol	O
-	O
dependent	O
cytoresistance	O
.	O

The	O
ABSCISIC	B-Protein
ACID	I-Protein
INSENSITIVE	I-Protein
3	I-Protein
(	O
ABI3	B-Protein
)	O
gene	O
is	O
modulated	O
by	O
farnesylation	O
and	O
is	O
involved	O
in	O
auxin	O
signaling	O
and	O
lateral	O
root	O
development	O
in	O
Arabidopsis	O
.	O

Genetic	O
screens	O
have	O
identified	O
a	O
number	O
of	O
genes	O
that	O
regulate	O
abscisic	O
acid	O
(	O
ABA	O
)	O
responsiveness	O
in	O
Arabidopsis	O
.	O

Using	O
a	O
combination	O
of	O
suppressor	O
screens	O
and	O
double	O
mutant	O
analysis	O
,	O
we	O
have	O
determined	O
a	O
genetic	O
relationship	O
for	O
a	O
number	O
of	O
these	O
ABA	O
response	O
loci	O
.	O

Based	O
on	O
germination	O
in	O
the	O
presence	O
of	O
exogenous	O
ABA	O
,	O
the	O
ABI1	B-Protein
and	O
ABI2	B-Protein
phosphatases	O
act	O
at	O
or	O
upstream	O
of	O
the	O
ERA1	B-Protein
farnesyl	O
transferase	O
and	O
the	O
ABI3	B-Protein
and	O
ABI5	B-Protein
transcription	O
factors	O
act	O
at	O
or	O
downstream	O
of	O
ERA1	B-Protein
.	O

In	O
contrast	O
with	O
ABI3	B-Protein
and	O
ABI5	B-Protein
,	O
the	O
ABI4	B-Protein
transcription	O
factor	O
appears	O
to	O
act	O
at	O
or	O
upstream	O
of	O
ERA1	B-Protein
.	O

Based	O
on	O
reporter	O
gene	O
constructs	O
,	O
the	O
upstream	O
regulation	O
of	O
ABI3	B-Protein
by	O
ERA1	B-Protein
occurs	O
at	O
least	O
partially	O
at	O
the	O
level	O
of	O
transcription	O
,	O
suggesting	O
that	O
this	O
lipid	O
modification	O
is	O
required	O
to	O
attenuate	O
ABI3	B-Protein
expression	O
.	O

Similar	O
experiments	O
also	O
indicate	O
that	O
ABI3	B-Protein
is	O
auxin	O
inducible	O
in	O
lateral	O
root	O
primordia	O
.	O

Related	O
to	O
this	O
,	O
loss	O
-	O
of	O
-	O
function	O
abi3	B-Protein
alleles	O
show	O
reduced	O
lateral	O
root	O
responsiveness	O
in	O
the	O
presence	O
of	O
auxin	O
and	O
an	O
auxin	O
transport	O
inhibitor	O
,	O
and	O
era1	B-Protein
mutants	O
have	O
increased	O
numbers	O
of	O
lateral	O
roots	O
.	O

These	O
results	O
suggest	O
the	O
possibility	O
that	O
genes	O
identified	O
through	O
ABA	O
responsive	O
germination	O
screens	O
such	O
as	O
ERA1	B-Protein
and	O
ABI3	B-Protein
have	O
functions	O
in	O
auxin	O
action	O
in	O
Arabidopsis	O
.	O

The	O
COP9	O
signalosome	O
interacts	O
with	O
SCF	O
UFO	B-Protein
and	O
participates	O
in	O
Arabidopsis	O
flower	O
development	O
.	O

The	O
COP9	O
signalosome	O
(	O
CSN	O
)	O
is	O
involved	O
in	O
multiple	O
developmental	O
processes	O
.	O

It	O
interacts	O
with	O
SCF	O
ubiquitin	B-Protein
ligases	O
and	O
deconjugates	O
Nedd8	B-Protein
/	O
Rub1	B-Protein
from	O
cullins	O
(	O
deneddylation	O
)	O
.	O

CSN	O
is	O
highly	O
expressed	O
in	O
Arabidopsis	O
floral	O
tissues	O
.	O

To	O
investigate	O
the	O
role	O
of	O
CSN	O
in	O
flower	O
development	O
,	O
we	O
examined	O
the	O
expression	O
pattern	O
of	O
CSN	O
in	O
developing	O
flowers	O
.	O

We	O
report	O
here	O
that	O
two	O
csn1	B-Protein
partially	O
deficient	O
Arabidopsis	O
strains	O
exhibit	O
aberrant	O
development	O
of	O
floral	O
organs	O
,	O
decline	O
of	O
APETALA3	B-Protein
(	O
AP3	B-Protein
)	O
expression	O
,	O
and	O
low	O
fertility	O
in	O
addition	O
to	O
defects	O
in	O
shoot	O
and	O
inflorescence	O
meristems	O
.	O

We	O
show	O
that	O
UNUSUAL	B-Protein
FLORAL	I-Protein
ORGANS	I-Protein
(	O
UFO	B-Protein
)	O
forms	O
a	O
SCF	O
(	O
UFO	B-Protein
)	O
complex	O
,	O
which	O
is	O
associated	O
with	O
CSN	O
in	O
vivo	O
.	O

Genetic	O
interaction	O
analysis	O
indicates	O
that	O
CSN	O
is	O
necessary	O
for	O
the	O
gain	O
-	O
of	O
-	O
function	O
activity	O
of	O
the	O
F	O
-	O
box	O
protein	O
UFO	B-Protein
in	O
AP3	B-Protein
activation	O
and	O
in	O
floral	O
organ	O
transformation	O
.	O

Compared	O
with	O
the	O
previously	O
reported	O
csn5	B-Protein
antisense	O
and	O
csn1	B-Protein
null	O
mutants	O
,	O
partial	O
deficiency	O
of	O
CSN1	B-Protein
causes	O
a	O
reduction	O
in	O
the	O
level	O
of	O
CUL1	B-Protein
in	O
the	O
mutant	O
flowers	O
without	O
an	O
obvious	O
defect	O
in	O
CUL1	B-Protein
deneddylation	O
.	O

We	O
conclude	O
that	O
CSN	O
is	O
an	O
essential	O
regulator	O
of	O
Arabidopsis	O
flower	O
development	O
and	O
suggest	O
that	O
CSN	O
regulates	O
Arabidopsis	O
flower	O
development	O
in	O
part	O
by	O
modulating	O
SCF	O
(	O
UFO	B-Protein
)	O
-	O
mediated	O
AP3	B-Protein
activation	O
.	O

A	O
comparative	O
kinetic	O
study	O
on	O
the	O
singlet	O
molecular	O
oxygen	O
-	O
mediated	O
photoxidation	O
of	O
alpha	B-Protein
-	I-Protein
and	O
beta	B-Protein
-	I-Protein
chymotrypsins	I-Protein
.	O

Kinetic	O
aspects	O
of	O
the	O
sensitized	O
photooxidation	O
of	O
alpha	B-Protein
-	I-Protein
and	O
beta	B-Protein
-	I-Protein
chymotrypsins	I-Protein
have	O
been	O
studied	O
at	O
pH	O
6	O
and	O
8	O
.	O

The	O
sensitization	O
,	O
employing	O
classical	O
O2	O
(	O
1Deltag	O
)	O
-	O
photogenerators	O
,	O
such	O
as	O
xanthene	O
dyes	O
,	O
is	O
a	O
kinetically	O
intricate	O
process	O
because	O
of	O
the	O
presence	O
of	O
ground	O
state	O
dye	O
-	O
protein	O
associations	O
and	O
to	O
the	O
simultaneous	O
participation	O
of	O
superoxide	O
ion	O
and	O
singlet	O
molecular	O
oxygen	O
[	O
O2	O
(	O
1Deltag	O
)	O
]	O
.	O

Both	O
proteins	O
,	O
that	O
possess	O
the	O
same	O
distribution	O
pattern	O
of	O
photooxidizable	O
amino	O
acids	O
,	O
suffer	O
a	O
pure	O
O2	O
(	O
1Deltag	O
)	O
-	O
mediated	O
photodynamic	O
attack	O
,	O
using	O
the	O
carbonylic	O
sensitizer	O
Perinaphthenone	O
.	O

Overall	O
and	O
reactive	O
rate	O
constants	O
for	O
the	O
O2	O
(	O
1Deltag	O
)	O
-	O
quenching	O
(	O
in	O
the	O
order	O
of	O
108	O
and	O
107	O
/	O
M	O
/	O
s	O
,	O
respectively	O
)	O
,	O
and	O
rates	O
of	O
oxygen	O
consumption	O
determined	O
by	O
time	O
-	O
resolved	O
,	O
spectroscopic	O
and	O
polarographic	O
methods	O
indicate	O
that	O
alpha	B-Protein
-	I-Protein
and	O
beta	B-Protein
-	I-Protein
chymotrypsins	I-Protein
are	O
less	O
photooxidizable	O
at	O
pH	O
6	O
,	O
as	O
a	O
result	O
of	O
an	O
enhancement	O
of	O
the	O
O2	O
(	O
1Deltag	O
)	O
-	O
physical	O
quenching	O
component	O
.	O

In	O
general	O
terms	O
,	O
beta	B-Protein
-	I-Protein
chymotrypsin	I-Protein
exhibits	O
the	O
greater	O
overall	O
proclivity	O
to	O
interact	O
with	O
O2	O
(	O
1Deltag	O
)	O
,	O
whereas	O
structural	O
factors	O
,	O
possibly	O
evidenced	O
by	O
a	O
higher	O
exposure	O
of	O
the	O
reactive	O
tryptophan	O
residues	O
,	O
impart	O
an	O
increased	O
photooxidation	O
degree	O
to	O
the	O
proteins	O
at	O
pH	O
8	O
,	O
specially	O
to	O
the	O
alpha	B-Protein
-	I-Protein
chymotrypsin	I-Protein
.	O

Sequence	O
analysis	O
of	O
a	O
gene	O
product	O
synthesized	O
by	O
Xanthomonas	O
sp	O
.	O
during	O
growth	O
on	O
natural	O
rubber	O
latex	O
.	O

Xanthomonas	O
sp	O
.	O
secretes	O
an	O
extracellular	O
protein	O
(	O
Mr	O
approximately	O
70	O
+	O
/	O
-	O
5	O
kDa	O
)	O
during	O
growth	O
on	O
purified	O
natural	O
rubber	O
[	O
poly	O
(	O
1	O
,	O
4	O
-	O
cis	O
-	O
isoprene	O
)	O
]	O
but	O
not	O
during	O
growth	O
on	O
water	O
-	O
soluble	O
carbon	O
sources	O
such	O
as	O
glucose	O
or	O
gluconate	O
.	O

A	O
1	O
.	O
3	O
kbp	O
DNA	O
fragment	O
coding	O
for	O
an	O
internal	O
part	O
of	O
the	O
structural	O
gene	O
of	O
the	O
70	O
kDa	O
protein	O
was	O
amplified	O
by	O
nested	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
using	O
amino	O
acid	O
sequence	O
information	O
obtained	O
after	O
Edman	O
degradation	O
of	O
selected	O
trypsin	O
-	O
generated	O
peptides	O
of	O
the	O
purified	O
70	O
kDa	O
protein	O
.	O

The	O
PCR	O
product	O
was	O
used	O
as	O
a	O
DNA	O
probe	O
to	O
clone	O
the	O
complete	O
structural	O
gene	O
from	O
genomic	O
DNA	O
of	O
Xanthomonas	O
sp	O
.	O

The	O
sequenced	O
DNA	O
contained	O
a	O
2037	O
bp	O
open	O
reading	O
frame	O
which	O
coded	O
for	O
a	O
polypeptide	O
of	O
678	O
amino	O
acids	O
(	O
Mr	O
74	O
.	O
6	O
kDa	O
)	O
and	O
which	O
included	O
the	O
features	O
of	O
the	O
N	O
-	O
terminal	O
signal	O
peptidase	O
cleavage	O
site	O
(	O
Mr	O
approximately	O
72	O
.	O
9	O
kDa	O
for	O
the	O
mature	O
protein	O
)	O
.	O

Analysis	O
of	O
the	O
amino	O
acid	O
sequence	O
revealed	O
the	O
presence	O
of	O
two	O
heme	O
binding	O
motifs	O
(	O
CXXCH	O
)	O
and	O
a	O
approximately	O
20	O
amino	O
acids	O
long	O
sequence	O
that	O
is	O
conserved	O
in	O
the	O
Paracoccus	O
denitrificans	O
and	O
Pseudomonas	O
aeruginosa	O
diheme	O
cytochrome	B-Protein
c	I-Protein
peroxidases	I-Protein
(	O
CCPs	B-Protein
)	O
.	O

This	O
region	O
includes	O
a	O
histidine	O
residue	O
(	O
H519	O
in	O
Xanthomonas	O
sp	O
.	O
and	O
H265	O
and	O
H271	O
in	O
the	O
Pseudomonas	O
strains	O
,	O
respectively	O
)	O
that	O
is	O
essential	O
for	O
activity	O
in	O
CCPs	B-Protein
and	O
that	O
is	O
also	O
conserved	O
in	O
other	O
bacterial	O
oxidases	O
.	O

Blast	O
analysis	O
confirmed	O
the	O
relatedness	O
of	O
the	O
70	O
kDa	O
protein	O
to	O
heme	O
-	O
containing	O
oxidases	O
and	O
suggested	O
that	O
it	O
is	O
a	O
member	O
of	O
a	O
new	O
family	O
of	O
relatively	O
large	O
(	O
approximately	O
500	O
to	O
approximately	O
1000	O
amino	O
acids	O
)	O
extracellular	O
proteins	O
with	O
so	O
far	O
unknown	O
function	O
being	O
only	O
far	O
related	O
in	O
amino	O
acid	O
sequence	O
to	O
P	O
.	O
denitrificans	O
and	O
P	O
.	O
aeruginosa	O
CCPs	B-Protein
.	O

High	O
affinity	O
for	O
farnesyltransferase	O
and	O
alternative	O
prenylation	O
contribute	O
individually	O
to	O
K	B-Protein
-	I-Protein
Ras4B	I-Protein
resistance	O
to	O
farnesyltransferase	O
inhibitors	O
.	O

Farnesyltransferase	O
inhibitors	O
(	O
FTIs	O
)	O
block	O
Ras	O
farnesylation	O
,	O
subcellular	O
localization	O
and	O
activity	O
,	O
and	O
inhibit	O
the	O
growth	O
of	O
Ras	O
-	O
transformed	O
cells	O
.	O

Although	O
FTIs	O
are	O
ineffective	O
against	O
K	B-Protein
-	I-Protein
Ras4B	I-Protein
,	O
the	O
Ras	O
isoform	O
most	O
commonly	O
mutated	O
in	O
human	O
cancers	O
,	O
they	O
can	O
inhibit	O
the	O
growth	O
of	O
tumors	O
containing	O
oncogenic	O
K	B-Protein
-	I-Protein
Ras4B	I-Protein
,	O
implicating	O
other	O
farnesylated	O
proteins	O
or	O
suggesting	O
distinct	O
functions	O
for	O
farnesylated	O
and	O
for	O
geranylgeranylated	O
K	B-Protein
-	I-Protein
Ras	I-Protein
,	O
which	O
is	O
generated	O
when	O
farnesyltransferase	O
is	O
inhibited	O
.	O

In	O
addition	O
to	O
bypassing	O
FTI	O
blockade	O
through	O
geranylgeranylation	O
,	O
K	B-Protein
-	I-Protein
Ras4B	I-Protein
resistance	O
to	O
FTIs	O
may	O
also	O
result	O
from	O
its	O
higher	O
affinity	O
for	O
farnesyltransferase	O
.	O

Using	O
chimeric	O
Ras	O
proteins	O
containing	O
all	O
combinations	O
of	O
Ras	O
background	O
,	O
CAAX	O
motif	O
,	O
and	O
K	B-Protein
-	I-Protein
Ras	I-Protein
polybasic	O
domain	O
,	O
we	O
show	O
that	O
either	O
a	O
polybasic	O
domain	O
or	O
an	O
alternatively	O
prenylated	O
CAAX	O
renders	O
Ras	O
prenylation	O
,	O
Ras	O
-	O
induced	O
Elk	B-Protein
-	I-Protein
1	I-Protein
activation	O
,	O
and	O
anchorage	O
-	O
independent	O
cell	O
growth	O
FTI	O
-	O
resistant	O
.	O

The	O
polybasic	O
domain	O
alone	O
increases	O
the	O
affinity	O
of	O
Ras	O
for	O
farnesyltransferase	O
,	O
implying	O
independent	O
roles	O
for	O
each	O
K	B-Protein
-	I-Protein
Ras4B	I-Protein
sequence	O
element	O
in	O
FTI	O
resistance	O
.	O

Using	O
microarray	O
analysis	O
and	O
colony	O
formation	O
assays	O
,	O
we	O
confirm	O
that	O
K	B-Protein
-	I-Protein
Ras	I-Protein
function	O
is	O
independent	O
of	O
the	O
identity	O
of	O
the	O
prenyl	O
group	O
and	O
,	O
therefore	O
,	O
that	O
FTI	O
inhibition	O
of	O
K	B-Protein
-	I-Protein
Ras	I-Protein
transformed	O
cells	O
is	O
likely	O
to	O
be	O
independent	O
of	O
K	B-Protein
-	I-Protein
Ras	I-Protein
inhibition	O
.	O

Our	O
results	O
imply	O
that	O
relevant	O
FTI	O
targets	O
will	O
lack	O
both	O
polybasic	O
and	O
potentially	O
geranylgeranylated	O
methionine	O
-	O
CAAX	O
motifs	O
.	O

Disruption	O
of	O
the	O
COP9	O
signalosome	O
Csn2	B-Protein
subunit	O
in	O
mice	O
causes	O
deficient	O
cell	O
proliferation	O
,	O
accumulation	O
of	O
p53	B-Protein
and	O
cyclin	O
E	O
,	O
and	O
early	O
embryonic	O
death	O
.	O

Csn2	B-Protein
(	O
Trip15	B-Protein
/	O
Cops2	B-Protein
/	O
Alien	B-Protein
)	O
encodes	O
the	O
second	O
subunit	O
of	O
the	O
COP9	O
signalosome	O
(	O
CSN	O
)	O
,	O
an	O
eight	O
-	O
subunit	O
heteromeric	O
complex	O
homologous	O
to	O
the	O
lid	O
subcomplex	O
of	O
the	O
26S	O
proteasome	O
.	O

CSN	O
is	O
a	O
regulator	O
of	O
SCF	O
(	O
Skp1	B-Protein
-	O
cullin	O
-	O
F	O
-	O
box	O
protein	O
)	O
ubiquitin	B-Protein
ligases	O
,	O
mostly	O
through	O
the	O
enzymatic	O
activity	O
that	O
deconjugates	O
the	O
ubiquitin	B-Protein
-	O
like	O
protein	O
Nedd8	B-Protein
from	O
the	O
SCF	O
Cul1	B-Protein
component	O
.	O

In	O
addition	O
,	O
CSN	O
associates	O
with	O
protein	O
kinase	O
activities	O
targeting	O
p53	B-Protein
,	O
c	B-Protein
-	I-Protein
Jun	I-Protein
,	O
and	O
IkappaB	O
for	O
phosphorylation	O
.	O

Csn2	B-Protein
also	O
interacts	O
with	O
and	O
regulates	O
a	O
subset	O
of	O
nuclear	O
hormone	O
receptors	O
and	O
is	O
considered	O
a	O
novel	O
corepressor	O
.	O

We	O
report	O
that	O
targeted	O
disruption	O
of	O
Csn2	B-Protein
in	O
mice	O
caused	O
arrest	O
of	O
embryo	O
development	O
at	O
the	O
peri	O
-	O
implantation	O
stage	O
.	O

Csn2	B-Protein
(	O
-	O
/	O
-	O
)	O
blastocysts	O
failed	O
to	O
outgrow	O
in	O
culture	O
and	O
exhibited	O
a	O
cell	O
proliferation	O
defect	O
in	O
inner	O
cell	O
mass	O
,	O
accompanied	O
by	O
a	O
slight	O
decrease	O
in	O
Oct4	B-Protein
.	O

In	O
addition	O
,	O
lack	O
of	O
Csn2	B-Protein
disrupted	O
the	O
CSN	O
complex	O
and	O
resulted	O
in	O
a	O
drastic	O
increase	O
in	O
cyclin	O
E	O
,	O
supporting	O
a	O
role	O
for	O
CSN	O
in	O
cooperating	O
with	O
the	O
SCF	O
-	O
ubiquitin	B-Protein
-	O
proteasome	O
system	O
to	O
regulate	O
protein	O
turnover	O
.	O

Furthermore	O
,	O
Csn2	B-Protein
(	O
-	O
/	O
-	O
)	O
embryos	O
contained	O
elevated	O
levels	O
of	O
p53	B-Protein
and	O
p21	B-Protein
,	O
which	O
may	O
contribute	O
to	O
premature	O
cell	O
cycle	O
arrest	O
of	O
the	O
mutant	O
.	O

On	O
again	O
-	O
off	O
again	O
:	O
COP9	O
signalosome	O
turns	O
the	O
key	O
on	O
protein	O
degradation	O
.	O

The	O
COP9	O
signalosome	O
is	O
an	O
eight	O
-	O
subunit	O
protein	O
complex	O
that	O
regulates	O
protein	O
ubiquitination	O
and	O
protein	O
turnover	O
in	O
a	O
variety	O
of	O
plant	O
developmental	O
and	O
physiological	O
contexts	O
,	O
including	O
light	O
-	O
regulated	O
development	O
,	O
hormone	O
signaling	O
,	O
and	O
defense	O
against	O
pathogens	O
.	O

In	O
all	O
eukaryotes	O
tested	O
,	O
the	O
COP9	O
signalosome	O
is	O
able	O
to	O
posttranslationally	O
modify	O
the	O
cullin	O
subunit	O
of	O
E3	O
-	O
ubiquitin	B-Protein
-	O
ligase	O
complexes	O
by	O
cleaving	O
off	O
the	O
covalently	O
coupled	O
peptide	O
,	O
Nedd8	B-Protein
.	O

Two	O
contrasting	O
models	O
ascribe	O
stimulatory	O
or	O
inhibitory	O
roles	O
to	O
the	O
modification	O
of	O
cullin	O
/	O
E3	O
that	O
is	O
mediated	O
by	O
the	O
COP9	O
signalosome	O
.	O

There	O
is	O
considerable	O
disagreement	O
as	O
to	O
whether	O
Nedd8	B-Protein
cleavage	O
underlies	O
all	O
of	O
the	O
COP9	O
signalosome	O
'	O
s	O
numerous	O
cellular	O
and	O
phenotypic	O
effects	O
.	O

This	O
is	O
because	O
macroscopic	O
phenotypes	O
do	O
not	O
always	O
correlate	O
with	O
biochemical	O
defects	O
in	O
COP9	O
signalosome	O
mutants	O
.	O

Additional	O
biochemical	O
activities	O
,	O
including	O
protein	O
interactions	O
with	O
the	O
cellular	O
machineries	O
for	O
protein	O
phosphorylation	O
,	O
protein	O
turnover	O
,	O
and	O
protein	O
translation	O
,	O
have	O
been	O
proposed	O
to	O
account	O
for	O
the	O
role	O
of	O
the	O
COP9	O
signalosome	O
in	O
development	O
and	O
disease	O
.	O

But1	B-Protein
and	O
But2	B-Protein
proteins	O
bind	O
to	O
Uba3	B-Protein
,	O
a	O
catalytic	O
subunit	O
of	O
E1	O
for	O
neddylation	O
,	O
in	O
fission	O
yeast	O
.	O

NEDD8	B-Protein
/	O
Rub1	B-Protein
is	O
the	O
most	O
homologous	O
protein	O
to	O
ubiquitin	B-Protein
among	O
the	O
ubiquitin	B-Protein
-	O
like	O
proteins	O
,	O
and	O
it	O
is	O
covalently	O
linked	O
to	O
target	O
proteins	O
via	O
the	O
C	O
-	O
terminal	O
glycine	O
residue	O
in	O
a	O
manner	O
analogous	O
to	O
ubiquitylation	O
.	O

However	O
,	O
the	O
mechanism	O
(	O
s	O
)	O
involved	O
in	O
the	O
regulation	O
of	O
the	O
NEDD8	B-Protein
ligation	O
pathway	O
remains	O
elusive	O
.	O

Using	O
the	O
two	O
-	O
hybrid	O
system	O
,	O
we	O
isolated	O
novel	O
genes	O
from	O
the	O
Schizosaccharomyces	O
pombe	O
cDNA	O
library	O
whose	O
products	O
bind	O
to	O
Uba3	B-Protein
,	O
which	O
is	O
a	O
catalytic	O
protein	O
for	O
E1	O
-	O
like	O
activity	O
of	O
the	O
NEDD8	B-Protein
pathway	O
.	O

We	O
designated	O
these	O
genes	O
but1	B-Protein
(	O
+	O
)	O
and	O
but2	B-Protein
(	O
+	O
)	O
(	O
for	O
proteins	O
that	O
bind	O
to	O
Uba	B-Protein
three	I-Protein
)	O
.	O

But1	B-Protein
is	O
a	O
nuclear	O
protein	O
and	O
its	O
overexpression	O
caused	O
cell	O
elongation	O
,	O
which	O
is	O
a	O
common	O
phenotype	O
of	O
the	O
NEDD8	B-Protein
pathway	O
defective	O
mutant	O
in	O
S	O
.	O
pombe	O
.	O

Furthermore	O
,	O
overexpression	O
of	O
but1	B-Protein
(	O
+	O
)	O
in	O
ned8	B-Protein
-	O
temperature	O
sensitive	O
mutant	O
had	O
a	O
deleterious	O
effect	O
even	O
under	O
permissive	O
temperatures	O
.	O

Our	O
results	O
suggest	O
that	O
But1	B-Protein
may	O
have	O
an	O
inhibitory	O
role	O
in	O
the	O
NEDD8	B-Protein
pathway	O
.	O

Rac	O
GTPase	O
instructs	O
nuclear	O
factor	O
-	O
kappaB	O
activation	O
by	O
conveying	O
the	O
SCF	O
complex	O
and	O
IkBalpha	B-Protein
to	O
the	O
ruffling	O
membranes	O
.	O

Nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
is	O
a	O
ubiquitously	O
expressed	O
transcription	O
factor	O
that	O
plays	O
a	O
central	O
role	O
in	O
directing	O
a	O
vast	O
range	O
of	O
cellular	O
functions	O
.	O

Its	O
activation	O
is	O
controlled	O
by	O
the	O
Rac	O
GTPase	O
and	O
relies	O
on	O
the	O
coordinated	O
cooperation	O
of	O
the	O
E3	O
-	O
ligase	O
complex	O
SCF	O
(	O
betaTrCP	B-Protein
)	O
,	O
composed	O
by	O
Skp	B-Protein
-	I-Protein
1	I-Protein
/	O
Cullin	B-Protein
-	I-Protein
1	I-Protein
,	O
Rbx	B-Protein
/	O
Roc1	B-Protein
,	O
and	O
the	O
beta	B-Protein
-	I-Protein
TrCP	I-Protein
proteins	O
.	O

Recently	O
,	O
Cullin	B-Protein
-	I-Protein
1	I-Protein
has	O
been	O
reported	O
to	O
form	O
a	O
complex	O
with	O
the	O
activated	O
Rac	O
GTPase	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
specific	O
activation	O
of	O
the	O
Rac	O
GTPase	O
,	O
besides	O
directing	O
its	O
own	O
positioning	O
,	O
induces	O
the	O
relocalization	O
of	O
the	O
SCF	O
component	O
Cullin	B-Protein
-	I-Protein
1	I-Protein
to	O
the	O
ruffling	O
membranes	O
.	O

This	O
occurred	O
only	O
if	O
the	O
ruffles	O
were	O
stimulated	O
by	O
the	O
Rac	O
GTPase	O
and	O
was	O
accompanied	O
by	O
the	O
repositioning	O
to	O
the	O
same	O
intracellular	O
compartment	O
of	O
the	O
SCF	O
protein	O
Skp	B-Protein
-	I-Protein
1	I-Protein
and	O
the	O
ubiquitin	B-Protein
-	O
like	O
molecule	O
Nedd	B-Protein
-	I-Protein
8	I-Protein
.	O

The	O
SCF	O
substrate	O
IkBalpha	B-Protein
was	O
also	O
directed	O
to	O
the	O
ruffling	O
membranes	O
in	O
a	O
Rac	O
-	O
dependent	O
way	O
.	O

The	O
novelty	O
of	O
these	O
findings	O
is	O
in	O
respect	O
to	O
the	O
demonstration	O
that	O
the	O
correct	O
positioning	O
at	O
the	O
ruffling	O
membranes	O
is	O
crucial	O
for	O
the	O
subsequent	O
series	O
of	O
events	O
that	O
leads	O
to	O
IkBalpha	B-Protein
proteasomal	O
degradation	O
and	O
the	O
resultant	O
activation	O
of	O
NF	O
-	O
kappaB	O
.	O

Consequently	O
,	O
this	O
points	O
to	O
the	O
role	O
of	O
Rac	O
as	O
a	O
docking	O
molecule	O
in	O
NF	O
-	O
kappaB	O
activation	O
.	O

PIASy	B-Protein
-	O
mediated	O
repression	O
of	O
the	O
androgen	B-Protein
receptor	I-Protein
is	O
independent	O
of	O
sumoylation	O
.	O

PIASy	B-Protein
,	O
a	O
member	O
of	O
the	O
protein	O
inhibitor	O
of	O
activated	O
STAT	O
(	O
PIAS	O
)	O
family	O
,	O
represses	O
the	O
transcriptional	O
activity	O
of	O
the	O
androgen	B-Protein
receptor	I-Protein
(	O
AR	B-Protein
)	O
.	O

In	O
this	O
report	O
,	O
we	O
investigate	O
the	O
mechanism	O
of	O
PIASy	B-Protein
-	O
mediated	O
repression	O
of	O
AR	B-Protein
.	O

We	O
show	O
that	O
AR	B-Protein
binds	O
to	O
the	O
RING	O
-	O
finger	O
like	O
domain	O
of	O
PIASy	B-Protein
.	O

PIASy	B-Protein
contains	O
two	O
transcriptional	O
repression	O
domains	O
,	O
RD1	O
and	O
RD2	O
.	O

RD1	O
,	O
but	O
not	O
RD2	O
,	O
is	O
required	O
for	O
PIASy	B-Protein
-	O
mediated	O
repression	O
of	O
AR	B-Protein
.	O

We	O
show	O
that	O
the	O
RD1	O
domain	O
binds	O
HDAC1	B-Protein
and	O
HDAC2	B-Protein
and	O
that	O
HDAC	O
activity	O
is	O
required	O
for	O
PIASy	B-Protein
-	O
mediated	O
AR	B-Protein
repression	O
.	O

PIAS	O
proteins	O
possess	O
small	O
ubiquitin	B-Protein
-	O
related	O
modifier	O
(	O
SUMO	O
)	O
E3	O
ligase	O
activity	O
.	O

Conjugation	O
of	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
to	O
AR	B-Protein
has	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
AR	B-Protein
activity	O
.	O

We	O
examine	O
if	O
the	O
SUMO	O
ligase	O
activity	O
of	O
PIASy	B-Protein
is	O
required	O
for	O
PIASy	B-Protein
to	O
repress	O
AR	B-Protein
.	O

We	O
show	O
that	O
a	O
mutant	O
PIASy	B-Protein
,	O
defective	O
in	O
promoting	O
sumoylation	O
,	O
retains	O
the	O
ability	O
to	O
repress	O
AR	B-Protein
transcription	O
.	O

In	O
addition	O
,	O
mutation	O
of	O
all	O
the	O
known	O
sumoylation	O
acceptor	O
sites	O
of	O
AR	B-Protein
does	O
not	O
affect	O
the	O
transrepression	O
activity	O
of	O
PIASy	B-Protein
on	O
AR	B-Protein
.	O

Our	O
results	O
suggest	O
that	O
PIASy	B-Protein
may	O
repress	O
AR	B-Protein
by	O
recruiting	O
histone	O
deacetylases	O
,	O
independent	O
of	O
its	O
SUMO	O
ligase	O
activity	O
.	O

pVHL	B-Protein
modification	O
by	O
NEDD8	B-Protein
is	O
required	O
for	O
fibronectin	B-Protein
matrix	O
assembly	O
and	O
suppression	O
of	O
tumor	O
development	O
.	O

Functional	O
inactivation	O
of	O
the	O
von	B-Protein
Hippel	I-Protein
-	I-Protein
Lindau	I-Protein
(	I-Protein
VHL	I-Protein
)	I-Protein
tumor	I-Protein
suppressor	I-Protein
gene	O
is	O
the	O
cause	O
of	O
the	O
familial	O
VHL	O
disease	O
and	O
most	O
sporadic	O
renal	O
clear	O
-	O
cell	O
carcinomas	O
(	O
RCC	O
)	O
.	O

pVHL	B-Protein
has	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
the	O
destruction	O
of	O
hypoxia	B-Protein
-	I-Protein
inducible	I-Protein
factor	I-Protein
alpha	I-Protein
(	O
HIF	B-Protein
-	I-Protein
alpha	I-Protein
)	O
subunits	O
via	O
ubiquitin	B-Protein
-	O
mediated	O
proteolysis	O
and	O
in	O
the	O
regulation	O
of	O
fibronectin	B-Protein
matrix	O
assembly	O
.	O

Although	O
most	O
disease	O
-	O
causing	O
pVHL	B-Protein
mutations	O
hinder	O
the	O
regulation	O
of	O
the	O
HIF	O
pathway	O
,	O
every	O
disease	O
-	O
causing	O
pVHL	B-Protein
mutant	O
tested	O
to	O
date	O
has	O
failed	O
to	O
promote	O
the	O
assembly	O
of	O
the	O
fibronectin	B-Protein
matrix	O
,	O
underscoring	O
its	O
potential	O
importance	O
in	O
VHL	O
disease	O
.	O

Here	O
,	O
we	O
report	O
that	O
a	O
ubiquitin	B-Protein
-	O
like	O
molecule	O
called	O
NEDD8	B-Protein
covalently	O
modifies	O
pVHL	B-Protein
.	O

A	O
nonneddylateable	O
pVHL	B-Protein
mutant	O
,	O
while	O
retaining	O
its	O
ability	O
to	O
ubiquitylate	O
HIF	O
,	O
failed	O
to	O
bind	O
to	O
and	O
promote	O
the	O
assembly	O
of	O
the	O
fibronectin	B-Protein
matrix	O
.	O

Expression	O
of	O
the	O
neddylation	O
-	O
defective	O
pVHL	B-Protein
in	O
RCC	O
cells	O
,	O
while	O
restoring	O
the	O
regulation	O
of	O
HIF	O
,	O
failed	O
to	O
promote	O
the	O
differentiated	O
morphology	O
in	O
a	O
three	O
-	O
dimensional	O
growth	O
assay	O
and	O
was	O
insufficient	O
to	O
suppress	O
the	O
formation	O
of	O
tumors	O
in	O
SCID	O
mice	O
.	O

These	O
results	O
suggest	O
that	O
NEDD8	B-Protein
modification	O
of	O
pVHL	B-Protein
plays	O
an	O
important	O
role	O
in	O
fibronectin	B-Protein
matrix	O
assembly	O
and	O
that	O
in	O
the	O
absence	O
of	O
such	O
regulation	O
,	O
an	O
intact	O
HIF	O
pathway	O
is	O
insufficient	O
to	O
prevent	O
VHL	B-Protein
-	O
associated	O
tumorigenesis	O
.	O

Role	O
of	O
the	O
isoprenyl	O
pocket	O
of	O
the	O
G	O
protein	O
beta	O
gamma	O
subunit	O
complex	O
in	O
the	O
binding	O
of	O
phosducin	B-Protein
and	O
phosducin	B-Protein
-	I-Protein
like	I-Protein
protein	O
.	O

Phosducin	B-Protein
(	O
Pdc	B-Protein
)	O
and	O
phosducin	B-Protein
-	I-Protein
like	I-Protein
protein	I-Protein
(	O
PhLP	B-Protein
)	O
regulate	O
G	O
protein	O
-	O
mediated	O
signaling	O
by	O
binding	O
to	O
the	O
betagamma	O
subunit	O
complex	O
of	O
heterotrimeric	O
G	O
proteins	O
(	O
Gbetagamma	O
)	O
and	O
removing	O
the	O
dimer	O
from	O
cell	O
membranes	O
.	O

The	O
binding	O
of	O
Pdc	B-Protein
induces	O
a	O
conformational	O
change	O
in	O
the	O
beta	O
-	O
propeller	O
structure	O
of	O
Gbetagamma	O
,	O
creating	O
a	O
pocket	O
between	O
blades	O
6	O
and	O
7	O
.	O

It	O
has	O
been	O
proposed	O
that	O
the	O
isoprenyl	O
group	O
of	O
Gbetagamma	O
inserts	O
into	O
this	O
pocket	O
,	O
stabilizing	O
the	O
Pdc	B-Protein
.	O
Gbetagamma	O
structure	O
and	O
decreasing	O
the	O
affinity	O
of	O
the	O
complex	O
for	O
the	O
lipid	O
bilayer	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
the	O
binding	O
of	O
Pdc	B-Protein
and	O
PhLP	B-Protein
to	O
several	O
Gbetagamma	O
dimers	O
containing	O
variants	O
of	O
the	O
beta	O
or	O
gamma	O
subunit	O
was	O
measured	O
.	O

These	O
variants	O
included	O
modifications	O
of	O
the	O
isoprenyl	O
group	O
(	O
gamma	O
)	O
,	O
residues	O
involved	O
in	O
the	O
conformational	O
change	O
(	O
beta	O
)	O
,	O
and	O
residues	O
lining	O
the	O
proposed	O
prenyl	O
pocket	O
(	O
beta	O
)	O
.	O

Switching	O
prenyl	O
groups	O
from	O
farnesyl	O
to	O
geranylgeranyl	O
or	O
vice	O
versa	O
had	O
little	O
effect	O
on	O
binding	O
.	O

However	O
,	O
alanine	O
substitution	O
of	O
one	O
residue	O
in	O
the	O
beta	O
subunit	O
involved	O
in	O
the	O
conformational	O
change	O
(	O
W332	O
)	O
decreased	O
binding	O
5	O
-	O
fold	O
.	O

Alanine	O
substitution	O
of	O
certain	O
residues	O
within	O
the	O
prenyl	O
pocket	O
caused	O
only	O
minor	O
decreases	O
in	O
binding	O
,	O
while	O
a	O
lysine	O
substitution	O
of	O
T329	O
within	O
the	O
pocket	O
inhibited	O
binding	O
10	O
-	O
fold	O
.	O

Molecular	O
modeling	O
of	O
the	O
binding	O
energy	O
of	O
the	O
Pdc	B-Protein
.	O
Gbeta	B-Protein
(	I-Protein
1	I-Protein
)	I-Protein
gamma	B-Protein
(	I-Protein
2	I-Protein
)	I-Protein
complex	O
required	O
insertion	O
of	O
the	O
geranylgeranyl	O
group	O
into	O
the	O
prenyl	O
pocket	O
in	O
order	O
to	O
accurately	O
predict	O
the	O
effects	O
of	O
prenyl	O
pocket	O
amino	O
acid	O
substitutions	O
.	O

Finally	O
,	O
a	O
dimer	O
containing	O
a	O
gamma	O
subunit	O
with	O
no	O
prenyl	O
group	O
(	O
gamma	B-Protein
(	I-Protein
2	I-Protein
)	I-Protein
-	O
C68S	O
)	O
decreased	O
binding	O
by	O
nearly	O
20	O
-	O
fold	O
.	O

These	O
results	O
support	O
the	O
structural	O
model	O
in	O
which	O
the	O
prenyl	O
group	O
escapes	O
contact	O
with	O
the	O
aqueous	O
milieu	O
by	O
inserting	O
into	O
the	O
prenyl	O
pocket	O
and	O
stabilizing	O
the	O
Pdc	B-Protein
-	O
binding	O
conformation	O
of	O
Gbetagamma	O
.	O

Atg21	B-Protein
is	O
a	O
phosphoinositide	O
binding	O
protein	O
required	O
for	O
efficient	O
lipidation	O
and	O
localization	O
of	O
Atg8	B-Protein
during	O
uptake	O
of	O
aminopeptidase	B-Protein
I	I-Protein
by	O
selective	O
autophagy	O
.	O

Delivery	O
of	O
proteins	O
and	O
organelles	O
to	O
the	O
vacuole	O
by	O
autophagy	O
and	O
the	O
cytoplasm	O
to	O
vacuole	O
targeting	O
(	O
Cvt	O
)	O
pathway	O
involves	O
novel	O
rearrangements	O
of	O
membrane	O
resulting	O
in	O
the	O
formation	O
of	O
vesicles	O
that	O
fuse	O
with	O
the	O
vacuole	O
.	O

The	O
mechanism	O
of	O
vesicle	O
formation	O
and	O
the	O
origin	O
of	O
the	O
membrane	O
are	O
complex	O
issues	O
still	O
to	O
be	O
resolved	O
.	O

Atg18	B-Protein
and	O
Atg21	B-Protein
are	O
proteins	O
essential	O
to	O
vesicle	O
formation	O
and	O
together	O
with	O
Ygr223c	B-Protein
form	O
a	O
novel	O
family	O
of	O
phosphoinositide	O
binding	O
proteins	O
that	O
are	O
associated	O
with	O
the	O
vacuole	O
and	O
perivacuolar	O
structures	O
.	O

Their	O
localization	O
requires	O
the	O
activity	O
of	O
Vps34	B-Protein
,	O
suggesting	O
that	O
phosphatidylinositol	O
(	O
3	O
)	O
phosphate	O
may	O
be	O
essential	O
for	O
their	O
function	O
.	O

The	O
activity	O
of	O
Atg18	B-Protein
is	O
vital	O
for	O
all	O
forms	O
of	O
autophagy	O
,	O
whereas	O
Atg21	B-Protein
is	O
required	O
for	O
the	O
Cvt	O
pathway	O
but	O
not	O
for	O
nitrogen	O
starvation	O
-	O
induced	O
autophagy	O
.	O

The	O
loss	O
of	O
Atg21	B-Protein
results	O
in	O
the	O
absence	O
of	O
Atg8	B-Protein
from	O
the	O
pre	O
-	O
autophagosomal	O
structure	O
(	O
PAS	O
)	O
,	O
which	O
may	O
be	O
ascribed	O
to	O
a	O
reduced	O
rate	O
of	O
conjugation	O
of	O
Atg8	B-Protein
to	O
phosphatidylethanolamine	O
.	O

A	O
similar	O
defect	O
in	O
localization	O
of	O
a	O
second	O
ubiquitin	B-Protein
-	O
like	O
conjugate	O
,	O
Atg12	B-Protein
-	O
Atg5	B-Protein
,	O
suggests	O
that	O
Atg21	B-Protein
may	O
be	O
involved	O
in	O
the	O
recruitment	O
of	O
membrane	O
to	O
the	O
PAS	O
.	O

Effect	O
of	O
the	O
statin	O
atorvastatin	O
on	O
intracellular	O
signalling	O
by	O
the	O
prostacyclin	B-Protein
receptor	I-Protein
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Prostacyclin	O
plays	O
a	O
central	O
role	O
within	O
the	O
vasculature	O
.	O

We	O
have	O
previously	O
established	O
that	O
the	O
prostacyclin	B-Protein
receptor	I-Protein
(	O
IP	B-Protein
)	O
undergoes	O
isoprenylation	O
,	O
a	O
lipid	O
modification	O
obligate	O
for	O
its	O
function	O
.	O

The	O
aim	O
of	O
the	O
current	O
study	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
the	O
hydroxy	O
methyl	O
glutaryl	O
co	O
-	O
enzyme	O
A	O
reductase	O
inhibitor	O
atorvastatin	O
on	O
signalling	O
and	O
function	O
of	O
the	O
IP	B-Protein
expressed	O
in	O
mammalian	O
whole	O
cells	O
and	O
in	O
platelets	O
isolated	O
from	O
patients	O
undergoing	O
therapeutic	O
intervention	O
with	O
atorvastatin	O
.	O

Initially	O
,	O
the	O
effect	O
of	O
atorvastatin	O
on	O
signalling	O
by	O
the	O
human	O
(	O
h	O
)	O
and	O
mouse	O
(	O
m	O
)	O
IP	B-Protein
overexpressed	O
in	O
human	O
embryonic	O
kidney	O
293	O
cells	O
and	O
the	O
hIP	B-Protein
endogenously	O
expressed	O
in	O
human	O
erythroleukaemic	O
92	O
.	O
1	O
.	O
7	O
cells	O
was	O
investigated	O
.	O

Atorvastatin	O
significantly	O
reduced	O
IP	B-Protein
-	O
mediated	O
cAMP	O
generation	O
(	O
IC	O
(	O
50	O
)	O
6	O
.	O
6	O
-	O
11	O
.	O
1	O
microm	O
)	O
and	O
[	O
Ca	O
(	O
2	O
+	O
)	O
]	O
(	O
i	O
)	O
mobilization	O
(	O
IC	O
(	O
50	O
)	O
7	O
.	O
2	O
-	O
16	O
.	O
4	O
microm	O
)	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
,	O
but	O
had	O
no	O
effect	O
on	O
signalling	O
by	O
the	O
nonisoprenylated	O
beta	B-Protein
(	I-Protein
2	I-Protein
)	I-Protein
adrenergic	I-Protein
receptor	I-Protein
or	O
the	O
alpha	O
or	O
beta	O
isoforms	O
of	O
the	O
human	O
thromboxane	B-Protein
A	I-Protein
(	I-Protein
2	I-Protein
)	I-Protein
receptor	I-Protein
(	O
TP	B-Protein
)	O
.	O

Moreover	O
,	O
atorvastatin	O
significantly	O
reduced	O
IP	B-Protein
-	O
mediated	O
crossdesensitization	O
of	O
signalling	O
by	O
TP	B-Protein
alpha	I-Protein
(	O
IC	O
(	O
50	O
)	O
10	O
.	O
4	O
microm	O
)	O
,	O
but	O
not	O
by	O
TP	B-Protein
beta	I-Protein
.	O

In	O
contrast	O
to	O
the	O
whole	O
-	O
cell	O
data	O
,	O
atorvastatin	O
therapy	O
did	O
not	O
interfere	O
with	O
IP	B-Protein
-	O
mediated	O
cAMP	O
generation	O
or	O
IP	B-Protein
-	O
induced	O
inhibition	O
of	O
TP	B-Protein
-	O
mediated	O
aggregation	O
of	O
platelets	O
isolated	O
from	O
human	O
volunteers	O
undergoing	O
therapeutic	O
intervention	O
with	O
atorvastatin	O
(	O
10	O
-	O
80	O
mg	O
per	O
daily	O
dose	O
)	O
.	O

In	O
conclusion	O
,	O
while	O
data	O
generated	O
in	O
whole	O
cells	O
indicated	O
that	O
atorvastatin	O
significantly	O
impairs	O
signalling	O
by	O
both	O
the	O
hIP	B-Protein
and	O
mP	O
,	O
the	O
in	O
vivo	O
clinical	O
data	O
indicated	O
that	O
,	O
at	O
the	O
administered	O
therapeutic	O
dose	O
,	O
atorvastatin	O
does	O
not	O
significantly	O
compromise	O
IP	B-Protein
signalling	O
and	O
function	O
in	O
humans	O
.	O

Novel	O
role	O
of	O
ARF6	B-Protein
in	O
vascular	O
endothelial	O
growth	O
factor	O
-	O
induced	O
signaling	O
and	O
angiogenesis	O
.	O

Vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
stimulates	O
endothelial	O
cell	O
(	O
EC	O
)	O
migration	O
and	O
proliferation	O
primarily	O
through	O
the	O
VEGF	B-Protein
receptor	I-Protein
-	I-Protein
2	I-Protein
(	O
VEGFR2	B-Protein
)	O
.	O

We	O
have	O
shown	O
that	O
VEGF	O
stimulates	O
a	O
Rac1	B-Protein
-	O
dependent	O
NAD	O
(	O
P	O
)	O
H	O
oxidase	O
to	O
produce	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
that	O
are	O
involved	O
in	O
VEGFR2	B-Protein
autophosphorylation	O
and	O
angiogenic	O
-	O
related	O
responses	O
in	O
ECs	O
.	O

The	O
small	O
GTPase	O
ARF6	B-Protein
is	O
involved	O
in	O
membrane	O
trafficking	O
and	O
cell	O
motility	O
;	O
however	O
,	O
its	O
roles	O
in	O
VEGF	O
signaling	O
and	O
physiological	O
responses	O
in	O
ECs	O
are	O
unknown	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
overexpression	O
of	O
dominant	O
-	O
negative	O
ARF6	B-Protein
[	O
ARF6	B-Protein
(	O
T27N	O
)	O
]	O
almost	O
completely	O
inhibits	O
VEGF	O
-	O
induced	O
Rac1	B-Protein
activation	O
,	O
ROS	O
production	O
,	O
and	O
VEGFR2	B-Protein
autophosphorylation	O
in	O
ECs	O
.	O

Fractionation	O
of	O
caveolae	O
/	O
lipid	O
raft	O
membranes	O
demonstrates	O
that	O
ARF6	B-Protein
,	O
Rac1	B-Protein
,	O
and	O
VEGFR2	B-Protein
are	O
localized	O
in	O
caveolin	O
-	O
enriched	O
fractions	O
basally	O
.	O

VEGF	O
stimulation	O
results	O
in	O
the	O
release	O
of	O
VEGFR2	B-Protein
from	O
caveolae	O
/	O
lipid	O
rafts	O
and	O
caveolin	B-Protein
-	I-Protein
1	I-Protein
without	O
affecting	O
localization	O
of	O
ARF6	B-Protein
,	O
Rac1	B-Protein
,	O
or	O
caveolin	B-Protein
-	I-Protein
1	I-Protein
in	O
these	O
fractions	O
.	O

The	O
egress	O
of	O
VEGFR2	B-Protein
from	O
caveolae	O
/	O
lipid	O
rafts	O
is	O
contemporaneous	O
with	O
the	O
tyrosine	O
phosphorylation	O
of	O
caveolin	B-Protein
-	I-Protein
1	I-Protein
(	O
Tyr14	O
)	O
and	O
VEGFR2	B-Protein
and	O
with	O
their	O
association	O
with	O
each	O
other	O
.	O

ARF6	B-Protein
(	O
T27N	O
)	O
significantly	O
inhibits	O
both	O
VEGF	O
-	O
induced	O
responses	O
.	O

Immunofluorescence	O
studies	O
show	O
that	O
activated	O
VEGFR2	B-Protein
and	O
phosphocaveolin	O
colocalize	O
at	O
focal	O
complexes	O
/	O
adhesions	O
after	O
VEGF	O
stimulation	O
.	O

Both	O
overexpression	O
of	O
ARF6	B-Protein
(	O
T27N	O
)	O
and	O
mutant	O
caveolin	B-Protein
-	I-Protein
1	I-Protein
(	O
Y14F	O
)	O
,	O
which	O
cannot	O
be	O
phosphorylated	O
,	O
block	O
VEGF	O
-	O
stimulated	O
EC	O
migration	O
and	O
proliferation	O
.	O

Moreover	O
,	O
ARF6	B-Protein
expression	O
is	O
markedly	O
upregulated	O
in	O
association	O
with	O
an	O
increase	O
in	O
capillary	O
density	O
in	O
a	O
mouse	O
hindlimb	O
ischemia	O
model	O
of	O
angiogenesis	O
.	O

Thus	O
,	O
ARF6	B-Protein
is	O
involved	O
in	O
the	O
temporal	O
-	O
spatial	O
organization	O
of	O
caveolae	O
/	O
lipid	O
rafts	O
-	O
and	O
ROS	O
-	O
dependent	O
VEGF	O
signaling	O
in	O
ECs	O
as	O
well	O
as	O
in	O
angiogenesis	O
in	O
vivo	O
.	O

Golgi	O
targeting	O
of	O
human	O
guanylate	B-Protein
-	I-Protein
binding	I-Protein
protein	I-Protein
-	I-Protein
1	I-Protein
requires	O
nucleotide	O
binding	O
,	O
isoprenylation	O
,	O
and	O
an	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
-	O
inducible	O
cofactor	O
.	O

Human	O
guanylate	B-Protein
-	I-Protein
binding	I-Protein
protein	I-Protein
-	I-Protein
1	I-Protein
(	O
hGBP	B-Protein
-	I-Protein
1	I-Protein
)	O
is	O
a	O
large	O
GTPase	O
,	O
similar	O
in	O
structure	O
to	O
the	O
dynamins	O
.	O

Like	O
many	O
smaller	O
GTPases	O
of	O
the	O
Ras	O
/	O
Rab	O
family	O
,	O
it	O
is	O
farnesylated	O
,	O
suggesting	O
it	O
may	O
dock	O
into	O
membranes	O
and	O
perhaps	O
play	O
a	O
role	O
in	O
intracellular	O
trafficking	O
.	O

To	O
date	O
,	O
however	O
,	O
hGBP	B-Protein
-	I-Protein
1	I-Protein
has	O
never	O
been	O
associated	O
with	O
a	O
specific	O
intracellular	O
compartment	O
.	O

Here	O
we	O
present	O
evidence	O
that	O
hGBP	B-Protein
-	I-Protein
1	I-Protein
can	O
associate	O
with	O
the	O
Golgi	O
apparatus	O
.	O

Redistribution	O
from	O
the	O
cytosol	O
to	O
the	O
Golgi	O
was	O
observed	O
by	O
immunofluorescence	O
and	O
subcellular	O
fractionation	O
after	O
aluminum	O
fluoride	O
treatment	O
,	O
suggesting	O
that	O
it	O
occurs	O
when	O
hGBP	B-Protein
-	I-Protein
1	I-Protein
is	O
in	O
its	O
GTP	O
-	O
bound	O
state	O
.	O

Relocalization	O
was	O
blocked	O
by	O
a	O
farnesyl	O
transferase	O
inhibitor	O
.	O

The	O
C589S	O
mutant	O
of	O
hGBP	B-Protein
-	I-Protein
1	I-Protein
,	O
which	O
cannot	O
be	O
farnesylated	O
,	O
and	O
the	O
previously	O
uncharacterized	O
R48P	O
mutant	O
,	O
which	O
cannot	O
bind	O
GTP	O
,	O
both	O
failed	O
to	O
localize	O
to	O
the	O
Golgi	O
.	O

These	O
two	O
mutants	O
had	O
a	O
dominant	O
-	O
negative	O
effect	O
,	O
preventing	O
endogenous	O
wild	O
-	O
type	O
hGBP	B-Protein
-	I-Protein
1	I-Protein
from	O
efficiently	O
redistributing	O
after	O
aluminum	O
fluoride	O
treatment	O
.	O

Furthermore	O
,	O
hGBP	B-Protein
-	I-Protein
1	I-Protein
requires	O
another	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
-	O
induced	O
factor	O
to	O
be	O
targeted	O
to	O
the	O
Golgi	O
,	O
because	O
constitutively	O
expressed	O
hGBP	B-Protein
-	I-Protein
1	I-Protein
remained	O
cytosolic	O
in	O
cells	O
treated	O
with	O
aluminum	O
fluoride	O
unless	O
the	O
cells	O
were	O
preincubated	O
with	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
.	O

Finally	O
,	O
two	O
nonhydrolyzing	O
mutants	O
of	O
hGBP	B-Protein
-	I-Protein
1	I-Protein
,	O
corresponding	O
to	O
active	O
mutants	O
of	O
Ras	O
family	O
proteins	O
,	O
failed	O
to	O
constitutively	O
associate	O
with	O
the	O
Golgi	O
;	O
we	O
propose	O
three	O
possible	O
explanations	O
for	O
this	O
surprising	O
result	O
.	O

Pc2	B-Protein
-	O
mediated	O
sumoylation	O
of	O
Smad	B-Protein
-	I-Protein
interacting	I-Protein
protein	I-Protein
1	I-Protein
attenuates	O
transcriptional	O
repression	O
of	O
E	B-Protein
-	I-Protein
cadherin	I-Protein
.	O

Epithelial	O
-	O
mesenchymal	O
transition	O
(	O
EMT	O
)	O
is	O
important	O
in	O
embryonic	O
development	O
and	O
tumorigenesis	O
.	O

Smad	B-Protein
-	I-Protein
interacting	I-Protein
protein	I-Protein
1	I-Protein
(	O
SIP1	B-Protein
)	O
can	O
induce	O
EMT	O
by	O
repressing	O
the	O
transcription	O
of	O
E	B-Protein
-	I-Protein
cadherin	I-Protein
through	O
recruitment	O
of	O
the	O
corepressor	O
C	B-Protein
-	I-Protein
terminal	I-Protein
-	I-Protein
binding	I-Protein
protein	I-Protein
(	O
CtBP	B-Protein
)	O
.	O

How	O
the	O
activity	O
of	O
SIP1	B-Protein
is	O
regulated	O
still	O
remains	O
unclear	O
.	O

Here	O
we	O
show	O
in	O
vivo	O
and	O
in	O
vitro	O
that	O
SIP1	B-Protein
is	O
covalently	O
modified	O
by	O
sumoylation	O
at	O
two	O
conserved	O
sites	O
,	O
Lys391	O
and	O
Lys866	O
.	O

The	O
polycomb	O
protein	O
Pc2	B-Protein
,	O
but	O
not	O
the	O
PIAS	O
(	O
protein	O
inhibitor	O
of	O
activated	O
STAT	O
)	O
family	O
proteins	O
,	O
acts	O
as	O
a	O
Small	O
ubiquitin	O
-	O
like	O
modifier	O
E3	O
ligase	O
for	O
SIP1	B-Protein
.	O

Sumoylation	O
of	O
SIP1	B-Protein
does	O
not	O
affect	O
its	O
subcellular	O
localization	O
,	O
but	O
regulates	O
its	O
transcriptional	O
activity	O
.	O

Compared	O
with	O
the	O
wild	O
-	O
type	O
,	O
a	O
SIP1	B-Protein
sumoylation	O
null	O
mutant	O
shows	O
more	O
potent	O
repression	O
on	O
E	B-Protein
-	I-Protein
cadherin	I-Protein
transcription	O
but	O
similar	O
repression	O
on	O
two	O
transforming	B-Protein
growth	I-Protein
factor	I-Protein
-	I-Protein
beta	I-Protein
-	O
responsive	O
reporter	O
genes	O
and	O
comparable	O
activation	O
on	O
vitamin	B-Protein
D3	I-Protein
receptor	I-Protein
transcription	O
.	O

Coexpression	O
of	O
SIP1	B-Protein
with	O
Pc2	B-Protein
can	O
partially	O
relieve	O
E	B-Protein
-	I-Protein
cadherin	I-Protein
repression	O
by	O
SIP1	B-Protein
.	O

We	O
further	O
show	O
that	O
SIP1	B-Protein
sumoylation	O
disrupts	O
the	O
recruitment	O
of	O
CtBP	B-Protein
.	O

Thus	O
SIP1	B-Protein
sumoylation	O
regulates	O
its	O
transcriptional	O
activity	O
in	O
a	O
promoter	O
context	O
-	O
dependent	O
manner	O
and	O
may	O
represent	O
an	O
important	O
intervention	O
target	O
to	O
modulate	O
EMT	O
in	O
tumorigenesis	O
.	O

Regulation	O
of	O
MEF2	B-Protein
by	O
histone	B-Protein
deacetylase	I-Protein
4	I-Protein
-	O
and	O
SIRT1	B-Protein
deacetylase	O
-	O
mediated	O
lysine	O
modifications	O
.	O

The	O
class	O
II	O
deacetylase	O
histone	B-Protein
deacetylase	I-Protein
4	I-Protein
(	O
HDAC4	B-Protein
)	O
negatively	O
regulates	O
the	O
transcription	O
factor	O
MEF2	B-Protein
.	O

HDAC4	B-Protein
is	O
believed	O
to	O
repress	O
MEF2	B-Protein
transcriptional	O
activity	O
by	O
binding	O
to	O
MEF2	B-Protein
and	O
catalyzing	O
local	O
histone	B-Protein
deacetylation	O
.	O

Here	O
we	O
report	O
that	O
HDAC4	B-Protein
also	O
controls	O
MEF2	B-Protein
by	O
a	O
novel	O
SUMO	O
E3	O
ligase	O
activity	O
.	O

We	O
show	O
that	O
HDAC4	B-Protein
interacts	O
with	O
the	O
SUMO	O
E2	O
conjugating	O
enzyme	O
Ubc9	B-Protein
and	O
is	O
itself	O
sumoylated	O
.	O

The	O
overexpression	O
of	O
HDAC4	B-Protein
leads	O
to	O
prominent	O
MEF2	B-Protein
sumoylation	O
in	O
vivo	O
,	O
whereas	O
recombinant	O
HDAC4	B-Protein
stimulates	O
MEF2	B-Protein
sumoylation	O
in	O
a	O
reconstituted	O
system	O
in	O
vitro	O
.	O

Importantly	O
,	O
HDAC4	B-Protein
promotes	O
sumoylation	O
on	O
a	O
lysine	O
residue	O
that	O
is	O
also	O
subject	O
to	O
acetylation	O
by	O
a	O
MEF2	B-Protein
coactivator	O
,	O
the	O
acetyltransferase	O
CBP	B-Protein
,	O
suggesting	O
a	O
possible	O
interplay	O
between	O
acetylation	O
and	O
sumoylation	O
in	O
regulating	O
MEF2	B-Protein
activity	O
.	O

Indeed	O
,	O
MEF2	B-Protein
acetylation	O
is	O
correlated	O
with	O
MEF2	B-Protein
activation	O
and	O
dynamically	O
induced	O
upon	O
muscle	O
cell	O
differentiation	O
,	O
while	O
sumoylation	O
inhibits	O
MEF2	B-Protein
transcriptional	O
activity	O
.	O

Unexpectedly	O
,	O
we	O
found	O
that	O
HDAC4	B-Protein
does	O
not	O
function	O
as	O
a	O
MEF2	B-Protein
deacetylase	O
.	O

Instead	O
,	O
the	O
NAD	O
+	O
-	O
dependent	O
deacetylase	O
SIRT1	B-Protein
can	O
potently	O
induce	O
MEF2	B-Protein
deacetylation	O
.	O

Our	O
studies	O
reveal	O
a	O
novel	O
regulation	O
of	O
MEF2	B-Protein
transcriptional	O
activity	O
by	O
two	O
distinct	O
classes	O
of	O
deacetylases	O
that	O
affect	O
MEF2	B-Protein
sumoylation	O
and	O
acetylation	O
.	O

Different	O
transition	O
-	O
state	O
structures	O
for	O
the	O
reactions	O
of	O
beta	O
-	O
lactams	O
and	O
analogous	O
beta	O
-	O
sultams	O
with	O
serine	O
beta	O
-	O
lactamases	O
.	O

Beta	O
-	O
sultams	O
are	O
the	O
sulfonyl	O
analogues	O
of	O
beta	O
-	O
lactams	O
,	O
and	O
N	O
-	O
acyl	O
beta	O
-	O
sultams	O
are	O
novel	O
inactivators	O
of	O
the	O
class	O
C	O
beta	O
-	O
lactamase	O
of	O
Enterobacter	O
cloacae	O
P99	O
.	O

They	O
sulfonylate	O
the	O
active	O
site	O
serine	O
residue	O
to	O
form	O
a	O
sulfonate	O
ester	O
which	O
subsequently	O
undergoes	O
C	O
-	O
O	O
bond	O
fission	O
and	O
formation	O
of	O
a	O
dehydroalanine	O
residue	O
by	O
elimination	O
of	O
the	O
sulfonate	O
anion	O
as	O
shown	O
by	O
electrospray	O
ionization	O
mass	O
spectroscopy	O
.	O

The	O
analogous	O
N	O
-	O
acyl	O
beta	O
-	O
lactams	O
are	O
substrates	O
for	O
beta	O
-	O
lactamase	O
and	O
undergo	O
enzyme	O
-	O
catalyzed	O
hydrolysis	O
presumably	O
by	O
the	O
normal	O
acylation	O
-	O
deacylation	O
process	O
.	O

The	O
rates	O
of	O
acylation	O
of	O
the	O
enzyme	O
by	O
the	O
beta	O
-	O
lactams	O
,	O
measured	O
by	O
the	O
second	O
-	O
order	O
rate	O
constant	O
for	O
hydrolysis	O
,	O
kcat	O
/	O
K	O
(	O
m	O
)	O
,	O
and	O
those	O
of	O
sulfonylation	O
by	O
the	O
beta	O
-	O
sultams	O
,	O
measured	O
by	O
the	O
second	O
-	O
order	O
rate	O
constant	O
for	O
inactivation	O
,	O
k	O
(	O
i	O
)	O
,	O
both	O
show	O
a	O
similar	O
pH	O
dependence	O
to	O
that	O
exhibited	O
by	O
the	O
beta	O
-	O
lactamase	O
-	O
catalyzed	O
hydrolysis	O
of	O
beta	O
-	O
lactam	O
antibiotics	O
.	O

Electron	O
-	O
withdrawing	O
groups	O
in	O
the	O
aryl	O
residue	O
of	O
the	O
leaving	O
group	O
of	O
N	O
-	O
aroyl	O
beta	O
-	O
lactams	O
increase	O
the	O
rate	O
of	O
alkaline	O
hydrolysis	O
and	O
give	O
a	O
Bronsted	O
beta	O
(	O
lg	O
)	O
of	O
-	O
0	O
.	O
55	O
,	O
indicative	O
of	O
a	O
late	O
transition	O
state	O
for	O
rate	O
-	O
limiting	O
formation	O
of	O
the	O
tetrahedral	O
intermediate	O
.	O

Interestingly	O
,	O
the	O
corresponding	O
Bronsted	O
beta	O
(	O
lg	O
)	O
for	O
the	O
beta	O
-	O
lactamase	O
-	O
catalyzed	O
hydrolysis	O
of	O
the	O
same	O
substrates	O
is	O
-	O
0	O
.	O
06	O
,	O
indicative	O
of	O
an	O
earlier	O
transition	O
state	O
for	O
the	O
enzyme	O
-	O
catalyzed	O
reaction	O
.	O

By	O
contrast	O
,	O
although	O
the	O
Bronsted	O
beta	O
(	O
lg	O
)	O
for	O
the	O
alkaline	O
hydrolysis	O
of	O
N	O
-	O
aroyl	O
beta	O
-	O
sultams	O
is	O
-	O
0	O
.	O
73	O
,	O
similar	O
to	O
that	O
for	O
the	O
beta	O
-	O
lactams	O
,	O
that	O
for	O
the	O
sulfonylation	O
of	O
beta	O
-	O
lactamase	O
by	O
these	O
compounds	O
is	O
-	O
1	O
.	O
46	O
,	O
compatible	O
with	O
significant	O
amide	O
anion	O
expulsion	O
/	O
S	O
-	O
N	O
fission	O
in	O
the	O
transition	O
state	O
.	O

In	O
this	O
case	O
,	O
the	O
enzyme	O
reaction	O
displays	O
a	O
later	O
transition	O
state	O
compared	O
with	O
hydroxide	O
-	O
ion	O
-	O
catalyzed	O
hydrolysis	O
of	O
the	O
beta	O
-	O
sultam	O
.	O

Atorvastatin	O
desensitizes	O
beta	O
-	O
adrenergic	O
signaling	O
in	O
cardiac	O
myocytes	O
via	O
reduced	O
isoprenylation	O
of	O
G	O
-	O
protein	O
gamma	O
-	O
subunits	O
.	O

Statins	O
exert	O
pleiotropic	O
,	O
cholesterol	O
-	O
independent	O
effects	O
by	O
reducing	O
isoprenylation	O
of	O
monomeric	O
GTPases	O
.	O

Here	O
we	O
examined	O
whether	O
statins	O
also	O
reduce	O
isoprenylation	O
of	O
gamma	O
-	O
subunits	O
of	O
heterotrimeric	O
G	O
-	O
proteins	O
and	O
thereby	O
affect	O
beta	O
-	O
adrenergic	O
signaling	O
and	O
regulation	O
of	O
force	O
in	O
cardiac	O
myocytes	O
.	O

Neonatal	O
rat	O
cardiac	O
myocytes	O
(	O
NRCM	O
)	O
were	O
treated	O
with	O
atorvastatin	O
(	O
0	O
.	O
1	O
-	O
10	O
micromol	O
/	O
l	O
;	O
12	O
-	O
48	O
h	O
)	O
and	O
examined	O
for	O
adenylyl	O
cyclase	O
regulating	O
G	O
-	O
protein	O
alpha	O
-	O
(	O
Galpha	O
)	O
,	O
beta	O
-	O
(	O
Gbeta	O
)	O
,	O
and	O
gamma	O
-	O
(	O
Ggamma	O
)	O
subunits	O
and	O
cAMP	O
accumulation	O
.	O

Engineered	O
heart	O
tissue	O
(	O
EHT	O
)	O
from	O
NRCM	O
was	O
used	O
to	O
evaluate	O
contractile	O
consequences	O
.	O

In	O
atorvastatin	O
-	O
treated	O
NRCM	O
,	O
a	O
second	O
band	O
of	O
Ggamma3	B-Protein
with	O
a	O
lower	O
apparent	O
molecular	O
weight	O
appeared	O
in	O
cytosol	O
and	O
particulate	O
fractions	O
that	O
was	O
absent	O
in	O
vehicle	O
-	O
treated	O
NRCM	O
,	O
but	O
also	O
seen	O
after	O
GGTI	O
-	O
298	O
,	O
a	O
geranylgeranyl	O
transferase	O
inhibitor	O
.	O

In	O
parallel	O
,	O
Gbeta	O
accumulated	O
in	O
the	O
cytosol	O
and	O
total	O
cellular	O
content	O
of	O
Galphas	O
was	O
reduced	O
.	O

In	O
atorvastatin	O
-	O
treated	O
NRCM	O
,	O
the	O
cAMP	O
-	O
increasing	O
effect	O
of	O
isoprenaline	O
was	O
reduced	O
.	O

Likewise	O
,	O
the	O
positive	O
inotropic	O
effect	O
of	O
isoprenaline	O
was	O
desensitized	O
and	O
reduced	O
after	O
treatment	O
with	O
atorvastatin	O
.	O

The	O
effects	O
of	O
atorvastatin	O
were	O
abolished	O
by	O
mevalonate	O
and	O
/	O
or	O
geranylgeranyl	O
pyrophosphate	O
,	O
but	O
not	O
by	O
farnesyl	O
pyrophosphate	O
or	O
squalene	O
.	O

Taken	O
together	O
,	O
the	O
results	O
of	O
this	O
study	O
show	O
that	O
atorvastatin	O
desensitizes	O
NRCM	O
to	O
beta	O
-	O
adrenergic	O
stimulation	O
by	O
a	O
mechanism	O
that	O
involves	O
reduced	O
isoprenylation	O
of	O
Ggamma	O
and	O
subsequent	O
reductions	O
in	O
the	O
cellular	O
content	O
of	O
Galphas	O
.	O

The	O
proprotein	O
convertase	O
(	O
PC	O
)	O
PCSK9	B-Protein
is	O
inactivated	O
by	O
furin	B-Protein
and	O
/	O
or	O
PC5	B-Protein
/	O
6A	B-Protein
:	O
functional	O
consequences	O
of	O
natural	O
mutations	O
and	O
post	O
-	O
translational	O
modifications	O
.	O

PCSK9	B-Protein
is	O
the	O
ninth	O
member	O
of	O
the	O
proprotein	O
convertase	O
(	O
PC	O
)	O
family	O
.	O

Some	O
of	O
its	O
natural	O
mutations	O
have	O
been	O
genetically	O
associated	O
with	O
the	O
development	O
of	O
a	O
dominant	O
form	O
of	O
familial	O
hyper	O
-	O
or	O
hypocholesterolemia	O
.	O

The	O
exact	O
mechanism	O
of	O
action	O
of	O
PCSK9	B-Protein
is	O
not	O
clear	O
,	O
although	O
it	O
is	O
known	O
to	O
enhance	O
the	O
intracellular	O
degradation	O
of	O
the	O
low	B-Protein
density	I-Protein
lipoprotein	I-Protein
(	I-Protein
LDL	I-Protein
)	I-Protein
receptor	I-Protein
in	O
acidic	O
compartments	O
,	O
likely	O
the	O
endosomes	O
/	O
lysosomes	O
.	O

We	O
analyzed	O
the	O
post	O
-	O
translational	O
modifications	O
of	O
PCSK9	B-Protein
and	O
show	O
that	O
it	O
is	O
sulfated	O
within	O
its	O
prosegment	O
at	O
Tyr38	O
.	O

We	O
also	O
examined	O
the	O
susceptibility	O
of	O
PCSK9	B-Protein
to	O
proteolytic	O
cleavage	O
by	O
the	O
other	O
members	O
of	O
the	O
PC	O
family	O
.	O

The	O
data	O
show	O
that	O
the	O
natural	O
gain	O
-	O
of	O
-	O
function	O
mutations	O
R218S	O
,	O
F216L	O
,	O
and	O
D374Y	O
associated	O
with	O
hypercholesterolemia	O
result	O
in	O
total	O
or	O
partial	O
loss	O
of	O
furin	B-Protein
/	O
PC5	B-Protein
/	O
6A	B-Protein
processing	O
at	O
the	O
motif	O
RFHR218	O
downward	O
arrow	O
.	O

In	O
contrast	O
,	O
the	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
A443T	O
and	O
C679X	O
lead	O
either	O
to	O
the	O
lack	O
of	O
trans	O
-	O
Golgi	O
network	O
/	O
recycling	O
endosome	O
localization	O
and	O
an	O
enhanced	O
susceptibility	O
to	O
furin	B-Protein
cleavage	O
(	O
A443T	O
)	O
or	O
to	O
the	O
inability	O
of	O
PCSK9	B-Protein
to	O
exit	O
the	O
endoplasmic	O
reticulum	O
(	O
C679X	O
)	O
.	O

Furthermore	O
,	O
we	O
report	O
the	O
presence	O
of	O
both	O
native	O
and	O
furin	B-Protein
-	O
like	O
cleaved	O
forms	O
of	O
PCSK9	B-Protein
in	O
circulating	O
human	O
plasma	O
.	O

Thus	O
,	O
we	O
propose	O
that	O
PCSK9	B-Protein
levels	O
are	O
finely	O
regulated	O
by	O
the	O
basic	O
amino	O
acid	O
convertases	O
furin	B-Protein
and	O
PC5	B-Protein
/	O
6A	O
.	O

The	O
latter	O
may	O
reduce	O
the	O
lifetime	O
of	O
this	O
proteinase	O
and	O
its	O
ability	O
to	O
degrade	O
the	O
cell	O
-	O
surface	O
LDL	B-Protein
receptor	I-Protein
,	O
thereby	O
regulating	O
the	O
levels	O
of	O
circulating	O
LDL	O
cholesterol	O
.	O

Identification	O
by	O
functional	O
proteomics	O
of	O
a	O
deubiquitinating	O
/	O
deNeddylating	O
enzyme	O
in	O
Plasmodium	O
falciparum	O
.	O

Ubiquitination	O
is	O
a	O
post	O
-	O
translational	O
modification	O
implicated	O
in	O
a	O
variety	O
of	O
cellular	O
functions	O
,	O
including	O
transcriptional	O
regulation	O
,	O
protein	O
degradation	O
and	O
membrane	O
protein	O
trafficking	O
.	O

Ubiquitin	B-Protein
and	O
the	O
enzymes	O
that	O
act	O
on	O
it	O
,	O
although	O
conserved	O
and	O
essential	O
in	O
eukaryotes	O
,	O
have	O
not	O
been	O
well	O
studied	O
in	O
parasites	O
,	O
despite	O
sequencing	O
of	O
several	O
parasite	O
genomes	O
.	O

Several	O
putative	O
ubiquitin	B-Protein
hydrolases	O
have	O
been	O
identified	O
in	O
Plasmodium	O
falciparum	O
based	O
on	O
sequence	O
homology	O
alone	O
,	O
with	O
no	O
evidence	O
of	O
expression	O
or	O
function	O
.	O

Here	O
we	O
identify	O
the	O
first	O
deubiquitinating	O
enzyme	O
in	O
P	O
.	O
falciparum	O
,	O
PfUCH54	B-Protein
,	O
by	O
its	O
activity	O
.	O

We	O
show	O
that	O
PfUCH54	B-Protein
also	O
has	O
deNeddylating	O
activity	O
,	O
as	O
assayed	O
by	O
a	O
mammalian	O
Nedd8	B-Protein
-	O
based	O
probe	O
.	O

This	O
activity	O
is	O
absent	O
from	O
mammalian	O
homologues	O
of	O
PfUCH54	B-Protein
.	O

Given	O
the	O
importance	O
of	O
parasitic	O
membrane	O
protein	O
trafficking	O
as	O
well	O
as	O
protein	O
degradation	O
in	O
the	O
virulence	O
of	O
this	O
parasite	O
,	O
this	O
family	O
of	O
enzymes	O
may	O
represent	O
a	O
target	O
for	O
pharmacological	O
intervention	O
with	O
this	O
disease	O
.	O

Ubiquitin	B-Protein
and	O
ubiquitin	B-Protein
-	O
like	O
modifications	O
of	O
the	O
p53	B-Protein
family	O
.	O

Regulation	O
of	O
p53	B-Protein
by	O
the	O
ubiquitin	B-Protein
-	O
proteasomal	O
pathway	O
has	O
been	O
studied	O
considerably	O
.	O

Studies	O
have	O
also	O
demonstrated	O
that	O
the	O
ubiquitin	B-Protein
-	O
like	O
proteins	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
and	O
NEDD8	B-Protein
modify	O
p53	B-Protein
.	O

Similarly	O
,	O
p63	B-Protein
and	O
p73	B-Protein
are	O
subject	O
to	O
regulation	O
by	O
ubiquitin	B-Protein
and	O
ubiquitin	B-Protein
-	O
like	O
modifications	O
,	O
and	O
perturbations	O
of	O
these	O
pathways	O
in	O
the	O
regulation	O
of	O
the	O
p53	B-Protein
family	O
have	O
been	O
implicated	O
in	O
tumorigenesis	O
and	O
developmental	O
abnormalities	O
.	O

Here	O
,	O
we	O
provide	O
an	O
overview	O
of	O
the	O
current	O
understanding	O
of	O
the	O
regulation	O
of	O
the	O
p53	B-Protein
family	O
by	O
covalent	O
modification	O
by	O
ubiquitin	B-Protein
,	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
,	O
and	O
NEDD8	B-Protein
.	O

Transport	O
and	O
assembly	O
of	O
gag	B-Protein
proteins	O
into	O
Moloney	O
murine	O
leukemia	O
virus	O
.	O

We	O
have	O
studied	O
the	O
process	O
of	O
Moloney	O
murine	O
leukemia	O
virus	O
(	O
M	O
-	O
MuLV	O
)	O
assembly	O
by	O
characterization	O
of	O
core	O
(	O
gag	B-Protein
)	O
protein	O
mutants	O
and	O
analysis	O
of	O
wild	O
-	O
type	O
(	O
wt	O
)	O
gag	B-Protein
proteins	O
produced	O
by	O
cells	O
in	O
the	O
presence	O
of	O
the	O
ionophore	O
monensin	O
.	O

Our	O
genetic	O
studies	O
involved	O
examination	O
of	O
linker	O
insertion	O
mutants	O
of	O
a	O
Gag	B-Protein
-	O
beta	B-Protein
-	I-Protein
galactosidase	I-Protein
(	O
Gag	B-Protein
-	I-Protein
beta	I-Protein
-	I-Protein
gal	I-Protein
)	O
fusion	O
protein	O
,	O
GBG2051	O
,	O
which	O
is	O
incorporated	O
into	O
virus	O
particles	O
when	O
expressed	O
in	O
the	O
presence	O
of	O
wt	O
viral	O
proteins	O
.	O

Analysis	O
indicated	O
that	O
the	O
amino	O
-	O
terminal	O
two	O
-	O
thirds	O
of	O
the	O
gag	B-Protein
matrix	O
domain	O
is	O
essential	O
for	O
targeting	O
of	O
proteins	O
to	O
the	O
plasma	O
membrane	O
;	O
mutant	O
proteins	O
localized	O
to	O
the	O
cytoplasm	O
or	O
were	O
trapped	O
on	O
intracellular	O
membranes	O
.	O

Mutations	O
through	O
most	O
of	O
the	O
coding	O
region	O
of	O
the	O
gag	B-Protein
capsid	O
domain	O
generated	O
proteins	O
which	O
were	O
released	O
from	O
cells	O
in	O
membrane	O
vesicles	O
but	O
not	O
in	O
virions	O
.	O

In	O
contrast	O
,	O
linker	O
insertions	O
into	O
p12gag	B-Protein
or	O
carboxy	O
-	O
terminal	O
portions	O
of	O
the	O
matrix	O
or	O
capsid	O
coding	O
regions	O
did	O
not	O
affect	O
assembly	O
of	O
fusion	O
proteins	O
into	O
virus	O
particles	O
.	O

Monensin	O
,	O
which	O
blocks	O
vesicular	O
transport	O
,	O
inhibited	O
gag	B-Protein
protein	O
intracellular	O
transport	O
and	O
release	O
from	O
cells	O
.	O

Our	O
results	O
suggest	O
that	O
a	O
significant	O
proportion	O
of	O
M	O
-	O
MuLV	O
myristylated	O
gag	B-Protein
proteins	O
travel	O
via	O
vesicles	O
to	O
the	O
cell	O
surface	O
.	O

Specific	O
matrix	O
protein	O
polypeptide	O
regions	O
and	O
myristic	O
acid	O
modification	O
are	O
both	O
necessary	O
for	O
appropriate	O
gag	B-Protein
protein	O
transport	O
,	O
while	O
capsid	O
protein	O
interactions	O
appear	O
to	O
mediate	O
the	O
final	O
phase	O
of	O
virion	O
formation	O
.	O

Endothelial	O
cell	O
response	O
to	O
lactate	O
:	O
implication	O
of	O
PAR	O
modification	O
of	O
VEGF	O
.	O

Angiogenesis	O
,	O
the	O
process	O
of	O
formation	O
of	O
new	O
blood	O
vessels	O
from	O
pre	O
-	O
existing	O
one	O
,	O
occurs	O
in	O
many	O
physiological	O
and	O
pathological	O
conditions	O
,	O
most	O
of	O
which	O
are	O
underlined	O
by	O
hypoxia	O
and	O
resultant	O
accumulation	O
of	O
lactate	O
.	O

Although	O
lactate	O
is	O
known	O
to	O
induce	O
angiogenesis	O
,	O
the	O
mechanism	O
of	O
its	O
action	O
on	O
endothelial	O
cells	O
(	O
ECs	O
)	O
is	O
not	O
known	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
examine	O
the	O
response	O
of	O
ECs	O
to	O
lactate	O
.	O

Morphological	O
analysis	O
revealed	O
that	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
in	O
culture	O
respond	O
to	O
lactate	O
by	O
switching	O
over	O
to	O
angiogenic	O
phenotype	O
concomitant	O
with	O
upregulation	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
and	O
vascular	B-Protein
endothelial	I-Protein
growth	I-Protein
factor	I-Protein
receptor	I-Protein
-	I-Protein
2	I-Protein
(	O
VEGFR2	B-Protein
)	O
as	O
determined	O
by	O
reverse	O
transcription	O
-	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
.	O

Apart	O
from	O
increase	O
in	O
the	O
levels	O
of	O
VEGF	O
protein	O
as	O
determined	O
by	O
ELISA	O
,	O
chorio	O
allantoic	O
membrane	O
(	O
CAM	O
)	O
assay	O
using	O
the	O
cell	O
extracts	O
revealed	O
that	O
lactate	O
also	O
increased	O
the	O
angiogenic	O
potency	O
of	O
VEGF	O
.	O

Isolated	O
VEGF	O
,	O
when	O
blotted	O
and	O
subsequently	O
probed	O
with	O
anti	O
-	O
PAR	O
antibody	O
,	O
revealed	O
considerable	O
reduction	O
in	O
poly	O
-	O
adenosyl	O
ribosylation	O
of	O
VEGF	O
associated	O
with	O
a	O
significant	O
decrease	O
in	O
the	O
levels	O
of	O
NAD	O
(	O
+	O
)	O
,	O
in	O
presence	O
of	O
lactate	O
.	O

Thus	O
it	O
appears	O
that	O
ECs	O
respond	O
to	O
lactate	O
by	O
increasing	O
the	O
production	O
of	O
VEGF	O
and	O
modulating	O
its	O
angiogenic	O
potency	O
through	O
poly	O
-	O
ADP	O
ribosylation	O
(	O
PAR	O
)	O
-	O
dependent	O
mechanism	O
and	O
thereby	O
switch	O
over	O
to	O
angiogenic	O
phenotype	O
.	O

Tyrosine	O
sulfation	O
of	O
statherin	B-Protein
.	O

Tyrosylprotein	O
sulfotransferase	O
(	O
TPST	O
)	O
,	O
responsible	O
for	O
the	O
sulfation	O
of	O
a	O
variety	O
of	O
secretory	O
and	O
membrane	O
proteins	O
,	O
has	O
been	O
identified	O
and	O
characterized	O
in	O
submandibular	O
salivary	O
glands	O
(	O
William	O
et	O
al	O
.	O
Arch	O
Biochem	O
Biophys	O
1997	O
;	O
338	O
:	O
90	O
-	O
96	O
)	O
.	O

In	O
the	O
present	O
study	O
we	O
demonstrate	O
the	O
sulfation	O
of	O
a	O
salivary	O
secretory	O
protein	O
,	O
statherin	B-Protein
,	O
by	O
the	O
tyrosylprotein	O
sulfotransferase	O
present	O
in	O
human	O
saliva	O
.	O

Optimum	O
statherin	B-Protein
sulfation	O
was	O
observed	O
at	O
pH	O
6	O
.	O
5	O
and	O
at	O
20	O
mm	O
MnCl	O
(	O
2	O
)	O
.	O

Increase	O
in	O
the	O
level	O
of	O
total	O
sulfation	O
was	O
observed	O
with	O
increasing	O
statherin	B-Protein
concentration	O
.	O

The	O
K	O
(	O
m	O
)	O
value	O
of	O
tyrosylprotein	O
sulfotransferase	O
for	O
statherin	B-Protein
was	O
40	O
microM	O
.	O

Analysis	O
of	O
the	O
sulfated	O
statherin	B-Protein
product	O
on	O
SDS	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
followed	O
by	O
autoradiography	O
revealed	O
(	O
35	O
)	O
S	O
-	O
labelling	O
of	O
a	O
5	O
kDa	O
statherin	B-Protein
.	O

Further	O
analysis	O
of	O
the	O
sulfated	O
statherin	B-Protein
revealed	O
the	O
sulfation	O
on	O
tyrosyl	O
residue	O
.	O

This	O
study	O
is	O
the	O
first	O
report	O
demonstrating	O
tyrosine	O
sulfation	O
of	O
a	O
salivary	O
secretory	O
protein	O
.	O

The	O
implications	O
of	O
this	O
sulfation	O
of	O
statherin	B-Protein
in	O
hydroxyapatite	O
binding	O
and	O
Actinomyces	O
viscosus	O
interactions	O
are	O
discussed	O
.	O

Substrate	O
-	O
mediated	O
regulation	O
of	O
cullin	O
neddylation	O
.	O

Cullin	O
-	O
based	O
E3	O
ligases	O
are	O
a	O
large	O
family	O
of	O
multi	O
-	O
subunit	O
ubiquitin	B-Protein
ligases	O
with	O
diverse	O
cellular	O
functions	O
,	O
including	O
the	O
regulation	O
of	O
the	O
cell	O
cycle	O
,	O
of	O
the	O
DNA	O
damage	O
response	O
,	O
and	O
of	O
various	O
transcription	O
factors	O
.	O

These	O
ligases	O
are	O
composed	O
of	O
one	O
of	O
six	O
mammalian	O
cullin	O
homologs	O
(	O
Cul1	B-Protein
,	O
Cul2	B-Protein
,	O
Cul3	B-Protein
,	O
Cul4a	B-Protein
,	O
Cul4b	B-Protein
,	O
and	O
Cul5	B-Protein
)	O
,	O
the	O
Ring	O
finger	O
containing	O
protein	O
Roc1	B-Protein
/	O
Rbx1	B-Protein
,	O
and	O
cullin	O
homolog	O
-	O
specific	O
adaptor	O
and	O
substrate	O
recognition	O
subunits	O
.	O

To	O
be	O
active	O
,	O
cullin	O
-	O
based	O
ligases	O
require	O
the	O
covalent	O
modification	O
of	O
a	O
conserved	O
lysine	O
residue	O
in	O
the	O
cullin	O
protein	O
with	O
the	O
ubiquitin	B-Protein
-	O
like	O
protein	O
Nedd8	B-Protein
.	O

We	O
show	O
in	O
this	O
study	O
that	O
in	O
intact	O
cells	O
Cul1	B-Protein
neddylation	O
is	O
dependent	O
on	O
binding	O
to	O
adaptor	O
proteins	O
and	O
substrate	O
recognition	O
subunits	O
.	O

Mutant	O
Cul1	B-Protein
that	O
is	O
unable	O
to	O
recruit	O
adaptor	O
and	O
substrate	O
recognition	O
subunits	O
exhibits	O
markedly	O
reduced	O
neddylation	O
,	O
and	O
inhibiting	O
binding	O
of	O
adaptor	O
and	O
substrate	O
recognition	O
subunits	O
to	O
wild	O
type	O
Cul1	B-Protein
reduces	O
Nedd8	B-Protein
modification	O
.	O

This	O
regulatory	O
mechanism	O
also	O
extends	O
to	O
other	O
cullin	O
-	O
based	O
E3	O
ligases	O
,	O
including	O
Cul2	B-Protein
,	O
Cul3	B-Protein
,	O
and	O
Cul4a	B-Protein
.	O

The	O
regulation	O
of	O
cullin	O
neddylation	O
by	O
adaptor	O
proteins	O
and	O
substrate	O
recognition	O
subunits	O
in	O
cells	O
was	O
found	O
to	O
be	O
independent	O
of	O
both	O
CAND1	B-Protein
and	O
the	O
COP9	O
signalosome	O
,	O
two	O
negative	O
regulators	O
of	O
cullin	O
Nedd8	B-Protein
modification	O
.	O

Using	O
hypoxia	B-Protein
-	I-Protein
inducible	I-Protein
factor	I-Protein
-	I-Protein
1alpha	I-Protein
(	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
)	O
,	O
a	O
substrate	O
of	O
the	O
Elongin	B-Protein
B	I-Protein
/	O
C	B-Protein
-	O
Cul2	B-Protein
-	O
VHL	B-Protein
ligase	O
,	O
we	O
demonstrate	O
the	O
critical	O
role	O
of	O
substrate	O
binding	O
to	O
promote	O
Cul2	B-Protein
neddylation	O
in	O
a	O
manner	O
that	O
does	O
not	O
require	O
substrate	O
ubiquitination	O
but	O
may	O
involve	O
a	O
conformational	O
change	O
.	O

These	O
findings	O
suggest	O
a	O
mechanism	O
through	O
which	O
availability	O
of	O
substrate	O
recognition	O
subunits	O
and	O
substrates	O
can	O
regulate	O
the	O
ubiquitin	B-Protein
ligase	O
activity	O
.	O

Pro	O
-	O
oxidant	O
activity	O
of	O
histatin	B-Protein
5	I-Protein
related	O
Cu	O
(	O
II	O
)	O
-	O
model	O
peptide	O
probed	O
by	O
mass	O
spectrometry	O
.	O

Histatin	B-Protein
5	I-Protein
is	O
a	O
cationic	O
salivary	O
peptide	O
with	O
strong	O
candidacidal	O
and	O
bactericidal	O
activity	O
at	O
physiological	O
concentration	O
.	O

In	O
this	O
paper	O
we	O
demonstrate	O
by	O
optical	O
spectroscopy	O
and	O
ESI	O
-	O
IT	O
-	O
MS	O
experiments	O
that	O
a	O
synthetic	O
peptide	O
related	O
to	O
the	O
N	O
-	O
terminus	O
of	O
histatin	B-Protein
5	I-Protein
specifically	O
binds	O
copper	O
ions	O
in	O
vitro	O
and	O
that	O
the	O
complex	O
metal	O
-	O
peptide	O
generates	O
reactive	O
oxygen	O
species	O
at	O
physiological	O
concentration	O
of	O
ascorbate	O
,	O
leading	O
to	O
significant	O
auto	O
-	O
oxidation	O
of	O
the	O
peptide	O
within	O
short	O
reaction	O
time	O
.	O

The	O
oxidative	O
activity	O
of	O
this	O
peptide	O
is	O
associated	O
to	O
the	O
presence	O
of	O
a	O
specific	O
metal	O
binding	O
site	O
present	O
at	O
its	O
N	O
-	O
terminus	O
.	O

The	O
motif	O
is	O
constituted	O
by	O
the	O
amino	O
acid	O
sequence	O
NH	O
(	O
2	O
)	O
-	O
Asp	O
-	O
Ser	O
-	O
His	O
,	O
representing	O
a	O
copper	O
and	O
nickel	O
amino	O
terminal	O
binding	O
site	O
,	O
known	O
as	O
"	O
ATCUN	O
motif	O
"	O
.	O

The	O
results	O
of	O
the	O
study	O
suggest	O
that	O
the	O
production	O
of	O
reactive	O
oxygen	O
species	O
can	O
be	O
an	O
intrinsic	O
property	O
of	O
histatin	B-Protein
5	I-Protein
connected	O
to	O
its	O
ability	O
to	O
bind	O
metals	O
.	O

Roles	O
for	O
negative	O
cell	O
regulator	O
14	B-Protein
-	I-Protein
3	I-Protein
-	I-Protein
3sigma	I-Protein
in	O
control	O
of	O
MDM2	B-Protein
activities	O
.	O

The	O
14	B-Protein
-	I-Protein
3	I-Protein
-	I-Protein
3sigma	I-Protein
,	O
upregulated	O
by	O
p53	B-Protein
in	O
response	O
to	O
DNA	O
damage	O
,	O
can	O
have	O
a	O
positive	O
-	O
feedback	O
impact	O
driving	O
p53	B-Protein
activities	O
and	O
is	O
a	O
human	O
cancer	O
epithelial	O
marker	O
downregulated	O
in	O
various	O
tumors	O
.	O

However	O
,	O
the	O
precise	O
roles	O
of	O
14	B-Protein
-	I-Protein
3	I-Protein
-	I-Protein
3sigma	I-Protein
during	O
tumorigenesis	O
are	O
not	O
well	O
characterized	O
.	O

Here	O
,	O
we	O
show	O
that	O
14	B-Protein
-	I-Protein
3	I-Protein
-	I-Protein
3sigma	I-Protein
is	O
a	O
critical	O
regulator	O
of	O
murine	O
double	O
minute	O
oncogene	O
(	O
MDM2	B-Protein
)	O
.	O

14	B-Protein
-	I-Protein
3	I-Protein
-	I-Protein
3sigma	I-Protein
interacts	O
with	O
MDM2	B-Protein
at	O
the	O
RING	O
domain	O
.	O

The	O
C	O
-	O
terminal	O
region	O
of	O
14	B-Protein
-	I-Protein
3	I-Protein
-	I-Protein
3sigma	I-Protein
binds	O
to	O
MDM2	B-Protein
very	O
efficiently	O
.	O

Importantly	O
,	O
14	B-Protein
-	I-Protein
3	I-Protein
-	I-Protein
3sigma	I-Protein
overexpression	O
leads	O
to	O
destabilization	O
of	O
MDM2	B-Protein
through	O
enhancing	O
MDM2	B-Protein
self	O
-	O
ubiquitination	O
and	O
accelerating	O
turnover	O
rate	O
.	O

Conversely	O
,	O
loss	O
of	O
14	B-Protein
-	I-Protein
3	I-Protein
-	I-Protein
3sigma	I-Protein
results	O
in	O
a	O
significant	O
increase	O
in	O
MDM2	B-Protein
protein	O
.	O

Moreover	O
,	O
live	O
-	O
cell	O
images	O
indicated	O
that	O
14	B-Protein
-	I-Protein
3	I-Protein
-	I-Protein
3sigma	I-Protein
can	O
affect	O
the	O
location	O
of	O
MDM2	B-Protein
from	O
the	O
nucleus	O
to	O
the	O
cytoplasm	O
,	O
and	O
that	O
MDM2	B-Protein
-	O
mediated	O
cytoplasmic	O
localization	O
of	O
p53	B-Protein
can	O
be	O
reversed	O
by	O
the	O
presence	O
of	O
14	B-Protein
-	I-Protein
3	I-Protein
-	I-Protein
3sigma	I-Protein
.	O

Significantly	O
,	O
we	O
further	O
showed	O
that	O
14	B-Protein
-	I-Protein
3	I-Protein
-	I-Protein
3sigma	I-Protein
causes	O
MDM2	B-Protein
downregulation	O
,	O
thereby	O
stabilizing	O
p53	B-Protein
and	O
inhibiting	O
tumor	O
growth	O
in	O
animal	O
tumors	O
.	O

Also	O
,	O
14	B-Protein
-	I-Protein
3	I-Protein
-	I-Protein
3sigma	I-Protein
blocks	O
MDM2	B-Protein
-	O
mediated	O
retinoblastoma	O
degradation	O
and	O
p53	B-Protein
NEDDylation	O
.	O

Our	O
results	O
provide	O
evidence	O
that	O
14	B-Protein
-	I-Protein
3	I-Protein
-	I-Protein
3sigma	I-Protein
is	O
a	O
pivotal	O
MDM2	B-Protein
regulator	O
involved	O
in	O
blocking	O
a	O
variety	O
of	O
activities	O
of	O
MDM2	B-Protein
.	O

Caspase	B-Protein
-	I-Protein
3	I-Protein
cleavage	O
of	O
GGA3	B-Protein
stabilizes	O
BACE	B-Protein
:	O
implications	O
for	O
Alzheimer	O
'	O
s	O
disease	O
.	O

BACE	B-Protein
initiates	O
the	O
production	O
of	O
beta	B-Protein
-	I-Protein
amyloid	I-Protein
(	O
Abeta	B-Protein
)	O
,	O
the	O
likely	O
cause	O
of	O
Alzheimer	O
'	O
s	O
disease	O
(	O
AD	O
)	O
.	O

In	O
this	O
issue	O
of	O
Neuron	O
,	O
Tesco	O
et	O
al	O
.	O
show	O
that	O
during	O
apoptosis	O
caspase	B-Protein
-	I-Protein
3	I-Protein
cleaves	O
the	O
adaptor	O
protein	O
GGA3	B-Protein
,	O
which	O
is	O
required	O
for	O
BACE	B-Protein
lysosomal	O
degradation	O
,	O
consequently	O
stabilizing	O
BACE	B-Protein
and	O
elevating	O
Abeta	B-Protein
generation	O
.	O

N	O
-	O
acylation	O
of	O
Aplysia	O
egg	B-Protein
-	I-Protein
laying	I-Protein
hormone	I-Protein
with	O
biotin	O
.	O

Characterization	O
of	O
bioactive	O
and	O
inactive	O
derivatives	O
.	O

Chemical	O
modification	O
of	O
the	O
egg	B-Protein
-	I-Protein
laying	I-Protein
hormone	I-Protein
(	O
ELH	B-Protein
)	O
of	O
Aplysia	O
by	O
reaction	O
with	O
the	O
N	O
-	O
hydroxysuccinimide	O
ester	O
of	O
biotin	O
,	O
which	O
contained	O
6	O
-	O
aminohexanoic	O
acid	O
as	O
spacer	O
,	O
yielded	O
seven	O
distinct	O
derivatives	O
that	O
were	O
readily	O
separated	O
by	O
reversed	O
-	O
phase	O
high	O
performance	O
liquid	O
chromatography	O
.	O

The	O
derivatives	O
were	O
chemically	O
characterized	O
by	O
amino	O
acid	O
compositional	O
analysis	O
,	O
sequence	O
analysis	O
,	O
and	O
mass	O
spectrometry	O
.	O

The	O
seven	O
derivatives	O
resulted	O
from	O
combinations	O
of	O
differential	O
modification	O
of	O
the	O
three	O
amino	O
groups	O
in	O
the	O
ELH	B-Protein
molecule	O
located	O
at	O
Ile1	O
(	O
alpha	O
-	O
NH2	O
)	O
,	O
Lys8	O
,	O
and	O
Lys36	O
.	O

Of	O
the	O
seven	O
derivatives	O
formed	O
,	O
only	O
one	O
,	O
monobiotinyl	O
Lys36	O
-	O
ELH	B-Protein
,	O
was	O
biologically	O
active	O
in	O
eliciting	O
egg	O
-	O
laying	O
activity	O
and	O
altering	O
the	O
electrophysiological	O
activity	O
of	O
the	O
abdominal	O
ganglion	O
neuron	O
R15	O
and	O
LB	O
and	O
LC	O
cluster	O
neurons	O
.	O

In	O
addition	O
,	O
evaluation	O
of	O
the	O
time	O
course	O
of	O
biotinylation	O
of	O
ELH	B-Protein
revealed	O
that	O
the	O
relative	O
rate	O
of	O
amino	O
group	O
reactivity	O
was	O
epsilon	O
-	O
NH2	O
-	O
Lys36	O
greater	O
than	O
epsilon	O
-	O
NH2	O
-	O
Lys8	O
much	O
greater	O
than	O
alpha	O
-	O
NH2	O
-	O
Ile1	O
.	O

The	O
slow	O
rate	O
of	O
reaction	O
of	O
the	O
terminal	O
alpha	O
-	O
amino	O
group	O
suggested	O
that	O
it	O
was	O
relatively	O
inaccessible	O
to	O
biotinylation	O
,	O
possibly	O
due	O
to	O
conformational	O
factors	O
or	O
to	O
ion	O
-	O
pair	O
formation	O
with	O
an	O
unidentified	O
carboxyl	O
group	O
.	O

Loss	O
of	O
bioactivity	O
of	O
ELH	B-Protein
monobiotinylated	O
on	O
the	O
alpha	O
-	O
amino	O
group	O
,	O
coupled	O
with	O
the	O
unusually	O
low	O
reactivity	O
of	O
the	O
alpha	O
-	O
amino	O
group	O
,	O
provided	O
strong	O
evidence	O
for	O
the	O
importance	O
of	O
the	O
alpha	O
-	O
amino	O
group	O
in	O
ELH	B-Protein
function	O
.	O

Furthermore	O
,	O
the	O
development	O
and	O
availability	O
of	O
a	O
bioactive	O
ELH	B-Protein
probe	O
should	O
greatly	O
facilitate	O
the	O
isolation	O
,	O
characterization	O
,	O
and	O
localization	O
of	O
the	O
ELH	B-Protein
receptor	O
.	O

Identification	O
of	O
differentially	O
expressed	O
genes	O
in	O
human	O
varicose	O
veins	O
:	O
involvement	O
of	O
matrix	B-Protein
gla	I-Protein
protein	I-Protein
in	O
extracellular	O
matrix	O
remodeling	O
.	O

This	O
study	O
was	O
designed	O
to	O
identify	O
the	O
global	O
pattern	O
of	O
differentially	O
expressed	O
genes	O
in	O
human	O
varicose	O
veins	O
.	O

Using	O
suppressive	O
subtractive	O
hybridization	O
,	O
we	O
identified	O
overexpression	O
of	O
genes	O
known	O
to	O
be	O
associated	O
with	O
extracellular	O
matrix	O
remodeling	O
,	O
including	O
collagen	B-Protein
III	I-Protein
,	O
tissue	B-Protein
inhibitor	I-Protein
of	I-Protein
metalloproteinases	I-Protein
I	I-Protein
,	O
dermatopontin	B-Protein
,	O
matrix	B-Protein
Gla	I-Protein
protein	I-Protein
(	O
MGP	B-Protein
)	O
and	O
tenascin	B-Protein
C	I-Protein
.	O

Real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
analysis	O
confirmed	O
the	O
differential	O
expression	O
of	O
these	O
genes	O
.	O

The	O
overexpression	O
of	O
MGP	B-Protein
transcript	O
was	O
associated	O
with	O
increased	O
MGP	B-Protein
level	O
in	O
varicose	O
veins	O
,	O
in	O
particular	O
the	O
undercarboxylated	O
form	O
of	O
the	O
protein	O
.	O

Smooth	O
muscle	O
cells	O
from	O
varicose	O
veins	O
showed	O
increased	O
proliferation	O
rate	O
and	O
enhanced	O
matrix	O
mineralization	O
.	O

This	O
observation	O
correlated	O
with	O
the	O
presence	O
of	O
ectopic	O
mineralization	O
areas	O
in	O
the	O
varicose	O
vein	O
walls	O
.	O

The	O
use	O
of	O
warfarin	O
,	O
to	O
inhibit	O
MGP	B-Protein
activity	O
,	O
or	O
siRNA	O
targeting	O
MGP	B-Protein
transcript	O
induced	O
a	O
reduction	O
in	O
the	O
exacerbated	O
proliferation	O
of	O
varicose	O
vein	O
smooth	O
muscle	O
cells	O
.	O

Our	O
results	O
suggest	O
that	O
high	O
expression	O
of	O
MGP	B-Protein
in	O
varicose	O
veins	O
may	O
contribute	O
to	O
venous	O
wall	O
remodeling	O
by	O
affecting	O
proliferation	O
and	O
mineralization	O
processes	O
probably	O
through	O
impaired	O
carboxylation	O
of	O
MGP	B-Protein
.	O

In	O
addition	O
,	O
suppressive	O
subtractive	O
hybridization	O
results	O
also	O
produce	O
a	O
profile	O
of	O
differentially	O
expressed	O
genes	O
in	O
varicose	O
veins	O
,	O
in	O
particular	O
extracellular	O
matrix	O
components	O
.	O

Further	O
study	O
of	O
these	O
genes	O
will	O
provide	O
insights	O
into	O
their	O
specific	O
roles	O
in	O
the	O
etiology	O
of	O
venous	O
disease	O
.	O

Statins	O
reduce	O
amyloid	B-Protein
-	I-Protein
beta	I-Protein
production	O
through	O
inhibition	O
of	O
protein	O
isoprenylation	O
.	O

Epidemiological	O
evidence	O
suggests	O
that	O
long	O
term	O
treatment	O
with	O
hydroxymethylglutaryl	O
-	O
CoA	O
reductase	O
inhibitors	O
,	O
or	O
statins	O
,	O
decreases	O
the	O
risk	O
for	O
developing	O
Alzheimer	O
disease	O
(	O
AD	O
)	O
.	O

However	O
,	O
statin	O
-	O
mediated	O
AD	O
protection	O
cannot	O
be	O
fully	O
explained	O
by	O
reduction	O
of	O
cholesterol	O
levels	O
.	O

In	O
addition	O
to	O
their	O
cholesterol	O
lowering	O
effects	O
,	O
statins	O
have	O
pleiotropic	O
actions	O
and	O
act	O
to	O
lower	O
the	O
concentrations	O
of	O
isoprenoid	O
intermediates	O
,	O
such	O
as	O
geranylgeranyl	O
pyrophosphate	O
and	O
farnesyl	O
pyrophosphate	O
.	O

The	O
Rho	O
and	O
Rab	O
family	O
small	O
G	O
-	O
proteins	O
require	O
addition	O
of	O
these	O
isoprenyl	O
moieties	O
at	O
their	O
C	O
termini	O
for	O
normal	O
GTPase	O
function	O
.	O

In	O
neuroblastoma	O
cell	O
lines	O
,	O
treatment	O
with	O
statins	O
inhibits	O
the	O
membrane	O
localization	O
of	O
Rho	O
and	O
Rab	O
proteins	O
at	O
statin	O
doses	O
as	O
low	O
as	O
200	O
nm	O
,	O
without	O
affecting	O
cellular	O
cholesterol	O
levels	O
.	O

In	O
addition	O
,	O
we	O
show	O
for	O
the	O
first	O
time	O
that	O
at	O
low	O
,	O
physiologically	O
relevant	O
,	O
doses	O
statins	O
preferentially	O
inhibit	O
the	O
isoprenylation	O
of	O
a	O
subset	O
of	O
GTPases	O
.	O

The	O
amyloid	B-Protein
precursor	I-Protein
protein	I-Protein
(	O
APP	B-Protein
)	O
is	O
proteolytically	O
cleaved	O
to	O
generate	O
beta	B-Protein
-	I-Protein
amyloid	I-Protein
(	O
Abeta	B-Protein
)	O
,	O
which	O
is	O
the	O
major	O
component	O
of	O
senile	O
plaques	O
found	O
in	O
AD	O
.	O

We	O
show	O
that	O
inhibition	O
of	O
protein	O
isoprenylation	O
by	O
statins	O
causes	O
the	O
accumulation	O
of	O
APP	B-Protein
within	O
the	O
cell	O
through	O
inhibition	O
of	O
Rab	O
family	O
proteins	O
involved	O
in	O
vesicular	O
trafficking	O
.	O

Moreover	O
,	O
inhibition	O
of	O
Rho	O
family	O
protein	O
function	O
reduces	O
levels	O
of	O
APP	B-Protein
C	O
-	O
terminal	O
fragments	O
due	O
to	O
enhanced	O
lysosomal	O
dependent	O
degradation	O
.	O

Statin	O
inhibition	O
of	O
protein	O
isoprenylation	O
results	O
in	O
decreased	O
Abeta	B-Protein
secretion	O
.	O

In	O
summary	O
,	O
we	O
show	O
that	O
statins	O
selectively	O
inhibit	O
GTPase	O
isoprenylation	O
at	O
clinically	O
relevant	O
doses	O
,	O
leading	O
to	O
reduced	O
Abeta	B-Protein
production	O
in	O
an	O
isoprenoid	O
-	O
dependent	O
manner	O
.	O

These	O
studies	O
provide	O
insight	O
into	O
the	O
mechanisms	O
by	O
which	O
statins	O
may	O
reduce	O
AD	O
pathogenesis	O
.	O

Mint3	B-Protein
/	O
X11gamma	B-Protein
is	O
an	O
ADP	O
-	O
ribosylation	O
factor	O
-	O
dependent	O
adaptor	O
that	O
regulates	O
the	O
traffic	O
of	O
the	O
Alzheimer	O
'	O
s	O
Precursor	O
protein	O
from	O
the	O
trans	O
-	O
Golgi	O
network	O
.	O

Beta	B-Protein
-	I-Protein
amyloid	I-Protein
peptides	O
(	O
Abeta	B-Protein
)	O
are	O
the	O
major	O
component	O
of	O
plaques	O
in	O
brains	O
of	O
Alzheimer	O
'	O
s	O
patients	O
,	O
and	O
are	O
they	O
derived	O
from	O
the	O
proteolytic	O
processing	O
of	O
the	O
beta	B-Protein
-	I-Protein
amyloid	I-Protein
precursor	I-Protein
protein	I-Protein
(	O
APP	B-Protein
)	O
.	O

The	O
movement	O
of	O
APP	B-Protein
between	O
organelles	O
is	O
highly	O
regulated	O
,	O
and	O
it	O
is	O
tightly	O
connected	O
to	O
its	O
processing	O
by	O
secretases	O
.	O

We	O
proposed	O
previously	O
that	O
transport	O
of	O
APP	B-Protein
within	O
the	O
cell	O
is	O
mediated	O
in	O
part	O
through	O
its	O
sorting	O
into	O
Mint	O
/	O
X11	O
-	O
containing	O
carriers	O
.	O

To	O
test	O
our	O
hypothesis	O
,	O
we	O
purified	O
APP	B-Protein
-	O
containing	O
vesicles	O
from	O
human	O
neuroblastoma	O
SH	O
-	O
SY5Y	O
cells	O
,	O
and	O
we	O
showed	O
that	O
Mint2	B-Protein
/	O
3	B-Protein
are	O
specifically	O
enriched	O
and	O
that	O
Mint3	B-Protein
and	O
APP	B-Protein
are	O
present	O
in	O
the	O
same	O
vesicles	O
.	O

Increasing	O
cellular	O
APP	B-Protein
levels	O
increased	O
the	O
amounts	O
of	O
both	O
APP	B-Protein
and	O
Mint3	B-Protein
in	O
purified	O
vesicles	O
.	O

Additional	O
evidence	O
supporting	O
an	O
obligate	O
role	O
for	O
Mint3	B-Protein
in	O
traffic	O
of	O
APP	B-Protein
from	O
the	O
trans	O
-	O
Golgi	O
network	O
to	O
the	O
plasma	O
membrane	O
include	O
the	O
observations	O
that	O
depletion	O
of	O
Mint3	B-Protein
by	O
small	O
interference	O
RNA	O
(	O
siRNA	O
)	O
or	O
mutation	O
of	O
the	O
Mint	O
binding	O
domain	O
of	O
APP	B-Protein
changes	O
the	O
export	O
route	O
of	O
APP	B-Protein
from	O
the	O
basolateral	O
to	O
the	O
endosomal	O
/	O
lysosomal	O
sorting	O
route	O
.	O

Finally	O
,	O
we	O
show	O
that	O
increased	O
expression	O
of	O
Mint3	B-Protein
decreased	O
and	O
siRNA	O
-	O
mediated	O
knockdowns	O
increased	O
the	O
secretion	O
of	O
the	O
neurotoxic	O
beta	B-Protein
-	I-Protein
amyloid	I-Protein
peptide	O
,	O
Abeta	B-Protein
(	O
1	O
-	O
40	O
)	O
.	O

Together	O
,	O
our	O
data	O
implicate	O
Mint3	B-Protein
activity	O
as	O
a	O
critical	O
determinant	O
of	O
post	O
-	O
Golgi	O
APP	B-Protein
traffic	O
.	O

Fbx8	B-Protein
makes	O
Arf6	B-Protein
refractory	O
to	O
function	O
via	O
ubiquitination	O
.	O

The	O
small	O
GTP	O
-	O
binding	O
protein	O
Arf6	B-Protein
regulates	O
membrane	O
remodeling	O
at	O
cell	O
peripheries	O
and	O
plays	O
crucial	O
roles	O
in	O
higher	O
orders	O
of	O
cellular	O
functions	O
including	O
tumor	O
invasion	O
.	O

Here	O
we	O
show	O
that	O
Fbx8	B-Protein
,	O
an	O
F	O
-	O
box	O
protein	O
bearing	O
the	O
Sec7	O
domain	O
,	O
mediates	O
ubiquitination	O
of	O
Arf6	B-Protein
.	O

This	O
ubiquitination	O
did	O
not	O
appear	O
to	O
be	O
linked	O
to	O
immediate	O
proteasomal	O
degradation	O
of	O
Arf6	B-Protein
,	O
whereas	O
Fbx8	B-Protein
knockdown	O
caused	O
hyperactivation	O
of	O
Arf6	B-Protein
.	O

Expression	O
of	O
Fbx8	B-Protein
protein	O
was	O
substantially	O
lost	O
in	O
several	O
breast	O
tumor	O
cell	O
lines	O
,	O
in	O
which	O
Arf6	B-Protein
activity	O
is	O
pivotal	O
for	O
their	O
invasion	O
.	O

Forced	O
expression	O
of	O
Fbx8	B-Protein
in	O
these	O
cells	O
suppressed	O
their	O
Arf6	B-Protein
activities	O
and	O
invasive	O
activities	O
,	O
in	O
which	O
the	O
F	O
-	O
box	O
and	O
Sec7	O
domains	O
of	O
Fbx8	B-Protein
are	O
required	O
.	O

Together	O
with	O
the	O
possible	O
mechanism	O
as	O
to	O
how	O
Fbx8	B-Protein
-	O
mediated	O
ubiquitination	O
interferes	O
with	O
the	O
functions	O
of	O
Arf6	B-Protein
,	O
we	O
propose	O
that	O
Fbx8	B-Protein
provides	O
a	O
novel	O
suppressive	O
control	O
of	O
Arf6	B-Protein
activity	O
through	O
noncanonical	O
ubiquitination	O
.	O

Our	O
results	O
indicate	O
that	O
dysfunction	O
of	O
Fbx8	B-Protein
expression	O
may	O
contribute	O
to	O
the	O
invasiveness	O
of	O
some	O
breast	O
cancer	O
cells	O
.	O

Acetylation	O
in	O
nuclear	O
receptor	O
signaling	O
and	O
the	O
role	O
of	O
sirtuins	O
.	O

It	O
has	O
been	O
known	O
since	O
the	O
early	O
1970s	O
that	O
nuclear	O
receptor	O
complexes	O
bind	O
DNA	O
in	O
association	O
with	O
coregulatory	O
proteins	O
.	O

Characterization	O
of	O
these	O
nuclear	O
receptor	O
coregulators	O
has	O
revealed	O
diverse	O
enzymatic	O
activities	O
that	O
temporally	O
and	O
spatially	O
coordinate	O
nuclear	O
receptor	O
activity	O
within	O
the	O
context	O
of	O
local	O
chromatin	O
in	O
response	O
to	O
diverse	O
hormone	O
signals	O
.	O

Chromatin	O
-	O
modifying	O
proteins	O
,	O
which	O
dictate	O
the	O
higher	O
-	O
order	O
chromatin	O
structure	O
in	O
which	O
DNA	O
is	O
packaged	O
,	O
in	O
turn	O
orchestrate	O
orderly	O
recruitment	O
of	O
nuclear	O
receptor	O
complexes	O
.	O

Modifications	O
of	O
histones	B-Protein
include	O
acetylation	O
,	O
methylation	O
,	O
phosphorylation	O
,	O
ubiquitylation	O
,	O
sumoylation	O
,	O
ADP	O
ribosylation	O
,	O
deimination	O
,	O
and	O
proline	O
isomerization	O
.	O

At	O
this	O
time	O
,	O
we	O
understand	O
how	O
a	O
subset	O
of	O
these	O
modifications	O
regulates	O
nuclear	O
receptor	O
signaling	O
.	O

However	O
,	O
the	O
effects	O
,	O
particularly	O
of	O
acetylation	O
and	O
demethylation	O
,	O
are	O
profound	O
.	O

The	O
finding	O
that	O
nuclear	O
receptors	O
are	O
directly	O
acetylated	O
and	O
that	O
acetylation	O
in	O
turn	O
directly	O
regulates	O
contact	O
-	O
independent	O
growth	O
has	O
broad	O
therapeutic	O
implications	O
.	O

Studies	O
over	O
the	O
past	O
7	O
yr	O
have	O
led	O
to	O
the	O
understanding	O
that	O
nuclear	O
receptor	O
acetylation	O
is	O
a	O
conserved	O
function	O
,	O
regulating	O
diverse	O
nuclear	O
receptor	O
activity	O
.	O

Furthermore	O
,	O
we	O
now	O
know	O
that	O
acetylation	O
of	O
multiple	O
and	O
distinct	O
substrates	O
within	O
nuclear	O
receptor	O
signaling	O
pathways	O
,	O
form	O
an	O
acetylation	O
signaling	O
network	O
from	O
the	O
cell	O
surface	O
to	O
the	O
nucleus	O
.	O

The	O
finding	O
that	O
nicotinamide	O
adenine	O
dinucleotide	O
(	O
NAD	O
)	O
-	O
dependent	O
histone	B-Protein
deacetylases	O
,	O
the	O
sirtuins	O
,	O
are	O
capable	O
of	O
deacetylating	O
nuclear	O
receptors	O
provides	O
a	O
new	O
level	O
of	O
complexity	O
in	O
the	O
control	O
of	O
nuclear	O
receptor	O
activity	O
in	O
which	O
local	O
intracellular	O
concentrations	O
of	O
NAD	O
may	O
regulate	O
nuclear	O
receptor	O
physiology	O
.	O

Trafficking	O
and	O
postsecretory	O
events	O
responsible	O
for	O
the	O
formation	O
of	O
secreted	O
human	O
salivary	O
peptides	O
:	O
a	O
proteomics	O
approach	O
.	O

To	O
elucidate	O
the	O
localization	O
of	O
post	O
-	O
translational	O
modifications	O
of	O
different	O
classes	O
of	O
human	O
salivary	O
proteins	O
and	O
peptides	O
(	O
acidic	O
and	O
basic	O
proline	O
-	O
rich	O
proteins	O
(	O
PRPs	O
)	O
,	O
Histatins	O
,	O
Statherin	B-Protein
,	O
P	B-Protein
-	I-Protein
B	I-Protein
peptide	O
,	O
and	O
"	O
S	O
type	O
"	O
Cystatins	O
)	O
a	O
comparative	O
reversed	O
phase	O
HPLC	O
-	O
ESI	O
-	O
MS	O
analysis	O
on	O
intact	O
proteins	O
of	O
enriched	O
granule	O
preparations	O
from	O
parotid	O
and	O
submandibular	O
glands	O
as	O
well	O
as	O
parotid	O
,	O
submandibular	O
/	O
sublingual	O
(	O
Sm	O
/	O
Sl	O
)	O
,	O
and	O
whole	O
saliva	O
was	O
performed	O
.	O

The	O
main	O
results	O
of	O
this	O
study	O
indicate	O
the	O
following	O
.	O

(	O
i	O
)	O
Phosphorylation	O
of	O
all	O
salivary	O
peptides	O
,	O
sulfation	O
of	O
Histatin	B-Protein
1	I-Protein
,	O
proteolytic	O
cleavages	O
of	O
acidic	O
and	O
precursor	O
basic	O
PRPs	O
occur	O
before	O
granule	O
storage	O
.	O

(	O
ii	O
)	O
In	O
agreement	O
with	O
previous	O
studies	O
,	O
basic	O
PRPs	O
are	O
secreted	O
by	O
the	O
parotid	O
gland	O
only	O
,	O
whereas	O
all	O
isoforms	O
of	O
acidic	O
PRPs	O
(	O
aPRPs	O
)	O
are	O
secreted	O
by	O
both	O
parotid	O
and	O
Sm	O
/	O
Sl	O
glands	O
.	O

(	O
iii	O
)	O
Phosphorylation	O
levels	O
of	O
aPRPs	O
,	O
Histatin	B-Protein
1	I-Protein
,	O
and	O
Statherin	B-Protein
are	O
higher	O
in	O
the	O
parotid	O
gland	O
,	O
whereas	O
the	O
extent	O
of	O
cleavage	O
of	O
aPRP	O
is	O
higher	O
in	O
Sm	O
/	O
Sl	O
glands	O
.	O

(	O
iv	O
)	O
O	O
-	O
Sulfation	O
of	O
tyrosines	O
of	O
Histatin	B-Protein
1	I-Protein
is	O
a	O
post	O
-	O
translational	O
modification	O
specific	O
for	O
the	O
submandibular	O
gland	O
.	O

(	O
v	O
)	O
The	O
concentration	O
of	O
Histatin	B-Protein
3	I-Protein
,	O
Histatin	B-Protein
5	I-Protein
,	O
and	O
Histatin	B-Protein
6	I-Protein
,	O
but	O
not	O
Histatin	B-Protein
1	I-Protein
,	O
is	O
higher	O
in	O
parotid	O
saliva	O
.	O

(	O
vi	O
)	O
Histatin	B-Protein
3	I-Protein
is	O
submitted	O
to	O
the	O
first	O
proteolytic	O
cleavage	O
(	O
generating	O
Histatins	B-Protein
6	I-Protein
and	O
5	B-Protein
)	O
during	O
granule	O
maturation	O
,	O
and	O
it	O
occurs	O
to	O
the	O
same	O
relative	O
extent	O
in	O
both	O
glands	O
.	O

(	O
vii	O
)	O
The	O
proteolytic	O
cleavages	O
of	O
Histatin	B-Protein
5	I-Protein
and	O
6	B-Protein
,	O
generating	O
a	O
cascade	O
of	O
Histatin	B-Protein
3	I-Protein
fragments	O
,	O
take	O
place	O
after	O
granule	O
secretion	O
and	O
are	O
more	O
extensive	O
in	O
parotid	O
secretion	O
.	O

(	O
viii	O
)	O
Basic	O
PRPs	O
are	O
cleaved	O
in	O
the	O
oral	O
cavity	O
by	O
unknown	O
peptidases	O
,	O
generating	O
various	O
small	O
proline	O
-	O
rich	O
peptides	O
.	O

(	O
ix	O
)	O
C	O
-	O
terminal	O
removal	O
from	O
Statherin	B-Protein
is	O
more	O
extensive	O
in	O
parotid	O
saliva	O
.	O

(	O
x	O
)	O
P	B-Protein
-	I-Protein
B	I-Protein
peptide	O
is	O
secreted	O
by	O
both	O
glands	O
,	O
and	O
its	O
relative	O
quantity	O
is	O
higher	O
in	O
submandibular	O
/	O
sublingual	O
secretion	O
.	O

(	O
xi	O
)	O
In	O
agreement	O
with	O
previous	O
studies	O
,	O
S	O
type	O
Cystatins	O
are	O
mainly	O
the	O
product	O
of	O
Sm	O
/	O
Sl	O
glands	O
.	O

Functional	O
and	O
structural	O
roles	O
of	O
conserved	O
cysteine	O
residues	O
in	O
the	O
carboxyl	O
-	O
terminal	O
domain	O
of	O
the	O
follicle	B-Protein
-	I-Protein
stimulating	I-Protein
hormone	I-Protein
receptor	I-Protein
in	O
human	O
embryonic	O
kidney	O
293	O
cells	O
.	O

The	O
carboxyl	O
-	O
terminal	O
segment	O
of	O
G	O
protein	O
-	O
coupled	O
receptors	O
has	O
one	O
or	O
more	O
conserved	O
cysteine	O
residues	O
that	O
are	O
potential	O
sites	O
for	O
palmitoylation	O
.	O

This	O
posttranslational	O
modification	O
contributes	O
to	O
membrane	O
association	O
,	O
internalization	O
,	O
and	O
membrane	O
targeting	O
of	O
proteins	O
.	O

In	O
contrast	O
to	O
other	O
members	O
of	O
the	O
glycoprotein	O
hormone	O
receptor	O
family	O
(	O
the	O
LH	B-Protein
and	O
thyroid	B-Protein
-	I-Protein
stimulating	I-Protein
hormone	I-Protein
receptors	I-Protein
)	O
,	O
it	O
is	O
not	O
known	O
whether	O
the	O
follicle	B-Protein
-	I-Protein
stimulating	I-Protein
hormone	I-Protein
receptor	I-Protein
(	O
FSHR	B-Protein
)	O
is	O
palmitoylated	O
and	O
what	O
are	O
the	O
effects	O
of	O
abolishing	O
its	O
potential	O
palmitoylation	O
sites	O
.	O

In	O
the	O
present	O
study	O
,	O
a	O
functional	O
analysis	O
of	O
the	O
FSHR	B-Protein
carboxyl	O
-	O
terminal	O
segment	O
cysteine	O
residues	O
was	O
carried	O
out	O
.	O

We	O
constructed	O
a	O
series	O
of	O
mutant	O
FSHRs	B-Protein
by	O
substituting	O
cysteine	O
residues	O
with	O
alanine	O
,	O
serine	O
,	O
or	O
threonine	O
individually	O
and	O
together	O
at	O
positions	O
629	O
and	O
655	O
(	O
conserved	O
cysteines	O
)	O
and	O
627	O
(	O
nonconserved	O
)	O
.	O

The	O
results	O
showed	O
that	O
all	O
three	O
cysteine	O
residues	O
are	O
palmitoylated	O
but	O
that	O
only	O
modification	O
at	O
Cys629	O
is	O
functionally	O
relevant	O
.	O

The	O
lack	O
of	O
palmitoylation	O
does	O
not	O
appear	O
to	O
greatly	O
impair	O
coupling	O
to	O
G	O
(	O
s	O
)	O
but	O
,	O
when	O
absent	O
at	O
position	O
629	O
,	O
does	O
significantly	O
impair	O
cell	O
surface	O
membrane	O
expression	O
of	O
the	O
partially	O
palmitoylated	O
receptor	O
.	O

All	O
FSHR	B-Protein
Cys	O
mutants	O
were	O
capable	O
of	O
binding	O
agonist	O
with	O
the	O
same	O
affinity	O
as	O
the	O
wild	O
-	O
type	O
receptor	O
and	O
internalizing	O
on	O
agonist	O
stimulation	O
.	O

Molecular	O
dynamics	O
simulations	O
at	O
a	O
time	O
scale	O
of	O
approximately	O
100	O
nsec	O
revealed	O
that	O
replacement	O
of	O
Cys629	O
resulted	O
in	O
structures	O
that	O
differed	O
significantly	O
from	O
that	O
of	O
the	O
wild	O
-	O
type	O
receptor	O
.	O

Thus	O
,	O
deviations	O
from	O
wild	O
-	O
type	O
conformation	O
may	O
potentially	O
contribute	O
to	O
the	O
severe	O
impairment	O
in	O
plasma	O
membrane	O
expression	O
and	O
the	O
modest	O
effects	O
on	O
signaling	O
exhibited	O
by	O
the	O
receptors	O
modified	O
in	O
this	O
particular	O
position	O
.	O

Galectin	B-Protein
-	I-Protein
1	I-Protein
is	O
a	O
novel	O
structural	O
component	O
and	O
a	O
major	O
regulator	O
of	O
h	B-Protein
-	I-Protein
ras	I-Protein
nanoclusters	O
.	O

The	O
organization	O
of	O
Ras	O
proteins	O
into	O
nanoclusters	O
on	O
the	O
inner	O
plasma	O
membrane	O
is	O
essential	O
for	O
Ras	O
signal	O
transduction	O
,	O
but	O
the	O
mechanisms	O
that	O
drive	O
nanoclustering	O
are	O
unknown	O
.	O

Here	O
we	O
show	O
that	O
epidermal	B-Protein
growth	I-Protein
factor	I-Protein
receptor	I-Protein
activation	O
stimulates	O
the	O
formation	O
of	O
H	B-Protein
-	I-Protein
Ras	I-Protein
.	O
GTP	O
-	O
Galectin	B-Protein
-	I-Protein
1	I-Protein
(	O
Gal	B-Protein
-	I-Protein
1	I-Protein
)	O
complexes	O
on	O
the	O
plasma	O
membrane	O
that	O
are	O
then	O
assembled	O
into	O
transient	O
nanoclusters	O
.	O

Gal	B-Protein
-	I-Protein
1	I-Protein
is	O
therefore	O
an	O
integral	O
structural	O
component	O
of	O
the	O
H	B-Protein
-	I-Protein
Ras	I-Protein
-	O
signaling	O
nanocluster	O
.	O

Increasing	O
Gal	B-Protein
-	I-Protein
1	I-Protein
levels	O
increases	O
the	O
stability	O
of	O
H	B-Protein
-	I-Protein
Ras	I-Protein
nanoclusters	O
,	O
leading	O
to	O
enhanced	O
effector	O
recruitment	O
and	O
signal	O
output	O
.	O

Elements	O
in	O
the	O
H	B-Protein
-	I-Protein
Ras	I-Protein
C	O
-	O
terminal	O
hypervariable	O
region	O
and	O
an	O
activated	O
G	O
-	O
domain	O
are	O
required	O
for	O
H	B-Protein
-	I-Protein
Ras	I-Protein
-	O
Gal	B-Protein
-	I-Protein
1	I-Protein
interaction	O
.	O

Palmitoylation	O
is	O
not	O
required	O
for	O
H	B-Protein
-	I-Protein
Ras	I-Protein
-	O
Gal	B-Protein
-	I-Protein
1	I-Protein
complex	O
formation	O
,	O
but	O
is	O
required	O
to	O
anchor	O
H	B-Protein
-	I-Protein
Ras	I-Protein
-	O
Gal	B-Protein
-	I-Protein
1	I-Protein
complexes	O
to	O
the	O
plasma	O
membrane	O
.	O

Our	O
data	O
suggest	O
a	O
mechanism	O
for	O
H	B-Protein
-	I-Protein
Ras	I-Protein
nanoclustering	O
that	O
involves	O
a	O
dual	O
role	O
for	O
Gal	B-Protein
-	I-Protein
1	I-Protein
as	O
a	O
critical	O
scaffolding	O
protein	O
and	O
a	O
molecular	O
chaperone	O
that	O
contributes	O
to	O
H	B-Protein
-	I-Protein
Ras	I-Protein
trafficking	O
by	O
returning	O
depalmitoylated	O
H	B-Protein
-	I-Protein
Ras	I-Protein
to	O
the	O
Golgi	O
complex	O
for	O
repalmitoylation	O
.	O

A	O
targeted	O
proteomic	O
analysis	O
of	O
the	O
ubiquitin	B-Protein
-	O
like	O
modifier	O
nedd8	B-Protein
and	O
associated	O
proteins	O
.	O

Nedd8	B-Protein
is	O
a	O
small	O
ubiquitin	B-Protein
-	O
like	O
protein	O
that	O
can	O
be	O
conjugated	O
to	O
substrate	O
-	O
proteins	O
in	O
a	O
process	O
known	O
as	O
neddylation	O
.	O

Although	O
neddylation	O
plays	O
a	O
critical	O
regulatory	O
role	O
in	O
cell	O
proliferation	O
and	O
development	O
,	O
the	O
spectrum	O
of	O
Nedd8	B-Protein
substrates	O
and	O
its	O
interaction	O
network	O
remain	O
poorly	O
understood	O
.	O

To	O
explore	O
the	O
neddylation	O
pathway	O
at	O
the	O
proteome	O
level	O
,	O
we	O
have	O
affinity	O
purified	O
Nedd8	B-Protein
modified	O
and	O
associated	O
proteins	O
from	O
HEK293	O
cells	O
stably	O
expressing	O
GST	O
-	O
Nedd8	B-Protein
and	O
employed	O
LC	O
-	O
MS	O
/	O
MS	O
for	O
subsequent	O
protein	O
identification	O
.	O

A	O
total	O
of	O
496	O
GST	O
-	O
Nedd8	B-Protein
modified	O
and	O
associated	O
proteins	O
have	O
been	O
identified	O
,	O
including	O
all	O
of	O
the	O
eight	O
cullin	O
family	O
members	O
(	O
i	O
.	O
e	O
.	O
,	O
Cul	B-Protein
-	I-Protein
1	I-Protein
,	O
-	B-Protein
2	I-Protein
,	O
-	B-Protein
3	I-Protein
,	O
-	B-Protein
4A	I-Protein
,	O
-	B-Protein
4B	I-Protein
,	O
-	B-Protein
5	I-Protein
,	O
-	B-Protein
7	I-Protein
,	O
and	O
Parc	B-Protein
)	O
that	O
are	O
involved	O
in	O
the	O
neddylation	O
and	O
ubiquitin	B-Protein
-	O
proteasome	O
degradation	O
pathway	O
.	O

In	O
addition	O
,	O
a	O
group	O
of	O
proteins	O
involved	O
in	O
transcription	O
,	O
DNA	O
repair	O
and	O
replication	O
,	O
cell	O
cycle	O
regulation	O
and	O
chromatin	O
organization	O
,	O
and	O
remodeling	O
have	O
been	O
copurified	O
and	O
identified	O
.	O

Apart	O
from	O
protein	O
identification	O
,	O
the	O
neddylation	O
sites	O
of	O
cullins	O
were	O
determined	O
by	O
MS	O
/	O
MS	O
analysis	O
,	O
which	O
agree	O
well	O
with	O
previous	O
mutagenesis	O
studies	O
.	O

Furthermore	O
,	O
MS	O
analyses	O
revealed	O
that	O
Nedd8	B-Protein
K11	O
,	O
K22	O
,	O
K48	O
,	O
and	O
K60	O
can	O
form	O
chains	O
in	O
vivo	O
,	O
whereas	O
Nedd8	B-Protein
K22	O
and	O
K48	O
can	O
be	O
neddylated	O
in	O
vitro	O
.	O

These	O
results	O
present	O
the	O
first	O
molecular	O
evidence	O
for	O
in	O
vitro	O
and	O
in	O
vivo	O
polyneddylation	O
,	O
suggesting	O
that	O
chain	O
formation	O
of	O
ubiquitin	B-Protein
and	O
ubiquitin	B-Protein
-	O
like	O
proteins	O
may	O
be	O
a	O
general	O
phenomenon	O
for	O
these	O
modifications	O
.	O

Although	O
much	O
remains	O
to	O
be	O
explored	O
for	O
the	O
biological	O
significance	O
of	O
the	O
observations	O
,	O
this	O
work	O
provides	O
critically	O
important	O
information	O
regarding	O
Nedd8	B-Protein
chain	O
assembly	O
and	O
its	O
interaction	O
network	O
.	O

The	O
vast	O
amount	O
of	O
proteomic	O
information	O
obtained	O
here	O
can	O
provide	O
clues	O
on	O
the	O
biological	O
role	O
of	O
Nedd8	B-Protein
and	O
lay	O
the	O
foundation	O
for	O
an	O
in	O
-	O
depth	O
analysis	O
of	O
the	O
regulation	O
of	O
the	O
Nedd8	B-Protein
pathway	O
.	O

Docking	O
of	O
fatty	O
acids	O
into	O
the	O
WIF	O
domain	O
of	O
the	O
human	O
Wnt	B-Protein
inhibitory	I-Protein
factor	I-Protein
-	I-Protein
1	I-Protein
.	O

Palmitoylated	O
Wnt	O
proteins	O
comprise	O
a	O
conserved	O
family	O
of	O
secreted	O
signaling	O
molecules	O
associated	O
with	O
variety	O
of	O
human	O
cancers	O
.	O

WIF	O
domain	O
of	O
the	O
human	O
WIF	B-Protein
(	I-Protein
Wnt	I-Protein
inhibitory	I-Protein
factor	I-Protein
)	I-Protein
-	I-Protein
1	I-Protein
is	O
sufficient	O
for	O
Wnt	O
binding	O
and	O
signaling	O
inhibition	O
.	O

Detailed	O
interactions	O
between	O
Wnt	O
and	O
WIF	B-Protein
-	I-Protein
1	I-Protein
are	O
not	O
known	O
.	O

Computational	O
docking	O
was	O
employed	O
to	O
identify	O
a	O
possible	O
fatty	O
acid	O
binding	O
site	O
in	O
the	O
WIF	O
domain	O
.	O

A	O
putative	O
binding	O
site	O
was	O
identified	O
inside	O
the	O
domain	O
.	O

WIF	O
domain	O
exhibited	O
the	O
highest	O
affinity	O
for	O
C16	O
:	O
0	O
-	O
C18	O
:	O
0	O
(	O
-	O
22	O
kJ	O
/	O
mol	O
free	O
energy	O
of	O
binding	O
)	O
fatty	O
acids	O
.	O

The	O
results	O
suggest	O
a	O
role	O
of	O
the	O
WIF	O
domain	O
as	O
a	O
palmitoyl	O
binding	O
domain	O
required	O
for	O
WIF	B-Protein
-	I-Protein
1	I-Protein
binding	O
to	O
palmitoylated	O
Wnt	O
and	O
signaling	O
inhibition	O
.	O

Palmitoylation	O
and	O
ubiquitination	O
regulate	O
exit	O
of	O
the	O
Wnt	O
signaling	O
protein	O
LRP6	B-Protein
from	O
the	O
endoplasmic	O
reticulum	O
.	O

Canonical	O
Wnt	O
signaling	O
is	O
initiated	O
by	O
binding	O
of	O
Wnt	O
proteins	O
to	O
members	O
of	O
the	O
Frizzled	B-Protein
family	O
and	O
subsequent	O
complex	O
formation	O
with	O
lipoprotein	B-Protein
receptor	I-Protein
-	I-Protein
related	I-Protein
proteins	I-Protein
5	I-Protein
/	O
6	B-Protein
(	O
LRP5	B-Protein
/	O
6	B-Protein
)	O
.	O

Here	O
,	O
we	O
show	O
that	O
LRP6	B-Protein
is	O
palmitoylated	O
on	O
a	O
juxtamembranous	O
cysteine	O
and	O
that	O
palmitoylation	O
is	O
required	O
for	O
exit	O
from	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
.	O

We	O
propose	O
that	O
palmitoylation	O
serves	O
to	O
tilt	O
the	O
long	O
,	O
23	O
-	O
residue	O
transmembrane	O
domain	O
of	O
LRP6	B-Protein
with	O
respect	O
to	O
the	O
plane	O
of	O
membrane	O
to	O
prevent	O
a	O
hydrophobic	O
mismatch	O
and	O
subsequent	O
recognition	O
by	O
the	O
ER	O
quality	O
control	O
.	O

In	O
support	O
of	O
this	O
model	O
,	O
a	O
palmitoylation	O
-	O
deficient	O
LRP6	B-Protein
mutant	O
could	O
be	O
rescued	O
from	O
ER	O
retention	O
by	O
deletion	O
of	O
two	O
to	O
four	O
residues	O
in	O
the	O
transmembrane	O
domain	O
.	O

Importantly	O
,	O
we	O
found	O
that	O
palmitoylation	O
-	O
deficient	O
LRP6	B-Protein
was	O
retained	O
in	O
the	O
ER	O
by	O
a	O
completely	O
novel	O
monoubiquitination	O
-	O
dependent	O
ER	O
retention	O
mechanism	O
.	O

Mutation	O
of	O
a	O
specific	O
lysine	O
indeed	O
abolished	O
ubiquitination	O
of	O
palmitoylation	O
-	O
deficient	O
LRP6	B-Protein
and	O
led	O
to	O
a	O
rescue	O
from	O
ER	O
retention	O
.	O

Finally	O
,	O
at	O
the	O
cell	O
surface	O
,	O
we	O
found	O
that	O
interplay	O
between	O
palmitoylation	O
and	O
ubiquitination	O
was	O
necessary	O
for	O
efficient	O
Wnt	O
signaling	O
.	O

Quantification	O
of	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
-	O
modified	O
proteins	O
in	O
cerebrospinal	O
fluid	O
from	O
infants	O
and	O
children	O
after	O
traumatic	O
brain	O
injury	O
.	O

Poly	O
-	O
ADP	O
-	O
ribosylation	O
(	O
PAR	O
)	O
of	O
proteins	O
by	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerases	O
(	O
PARP	O
)	O
occurs	O
after	O
experimental	O
traumatic	O
brain	O
injury	O
(	O
TBI	O
)	O
and	O
modulates	O
neurologic	O
outcome	O
.	O

Several	O
promising	O
pharmacological	O
PARP	O
inhibitors	O
have	O
been	O
developed	O
for	O
use	O
in	O
humans	O
,	O
but	O
there	O
is	O
currently	O
no	O
clinically	O
relevant	O
means	O
of	O
monitoring	O
treatment	O
effects	O
.	O

We	O
therefore	O
used	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
to	O
measure	O
PAR	O
-	O
modified	O
proteins	O
in	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
.	O

Cerebrospinal	O
fluid	O
samples	O
from	O
17	O
pediatric	O
TBI	O
patients	O
and	O
15	O
controls	O
were	O
plated	O
overnight	O
and	O
then	O
incubated	O
with	O
polyclonal	O
antibody	O
against	O
PAR	O
.	O

Histone	B-Protein
-	I-Protein
1	I-Protein
,	O
a	O
PARP	O
substrate	O
,	O
was	O
incubated	O
with	O
active	O
PARP	O
,	O
NAD	O
,	O
and	O
nicked	O
DNA	O
,	O
and	O
served	O
as	O
the	O
standard	O
.	O

Both	O
peak	O
and	O
mean	O
CSF	O
PAR	O
-	O
modified	O
proteins	O
were	O
increased	O
in	O
TBI	O
patients	O
versus	O
controls	O
.	O

Peak	O
CSF	O
PAR	O
-	O
modified	O
protein	O
levels	O
occurred	O
on	O
day	O
1	O
and	O
levels	O
remained	O
increased	O
on	O
day	O
2	O
after	O
TBI	O
.	O

Increases	O
in	O
peak	O
CSF	O
PAR	O
-	O
modified	O
protein	O
concentrations	O
were	O
independently	O
associated	O
with	O
age	O
and	O
male	O
sex	O
,	O
but	O
not	O
initial	O
Glasgow	O
Coma	O
Scale	O
score	O
,	O
Glasgow	O
outcome	O
score	O
,	O
or	O
mechanism	O
of	O
injury	O
.	O

The	O
increase	O
in	O
PAR	O
-	O
modified	O
proteins	O
in	O
CSF	O
after	O
TBI	O
may	O
be	O
because	O
of	O
increased	O
PARP	O
activation	O
,	O
decreased	O
PAR	O
degradation	O
,	O
or	O
both	O
.	O

As	O
PAR	O
-	O
modified	O
protein	O
concentration	O
correlated	O
with	O
age	O
and	O
male	O
sex	O
,	O
developmental	O
and	O
sex	O
-	O
dependent	O
roles	O
for	O
PARP	O
after	O
TBI	O
are	O
implicated	O
.	O

Genetic	O
analysis	O
of	O
CAND1	B-Protein
-	O
CUL1	B-Protein
interactions	O
in	O
Arabidopsis	O
supports	O
a	O
role	O
for	O
CAND1	B-Protein
-	O
mediated	O
cycling	O
of	O
the	O
SCFTIR1	B-Protein
complex	O
.	O

SKP1	B-Protein
-	O
Cullin1	B-Protein
-	O
F	O
-	O
box	O
protein	O
(	O
SCF	O
)	O
ubiquitin	B-Protein
-	O
ligases	O
regulate	O
numerous	O
aspects	O
of	O
eukaryotic	O
growth	O
and	O
development	O
.	O

Cullin	O
-	O
Associated	O
and	O
Neddylation	O
-	O
Dissociated	O
(	O
CAND1	B-Protein
)	O
modulates	O
SCF	O
function	O
through	O
its	O
interactions	O
with	O
the	O
CUL1	B-Protein
subunit	O
.	O

Although	O
biochemical	O
studies	O
with	O
human	O
CAND1	B-Protein
suggested	O
that	O
CAND1	B-Protein
plays	O
a	O
negative	O
regulatory	O
role	O
by	O
sequestering	O
CUL1	B-Protein
and	O
preventing	O
SCF	O
complex	O
assembly	O
,	O
genetic	O
studies	O
in	O
Arabidopsis	O
have	O
shown	O
that	O
cand1	B-Protein
mutants	O
exhibit	O
reduced	O
SCF	O
activity	O
,	O
demonstrating	O
that	O
CAND1	B-Protein
is	O
required	O
for	O
optimal	O
SCF	O
function	O
in	O
vivo	O
.	O

Together	O
,	O
these	O
genetic	O
and	O
biochemical	O
studies	O
have	O
suggested	O
a	O
model	O
of	O
CAND1	B-Protein
-	O
mediated	O
cycles	O
of	O
SCF	O
complex	O
assembly	O
and	O
disassembly	O
.	O

Here	O
,	O
using	O
the	O
SCF	O
(	O
TIR1	B-Protein
)	O
complex	O
of	O
the	O
Arabidopsis	O
auxin	O
response	O
pathway	O
,	O
we	O
test	O
the	O
SCF	O
cycling	O
model	O
with	O
Arabidopsis	O
mutant	O
derivatives	O
of	O
CAND1	B-Protein
and	O
CUL1	B-Protein
that	O
have	O
opposing	O
effects	O
on	O
the	O
CAND1	B-Protein
-	O
CUL1	B-Protein
interaction	O
.	O

We	O
find	O
that	O
the	O
disruption	O
of	O
the	O
CAND1	B-Protein
-	O
CUL1	B-Protein
interaction	O
results	O
in	O
an	O
increased	O
abundance	O
of	O
assembled	O
SCF	O
(	O
TIR1	B-Protein
)	O
complex	O
.	O

In	O
contrast	O
,	O
stabilization	O
of	O
the	O
CAND1	B-Protein
-	O
CUL1	B-Protein
interaction	O
diminishes	O
SCF	O
(	O
TIR1	B-Protein
)	O
complex	O
abundance	O
.	O

The	O
fact	O
that	O
both	O
decreased	O
and	O
increased	O
CAND1	B-Protein
-	O
CUL1	B-Protein
interactions	O
result	O
in	O
reduced	O
SCF	O
(	O
TIR1	B-Protein
)	O
activity	O
in	O
vivo	O
strongly	O
supports	O
the	O
hypothesis	O
that	O
CAND1	B-Protein
-	O
mediated	O
cycling	O
is	O
required	O
for	O
optimal	O
SCF	O
function	O
.	O

Palmitoylation	O
and	O
membrane	O
interactions	O
of	O
the	O
neuroprotective	O
chaperone	O
cysteine	B-Protein
-	I-Protein
string	I-Protein
protein	I-Protein
.	O

Cysteine	B-Protein
-	I-Protein
string	I-Protein
protein	I-Protein
(	O
CSP	B-Protein
)	O
is	O
an	O
extensively	O
palmitoylated	O
DnaJ	B-Protein
-	O
family	O
chaperone	O
,	O
which	O
exerts	O
an	O
important	O
neuroprotective	O
function	O
.	O

Palmitoylation	O
is	O
required	O
for	O
the	O
intracellular	O
sorting	O
and	O
function	O
of	O
CSP	B-Protein
,	O
and	O
thus	O
it	O
is	O
important	O
to	O
understand	O
how	O
this	O
essential	O
modification	O
of	O
CSP	B-Protein
is	O
regulated	O
.	O

Recent	O
work	O
identified	O
23	O
putative	O
palmitoyl	O
transferases	O
containing	O
a	O
conserved	O
DHHC	O
domain	O
in	O
mammalian	O
cells	O
,	O
and	O
here	O
we	O
show	O
that	O
palmitoylation	O
of	O
CSP	B-Protein
is	O
enhanced	O
specifically	O
by	O
co	O
-	O
expression	O
of	O
the	O
Golgi	O
-	O
localized	O
palmitoyl	O
transferases	O
DHHC3	B-Protein
,	O
DHHC7	B-Protein
,	O
DHHC15	B-Protein
,	O
or	O
DHHC17	B-Protein
.	O

Indeed	O
,	O
these	O
DHHC	O
proteins	O
promote	O
stable	O
membrane	O
attachment	O
of	O
CSP	B-Protein
,	O
which	O
is	O
otherwise	O
cytosolic	O
.	O

An	O
inverse	O
correlation	O
was	O
identified	O
between	O
membrane	O
affinity	O
of	O
unpalmitoylated	O
CSP	B-Protein
mutants	O
and	O
subsequent	O
palmitoylation	O
:	O
mutants	O
with	O
an	O
increased	O
membrane	O
affinity	O
localize	O
to	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
and	O
are	O
physically	O
separated	O
from	O
the	O
Golgi	O
-	O
localized	O
DHHC	O
proteins	O
.	O

Palmitoylation	O
of	O
an	O
ER	O
-	O
localized	O
mutant	O
could	O
be	O
rescued	O
by	O
brefeldin	O
A	O
treatment	O
,	O
which	O
promotes	O
the	O
mixing	O
of	O
ER	O
and	O
Golgi	O
membranes	O
.	O

Interestingly	O
though	O
,	O
the	O
palmitoylated	O
mutant	O
remained	O
at	O
the	O
ER	O
following	O
brefeldin	O
A	O
washout	O
and	O
did	O
not	O
traffic	O
to	O
more	O
distal	O
membrane	O
compartments	O
.	O

We	O
propose	O
that	O
CSP	B-Protein
has	O
a	O
weak	O
membrane	O
affinity	O
that	O
allows	O
the	O
protein	O
to	O
locate	O
its	O
partner	O
Golgi	O
-	O
localized	O
DHHC	O
proteins	O
directly	O
by	O
membrane	O
"	O
sampling	O
.	O
"	O
Mutations	O
that	O
enhance	O
membrane	O
association	O
prevent	O
sampling	O
and	O
lead	O
to	O
accumulation	O
of	O
CSP	B-Protein
on	O
cellular	O
membranes	O
such	O
as	O
the	O
ER	O
.	O

The	O
coupling	O
of	O
CSP	B-Protein
palmitoylation	O
to	O
Golgi	O
membranes	O
may	O
thus	O
be	O
an	O
important	O
requirement	O
for	O
subsequent	O
sorting	O
.	O

The	O
HOOK	O
-	O
domain	O
between	O
the	O
SH3	O
and	O
the	O
GK	O
domains	O
of	O
Cavbeta	O
subunits	O
contains	O
key	O
determinants	O
controlling	O
calcium	O
channel	O
inactivation	O
.	O

Ca	O
(	O
v	O
)	O
beta	O
subunits	O
of	O
voltage	O
-	O
gated	O
calcium	O
channels	O
contain	O
two	O
conserved	O
domains	O
,	O
a	O
src	O
-	O
homology	O
-	O
3	O
(	O
SH3	O
)	O
-	O
domain	O
and	O
a	O
guanylate	O
kinase	O
-	O
like	O
(	O
GK	O
)	O
-	O
domain	O
.	O

The	O
SH3	O
-	O
domain	O
is	O
split	O
,	O
with	O
its	O
final	O
(	O
fifth	O
)	O
beta	O
-	O
strand	O
separated	O
from	O
the	O
rest	O
of	O
the	O
domain	O
by	O
an	O
intervening	O
sequence	O
termed	O
the	O
HOOK	O
-	O
domain	O
,	O
whose	O
sequence	O
varies	O
between	O
Ca	O
(	O
v	O
)	O
beta	O
subunits	O
.	O

Here	O
we	O
have	O
been	O
guided	O
by	O
the	O
recent	O
structural	O
studies	O
of	O
Ca	O
(	O
v	O
)	O
beta	O
subunits	O
in	O
the	O
design	O
of	O
specific	O
truncated	O
constructs	O
,	O
with	O
the	O
goal	O
of	O
investigating	O
the	O
role	O
of	O
the	O
HOOK	O
-	O
domain	O
of	O
Ca	O
(	O
v	O
)	O
beta	O
subunits	O
in	O
the	O
modulation	O
of	O
inactivation	O
of	O
N	O
-	O
type	O
calcium	O
channels	O
.	O

We	O
have	O
coexpressed	O
the	O
beta	O
subunit	O
constructs	O
with	O
Ca	B-Protein
(	I-Protein
v	I-Protein
)	I-Protein
2	I-Protein
.	I-Protein
2	I-Protein
and	O
alpha	B-Protein
(	I-Protein
2	I-Protein
)	I-Protein
delta	B-Protein
-	I-Protein
2	I-Protein
,	O
using	O
the	O
N	O
-	O
terminally	O
palmitoylated	O
beta	B-Protein
(	I-Protein
2a	I-Protein
)	I-Protein
subunit	O
,	O
because	O
it	O
supports	O
very	O
little	O
voltage	O
-	O
dependent	O
inactivation	O
,	O
and	O
made	O
comparisons	O
with	O
beta	B-Protein
(	I-Protein
1b	I-Protein
)	I-Protein
domains	O
.	O

Deletion	O
of	O
the	O
variable	O
region	O
of	O
the	O
beta	B-Protein
(	I-Protein
2a	I-Protein
)	I-Protein
HOOK	O
-	O
domain	O
resulted	O
in	O
currents	O
with	O
a	O
rapidly	O
inactivating	O
component	O
,	O
and	O
additional	O
mutation	O
of	O
the	O
beta	B-Protein
(	I-Protein
2a	I-Protein
)	I-Protein
palmitoylation	O
motif	O
further	O
enhanced	O
inactivation	O
.	O

The	O
isolated	O
GK	O
-	O
domain	O
of	O
beta	B-Protein
(	I-Protein
2a	I-Protein
)	I-Protein
alone	O
enhanced	O
current	O
amplitude	O
,	O
but	O
the	O
currents	O
were	O
rapidly	O
and	O
completely	O
inactivating	O
.	O

When	O
the	O
beta	B-Protein
(	I-Protein
2a	I-Protein
)	I-Protein
-	O
GK	O
-	O
domain	O
construct	O
was	O
extended	O
proximally	O
,	O
by	O
including	O
the	O
HOOK	O
-	O
domain	O
and	O
the	O
epsilon	O
-	O
strand	O
of	O
the	O
SH3	O
-	O
domain	O
,	O
inactivation	O
was	O
about	O
four	O
-	O
fold	O
slower	O
than	O
in	O
the	O
absence	O
of	O
the	O
HOOK	O
domain	O
.	O

When	O
the	O
SH3	O
-	O
domain	O
of	O
beta	B-Protein
(	I-Protein
2a	I-Protein
)	I-Protein
truncated	O
prior	O
to	O
the	O
HOOK	O
-	O
domain	O
was	O
coexpressed	O
with	O
the	O
(	O
HOOK	O
+	O
epsilonSH3	O
+	O
GK	O
)	O
-	O
domain	O
of	O
beta	B-Protein
(	I-Protein
2a	I-Protein
)	I-Protein
,	O
all	O
the	O
properties	O
of	O
beta	B-Protein
(	I-Protein
2a	I-Protein
)	I-Protein
were	O
restored	O
,	O
in	O
terms	O
of	O
loss	O
of	O
inactivation	O
.	O

Furthermore	O
,	O
removal	O
of	O
the	O
HOOK	O
sequence	O
from	O
the	O
(	O
HOOK	O
+	O
epsilonSH3	O
+	O
GK	O
)	O
-	O
beta	B-Protein
(	I-Protein
2a	I-Protein
)	I-Protein
construct	O
increased	O
inactivation	O
.	O

Together	O
,	O
these	O
results	O
provide	O
evidence	O
that	O
the	O
HOOK	O
domain	O
is	O
an	O
important	O
determinant	O
of	O
inactivation	O
.	O

Membrane	O
binding	O
of	O
lipidated	O
Ras	O
peptides	O
and	O
proteins	O
-	O
-	O
the	O
structural	O
point	O
of	O
view	O
.	O

Biological	O
membranes	O
are	O
interesting	O
interfaces	O
,	O
at	O
which	O
important	O
biological	O
processes	O
occur	O
.	O

In	O
addition	O
to	O
integral	O
membrane	O
proteins	O
,	O
a	O
number	O
of	O
proteins	O
bind	O
to	O
the	O
membrane	O
surface	O
and	O
associate	O
with	O
it	O
.	O

Posttranslational	O
lipid	O
modification	O
is	O
one	O
important	O
mechanism	O
,	O
by	O
which	O
soluble	O
molecules	O
develop	O
a	O
propensity	O
towards	O
the	O
membrane	O
and	O
reversibly	O
bind	O
to	O
it	O
.	O

Membrane	O
binding	O
by	O
insertion	O
of	O
hydrophobic	O
lipid	O
moieties	O
is	O
relevant	O
for	O
up	O
to	O
10	O
%	O
of	O
all	O
cellular	O
proteins	O
.	O

A	O
particular	O
interesting	O
lipid	O
-	O
modified	O
protein	O
is	O
the	O
small	O
GTPase	O
Ras	O
,	O
which	O
plays	O
a	O
key	O
role	O
in	O
cellular	O
signal	O
transduction	O
.	O

Until	O
recently	O
,	O
the	O
structural	O
basis	O
for	O
membrane	O
binding	O
of	O
Ras	O
was	O
not	O
well	O
-	O
defined	O
.	O

However	O
,	O
with	O
the	O
advent	O
of	O
new	O
synthesis	O
techniques	O
and	O
the	O
advancement	O
of	O
several	O
biophysical	O
methods	O
,	O
a	O
number	O
of	O
structural	O
and	O
dynamical	O
features	O
about	O
membrane	O
binding	O
of	O
Ras	O
proteins	O
have	O
been	O
revealed	O
.	O

This	O
review	O
will	O
summarize	O
the	O
chemical	O
biology	O
of	O
Ras	O
and	O
discuss	O
in	O
more	O
detail	O
the	O
biophysical	O
and	O
structural	O
features	O
of	O
the	O
membrane	O
bound	O
C	O
-	O
terminus	O
of	O
the	O
protein	O
.	O

RanBP2	B-Protein
and	O
SENP3	B-Protein
function	O
in	O
a	O
mitotic	O
SUMO2	B-Protein
/	O
3	B-Protein
conjugation	O
-	O
deconjugation	O
cycle	O
on	O
Borealin	B-Protein
.	O

The	O
ubiquitin	B-Protein
-	O
like	O
SUMO	O
system	O
controls	O
cellular	O
key	O
functions	O
,	O
and	O
several	O
lines	O
of	O
evidence	O
point	O
to	O
a	O
critical	O
role	O
of	O
SUMO	O
for	O
mitotic	O
progression	O
.	O

However	O
,	O
in	O
mammalian	O
cells	O
mitotic	O
substrates	O
of	O
sumoylation	O
and	O
the	O
regulatory	O
components	O
involved	O
are	O
not	O
well	O
defined	O
.	O

Here	O
,	O
we	O
identify	O
Borealin	B-Protein
,	O
a	O
component	O
of	O
the	O
chromosomal	O
passenger	O
complex	O
(	O
CPC	O
)	O
,	O
as	O
a	O
mitotic	O
target	O
of	O
SUMO	O
.	O

The	O
CPC	O
,	O
which	O
additionally	O
comprises	O
INCENP	B-Protein
,	O
Survivin	B-Protein
,	O
and	O
Aurora	B-Protein
B	I-Protein
,	O
regulates	O
key	O
mitotic	O
events	O
,	O
including	O
chromosome	O
congression	O
,	O
the	O
spindle	O
assembly	O
checkpoint	O
,	O
and	O
cytokinesis	O
.	O

We	O
show	O
that	O
Borealin	B-Protein
is	O
preferentially	O
modified	O
by	O
SUMO2	B-Protein
/	O
3	B-Protein
and	O
demonstrate	O
that	O
the	O
modification	O
is	O
dynamically	O
regulated	O
during	O
mitotic	O
progression	O
,	O
peaking	O
in	O
early	O
mitosis	O
.	O

Intriguingly	O
,	O
the	O
SUMO	O
ligase	O
RanBP2	B-Protein
interacts	O
with	O
the	O
CPC	O
,	O
stimulates	O
SUMO	O
modification	O
of	O
Borealin	B-Protein
in	O
vitro	O
,	O
and	O
is	O
required	O
for	O
its	O
modification	O
in	O
vivo	O
.	O

Moreover	O
,	O
the	O
SUMO	O
isopeptidase	O
SENP3	B-Protein
is	O
a	O
specific	O
interaction	O
partner	O
of	O
Borealin	B-Protein
and	O
catalyzes	O
the	O
removal	O
of	O
SUMO2	B-Protein
/	O
3	B-Protein
from	O
Borealin	B-Protein
.	O

These	O
data	O
thus	O
delineate	O
a	O
mitotic	O
SUMO2	B-Protein
/	O
3	B-Protein
conjugation	O
-	O
deconjugation	O
cycle	O
of	O
Borealin	B-Protein
and	O
further	O
assign	O
a	O
regulatory	O
function	O
of	O
RanBP2	B-Protein
and	O
SENP3	B-Protein
in	O
the	O
mitotic	O
SUMO	O
pathway	O
.	O

Structural	O
basis	O
and	O
specificity	O
of	O
human	O
otubain	B-Protein
1	I-Protein
-	O
mediated	O
deubiquitination	O
.	O

OTUB	B-Protein
(	I-Protein
otubain	I-Protein
)	I-Protein
1	I-Protein
is	O
a	O
human	O
deubiquitinating	O
enzyme	O
that	O
is	O
implicated	O
in	O
mediating	O
lymphocyte	O
antigen	O
responsiveness	O
,	O
but	O
whose	O
molecular	O
function	O
is	O
generally	O
not	O
well	O
defined	O
.	O

A	O
structural	O
analysis	O
of	O
OTUB1	B-Protein
shows	O
differences	O
in	O
accessibility	O
to	O
the	O
active	O
site	O
and	O
in	O
surface	O
properties	O
of	O
the	O
substrate	O
-	O
binding	O
regions	O
when	O
compared	O
with	O
its	O
close	O
homologue	O
,	O
OTUB2	B-Protein
,	O
suggesting	O
variations	O
in	O
regulatory	O
mechanisms	O
and	O
substrate	O
specificity	O
.	O

Biochemical	O
analysis	O
reveals	O
that	O
OTUB1	B-Protein
has	O
a	O
preference	O
for	O
cleaving	O
Lys	O
(	O
48	O
)	O
-	O
linked	O
polyubiquitin	B-Protein
chains	O
over	O
Lys	O
(	O
63	O
)	O
-	O
linked	O
polyubiquitin	B-Protein
chains	O
,	O
and	O
it	O
is	O
capable	O
of	O
cleaving	O
NEDD8	B-Protein
(	O
neural	B-Protein
-	I-Protein
precursor	I-Protein
-	I-Protein
cell	I-Protein
-	I-Protein
expressed	I-Protein
developmentally	I-Protein
down	I-Protein
-	I-Protein
regulated	I-Protein
8	I-Protein
)	O
,	O
but	O
not	O
SUMO	B-Protein
(	I-Protein
small	I-Protein
ubiquitin	I-Protein
-	I-Protein
related	I-Protein
modifier	I-Protein
)	I-Protein
1	I-Protein
/	O
2	B-Protein
/	O
3	B-Protein
and	O
ISG15	B-Protein
(	O
interferon	O
-	O
stimulated	O
gene	O
15	O
)	O
conjugates	O
.	O

A	O
functional	O
comparison	O
of	O
OTUB1	B-Protein
and	O
OTUB2	B-Protein
indicated	O
a	O
differential	O
reactivity	O
towards	O
ubiquitin	B-Protein
-	O
based	O
active	O
-	O
site	O
probes	O
carrying	O
a	O
vinyl	O
methyl	O
ester	O
,	O
a	O
2	O
-	O
chloroethyl	O
or	O
a	O
2	O
-	O
bromoethyl	O
group	O
at	O
the	O
C	O
-	O
terminus	O
.	O

Mutational	O
analysis	O
suggested	O
that	O
a	O
narrow	O
P1	O
'	O
site	O
,	O
as	O
observed	O
in	O
OTUB1	B-Protein
,	O
correlates	O
with	O
its	O
ability	O
to	O
preferentially	O
cleave	O
Lys	O
(	O
48	O
)	O
-	O
linked	O
ubiquitin	B-Protein
chains	O
.	O

Analysis	O
of	O
cellular	O
interaction	O
partners	O
of	O
OTUB1	B-Protein
by	O
co	O
-	O
immunoprecipitation	O
and	O
MS	O
/	O
MS	O
(	O
tandem	O
mass	O
spectrometry	O
)	O
experiments	O
demonstrated	O
that	O
FUS	B-Protein
[	O
fusion	B-Protein
involved	I-Protein
in	I-Protein
t	I-Protein
(	I-Protein
12	I-Protein
;	I-Protein
6	I-Protein
)	I-Protein
in	I-Protein
malignant	I-Protein
liposarcoma	I-Protein
;	O
also	O
known	O
as	O
TLS	B-Protein
(	O
translocation	B-Protein
in	I-Protein
liposarcoma	I-Protein
)	O
or	O
CHOP	B-Protein
(	O
CCAAT	B-Protein
/	I-Protein
enhancer	I-Protein
-	I-Protein
binding	I-Protein
protein	I-Protein
homologous	I-Protein
protein	I-Protein
)	O
]	O
and	O
RACK1	B-Protein
[	O
receptor	B-Protein
for	I-Protein
activated	I-Protein
kinase	I-Protein
1	I-Protein
;	O
also	O
known	O
as	O
GNB2L1	B-Protein
(	O
guanine	B-Protein
-	I-Protein
nucleotide	I-Protein
-	I-Protein
binding	I-Protein
protein	I-Protein
beta	I-Protein
polypeptide	I-Protein
2	I-Protein
-	I-Protein
like	I-Protein
1	I-Protein
)	O
]	O
are	O
part	O
of	O
OTUB1	B-Protein
-	O
containing	O
complexes	O
,	O
pointing	O
towards	O
a	O
molecular	O
function	O
of	O
this	O
deubiquitinating	O
enzyme	O
in	O
RNA	O
processing	O
and	O
cell	O
adhesion	O
/	O
morphology	O
.	O

O	O
-	O
linked	O
GlcNAc	O
modification	O
of	O
cardiac	O
myofilament	O
proteins	O
:	O
a	O
novel	O
regulator	O
of	O
myocardial	O
contractile	O
function	O
.	O

In	O
addition	O
to	O
O	O
-	O
phosphorylation	O
,	O
O	O
-	O
linked	O
modifications	O
of	O
serine	O
and	O
threonine	O
by	O
beta	O
-	O
N	O
-	O
acetyl	O
-	O
D	O
-	O
glucosamine	O
(	O
GlcNAc	O
)	O
may	O
regulate	O
muscle	O
contractile	O
function	O
.	O

This	O
study	O
assessed	O
the	O
potential	O
role	O
of	O
O	O
-	O
GlcNAcylation	O
in	O
cardiac	O
muscle	O
contractile	O
activation	O
.	O

To	O
identify	O
specific	O
sites	O
of	O
O	O
-	O
GlcNAcylation	O
in	O
cardiac	O
myofilament	O
proteins	O
,	O
a	O
recently	O
developed	O
methodology	O
based	O
on	O
GalNAz	O
-	O
biotin	O
labeling	O
followed	O
by	O
dithiothreitol	O
replacement	O
and	O
light	O
chromatography	O
/	O
tandem	O
mass	O
spectrometry	O
site	O
mapping	O
was	O
adopted	O
.	O

Thirty	O
-	O
two	O
O	O
-	O
GlcNAcylated	O
peptides	O
from	O
cardiac	O
myofilaments	O
were	O
identified	O
on	O
cardiac	O
myosin	O
heavy	O
chain	O
,	O
actin	B-Protein
,	O
myosin	B-Protein
light	I-Protein
chains	I-Protein
,	O
and	O
troponin	B-Protein
I	I-Protein
.	O

To	O
assess	O
the	O
potential	O
physiological	O
role	O
of	O
the	O
GlcNAc	O
,	O
force	O
-	O
[	O
Ca	O
(	O
2	O
+	O
)	O
]	O
relationships	O
were	O
studied	O
in	O
skinned	O
rat	O
trabeculae	O
.	O

Exposure	O
to	O
GlcNAc	O
significantly	O
decreased	O
calcium	O
sensitivity	O
(	O
pCa50	O
)	O
,	O
whereas	O
maximal	O
force	O
(	O
F	O
(	O
max	O
)	O
)	O
and	O
Hill	O
coefficient	O
(	O
n	O
)	O
were	O
not	O
modified	O
.	O

Using	O
a	O
pan	O
-	O
specific	O
O	O
-	O
GlcNAc	O
antibody	O
,	O
it	O
was	O
determined	O
that	O
acute	O
exposure	O
of	O
myofilaments	O
to	O
GlcNAc	O
induced	O
a	O
significant	O
increase	O
in	O
actin	O
O	O
-	O
GlcNAcylation	O
.	O

This	O
study	O
provides	O
the	O
first	O
identification	O
of	O
O	O
-	O
GlcNAcylation	O
sites	O
in	O
cardiac	O
myofilament	O
proteins	O
and	O
demonstrates	O
their	O
potential	O
role	O
in	O
regulating	O
myocardial	O
contractile	O
function	O
.	O

Biochemical	O
characterization	O
of	O
plasma	O
-	O
derived	O
tissue	B-Protein
factor	I-Protein
pathway	I-Protein
inhibitor	I-Protein
:	O
post	O
-	O
translational	O
modification	O
of	O
free	O
,	O
full	O
-	O
length	O
form	O
with	O
particular	O
reference	O
to	O
the	O
sugar	O
chain	O
.	O

BACKGROUND	O
:	O
Tissue	B-Protein
factor	I-Protein
pathway	I-Protein
inhibitor	I-Protein
(	O
TFPI	B-Protein
)	O
is	O
a	O
physiological	O
protease	O
inhibitor	O
that	O
inhibits	O
the	O
initial	O
reactions	O
of	O
the	O
extrinsic	O
blood	O
coagulation	O
pathway	O
.	O

Most	O
TFPI	B-Protein
in	O
human	O
plasma	O
is	O
associated	O
with	O
lipoproteins	O
;	O
however	O
,	O
the	O
most	O
functionally	O
active	O
form	O
is	O
thought	O
to	O
be	O
the	O
free	O
,	O
full	O
-	O
length	O
form	O
(	O
f	O
-	O
pTFPI	B-Protein
)	O
.	O

Cell	O
culture	O
derived	O
TFPI	B-Protein
and	O
recombinant	O
TFPI	B-Protein
(	O
rTFPI	B-Protein
)	O
exhibit	O
variations	O
in	O
their	O
respective	O
anticoagulant	O
activity	O
,	O
which	O
may	O
be	O
caused	O
by	O
post	O
-	O
translational	O
modifications	O
,	O
such	O
as	O
the	O
frequent	O
differences	O
in	O
sugar	O
chain	O
structures	O
among	O
recombinant	O
proteins	O
.	O

Sugar	O
chain	O
structures	O
in	O
rTFPI	B-Protein
expressed	O
in	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	O
)	O
cells	O
have	O
been	O
reported	O
previously	O
,	O
but	O
those	O
of	O
plasma	O
TFPI	B-Protein
have	O
not	O
been	O
.	O

OBJECTIVES	O
:	O
To	O
purify	O
f	O
-	O
pTFPI	B-Protein
and	O
analyze	O
the	O
sugar	O
chain	O
structures	O
.	O

RESULTS	O
AND	O
CONCLUSION	O
:	O
f	O
-	O
pTFPI	B-Protein
was	O
purified	O
to	O
homogeneity	O
from	O
blood	O
plasma	O
using	O
a	O
combination	O
of	O
anion	O
-	O
exchange	O
,	O
heparin	O
affinity	O
,	O
immunoaffinity	O
,	O
and	O
reversed	O
-	O
phase	O
chromatographies	O
,	O
resulting	O
in	O
a	O
yield	O
of	O
76	O
%	O
.	O

f	O
-	O
pTFPI	B-Protein
showed	O
a	O
partially	O
phosphorylated	O
glycoprotein	O
comprising	O
a	O
total	O
of	O
276	O
amino	O
acids	O
by	O
peptide	O
mapping	O
.	O

The	O
sugar	O
chain	O
structures	O
were	O
analyzed	O
by	O
two	O
-	O
dimensional	O
sugar	O
mapping	O
combined	O
with	O
exoglycosidase	O
digestion	O
of	O
the	O
pyridylamino	O
sugar	O
chains	O
and	O
the	O
following	O
results	O
were	O
obtained	O
.	O

(	O
Sialyl	O
)	O
Galbeta1	O
-	O
3GalNAc	O
was	O
linked	O
to	O
Thr	O
(	O
175	O
)	O
,	O
partially	O
to	O
Thr	O
(	O
14	O
)	O
and	O
Ser	O
(	O
174	O
)	O
;	O
sialyl	O
complex	O
-	O
type	O
sugar	O
chains	O
to	O
Asn	O
(	O
117	O
)	O
and	O
Asn	O
(	O
167	O
)	O
,	O
whereas	O
Asn	O
(	O
228	O
)	O
was	O
not	O
glycosylated	O
.	O

Neuraminidase	O
-	O
resistant	O
acidic	O
sugar	O
chains	O
including	O
sulfated	O
sugar	O
chains	O
were	O
not	O
observed	O
significantly	O
.	O

The	O
protease	O
inhibitory	O
activities	O
of	O
f	O
-	O
pTFPI	B-Protein
towards	O
activated	O
factor	B-Protein
(	I-Protein
F	I-Protein
)	I-Protein
X	I-Protein
and	O
tissue	B-Protein
factor	I-Protein
-	O
activated	O
FVII	O
complex	O
were	O
identical	O
to	O
those	O
of	O
full	O
-	O
length	O
rTFPI	B-Protein
expressed	O
in	O
CHO	O
cells	O
.	O

Site	O
-	O
specific	O
mutagenesis	O
identifies	O
three	O
cysteine	O
residues	O
in	O
the	O
cytoplasmic	O
tail	O
as	O
acylation	O
sites	O
of	O
influenza	O
virus	O
hemagglutinin	B-Protein
.	O

The	O
hemagglutinin	B-Protein
(	O
HA	B-Protein
)	O
of	O
influenza	O
virus	O
is	O
a	O
type	O
I	O
transmembrane	O
glycoprotein	O
which	O
is	O
acylated	O
with	O
long	O
-	O
chain	O
fatty	O
acids	O
.	O

In	O
this	O
study	O
we	O
have	O
used	O
oligonucleotide	O
-	O
directed	O
mutagenesis	O
of	O
cloned	O
cDNA	O
and	O
a	O
simian	O
virus	O
40	O
expression	O
system	O
to	O
determine	O
the	O
fatty	O
acid	O
binding	O
site	O
in	O
HA	B-Protein
and	O
to	O
examine	O
possible	O
functions	O
of	O
covalently	O
linked	O
fatty	O
acids	O
.	O

The	O
results	O
show	O
that	O
the	O
HA	B-Protein
is	O
acylated	O
through	O
thioester	O
linkages	O
at	O
three	O
highly	O
conserved	O
cysteine	O
residues	O
located	O
in	O
the	O
cytoplasmic	O
domain	O
and	O
at	O
the	O
carboxy	O
-	O
terminal	O
end	O
of	O
the	O
transmembrane	O
region	O
,	O
whereas	O
a	O
cysteine	O
located	O
in	O
the	O
middle	O
of	O
the	O
membrane	O
-	O
spanning	O
domain	O
is	O
not	O
acylated	O
.	O

Mutants	O
lacking	O
fatty	O
acids	O
at	O
individual	O
or	O
all	O
three	O
attachment	O
sites	O
acquire	O
endoglycosidase	B-Protein
H	I-Protein
-	O
resistant	O
oligosaccharide	O
side	O
chains	O
,	O
are	O
cleaved	O
into	O
HA1	B-Protein
and	O
HA2	B-Protein
subunits	O
,	O
and	O
are	O
transported	O
to	O
the	O
plasma	O
membrane	O
at	O
rates	O
similar	O
to	O
that	O
of	O
wild	O
-	O
type	O
HA	B-Protein
.	O

All	O
mutants	O
are	O
membrane	O
bound	O
and	O
not	O
secreted	O
into	O
the	O
medium	O
.	O

These	O
results	O
exclude	O
transport	O
signal	O
and	O
membrane	O
-	O
anchoring	O
functions	O
of	O
covalently	O
linked	O
fatty	O
acids	O
for	O
this	O
integral	O
membrane	O
glycoprotein	O
.	O

Furthermore	O
,	O
lack	O
of	O
acylation	O
has	O
no	O
obvious	O
influence	O
on	O
the	O
biological	O
activities	O
of	O
HA	B-Protein
:	O
cells	O
expressing	O
fatty	O
acid	O
-	O
free	O
HA	B-Protein
bind	O
to	O
and	O
,	O
after	O
brief	O
exposure	O
to	O
mildly	O
acidic	O
pH	O
,	O
fuse	O
with	O
erythrocytes	O
;	O
the	O
HA	B-Protein
-	O
induced	O
polykaryon	O
formation	O
is	O
not	O
impaired	O
,	O
either	O
.	O

Other	O
possible	O
functions	O
of	O
covalently	O
linked	O
fatty	O
acids	O
in	O
integral	O
membrane	O
glycoproteins	O
which	O
cannot	O
be	O
examined	O
in	O
conventional	O
cDNA	O
expression	O
systems	O
are	O
discussed	O
.	O

Subcellular	O
localization	O
directs	O
signaling	O
specificity	O
of	O
the	O
Cryptococcus	O
neoformans	O
Ras1	B-Protein
protein	O
.	O

In	O
the	O
human	O
fungal	O
pathogen	O
Cryptococcus	O
neoformans	O
,	O
Ras	O
signaling	O
mediates	O
sexual	O
differentiation	O
,	O
morphogenesis	O
,	O
and	O
pathogenesis	O
.	O

By	O
studying	O
Ras	O
prenylation	O
and	O
palmitoylation	O
in	O
this	O
organism	O
,	O
we	O
have	O
found	O
that	O
the	O
subcellular	O
localization	O
of	O
this	O
protein	O
dictates	O
its	O
downstream	O
signaling	O
specificity	O
.	O

Inhibiting	O
C	O
.	O
neoformans	O
Ras1	B-Protein
prenylation	O
results	O
in	O
the	O
defective	O
general	O
membrane	O
targeting	O
of	O
this	O
protein	O
and	O
the	O
loss	O
of	O
all	O
Ras	O
function	O
.	O

In	O
contrast	O
,	O
palmitoylation	O
mediates	O
localization	O
of	O
Ras1	B-Protein
to	O
the	O
plasma	O
membrane	O
and	O
is	O
required	O
for	O
normal	O
morphogenesis	O
and	O
survival	O
at	O
high	O
temperatures	O
.	O

However	O
,	O
palmitoylation	O
and	O
plasma	O
membrane	O
localization	O
are	O
not	O
required	O
for	O
Ras	O
-	O
dependent	O
sexual	O
differentiation	O
.	O

Likely	O
as	O
a	O
result	O
of	O
its	O
effect	O
on	O
thermotolerance	O
,	O
Ras1	B-Protein
palmitoylation	O
is	O
also	O
required	O
for	O
the	O
pathogenesis	O
of	O
C	O
.	O
neoformans	O
.	O

These	O
data	O
support	O
an	O
emerging	O
paradigm	O
of	O
compartmentalized	O
Ras	O
signaling	O
.	O

However	O
,	O
our	O
studies	O
also	O
demonstrate	O
fundamental	O
differences	O
between	O
the	O
Ras	O
pathways	O
in	O
different	O
organisms	O
that	O
emphasize	O
the	O
functional	O
flexibility	O
of	O
conserved	O
signaling	O
cascades	O
.	O

Both	O
FMNH2	O
and	O
FADH2	O
can	O
be	O
utilized	O
by	O
the	O
dibenzothiophene	B-Protein
monooxygenase	I-Protein
from	O
a	O
desulfurizing	O
bacterium	O
Mycobacterium	O
goodii	O
X7B	O
.	O

To	O
investigate	O
the	O
flavin	O
utilization	O
by	O
dibenzothiophene	B-Protein
monooxygenase	I-Protein
(	O
DszC	B-Protein
)	O
,	O
DszC	B-Protein
of	O
a	O
desulfurizing	O
bacterium	O
Mycobacterium	O
goodii	O
X7B	O
was	O
purified	O
from	O
the	O
recombinant	O
Escherichia	O
coli	O
.	O

It	O
was	O
shown	O
to	O
be	O
able	O
to	O
utilize	O
either	O
FMNH	O
(	O
2	O
)	O
or	O
FADH	O
(	O
2	O
)	O
when	O
coupled	O
with	O
a	O
flavin	B-Protein
reductase	I-Protein
that	O
reduces	O
either	O
FMN	O
or	O
FAD	O
.	O

Sequence	O
analysis	O
indicated	O
that	O
DszC	B-Protein
was	O
similar	O
to	O
the	O
C	O
(	O
2	O
)	O
component	O
of	O
p	O
-	O
hydroxyphenylacetate	O
hydroxylase	O
from	O
Acinetobacter	O
baumannii	O
,	O
which	O
can	O
use	O
both	O
FADH	O
(	O
2	O
)	O
and	O
FMNH	O
(	O
2	O
)	O
as	O
substrates	O
.	O

Both	O
flavins	O
at	O
high	O
concentrations	O
could	O
inhibit	O
the	O
activity	O
of	O
DszC	B-Protein
due	O
to	O
autocatalytic	O
oxidation	O
of	O
reduced	O
flavins	O
.	O

The	O
results	O
suggest	O
that	O
DszC	B-Protein
should	O
be	O
reclassified	O
as	O
an	O
FMNH	O
(	O
2	O
)	O
and	O
FADH	O
(	O
2	O
)	O
both	O
-	O
utilizing	O
monooxygenase	O
component	O
and	O
the	O
flavins	O
should	O
be	O
controlled	O
at	O
properly	O
reduced	O
levels	O
to	O
obtain	O
optimal	O
biodesulfurization	O
results	O
.	O

Generation	O
of	O
branched	O
-	O
chain	O
fatty	O
acids	O
through	O
lipoate	O
-	O
dependent	O
metabolism	O
facilitates	O
intracellular	O
growth	O
of	O
Listeria	O
monocytogenes	O
.	O

The	O
gram	O
-	O
positive	O
bacterial	O
pathogen	O
Listeria	O
monocytogenes	O
has	O
evolved	O
mechanisms	O
to	O
rapidly	O
replicate	O
in	O
the	O
host	O
cytosol	O
,	O
implying	O
efficient	O
utilization	O
of	O
host	O
-	O
derived	O
nutrients	O
.	O

However	O
,	O
the	O
contribution	O
of	O
host	O
nutrient	O
scavenging	O
versus	O
that	O
of	O
bacterial	O
biosynthesis	O
toward	O
rapid	O
intracellular	O
growth	O
remains	O
unclear	O
.	O

Nutrients	O
that	O
contribute	O
to	O
growth	O
of	O
L	O
.	O
monocytogenes	O
include	O
branched	O
-	O
chain	O
fatty	O
acids	O
(	O
BCFAs	O
)	O
,	O
amino	O
acids	O
,	O
and	O
other	O
metabolic	O
intermediates	O
generated	O
from	O
acyl	O
-	O
coenzyme	O
A	O
,	O
which	O
is	O
synthesized	O
using	O
lipoylated	O
metabolic	O
enzyme	O
complexes	O
.	O

To	O
characterize	O
which	O
biosynthetic	O
pathways	O
support	O
replication	O
of	O
L	O
.	O
monocytogenes	O
inside	O
the	O
host	O
cytosol	O
,	O
we	O
impaired	O
lipoate	O
-	O
dependent	O
metabolism	O
by	O
disrupting	O
two	O
lipoate	O
ligase	O
genes	O
that	O
are	O
responsible	O
for	O
bacterial	O
protein	O
lipoylation	O
.	O

Interrupting	O
lipoate	O
-	O
dependent	O
metabolism	O
modestly	O
impaired	O
replication	O
in	O
rich	O
broth	O
medium	O
but	O
strongly	O
inhibited	O
growth	O
in	O
defined	O
medium	O
and	O
host	O
cells	O
and	O
impaired	O
the	O
generation	O
of	O
BCFAs	O
.	O

Addition	O
of	O
short	O
BCFAs	O
and	O
amino	O
acids	O
restored	O
growth	O
of	O
the	O
A1A2	O
-	O
deficient	O
(	O
A1A2	O
-	O
)	O
mutant	O
in	O
minimal	O
medium	O
,	O
implying	O
that	O
lipoate	O
-	O
dependent	O
metabolism	O
generates	O
amino	O
acids	O
and	O
BCFAs	O
.	O

BCFAs	O
alone	O
rescued	O
intracellular	O
growth	O
and	O
spread	O
in	O
L2	O
fibroblasts	O
of	O
the	O
A1A2	O
-	O
mutant	O
.	O

Lipoate	O
-	O
dependent	O
metabolism	O
was	O
also	O
required	O
in	O
vivo	O
,	O
as	O
a	O
wild	O
-	O
type	O
strain	O
robustly	O
outcompeted	O
the	O
lipoylation	O
-	O
deficient	O
mutant	O
in	O
a	O
murine	O
model	O
of	O
listeriosis	O
.	O

The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
lipoate	O
-	O
dependent	O
metabolism	O
contributes	O
to	O
both	O
amino	O
acid	O
and	O
BCFA	O
biosynthesis	O
and	O
that	O
BCFA	O
biosynthesis	O
is	O
preferentially	O
required	O
for	O
intracellular	O
growth	O
of	O
L	O
.	O
monocytogenes	O
.	O

Eliminylation	O
:	O
a	O
post	O
-	O
translational	O
modification	O
catalyzed	O
by	O
phosphothreonine	O
lyases	O
.	O

We	O
propose	O
the	O
classification	O
of	O
a	O
protein	O
post	O
-	O
translational	O
modification	O
,	O
eliminylation	O
,	O
based	O
on	O
the	O
recently	O
delineated	O
mechanism	O
of	O
the	O
Shigella	O
OspF	B-Protein
and	O
Salmonella	O
SpvC	B-Protein
phosphothreonine	O
lyases	O
.	O

These	O
bacterial	O
type	O
-	O
III	O
secretion	O
-	O
system	O
virulence	O
factors	O
are	O
injected	O
into	O
eukaryotic	O
cells	O
and	O
inhibit	O
signalling	O
by	O
irreversibly	O
inactivating	O
mitogen	O
-	O
activated	O
protein	O
kinases	O
(	O
MAPKs	O
)	O
.	O

Remarkably	O
,	O
they	O
employ	O
an	O
unusual	O
beta	O
-	O
elimination	O
reaction	O
,	O
removing	O
the	O
phosphate	O
from	O
phosphothreonine	O
and	O
converting	O
it	O
into	O
dehydrobutyrine	O
(	O
an	O
alkene	O
)	O
.	O

Eliminylated	O
cysteine	O
can	O
also	O
be	O
produced	O
by	O
decarboxylation	O
and	O
eliminylated	O
serine	O
and	O
threonine	O
by	O
dehydration	O
;	O
these	O
residues	O
are	O
found	O
in	O
the	O
eye	O
lens	O
and	O
in	O
bacterial	O
lantibiotics	O
.	O

We	O
postulate	O
that	O
eliminylation	O
might	O
be	O
a	O
widespread	O
regulatory	O
modification	O
,	O
and	O
we	O
propose	O
the	O
use	O
of	O
phosphothreonine	O
lyases	O
as	O
in	O
vivo	O
MAPK	O
inhibitors	O
both	O
therapeutically	O
and	O
to	O
investigate	O
MAPK	O
signalling	O
regulation	O
.	O

Antigenic	O
protein	O
modifications	O
in	O
Ehrlichia	O
.	O

To	O
develop	O
effective	O
vaccination	O
strategies	O
against	O
Ehrlichia	O
,	O
we	O
have	O
previously	O
reported	O
developing	O
an	O
animal	O
model	O
of	O
cross	O
-	O
protection	O
in	O
which	O
C57BL	O
/	O
6	O
mice	O
primed	O
with	O
E	O
.	O
muris	O
were	O
resistant	O
to	O
lethal	O
infection	O
with	O
Ixodes	O
ovatus	O
ehrlichia	O
(	O
IOE	O
)	O
.	O

Polyclonal	O
antibody	O
produced	O
in	O
mice	O
after	O
priming	O
with	O
E	O
.	O
muris	O
and	O
later	O
injected	O
with	O
IOE	O
-	O
detected	O
antigenic	O
proteins	O
in	O
E	O
.	O
muris	O
and	O
IOE	O
cell	O
lysates	O
.	O

Cross	O
-	O
reaction	O
of	O
antigenic	O
proteins	O
was	O
observed	O
when	O
we	O
probed	O
both	O
the	O
E	O
.	O
muris	O
and	O
IOE	O
cell	O
lysates	O
with	O
IOE	O
and	O
E	O
.	O
muris	O
-	O
specific	O
polyclonal	O
antibody	O
.	O

Analysis	O
of	O
the	O
total	O
proteins	O
of	O
E	O
.	O
muris	O
and	O
IOE	O
by	O
two	O
dimensional	O
electrophoresis	O
showed	O
that	O
both	O
E	O
.	O
muris	O
and	O
IOE	O
have	O
the	O
same	O
antigenic	O
proteins	O
.	O

Finally	O
,	O
studies	O
on	O
post	O
-	O
translational	O
protein	O
modifications	O
using	O
a	O
novel	O
technique	O
,	O
Eastern	O
blotting	O
,	O
showed	O
that	O
E	O
.	O
muris	O
proteins	O
are	O
more	O
lipoylated	O
and	O
glycosylated	O
than	O
those	O
of	O
IOE	O
.	O

Regulation	O
of	O
AMPA	O
receptor	O
extrasynaptic	O
insertion	O
by	O
4	B-Protein
.	I-Protein
1N	I-Protein
,	O
phosphorylation	O
and	O
palmitoylation	O
.	O

The	O
insertion	O
of	O
AMPA	O
receptors	O
(	O
AMPARs	O
)	O
into	O
the	O
plasma	O
membrane	O
is	O
an	O
important	O
step	O
in	O
the	O
synaptic	O
delivery	O
of	O
AMPARs	O
during	O
the	O
expression	O
of	O
synaptic	O
plasticity	O
.	O

However	O
,	O
the	O
molecular	O
mechanisms	O
regulating	O
AMPAR	O
insertion	O
remain	O
elusive	O
.	O

By	O
directly	O
visualizing	O
individual	O
insertion	O
events	O
of	O
the	O
AMPAR	O
subunit	O
GluR1	B-Protein
in	O
rodents	O
,	O
we	O
found	O
that	O
the	O
protein	O
4	B-Protein
.	I-Protein
1N	I-Protein
was	O
required	O
for	O
activity	O
-	O
dependent	O
GluR1	B-Protein
insertion	O
.	O

Protein	O
kinase	O
C	O
(	O
PKC	O
)	O
phosphorylation	O
of	O
the	O
serine	O
816	O
(	O
S816	O
)	O
and	O
S818	O
residues	O
of	O
GluR1	B-Protein
enhanced	O
4	B-Protein
.	I-Protein
1N	I-Protein
binding	O
to	O
GluR1	B-Protein
and	O
facilitated	O
GluR1	B-Protein
insertion	O
.	O

In	O
addition	O
,	O
palmitoylation	O
of	O
GluR1	B-Protein
C811	O
residue	O
modulated	O
PKC	O
phosphorylation	O
and	O
GluR1	B-Protein
insertion	O
.	O

Finally	O
,	O
disrupting	O
4	B-Protein
.	I-Protein
1N	I-Protein
-	O
dependent	O
GluR1	B-Protein
insertion	O
decreased	O
surface	O
expression	O
of	O
GluR1	B-Protein
and	O
the	O
expression	O
of	O
long	O
-	O
term	O
potentiation	O
.	O

Our	O
study	O
uncovers	O
a	O
previously	O
unknown	O
mechanism	O
that	O
governs	O
activity	O
-	O
dependent	O
GluR1	B-Protein
trafficking	O
,	O
reveals	O
an	O
interaction	O
between	O
AMPAR	O
palmitoylation	O
and	O
phosphorylation	O
,	O
and	O
underscores	O
the	O
functional	O
importance	O
of	O
4	B-Protein
.	I-Protein
1N	I-Protein
in	O
AMPAR	O
trafficking	O
and	O
synaptic	O
plasticity	O
.	O

Using	O
RNA	O
interference	O
to	O
identify	O
specific	O
modifiers	O
of	O
a	O
temperature	O
-	O
sensitive	O
,	O
embryonic	O
-	O
lethal	O
mutation	O
in	O
the	O
Caenorhabditis	O
elegans	O
ubiquitin	B-Protein
-	O
like	O
Nedd8	B-Protein
protein	O
modification	O
pathway	O
E1	O
-	O
activating	O
gene	O
rfl	B-Protein
-	I-Protein
1	I-Protein
.	O

The	O
essential	O
Caenorhabditis	O
elegans	O
gene	O
rfl	B-Protein
-	I-Protein
1	I-Protein
encodes	O
one	O
subunit	O
of	O
a	O
heterodimeric	O
E1	O
-	O
activating	O
enzyme	O
in	O
the	O
Nedd8	B-Protein
ubiquitin	B-Protein
-	O
like	O
protein	O
conjugation	O
pathway	O
.	O

This	O
pathway	O
modifies	O
the	O
Cullin	O
scaffolds	O
of	O
E3	O
ubiquitin	B-Protein
ligases	O
with	O
a	O
single	O
Nedd8	B-Protein
moiety	O
to	O
promote	O
ligase	O
function	O
.	O

To	O
identify	O
genes	O
that	O
influence	O
neddylation	O
,	O
we	O
used	O
a	O
synthetic	O
screen	O
to	O
identify	O
genes	O
that	O
,	O
when	O
depleted	O
with	O
RNAi	O
,	O
enhance	O
or	O
suppress	O
the	O
embryonic	O
lethality	O
caused	O
by	O
or198ts	O
,	O
a	O
temperature	O
-	O
sensitive	O
(	O
ts	O
)	O
mutation	O
in	O
rfl	B-Protein
-	I-Protein
1	I-Protein
.	O

We	O
identified	O
reproducible	O
suppressor	O
and	O
enhancer	O
genes	O
and	O
employed	O
a	O
systematic	O
specificity	O
analysis	O
for	O
each	O
modifier	O
using	O
four	O
unrelated	O
ts	O
embryonic	O
lethal	O
mutants	O
.	O

Results	O
of	O
this	O
analysis	O
highlight	O
the	O
importance	O
of	O
specificity	O
controls	O
in	O
identifying	O
genetic	O
interactions	O
relevant	O
to	O
a	O
particular	O
biological	O
process	O
because	O
8	O
/	O
14	O
enhancers	O
and	O
7	O
/	O
21	O
suppressors	O
modified	O
lethality	O
in	O
other	O
mutants	O
.	O

Depletion	O
of	O
the	O
strongest	O
specific	O
suppressors	O
rescued	O
the	O
early	O
embryonic	O
cell	O
division	O
defects	O
in	O
rfl	B-Protein
-	I-Protein
1	I-Protein
(	O
or198ts	O
)	O
mutants	O
.	O

RNAi	O
knockdown	O
of	O
some	O
specific	O
suppressors	O
partially	O
restored	O
Cullin	O
neddylation	O
in	O
rfl	B-Protein
-	I-Protein
1	I-Protein
(	O
or198ts	O
)	O
mutants	O
,	O
consistent	O
with	O
their	O
gene	O
products	O
normally	O
opposing	O
neddylation	O
,	O
and	O
GFP	B-Protein
fusions	O
to	O
several	O
suppressors	O
were	O
detected	O
in	O
the	O
cytoplasm	O
or	O
the	O
nucleus	O
,	O
similar	O
in	O
pattern	O
to	O
Nedd8	B-Protein
conjugation	O
pathway	O
components	O
in	O
early	O
embryonic	O
cells	O
.	O

In	O
contrast	O
,	O
depletion	O
of	O
the	O
two	O
strongest	O
specific	O
enhancers	O
did	O
not	O
affect	O
the	O
early	O
embryonic	O
cell	O
division	O
defects	O
observed	O
in	O
rfl	B-Protein
-	I-Protein
1	I-Protein
(	O
or198ts	O
)	O
mutants	O
,	O
suggesting	O
that	O
they	O
may	O
act	O
at	O
later	O
times	O
in	O
other	O
essential	O
processes	O
.	O

Many	O
of	O
the	O
specific	O
modifiers	O
are	O
conserved	O
in	O
other	O
organisms	O
,	O
and	O
most	O
are	O
nonessential	O
.	O

Thus	O
,	O
when	O
controlled	O
properly	O
for	O
specificity	O
,	O
modifier	O
screens	O
using	O
conditionally	O
lethal	O
C	O
.	O
elegans	O
mutants	O
can	O
identify	O
roles	O
for	O
nonessential	O
but	O
conserved	O
genes	O
in	O
essential	O
processes	O
.	O

Characterization	O
of	O
subcellular	O
localization	O
of	O
duck	O
enteritis	O
virus	O
UL51	B-Protein
protein	O
.	O

BACKGROUND	O
:	O
Knowledge	O
of	O
the	O
subcellular	O
localization	O
of	O
a	O
protein	O
can	O
provide	O
useful	O
insights	O
about	O
its	O
function	O
.	O

While	O
the	O
subcellular	O
localization	O
of	O
many	O
alphaherpesvirus	O
UL51	B-Protein
proteins	O
has	O
been	O
well	O
characterized	O
,	O
little	O
is	O
known	O
about	O
where	O
duck	O
enteritis	O
virus	O
(	O
DEV	O
)	O
UL51	B-Protein
protein	O
(	O
pUL51	B-Protein
)	O
is	O
targeted	O
to	O
.	O

Thus	O
,	O
in	O
this	O
study	O
,	O
we	O
investigated	O
the	O
subcellular	O
localization	O
and	O
distribution	O
of	O
DEV	O
pUL51	B-Protein
by	O
computer	O
aided	O
analysis	O
,	O
as	O
well	O
as	O
indirect	O
immunofluorescence	O
(	O
IIF	O
)	O
and	O
transmission	O
immunoelectron	O
microscopy	O
(	O
TIEM	O
)	O
approaches	O
in	O
DEV	O
-	O
infected	O
cells	O
.	O

RESULTS	O
:	O
The	O
DEV	O
UL51	B-Protein
gene	O
product	O
was	O
identified	O
as	O
an	O
approximate	O
34	O
kDa	O
protein	O
in	O
DEV	O
-	O
infected	O
cells	O
analyzed	O
by	O
western	O
blotting	O
.	O

Computer	O
aided	O
analysis	O
suggested	O
that	O
DEV	O
pUL51	B-Protein
is	O
not	O
targeted	O
to	O
the	O
mitochondrial	O
,	O
extra	O
-	O
cellular	O
or	O
nucleus	O
,	O
but	O
be	O
targeted	O
to	O
the	O
cytoplasmic	O
in	O
host	O
cells	O
,	O
more	O
specifically	O
,	O
palmitoylation	O
of	O
the	O
pUL51	B-Protein
through	O
the	O
N	O
-	O
terminal	O
cysteine	O
at	O
position	O
9	O
makes	O
membrane	O
association	O
and	O
Golgi	O
localization	O
possible	O
.	O

Using	O
IIF	O
analysis	O
,	O
we	O
found	O
that	O
DEV	O
pUL51	B-Protein
was	O
first	O
detected	O
in	O
a	O
juxtanuclear	O
region	O
of	O
DEV	O
-	O
infected	O
cells	O
at	O
9	O
h	O
postinfection	O
(	O
p	O
.	O
i	O
.	O
)	O
,	O
and	O
then	O
was	O
detected	O
widely	O
distributed	O
in	O
the	O
cytoplasm	O
and	O
especially	O
was	O
stronger	O
in	O
the	O
juxtanuclear	O
region	O
from	O
12	O
to	O
60	O
h	O
p	O
.	O
i	O
.	O

TIEM	O
analysis	O
revealed	O
that	O
DEV	O
pUL51	B-Protein
was	O
mainly	O
associated	O
with	O
cytoplasmic	O
virions	O
and	O
also	O
with	O
some	O
membranous	O
structure	O
near	O
the	O
pUL51	B-Protein
-	O
specific	O
immuno	O
-	O
labeling	O
intracellular	O
virion	O
in	O
the	O
cytoplasmic	O
vesicles	O
;	O
moreover	O
,	O
the	O
pUL51	B-Protein
efficiently	O
accumulated	O
in	O
the	O
Golgi	O
apparatus	O
at	O
first	O
,	O
and	O
then	O
was	O
sent	O
to	O
the	O
plasma	O
membrane	O
from	O
the	O
Golgi	O
by	O
some	O
unknown	O
mechanism	O
.	O

CONCLUSION	O
:	O
In	O
this	O
work	O
,	O
we	O
described	O
the	O
basic	O
characteristics	O
of	O
pUL51	B-Protein
subcellular	O
localization	O
and	O
distribution	O
for	O
the	O
first	O
time	O
.	O

From	O
these	O
results	O
,	O
we	O
concluded	O
that	O
palmitoylation	O
at	O
the	O
N	O
-	O
terminal	O
cysteine	O
,	O
which	O
is	O
conserved	O
in	O
all	O
alphaherpesvirus	O
UL51	B-Protein
homologs	O
,	O
is	O
required	O
for	O
its	O
membrane	O
association	O
and	O
Golgi	O
localization	O
,	O
and	O
the	O
pUL51	B-Protein
mainly	O
localized	O
to	O
the	O
juxtanuclear	O
region	O
of	O
DEV	O
-	O
infected	O
cells	O
,	O
as	O
well	O
seemed	O
to	O
be	O
incorporated	O
into	O
mature	O
virions	O
as	O
a	O
component	O
of	O
the	O
tegument	O
.	O

The	O
research	O
will	O
provide	O
useful	O
clues	O
for	O
DEV	O
pUL51	B-Protein
functional	O
analysis	O
,	O
and	O
will	O
be	O
usefull	O
for	O
further	O
understanding	O
the	O
localization	O
properties	O
of	O
alphaherpesvirus	O
UL51	B-Protein
homologs	O
.	O

Palmitoylation	O
of	O
the	O
sphingosine	O
1	O
-	O
phosphate	O
receptor	O
S1P	O
is	O
involved	O
in	O
its	O
signaling	O
functions	O
and	O
internalization	O
.	O

The	O
lipid	O
mediator	O
sphingosine	O
1	O
-	O
phosphate	O
(	O
S1P	O
)	O
regulates	O
several	O
cellular	O
processes	O
through	O
binding	O
to	O
its	O
receptors	O
(	O
S1P	B-Protein
(	I-Protein
1	I-Protein
)	I-Protein
-	O
S1P	B-Protein
(	I-Protein
5	I-Protein
)	I-Protein
)	O
,	O
which	O
are	O
heterotrimeric	O
G	O
protein	O
-	O
coupled	O
receptors	O
.	O

Here	O
,	O
we	O
report	O
that	O
all	O
S1P	O
receptors	O
are	O
palmitoylated	O
.	O

In	O
S1P	B-Protein
(	I-Protein
1	I-Protein
)	I-Protein
,	O
three	O
Cys	O
residues	O
in	O
the	O
cytoplasmic	O
tail	O
are	O
palmitoylated	O
.	O

We	O
examined	O
the	O
roles	O
of	O
palmitoylation	O
of	O
S1P	B-Protein
(	I-Protein
1	I-Protein
)	I-Protein
using	O
model	O
cells	O
in	O
which	O
wild	O
-	O
type	O
S1P	B-Protein
(	I-Protein
1	I-Protein
)	I-Protein
or	O
a	O
non	O
-	O
palmitoylated	O
mutant	O
S1P	B-Protein
(	I-Protein
1	I-Protein
)	I-Protein
was	O
overproduced	O
.	O

Compared	O
with	O
wild	O
-	O
type	O
S1P	B-Protein
(	I-Protein
1	I-Protein
)	I-Protein
,	O
the	O
non	O
-	O
palmitoylated	O
S1P	B-Protein
(	I-Protein
1	I-Protein
)	I-Protein
exhibited	O
binding	O
affinity	O
similar	O
to	O
the	O
natural	O
ligand	O
S1P	O
but	O
lower	O
to	O
the	O
synthetic	O
ligand	O
FTY720	O
phosphate	O
(	O
FTY720	O
-	O
P	O
)	O
,	O
the	O
active	O
form	O
of	O
the	O
immunomodulator	O
FTY720	O
.	O

However	O
,	O
downstream	O
signaling	O
of	O
non	O
-	O
palmitoylated	O
S1P	B-Protein
(	I-Protein
1	I-Protein
)	I-Protein
was	O
similarly	O
affected	O
by	O
S1P	O
and	O
FTY720	O
-	O
P	O
stimulation	O
.	O

Moreover	O
,	O
upon	O
stimulation	O
with	O
S1P	O
,	O
internalization	O
of	O
the	O
mutant	O
non	O
-	O
palmitoylated	O
S1P	B-Protein
(	I-Protein
1	I-Protein
)	I-Protein
was	O
retarded	O
,	O
compared	O
with	O
that	O
of	O
the	O
wild	O
-	O
type	O
protein	O
.	O

This	O
effect	O
was	O
much	O
more	O
pronounced	O
with	O
FTY720	O
-	O
P	O
stimulation	O
.	O

Similar	O
differences	O
were	O
observed	O
for	O
the	O
phosphorylation	O
of	O
S1P	B-Protein
(	I-Protein
1	I-Protein
)	I-Protein
and	O
its	O
mutant	O
.	O

These	O
findings	O
may	O
provide	O
insights	O
into	O
the	O
molecular	O
mechanisms	O
of	O
the	O
pharmacological	O
effects	O
of	O
FTY720	O
.	O

Finally	O
,	O
palmitoylation	O
of	O
wild	O
-	O
type	O
S1P	B-Protein
(	I-Protein
1	I-Protein
)	I-Protein
increased	O
upon	O
treatment	O
with	O
S1P	O
,	O
suggesting	O
that	O
S1P	B-Protein
(	I-Protein
1	I-Protein
)	I-Protein
undergoes	O
a	O
palmitoylation	O
/	O
depalmitoylation	O
cycle	O
after	O
stimulation	O
by	O
its	O
ligands	O
.	O

Tyrosine	O
sulfation	O
:	O
an	O
increasingly	O
recognised	O
post	O
-	O
translational	O
modification	O
of	O
secreted	O
proteins	O
.	O

The	O
post	O
-	O
translational	O
sulfation	O
of	O
tyrosine	O
residues	O
occurs	O
in	O
numerous	O
secreted	O
and	O
integral	O
membrane	O
proteins	O
and	O
,	O
in	O
many	O
cases	O
,	O
plays	O
a	O
crucial	O
role	O
in	O
controlling	O
the	O
interactions	O
of	O
these	O
proteins	O
with	O
physiological	O
binding	O
partners	O
as	O
well	O
as	O
invading	O
pathogens	O
.	O

Recent	O
advances	O
in	O
our	O
understanding	O
of	O
protein	O
tyrosine	O
sulfation	O
have	O
come	O
about	O
owing	O
to	O
the	O
cloning	O
of	O
two	O
human	O
tyrosylprotein	O
sulfotransferases	O
(	O
TPST	B-Protein
-	I-Protein
1	I-Protein
and	O
TPST	B-Protein
-	I-Protein
2	I-Protein
)	O
,	O
the	O
development	O
of	O
novel	O
analytical	O
and	O
synthetic	O
methodologies	O
and	O
detailed	O
studies	O
of	O
proteins	O
and	O
peptides	O
containing	O
sulfotyrosine	O
residues	O
.	O

In	O
this	O
article	O
,	O
we	O
describe	O
the	O
TPST	O
enzymes	O
,	O
review	O
the	O
major	O
techniques	O
available	O
for	O
studying	O
the	O
presence	O
,	O
location	O
and	O
function	O
of	O
tyrosine	O
sulfation	O
in	O
proteins	O
and	O
discuss	O
the	O
biological	O
functions	O
and	O
biochemical	O
interactions	O
of	O
several	O
proteins	O
(	O
or	O
protein	O
families	O
)	O
in	O
which	O
tyrosine	O
sulfation	O
influences	O
the	O
protein	O
function	O
.	O

In	O
particular	O
,	O
we	O
describe	O
the	O
detailed	O
evidence	O
supporting	O
the	O
importance	O
of	O
tyrosine	O
sulfation	O
in	O
the	O
cellular	O
adhesion	O
function	O
of	O
P	B-Protein
-	I-Protein
selectin	I-Protein
glycoprotein	I-Protein
ligand	I-Protein
-	I-Protein
1	I-Protein
,	O
the	O
leukocyte	O
trafficking	O
and	O
pathogen	O
invasion	O
functions	O
of	O
chemokine	O
receptors	O
and	O
the	O
ligand	O
binding	O
and	O
activation	O
of	O
other	O
G	O
-	O
protein	O
-	O
coupled	O
receptors	O
by	O
complement	O
proteins	O
,	O
phospholipdis	O
and	O
glycoprotein	O
hormones	O
.	O

Detection	O
of	O
protein	O
ubiquitination	O
.	O

Ubiquitination	O
,	O
the	O
covalent	O
attachment	O
of	O
the	O
polypeptide	O
ubiquitin	B-Protein
to	O
target	O
proteins	O
,	O
is	O
a	O
key	O
posttranslational	O
modification	O
carried	O
out	O
by	O
a	O
set	O
of	O
three	O
enzymes	O
.	O

They	O
include	O
ubiquitin	B-Protein
-	O
activating	O
enzyme	O
E1	O
,	O
ubiquitin	B-Protein
-	O
conjugating	O
enzyme	O
E2	B-Protein
,	O
and	O
ubiquitin	B-Protein
ligase	O
E3	O
.	O

Unlike	O
to	O
E1	O
and	O
E2	O
,	O
E3	O
ubiquitin	B-Protein
ligases	O
display	O
substrate	O
specificity	O
.	O

On	O
the	O
other	O
hand	O
,	O
numerous	O
deubiquitylating	O
enzymes	O
have	O
roles	O
in	O
processing	O
polyubiquitinated	O
proteins	O
.	O

Ubiquitination	O
can	O
result	O
in	O
change	O
of	O
protein	O
stability	O
,	O
cellular	O
localization	O
,	O
and	O
biological	O
activity	O
.	O

Mutations	O
of	O
genes	O
involved	O
in	O
the	O
ubiquitination	O
/	O
deubiquitination	O
pathway	O
or	O
altered	O
ubiquitin	B-Protein
system	O
function	O
are	O
associated	O
with	O
many	O
different	O
human	O
diseases	O
such	O
as	O
various	O
types	O
of	O
cancer	O
,	O
neurodegeneration	O
,	O
and	O
metabolic	O
disorders	O
.	O

The	O
detection	O
of	O
altered	O
or	O
normal	O
ubiquitination	O
of	O
target	O
proteins	O
may	O
provide	O
a	O
better	O
understanding	O
on	O
the	O
pathogenesis	O
of	O
these	O
diseases	O
.	O

Here	O
,	O
we	O
describe	O
protocols	O
to	O
detect	O
protein	O
ubiquitination	O
in	O
cultured	O
cells	O
in	O
vivo	O
and	O
test	O
tubes	O
in	O
vitro	O
.	O

These	O
protocols	O
are	O
also	O
useful	O
to	O
detect	O
other	O
ubiquitin	B-Protein
-	O
like	O
small	O
molecule	O
modification	O
such	O
as	O
sumolyation	O
and	O
neddylation	O
.	O

Resolving	O
the	O
CSN	O
and	O
CAND1	B-Protein
paradoxes	O
.	O

In	O
this	O
issue	O
of	O
Molecular	O
Cell	O
,	O
Schmidt	O
et	O
al	O
.	O

(	O
2009	O
)	O
untangle	O
the	O
interplay	O
between	O
the	O
COP9	O
signalosome	O
(	O
CSN	O
)	O
,	O
cullin	B-Protein
-	I-Protein
associated	I-Protein
and	I-Protein
neddylation	I-Protein
-	I-Protein
dissociated	I-Protein
1	I-Protein
(	O
CAND1	B-Protein
)	O
protein	O
,	O
and	O
cullin	O
-	O
RING	O
ubiquitin	B-Protein
ligases	O
(	O
CRLs	O
)	O
.	O

PARP	B-Protein
-	I-Protein
1	I-Protein
transcriptional	O
activity	O
is	O
regulated	O
by	O
sumoylation	O
upon	O
heat	O
shock	O
.	O

Heat	O
shock	O
and	O
other	O
environmental	O
stresses	O
rapidly	O
induce	O
transcriptional	O
responses	O
subject	O
to	O
regulation	O
by	O
a	O
variety	O
of	O
post	O
-	O
translational	O
modifications	O
.	O

Among	O
these	O
,	O
poly	O
(	O
ADP	O
-	O
ribosyl	O
)	O
ation	O
and	O
sumoylation	O
have	O
received	O
growing	O
attention	O
.	O

Here	O
we	O
show	O
that	O
the	O
SUMO	O
E3	O
ligase	O
PIASy	B-Protein
interacts	O
with	O
the	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
PARP	B-Protein
-	I-Protein
1	I-Protein
,	O
and	O
that	O
PIASy	B-Protein
mediates	O
heat	O
shock	O
-	O
induced	O
poly	O
-	O
sumoylation	O
of	O
PARP	B-Protein
-	I-Protein
1	I-Protein
.	O

Furthermore	O
,	O
PIASy	B-Protein
,	O
and	O
hence	O
sumoylation	O
,	O
appears	O
indispensable	O
for	O
full	O
activation	O
of	O
the	O
inducible	O
HSP70	B-Protein
.	I-Protein
1	I-Protein
gene	O
.	O

Chromatin	O
immunoprecipitation	O
experiments	O
show	O
that	O
PIASy	B-Protein
,	O
SUMO	O
and	O
the	O
SUMO	O
-	O
conjugating	O
enzyme	O
Ubc9	B-Protein
are	O
rapidly	O
recruited	O
to	O
the	O
HSP70	B-Protein
.	I-Protein
1	I-Protein
promoter	O
upon	O
heat	O
shock	O
,	O
and	O
that	O
they	O
are	O
subsequently	O
released	O
with	O
kinetics	O
similar	O
to	O
PARP	B-Protein
-	I-Protein
1	I-Protein
.	O

Finally	O
,	O
we	O
provide	O
evidence	O
that	O
the	O
SUMO	O
-	O
targeted	O
ubiquitin	B-Protein
ligase	O
RNF4	B-Protein
mediates	O
heat	O
-	O
shock	O
-	O
inducible	O
ubiquitination	O
of	O
PARP	B-Protein
-	I-Protein
1	I-Protein
,	O
regulates	O
the	O
stability	O
of	O
PARP	B-Protein
-	I-Protein
1	I-Protein
,	O
and	O
,	O
like	O
PIASy	B-Protein
,	O
is	O
a	O
positive	O
regulator	O
of	O
HSP70	B-Protein
.	I-Protein
1	I-Protein
gene	O
activity	O
.	O

These	O
results	O
,	O
thus	O
,	O
point	O
to	O
a	O
novel	O
mechanism	O
for	O
regulating	O
PARP	B-Protein
-	I-Protein
1	I-Protein
transcription	O
function	O
,	O
and	O
suggest	O
crosstalk	O
between	O
sumoylation	O
and	O
RNF4	B-Protein
-	O
mediated	O
ubiquitination	O
in	O
regulating	O
gene	O
expression	O
in	O
response	O
to	O
heat	O
shock	O
.	O

Distinct	O
domains	O
within	O
PSD	B-Protein
-	I-Protein
95	I-Protein
mediate	O
synaptic	O
incorporation	O
,	O
stabilization	O
,	O
and	O
activity	O
-	O
dependent	O
trafficking	O
.	O

The	O
postsynaptic	O
density	O
(	O
PSD	O
)	O
consists	O
of	O
a	O
lattice	O
-	O
like	O
array	O
of	O
interacting	O
proteins	O
that	O
organizes	O
and	O
stabilizes	O
receptors	O
,	O
ion	O
channels	O
,	O
structural	O
,	O
and	O
signaling	O
proteins	O
necessary	O
for	O
synaptic	O
function	O
.	O

To	O
study	O
the	O
stabilization	O
of	O
proteins	O
within	O
this	O
structure	O
and	O
the	O
contribution	O
of	O
these	O
proteins	O
to	O
the	O
integrity	O
of	O
the	O
PSD	O
,	O
we	O
tagged	O
synaptic	O
proteins	O
with	O
PAGFP	B-Protein
(	O
photoactivatable	O
green	B-Protein
fluorescent	I-Protein
protein	I-Protein
)	O
and	O
used	O
combined	O
two	O
-	O
photon	O
laser	O
-	O
scanning	O
microscopy	O
and	O
two	O
-	O
photon	O
laser	O
photoactivation	O
to	O
measure	O
their	O
rate	O
of	O
turnover	O
in	O
individual	O
spines	O
of	O
rat	O
CA1	O
pyramidal	O
neurons	O
.	O

We	O
find	O
that	O
PSD	B-Protein
-	I-Protein
95	I-Protein
is	O
highly	O
stable	O
within	O
the	O
spine	O
,	O
more	O
so	O
than	O
other	O
PSD	O
-	O
associated	O
proteins	O
such	O
as	O
CaMKIIalpha	B-Protein
,	O
CaMKIIbeta	B-Protein
,	O
GluR2	B-Protein
,	O
and	O
Stargazin	B-Protein
.	O

Analysis	O
of	O
a	O
series	O
of	O
PSD	B-Protein
-	I-Protein
95	I-Protein
mutants	O
revealed	O
that	O
distinct	O
domains	O
stabilize	O
PSD	B-Protein
-	I-Protein
95	I-Protein
within	O
the	O
PSD	O
and	O
contribute	O
to	O
PSD	O
formation	O
.	O

Stabilization	O
of	O
PSD	B-Protein
-	I-Protein
95	I-Protein
within	O
the	O
PSD	O
requires	O
N	O
-	O
terminal	O
palmitoylation	O
and	O
protein	O
interactions	O
mediated	O
by	O
the	O
first	O
and	O
second	O
PDZ	O
domains	O
,	O
whereas	O
formation	O
of	O
a	O
stable	O
lattice	O
of	O
PSD	B-Protein
-	I-Protein
95	I-Protein
molecules	O
within	O
the	O
PSD	O
additionally	O
requires	O
the	O
C	O
-	O
terminal	O
SH3	O
domain	O
.	O

Furthermore	O
,	O
in	O
a	O
PDZ	O
domain	O
1	O
and	O
2	O
dependent	O
manner	O
,	O
activation	O
of	O
NMDA	O
receptors	O
with	O
a	O
chemical	O
long	O
-	O
term	O
depression	O
protocol	O
rapidly	O
destabilizes	O
PSD	B-Protein
-	I-Protein
95	I-Protein
and	O
causes	O
a	O
subset	O
of	O
the	O
PSD	B-Protein
-	I-Protein
95	I-Protein
molecules	O
previously	O
anchored	O
in	O
the	O
spine	O
to	O
be	O
released	O
.	O

Thus	O
,	O
through	O
the	O
analysis	O
of	O
rates	O
of	O
exchange	O
of	O
synaptic	O
PSD	B-Protein
-	I-Protein
95	I-Protein
,	O
we	O
determine	O
separate	O
domains	O
of	O
PSD	B-Protein
-	I-Protein
95	I-Protein
that	O
play	O
specific	O
roles	O
in	O
establishing	O
a	O
stable	O
postsynaptic	O
lattice	O
,	O
in	O
allowing	O
proteins	O
to	O
enter	O
this	O
lattice	O
,	O
and	O
in	O
reorganizing	O
this	O
structure	O
in	O
response	O
to	O
plasticity	O
-	O
inducing	O
stimuli	O
.	O

Avidin	B-Protein
acylation	O
prevents	O
the	O
complement	O
-	O
dependent	O
lysis	O
of	O
avidin	B-Protein
-	O
carrying	O
erythrocytes	O
.	O

Non	O
-	O
covalent	O
binding	O
of	O
avidin	B-Protein
to	O
biotinylated	O
erythrocytes	O
results	O
in	O
complement	O
-	O
dependent	O
haemolysis	O
.	O

Biotinylated	O
erythrocytes	O
,	O
as	O
well	O
as	O
native	O
cells	O
,	O
are	O
not	O
lysed	O
by	O
complement	O
.	O

Complement	O
activation	O
requires	O
a	O
tight	O
contact	O
between	O
avidin	B-Protein
and	O
the	O
erythrocyte	O
membrane	O
,	O
since	O
avidin	B-Protein
does	O
not	O
in	O
itself	O
activate	O
complement	O
and	O
does	O
not	O
inhibit	O
lysis	O
of	O
sensitized	O
sheep	O
erythrocytes	O
.	O

The	O
efficiency	O
of	O
haemolysis	O
depends	O
on	O
avidin	B-Protein
'	O
s	O
surface	O
density	O
.	O

When	O
the	O
avidin	B-Protein
concentration	O
in	O
the	O
reaction	O
mixture	O
is	O
less	O
than	O
15	O
micrograms	O
/	O
ml	O
,	O
erythrocyte	O
lysis	O
is	O
not	O
induced	O
.	O

However	O
,	O
the	O
attachment	O
of	O
biotinylated	O
antibodies	O
to	O
avidin	B-Protein
-	O
carrying	O
erythrocytes	O
decreases	O
dramatically	O
.	O

Acylation	O
of	O
avidin	B-Protein
with	O
succinic	O
anhydride	O
strongly	O
decreases	O
its	O
ability	O
to	O
induce	O
complement	O
-	O
dependent	O
haemolysis	O
.	O

However	O
,	O
the	O
ability	O
of	O
avidin	B-Protein
to	O
cross	O
-	O
link	O
the	O
biotin	O
-	O
containing	O
structures	O
decreases	O
after	O
acylation	O
.	O

A	O
50	O
%	O
modification	O
of	O
avidin	B-Protein
by	O
succinic	O
anhydride	O
(	O
pI	O
about	O
7	O
.	O
0	O
)	O
allows	O
preparation	O
of	O
'	O
immunoerythrocytes	O
'	O
,	O
which	O
retain	O
their	O
affinity	O
to	O
antigen	O
and	O
stability	O
in	O
the	O
presence	O
of	O
complement	O
.	O

NUB1	B-Protein
promotes	O
cytoplasmic	O
localization	O
of	O
p53	B-Protein
through	O
cooperation	O
of	O
the	O
NEDD8	B-Protein
and	O
ubiquitin	B-Protein
pathways	O
.	O

Non	O
-	O
covalent	O
recognition	O
of	O
ubiquitin	B-Protein
(	O
Ub	B-Protein
)	O
and	O
ubiquitin	B-Protein
-	O
like	O
molecules	O
(	O
Ubls	O
)	O
by	O
interacting	O
proteins	O
has	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
protein	O
function	O
and	O
initiation	O
of	O
signalling	O
events	O
.	O

In	O
addition	O
,	O
growing	O
evidence	O
suggests	O
that	O
regulation	O
of	O
p53	B-Protein
subcellular	O
localization	O
contributes	O
to	O
the	O
biological	O
outcome	O
of	O
the	O
p53	B-Protein
response	O
.	O

Cytoplasmic	O
p53	B-Protein
is	O
shown	O
to	O
promote	O
apoptosis	O
and	O
inhibit	O
the	O
induction	O
of	O
autophagy	O
.	O

In	O
this	O
study	O
we	O
show	O
that	O
NEDD8	B-Protein
ultimate	I-Protein
buster	I-Protein
1	I-Protein
(	O
NUB1	B-Protein
)	O
,	O
a	O
non	O
-	O
covalent	O
interactor	O
of	O
the	O
Ubl	O
NEDD8	B-Protein
(	O
neural	B-Protein
precursor	I-Protein
cell	I-Protein
expressed	I-Protein
,	I-Protein
developmentally	I-Protein
downregulated	I-Protein
8	I-Protein
)	O
,	O
controls	O
the	O
localization	O
of	O
p53	B-Protein
.	O

Expression	O
of	O
NUB1	B-Protein
leads	O
to	O
decreased	O
modification	O
of	O
p53	B-Protein
with	O
NEDD8	B-Protein
and	O
stimulation	O
of	O
p53	B-Protein
ubiquitination	O
.	O

The	O
biological	O
outcome	O
is	O
the	O
cytoplasmic	O
localization	O
and	O
inhibition	O
of	O
the	O
transcriptional	O
activity	O
of	O
p53	B-Protein
.	O

Although	O
the	O
effects	O
of	O
NUB1	B-Protein
on	O
p53	B-Protein
depend	O
on	O
NEDDylation	O
and	O
the	O
murine	B-Protein
double	I-Protein
minute	I-Protein
2	I-Protein
(	O
Mdm2	B-Protein
)	O
E3	O
-	O
ligase	O
,	O
the	O
cooperation	O
of	O
NEDD8	B-Protein
with	O
ubiquitin	B-Protein
is	O
required	O
.	O

The	O
data	O
identify	O
a	O
role	O
for	O
NEDD8	B-Protein
in	O
controlling	O
p53	B-Protein
localization	O
and	O
suggest	O
that	O
NEDD8	B-Protein
can	O
control	O
protein	O
function	O
through	O
its	O
non	O
-	O
covalent	O
recognition	O
by	O
interacting	O
proteins	O
.	O

Small	O
-	O
molecule	O
inhibition	O
of	O
APT1	B-Protein
affects	O
Ras	O
localization	O
and	O
signaling	O
.	O

Cycles	O
of	O
depalmitoylation	O
and	O
repalmitoylation	O
critically	O
control	O
the	O
steady	O
-	O
state	O
localization	O
and	O
function	O
of	O
various	O
peripheral	O
membrane	O
proteins	O
,	O
such	O
as	O
Ras	O
proto	O
-	O
oncogene	O
products	O
.	O

Interference	O
with	O
acylation	O
using	O
small	O
molecules	O
is	O
a	O
strategy	O
to	O
modulate	O
cellular	O
localization	O
-	O
-	O
and	O
thereby	O
unregulated	O
signaling	O
-	O
-	O
caused	O
by	O
palmitoylated	O
Ras	O
proteins	O
.	O

We	O
present	O
the	O
knowledge	O
-	O
based	O
development	O
and	O
characterization	O
of	O
a	O
potent	O
inhibitor	O
of	O
acyl	B-Protein
protein	I-Protein
thioesterase	I-Protein
1	I-Protein
(	O
APT1	B-Protein
)	O
,	O
a	O
bona	O
fide	O
depalmitoylating	O
enzyme	O
that	O
is	O
,	O
so	O
far	O
,	O
poorly	O
characterized	O
in	O
cells	O
.	O

The	O
inhibitor	O
,	O
palmostatin	O
B	O
,	O
perturbs	O
the	O
cellular	O
acylation	O
cycle	O
at	O
the	O
level	O
of	O
depalmitoylation	O
and	O
thereby	O
causes	O
a	O
loss	O
of	O
the	O
precise	O
steady	O
-	O
state	O
localization	O
of	O
palmitoylated	O
Ras	O
.	O

As	O
a	O
consequence	O
,	O
palmostatin	O
B	O
induces	O
partial	O
phenotypic	O
reversion	O
in	O
oncogenic	O
HRasG12V	B-Protein
-	O
transformed	O
fibroblasts	O
.	O

We	O
identify	O
APT1	B-Protein
as	O
one	O
of	O
the	O
thioesterases	O
in	O
the	O
acylation	O
cycle	O
and	O
show	O
that	O
this	O
protein	O
is	O
a	O
cellular	O
target	O
of	O
the	O
inhibitor	O
.	O

Ohr	O
(	O
organic	O
hydroperoxide	O
resistance	O
protein	O
)	O
possesses	O
a	O
previously	O
undescribed	O
activity	O
,	O
lipoyl	O
-	O
dependent	O
peroxidase	O
.	O

The	O
Ohr	O
(	O
organic	O
hydroperoxide	O
resistance	O
)	O
family	O
of	O
15	O
-	O
kDa	O
Cys	O
-	O
based	O
,	O
thiol	O
-	O
dependent	O
peroxidases	O
is	O
central	O
to	O
the	O
bacterial	O
response	O
to	O
stress	O
induced	O
by	O
organic	O
hydroperoxides	O
but	O
not	O
by	O
hydrogen	O
peroxide	O
.	O

Ohr	O
has	O
a	O
unique	O
three	O
-	O
dimensional	O
structure	O
and	O
requires	O
dithiols	O
,	O
but	O
not	O
monothiols	O
,	O
to	O
support	O
its	O
activity	O
.	O

However	O
,	O
the	O
physiological	O
reducing	O
system	O
of	O
Ohr	O
has	O
not	O
yet	O
been	O
identified	O
.	O

Here	O
we	O
show	O
that	O
lipoylated	O
enzymes	O
present	O
in	O
the	O
bacterial	O
extracts	O
of	O
Xylella	O
fastidiosa	O
interacted	O
physically	O
and	O
functionally	O
with	O
this	O
Cys	O
-	O
based	O
peroxidase	O
,	O
whereas	O
thioredoxin	O
and	O
glutathione	O
systems	O
failed	O
to	O
support	O
Ohr	O
peroxidase	O
activity	O
.	O

Furthermore	O
,	O
we	O
could	O
reconstitute	O
in	O
vitro	O
three	O
lipoyl	O
-	O
dependent	O
systems	O
as	O
the	O
Ohr	O
physiological	O
reducing	O
systems	O
.	O

We	O
also	O
showed	O
that	O
OsmC	B-Protein
from	O
Escherichia	O
coli	O
,	O
an	O
orthologue	O
of	O
Ohr	O
from	O
Xylella	O
fastidiosa	O
,	O
is	O
specifically	O
reduced	O
by	O
lipoyl	O
-	O
dependent	O
systems	O
.	O

These	O
results	O
represent	O
the	O
first	O
description	O
of	O
a	O
Cys	O
-	O
based	O
peroxidase	O
that	O
is	O
directly	O
reduced	O
by	O
lipoylated	O
enzymes	O
.	O

One	O
SUMO	O
is	O
sufficient	O
to	O
silence	O
the	O
dimeric	O
potassium	O
channel	O
K2P1	B-Protein
.	O

Small	B-Protein
ubiquitin	I-Protein
modifier	I-Protein
1	I-Protein
(	O
SUMO1	B-Protein
)	O
is	O
shown	O
to	O
regulate	O
K2P1	B-Protein
background	O
channels	O
in	O
the	O
plasma	O
membrane	O
(	O
PM	O
)	O
of	O
live	O
mammalian	O
cells	O
.	O

Confocal	O
microscopy	O
reveals	O
native	O
SUMO1	B-Protein
,	O
SAE1	B-Protein
,	O
and	O
Ubc9	B-Protein
(	O
the	O
enzymes	O
that	O
activate	O
and	O
conjugate	O
SUMO1	B-Protein
)	O
at	O
PM	O
where	O
SUMO1	B-Protein
and	O
expressed	O
human	O
K2P1	B-Protein
are	O
demonstrated	O
to	O
colocalize	O
.	O

Silent	O
K2P1	B-Protein
channels	O
in	O
excised	O
PM	O
patches	O
are	O
activated	O
by	O
SUMO	O
isopeptidase	O
(	O
SENP1	B-Protein
)	O
and	O
resilenced	O
by	O
SUMO1	B-Protein
.	O

K2P1	B-Protein
-	O
Lys274	O
is	O
crucial	O
:	O
when	O
mutated	O
to	O
Gln	O
,	O
Arg	O
,	O
Glu	O
,	O
Asp	O
,	O
Cys	O
,	O
or	O
Ala	O
,	O
the	O
channels	O
are	O
constitutively	O
active	O
and	O
insensitive	O
to	O
SUMO1	B-Protein
and	O
SENP1	B-Protein
.	O

Tandem	O
mass	O
spectrometry	O
confirms	O
conjugation	O
of	O
SUMO1	B-Protein
to	O
the	O
epsilon	O
-	O
amino	O
group	O
of	O
Lys274	O
in	O
vitro	O
.	O

FRET	O
microscopy	O
shows	O
that	O
assembly	O
of	O
K2P1	B-Protein
and	O
SUMO1	B-Protein
requires	O
Lys274	O
.	O

Single	O
-	O
particle	O
TIRF	O
microscopy	O
shows	O
that	O
wild	O
-	O
type	O
channels	O
in	O
PM	O
have	O
two	O
K2P1	B-Protein
subunits	O
and	O
assemble	O
with	O
two	O
SUMO1	B-Protein
monomers	O
.	O

Although	O
channels	O
engineered	O
with	O
one	O
Lys274	O
site	O
carry	O
just	O
one	O
SUMO1	B-Protein
they	O
are	O
activated	O
and	O
silenced	O
by	O
SENP1	B-Protein
and	O
SUMO1	B-Protein
like	O
wild	O
-	O
type	O
channels	O
.	O

Role	O
of	O
the	O
Zn	O
(	O
2	O
+	O
)	O
motif	O
of	O
E1	O
in	O
SUMO	O
adenylation	O
.	O

Post	O
-	O
translational	O
modifications	O
by	O
ubiquitin	B-Protein
-	O
like	O
proteins	O
are	O
among	O
the	O
most	O
important	O
mechanisms	O
for	O
regulating	O
a	O
wide	O
variety	O
of	O
cellular	O
functions	O
.	O

In	O
these	O
modifications	O
an	O
E1	O
enzyme	O
activates	O
each	O
ubiquitin	B-Protein
-	O
like	O
protein	O
(	O
Ubl	O
)	O
by	O
adenylation	O
of	O
the	O
Ubl	O
C	O
-	O
terminal	O
COOH	O
group	O
and	O
then	O
forms	O
a	O
thioester	O
bond	O
with	O
the	O
adenylated	O
C	O
-	O
terminal	O
COOH	O
group	O
of	O
the	O
Ubl	O
.	O

Previous	O
x	O
-	O
ray	O
crystallography	O
studies	O
revealed	O
a	O
conserved	O
zinc	O
motif	O
in	O
the	O
SUMO	O
and	O
NEDD8	B-Protein
E1	O
;	O
however	O
,	O
the	O
function	O
of	O
this	O
Zn	O
(	O
2	O
+	O
)	O
motif	O
is	O
unclear	O
.	O

In	O
this	O
study	O
,	O
using	O
quantitative	O
ATP	O
:	O
PPi	O
isotope	O
exchange	O
assays	O
in	O
combination	O
with	O
site	O
-	O
directed	O
mutagenesis	O
,	O
we	O
show	O
that	O
the	O
conserved	O
Zn	O
(	O
2	O
+	O
)	O
motif	O
in	O
the	O
SUMO	O
E1	O
is	O
important	O
for	O
SUMO	O
adenylation	O
and	O
is	O
critical	O
for	O
the	O
E1	O
pseudo	O
-	O
ordered	O
substrate	O
binding	O
mechanism	O
.	O

Furthermore	O
,	O
Zn	O
(	O
2	O
+	O
)	O
motif	O
mutants	O
showed	O
significantly	O
reduced	O
k	O
(	O
cat	O
)	O
values	O
for	O
ATP	O
:	O
PPi	O
isotope	O
exchange	O
assays	O
,	O
suggesting	O
that	O
the	O
Zn	O
(	O
2	O
+	O
)	O
motif	O
is	O
important	O
in	O
binding	O
and	O
preventing	O
SUMO	O
adenylate	O
from	O
dissociating	O
from	O
E1	O
before	O
formation	O
of	O
the	O
thioester	O
conjugate	O
.	O

Because	O
the	O
Zn	O
(	O
2	O
+	O
)	O
motif	O
is	O
located	O
in	O
a	O
cross	O
-	O
over	O
loop	O
that	O
is	O
known	O
to	O
have	O
conformational	O
flexibility	O
,	O
the	O
results	O
described	O
here	O
suggest	O
that	O
this	O
cross	O
-	O
over	O
loop	O
interacts	O
with	O
Ubl	O
in	O
the	O
multistep	O
,	O
dynamic	O
process	O
of	O
Ubl	O
activation	O
by	O
E1s	O
.	O

Transcriptional	O
repression	O
by	O
sumoylation	O
of	O
Epstein	O
-	O
Barr	O
virus	O
BZLF1	B-Protein
protein	O
correlates	O
with	O
association	O
of	O
histone	O
deacetylase	O
.	O

The	O
transition	O
from	O
latent	O
to	O
lytic	O
phases	O
of	O
the	O
Epstein	O
-	O
Barr	O
virus	O
life	O
cycle	O
is	O
triggered	O
by	O
expression	O
of	O
a	O
viral	O
transactivator	O
,	O
BZLF1	B-Protein
,	O
that	O
then	O
induces	O
expression	O
of	O
the	O
viral	O
immediate	O
-	O
early	O
and	O
early	O
genes	O
.	O

The	O
BZLF1	B-Protein
protein	O
is	O
post	O
-	O
translationally	O
modified	O
by	O
a	O
small	B-Protein
ubiquitin	I-Protein
-	I-Protein
related	I-Protein
modifier	I-Protein
-	I-Protein
1	I-Protein
(	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
)	O
.	O

Here	O
we	O
found	O
that	O
BZLF1	B-Protein
is	O
conjugated	O
at	O
lysine	O
12	O
not	O
only	O
by	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
but	O
also	O
by	O
SUMO	B-Protein
-	I-Protein
2	I-Protein
and	O
3	B-Protein
.	O

The	O
K12R	O
mutant	O
of	O
BZLF1	B-Protein
,	O
which	O
no	O
longer	O
becomes	O
sumoylated	O
,	O
exhibits	O
stronger	O
transactivation	O
than	O
the	O
wild	O
-	O
type	O
BZLF1	B-Protein
in	O
a	O
reporter	O
assay	O
system	O
as	O
well	O
as	O
in	O
the	O
context	O
of	O
virus	O
genome	O
with	O
nucleosomal	O
structures	O
.	O

Furthermore	O
,	O
exogenous	O
supply	O
of	O
a	O
SUMO	O
-	O
specific	O
protease	O
,	O
SENP	B-Protein
,	O
caused	O
de	O
-	O
sumoylation	O
of	O
BZLF1	B-Protein
and	O
enhanced	O
BZLF1	B-Protein
-	O
mediated	O
transactivation	O
.	O

Immunoprecipitation	O
experiments	O
proved	O
that	O
histone	B-Protein
deacetylase	I-Protein
3	I-Protein
preferentially	O
associated	O
with	O
the	O
sumoylated	O
form	O
of	O
BZLF1	B-Protein
.	O

Levels	O
of	O
the	O
sumoylated	O
BZLF1	B-Protein
increased	O
as	O
lytic	O
replication	O
progressed	O
.	O

Based	O
on	O
these	O
observations	O
,	O
we	O
conclude	O
that	O
sumoylation	O
of	O
BZLF1	B-Protein
regulates	O
its	O
transcriptional	O
activity	O
through	O
histone	B-Protein
modification	O
during	O
Epstein	O
-	O
Barr	O
virus	O
productive	O
replication	O
.	O

Sequential	O
and	O
gamma	O
-	O
secretase	O
-	O
dependent	O
processing	O
of	O
the	O
betacellulin	B-Protein
precursor	O
generates	O
a	O
palmitoylated	O
intracellular	O
-	O
domain	O
fragment	O
that	O
inhibits	O
cell	O
growth	O
.	O

Betacellulin	B-Protein
(	O
BTC	B-Protein
)	O
belongs	O
to	O
the	O
family	O
of	O
epidermal	B-Protein
growth	I-Protein
factor	I-Protein
(	O
EGF	B-Protein
)	O
-	O
like	O
growth	O
factors	O
that	O
are	O
expressed	O
as	O
transmembrane	O
precursors	O
and	O
undergo	O
proteolytic	O
ectodomain	O
shedding	O
to	O
release	O
soluble	O
mature	O
ligands	O
.	O

BTC	B-Protein
is	O
a	O
dual	O
-	O
specificity	O
ligand	O
for	O
ErbB1	B-Protein
and	O
ErbB4	B-Protein
receptors	O
,	O
and	O
can	O
activate	O
unique	O
signal	O
-	O
transduction	O
pathways	O
that	O
are	O
beneficial	O
for	O
the	O
function	O
,	O
survival	O
and	O
regeneration	O
of	O
pancreatic	O
beta	O
-	O
cells	O
.	O

We	O
have	O
previously	O
shown	O
that	O
BTC	B-Protein
precursor	O
(	O
proBTC	B-Protein
)	O
is	O
cleaved	O
by	O
ADAM10	B-Protein
to	O
generate	O
soluble	O
ligand	O
and	O
a	O
stable	O
,	O
transmembrane	O
remnant	O
(	O
BTC	B-Protein
-	O
CTF	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
analyzed	O
the	O
fate	O
of	O
the	O
BTC	B-Protein
-	O
CTF	O
in	O
greater	O
detail	O
.	O

We	O
demonstrated	O
that	O
proBTC	B-Protein
is	O
cleaved	O
by	O
ADAM10	B-Protein
to	O
produce	O
BTC	B-Protein
-	O
CTF	O
,	O
which	O
then	O
undergoes	O
intramembrane	O
processing	O
by	O
presenilin	B-Protein
-	I-Protein
1	I-Protein
-	O
and	O
/	O
or	O
presenilin	B-Protein
-	I-Protein
2	I-Protein
-	O
dependent	O
gamma	O
-	O
secretase	O
to	O
generate	O
an	O
intracellular	O
-	O
domain	O
fragment	O
(	O
BTC	B-Protein
-	O
ICD	O
)	O
.	O

We	O
found	O
that	O
the	O
proBTC	B-Protein
cytoplasmic	O
domain	O
is	O
palmitoylated	O
and	O
that	O
palmitoylation	O
is	O
not	O
required	O
for	O
ADAM10	B-Protein
-	O
dependent	O
cleavage	O
but	O
is	O
necessary	O
for	O
the	O
stability	O
and	O
gamma	O
-	O
secretase	O
-	O
dependent	O
processing	O
of	O
BTC	B-Protein
-	O
CTF	O
to	O
generate	O
BTC	B-Protein
-	O
ICD	O
.	O

Additionally	O
,	O
palmitoylation	O
is	O
required	O
for	O
nuclear	O
-	O
membrane	O
localization	O
of	O
BTC	B-Protein
-	O
ICD	O
,	O
as	O
demonstrated	O
by	O
the	O
redistribution	O
of	O
non	O
-	O
palmitoylated	O
BTC	B-Protein
-	O
ICD	O
mutant	O
to	O
the	O
nucleoplasm	O
.	O

Importantly	O
,	O
a	O
novel	O
receptor	O
-	O
independent	O
role	O
for	O
BTC	B-Protein
-	O
ICD	O
signaling	O
is	O
suggested	O
by	O
the	O
ability	O
of	O
BTC	B-Protein
-	O
ICD	O
to	O
inhibit	O
cell	O
growth	O
in	O
vitro	O
.	O

Palmitoylation	O
of	O
SARS	O
-	O
CoV	O
S	B-Protein
protein	I-Protein
is	O
necessary	O
for	O
partitioning	O
into	O
detergent	O
-	O
resistant	O
membranes	O
and	O
cell	O
-	O
cell	O
fusion	O
but	O
not	O
interaction	O
with	O
M	B-Protein
protein	I-Protein
.	O

Coronaviruses	O
are	O
enveloped	O
RNA	O
viruses	O
that	O
generally	O
cause	O
mild	O
disease	O
in	O
humans	O
.	O

However	O
,	O
the	O
recently	O
emerged	O
coronavirus	O
that	O
caused	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
-	O
CoV	O
)	O
is	O
the	O
most	O
pathogenic	O
human	O
coronavirus	O
discovered	O
to	O
date	O
.	O

The	O
SARS	O
-	O
CoV	O
spike	B-Protein
(	I-Protein
S	I-Protein
)	I-Protein
protein	I-Protein
mediates	O
virus	O
entry	O
by	O
binding	O
cellular	O
receptors	O
and	O
inducing	O
fusion	O
between	O
the	O
viral	O
envelope	O
and	O
the	O
host	O
cell	O
membrane	O
.	O

Coronavirus	O
S	O
proteins	O
are	O
palmitoylated	O
,	O
which	O
may	O
affect	O
function	O
.	O

Here	O
,	O
we	O
created	O
a	O
non	O
-	O
palmitoylated	O
SARS	O
-	O
CoV	O
S	B-Protein
protein	I-Protein
by	O
mutating	O
all	O
nine	O
cytoplasmic	O
cysteine	O
residues	O
.	O

Palmitoylation	O
of	O
SARS	O
-	O
CoV	O
S	B-Protein
was	O
required	O
for	O
partitioning	O
into	O
detergent	O
-	O
resistant	O
membranes	O
and	O
for	O
cell	O
-	O
cell	O
fusion	O
.	O

Surprisingly	O
,	O
however	O
,	O
palmitoylation	O
of	O
S	B-Protein
was	O
not	O
required	O
for	O
interaction	O
with	O
SARS	O
-	O
CoV	O
M	B-Protein
protein	I-Protein
.	O

This	O
contrasts	O
with	O
the	O
requirement	O
for	O
palmitoylation	O
of	O
mouse	O
hepatitis	O
virus	O
S	B-Protein
protein	I-Protein
for	O
interaction	O
with	O
M	B-Protein
protein	I-Protein
and	O
may	O
point	O
to	O
important	O
differences	O
in	O
assembly	O
and	O
infectivity	O
of	O
these	O
two	O
coronaviruses	O
.	O

Elucidation	O
of	O
XA21	B-Protein
-	O
mediated	O
innate	O
immunity	O
.	O

In	O
the	O
early	O
1970s	O
,	O
the	O
Xa21	B-Protein
gene	O
from	O
the	O
wild	O
rice	O
species	O
Oryza	O
longistaminata	O
drew	O
attention	O
of	O
rice	O
breeders	O
because	O
of	O
its	O
broad	O
-	O
spectrum	O
resistance	O
to	O
diverse	O
strains	O
of	O
a	O
serious	O
bacterial	O
disease	O
of	O
rice	O
in	O
Asia	O
and	O
Africa	O
,	O
called	O
'	O
bacterial	O
blight	O
disease	O
'	O
,	O
caused	O
by	O
the	O
Gram	O
-	O
negative	O
bacterium	O
,	O
Xanthomonas	O
oryzae	O
pv	O
.	O
oryzae	O
(	O
Xoo	O
)	O
.	O

In	O
1995	O
,	O
we	O
isolated	O
the	O
gene	O
controlling	O
this	O
resistance	O
and	O
in	O
2009	O
demonstrated	O
that	O
XA21	B-Protein
recognizes	O
a	O
highly	O
conserved	O
peptide	O
,	O
called	O
'	O
Ax21	B-Protein
'	O
(	O
activator	B-Protein
of	I-Protein
XA21	I-Protein
-	I-Protein
mediated	I-Protein
immunity	I-Protein
)	O
.	O

Tyrosine	O
sulfation	O
of	O
Ax21	B-Protein
is	O
required	O
for	O
recognition	O
by	O
rice	O
XA21	B-Protein
.	O

A	O
decade	O
of	O
genetic	O
,	O
molecular	O
and	O
biochemical	O
studies	O
have	O
uncovered	O
key	O
components	O
of	O
the	O
XA21	B-Protein
-	O
mediated	O
signalling	O
cascade	O
.	O

Ax21	B-Protein
recognition	O
by	O
XA21	B-Protein
at	O
the	O
cell	O
surface	O
induces	O
phosphorylation	O
-	O
mediated	O
events	O
,	O
which	O
are	O
predicted	O
to	O
alter	O
subcellular	O
localization	O
and	O
/	O
or	O
DNA	O
-	O
binding	O
activity	O
of	O
a	O
WRKY	O
family	O
of	O
transcription	O
factors	O
.	O

Because	O
XA21	B-Protein
is	O
representative	O
of	O
the	O
large	O
number	O
of	O
predicted	O
pattern	O
recognition	O
receptors	O
(	O
PRRs	O
)	O
in	O
rice	O
(	O
n	O
=	O
328	O
)	O
,	O
Arabidopsis	O
(	O
n	O
=	O
35	O
)	O
and	O
other	O
plant	O
species	O
,	O
further	O
characterization	O
of	O
XA21	B-Protein
-	O
mediated	O
signalling	O
pathways	O
will	O
contribute	O
to	O
elucidation	O
of	O
these	O
important	O
defence	O
responses	O
.	O

dHIP14	B-Protein
-	O
dependent	O
palmitoylation	O
promotes	O
secretion	O
of	O
the	O
BMP	O
antagonist	O
Sog	B-Protein
.	O

Analysis	O
of	O
diverse	O
signaling	O
systems	O
has	O
revealed	O
that	O
one	O
important	O
level	O
of	O
control	O
is	O
regulation	O
of	O
membrane	O
trafficking	O
of	O
ligands	O
and	O
receptors	O
.	O

The	O
activities	O
of	O
some	O
ligands	O
are	O
also	O
regulated	O
by	O
whether	O
they	O
are	O
membrane	O
bound	O
or	O
secreted	O
.	O

In	O
Drosophila	O
,	O
several	O
morphogenetic	O
signals	O
that	O
play	O
critical	O
roles	O
in	O
development	O
have	O
been	O
found	O
to	O
be	O
subject	O
to	O
such	O
regulation	O
.	O

For	O
example	O
,	O
activity	O
of	O
the	O
Hedgehog	B-Protein
(	O
Hh	B-Protein
)	O
is	O
regulated	O
by	O
Raspberry	B-Protein
,	O
which	O
palmitoylates	O
Hh	B-Protein
.	O

Similarly	O
,	O
the	O
palmitoylases	O
Porcupine	B-Protein
and	O
Raspberry	B-Protein
increase	O
the	O
activities	O
of	O
Wingless	B-Protein
(	O
Wg	B-Protein
)	O
and	O
the	O
EGF	O
-	O
ligand	O
Spitz	B-Protein
(	O
Spi	B-Protein
)	O
,	O
respectively	O
.	O

In	O
contrast	O
to	O
its	O
vertebrate	O
homologues	O
,	O
which	O
have	O
typical	O
N	O
-	O
terminal	O
signal	O
sequences	O
,	O
the	O
precursor	O
form	O
of	O
Drosophila	O
Hh	B-Protein
contains	O
an	O
internal	O
type	O
-	O
II	O
secretory	O
signal	O
motif	O
.	O

The	O
Short	B-Protein
Gastrulation	I-Protein
(	O
Sog	B-Protein
)	O
protein	O
is	O
another	O
secreted	O
Drosophila	O
protein	O
that	O
contains	O
a	O
type	O
-	O
II	O
signal	O
and	O
differs	O
from	O
its	O
vertebrate	O
ortholog	O
Chordin	B-Protein
which	O
contains	O
a	O
standard	O
signal	O
peptide	O
.	O

In	O
this	O
study	O
,	O
we	O
examine	O
the	O
regulation	O
of	O
Sog	B-Protein
secretion	O
and	O
regulation	O
by	O
dHIP14	B-Protein
,	O
the	O
ortholog	O
of	O
a	O
mammalian	O
palmitoylase	O
first	O
identified	O
as	O
Huntington	O
Interacting	O
Protein	O
(	O
HIP	O
)	O
.	O

We	O
show	O
that	O
dHIP14	B-Protein
binds	O
to	O
Sog	B-Protein
and	O
that	O
Sog	B-Protein
is	O
palmitoylated	O
.	O

In	O
S2	O
cells	O
,	O
dHIP14	B-Protein
promotes	O
secretion	O
of	O
Sog	B-Protein
as	O
well	O
as	O
stabilizing	O
a	O
membrane	O
associated	O
form	O
of	O
Sog	B-Protein
.	O

We	O
examined	O
the	O
requirement	O
for	O
candidate	O
cysteine	O
residues	O
in	O
the	O
N	O
-	O
terminal	O
predicted	O
cytoplasmic	O
domain	O
of	O
Sog	B-Protein
and	O
find	O
that	O
Cys27	O
,	O
one	O
of	O
two	O
adjacent	O
cysteines	O
(	O
Cys27	O
and	O
Cys28	O
)	O
,	O
is	O
essential	O
for	O
the	O
full	O
activity	O
of	O
dHIP14	B-Protein
and	O
its	O
effect	O
on	O
Sog	B-Protein
.	O

Finally	O
,	O
we	O
find	O
that	O
dHIP14	B-Protein
promotes	O
the	O
activity	O
of	O
Sog	B-Protein
in	O
vivo	O
.	O

These	O
studies	O
highlight	O
the	O
growing	O
importance	O
of	O
lipid	O
modification	O
in	O
regulating	O
signaling	O
at	O
the	O
level	O
of	O
ligand	O
production	O
and	O
localization	O
.	O

GlcNAcylation	O
plays	O
an	O
essential	O
role	O
in	O
breast	O
cancer	O
metastasis	O
.	O

GlcNAcylation	O
,	O
a	O
dynamic	O
posttranslational	O
modification	O
,	O
is	O
involved	O
in	O
a	O
wide	O
range	O
of	O
biological	O
processes	O
and	O
some	O
human	O
diseases	O
.	O

Although	O
there	O
is	O
emerging	O
evidence	O
that	O
some	O
tumor	O
-	O
associated	O
proteins	O
are	O
modified	O
by	O
GlcNAcylation	O
,	O
the	O
role	O
of	O
GlcNAcylation	O
in	O
tumor	O
progression	O
remains	O
unclear	O
.	O

Here	O
,	O
we	O
show	O
that	O
GlcNAcylation	O
enhances	O
the	O
migration	O
/	O
invasion	O
of	O
breast	O
cancer	O
cells	O
in	O
vitro	O
and	O
lung	O
metastasis	O
in	O
vivo	O
.	O

The	O
decrease	O
of	O
cell	O
surface	O
E	B-Protein
-	I-Protein
cadherin	I-Protein
is	O
the	O
molecular	O
mechanism	O
underlying	O
GlcNAcylation	O
-	O
induced	O
breast	O
cancer	O
metastasis	O
.	O

p120	B-Protein
and	O
beta	B-Protein
-	I-Protein
catenin	I-Protein
,	O
but	O
not	O
E	B-Protein
-	I-Protein
cadherin	I-Protein
,	O
are	O
GlcNAcylated	O
;	O
the	O
GlcNAcylation	O
of	O
p120	B-Protein
and	O
beta	B-Protein
-	I-Protein
catenin	I-Protein
might	O
play	O
roles	O
in	O
the	O
decrease	O
of	O
cell	O
surface	O
E	B-Protein
-	I-Protein
cadherin	I-Protein
.	O

Moreover	O
,	O
immunohistochemistry	O
analysis	O
indicated	O
that	O
the	O
global	O
GlcNAcylation	O
level	O
in	O
breast	O
tumor	O
tissues	O
is	O
elevated	O
significantly	O
as	O
compared	O
with	O
that	O
in	O
the	O
corresponding	O
adjacent	O
tissues	O
;	O
further	O
,	O
GlcNAcylation	O
was	O
significantly	O
enhanced	O
in	O
metastatic	O
lymph	O
nodes	O
compared	O
with	O
their	O
corresponding	O
primary	O
tumor	O
tissues	O
.	O

This	O
is	O
the	O
first	O
report	O
to	O
clearly	O
elucidate	O
the	O
roles	O
and	O
mechanisms	O
whereby	O
GlcNAcylation	O
influences	O
the	O
malignant	O
properties	O
of	O
breast	O
cancer	O
cells	O
.	O

These	O
results	O
also	O
suggest	O
that	O
GlcNAcylation	O
might	O
be	O
a	O
potential	O
target	O
for	O
the	O
diagnosis	O
and	O
therapy	O
of	O
breast	O
cancer	O
.	O

C	O
.	O
elegans	O
CAND	B-Protein
-	I-Protein
1	I-Protein
regulates	O
cullin	O
neddylation	O
,	O
cell	O
proliferation	O
and	O
morphogenesis	O
in	O
specific	O
tissues	O
.	O

Cullin	O
-	O
RING	O
ubiquitin	B-Protein
ligases	O
(	O
CRLs	O
)	O
are	O
critical	O
regulators	O
of	O
multiple	O
developmental	O
and	O
cellular	O
processes	O
in	O
eukaryotes	O
.	O

CAND1	B-Protein
is	O
a	O
biochemical	O
inhibitor	O
of	O
CRLs	O
,	O
yet	O
has	O
been	O
shown	O
to	O
promote	O
CRL	O
activity	O
in	O
plant	O
and	O
mammalian	O
cells	O
.	O

Here	O
we	O
analyze	O
CAND1	B-Protein
function	O
in	O
the	O
context	O
of	O
a	O
developing	O
metazoan	O
organism	O
.	O

Caenorhabditis	O
elegans	O
CAND	B-Protein
-	I-Protein
1	I-Protein
is	O
capable	O
of	O
binding	O
to	O
all	O
of	O
the	O
cullins	O
,	O
and	O
we	O
show	O
that	O
it	O
physically	O
interacts	O
with	O
CUL	B-Protein
-	I-Protein
2	I-Protein
and	O
CUL	B-Protein
-	I-Protein
4	I-Protein
in	O
vivo	O
.	O

The	O
covalent	O
attachment	O
of	O
the	O
ubiquitin	B-Protein
-	O
like	O
protein	O
Nedd8	B-Protein
is	O
required	O
for	O
cullin	O
activity	O
in	O
animals	O
and	O
plants	O
.	O

In	O
cand	B-Protein
-	I-Protein
1	I-Protein
mutants	O
,	O
the	O
levels	O
of	O
the	O
neddylated	O
isoforms	O
of	O
CUL	B-Protein
-	I-Protein
2	I-Protein
and	O
CUL	B-Protein
-	I-Protein
4	I-Protein
are	O
increased	O
,	O
indicating	O
that	O
CAND	B-Protein
-	I-Protein
1	I-Protein
is	O
a	O
negative	O
regulator	O
of	O
cullin	O
neddylation	O
.	O

cand	B-Protein
-	I-Protein
1	I-Protein
mutants	O
are	O
hypersensitive	O
to	O
the	O
partial	O
loss	O
of	O
cullin	O
activity	O
,	O
suggesting	O
that	O
CAND	B-Protein
-	I-Protein
1	I-Protein
facilitates	O
CRL	O
functions	O
.	O

cand	B-Protein
-	I-Protein
1	I-Protein
mutants	O
exhibit	O
impenetrant	O
phenotypes	O
,	O
including	O
developmental	O
arrest	O
,	O
morphological	O
defects	O
of	O
the	O
vulva	O
and	O
tail	O
,	O
and	O
reduced	O
fecundity	O
.	O

cand	B-Protein
-	I-Protein
1	I-Protein
mutants	O
share	O
with	O
cul	B-Protein
-	I-Protein
1	I-Protein
and	O
lin	B-Protein
-	I-Protein
23	I-Protein
mutants	O
the	O
phenotypes	O
of	O
supernumerary	O
seam	O
cell	O
divisions	O
,	O
defective	O
alae	O
formation	O
,	O
and	O
the	O
accumulation	O
of	O
the	O
SCF	O
(	O
LIN	B-Protein
-	I-Protein
23	I-Protein
)	O
target	O
the	O
glutamate	O
receptor	O
GLR	B-Protein
-	I-Protein
1	I-Protein
.	O

The	O
observation	O
that	O
cand	B-Protein
-	I-Protein
1	I-Protein
mutants	O
have	O
phenotypes	O
associated	O
with	O
the	O
loss	O
of	O
the	O
SCF	O
(	O
LIN	B-Protein
-	I-Protein
23	I-Protein
)	O
complex	O
,	O
but	O
lack	O
phenotypes	O
associated	O
with	O
other	O
specific	O
CRL	O
complexes	O
,	O
suggests	O
that	O
CAND	B-Protein
-	I-Protein
1	I-Protein
is	O
differentially	O
required	O
for	O
the	O
activity	O
of	O
distinct	O
CRL	O
complexes	O
.	O

Engineering	O
a	O
protein	O
-	O
protein	O
interface	O
using	O
a	O
computationally	O
designed	O
library	O
.	O

Computational	O
algorithms	O
for	O
protein	O
design	O
can	O
sample	O
large	O
regions	O
of	O
sequence	O
space	O
,	O
but	O
suffer	O
from	O
undersampling	O
of	O
conformational	O
space	O
and	O
energy	O
function	O
inaccuracies	O
.	O

Experimental	O
screening	O
of	O
combinatorial	O
protein	O
libraries	O
avoids	O
the	O
need	O
for	O
accurate	O
energy	O
functions	O
,	O
but	O
has	O
limited	O
access	O
to	O
vast	O
amounts	O
of	O
sequence	O
space	O
.	O

Here	O
,	O
we	O
test	O
if	O
these	O
two	O
traditionally	O
alternative	O
,	O
but	O
potentially	O
complementary	O
approaches	O
can	O
be	O
combined	O
to	O
design	O
a	O
variant	O
of	O
the	O
ubiquitin	B-Protein
-	O
ligase	O
E6AP	B-Protein
that	O
will	O
bind	O
to	O
a	O
nonnatural	O
partner	O
,	O
the	O
NEDD8	B-Protein
-	O
conjugating	O
enzyme	O
Ubc12	B-Protein
.	O

Three	O
E6AP	B-Protein
libraries	O
were	O
constructed	O
:	O
(	O
i	O
)	O
a	O
naive	O
library	O
in	O
which	O
all	O
20	O
amino	O
acids	O
were	O
allowed	O
at	O
every	O
position	O
on	O
the	O
target	O
-	O
binding	O
surface	O
of	O
E6AP	B-Protein
(	O
13	O
positions	O
)	O
,	O
(	O
ii	O
)	O
a	O
semidirected	O
library	O
that	O
varied	O
the	O
same	O
residue	O
positions	O
as	O
in	O
the	O
naive	O
library	O
but	O
disallowed	O
mutations	O
computationally	O
predicted	O
to	O
destabilize	O
E6AP	B-Protein
,	O
and	O
(	O
iii	O
)	O
a	O
directed	O
library	O
that	O
used	O
docking	O
and	O
sequence	O
optimization	O
simulations	O
to	O
identify	O
mutations	O
predicted	O
to	O
be	O
favorable	O
for	O
binding	O
Ubc12	B-Protein
.	O

Both	O
of	O
the	O
directed	O
libraries	O
showed	O
>	O
30	O
-	O
fold	O
enrichment	O
over	O
the	O
naive	O
library	O
after	O
the	O
first	O
round	O
of	O
screening	O
with	O
a	O
split	O
-	O
dihydrofolate	B-Protein
reductase	I-Protein
complementation	O
assay	O
and	O
produced	O
multiple	O
tight	O
binders	O
(	O
K	O
(	O
d	O
)	O
<	O
100	O
nM	O
)	O
after	O
four	O
rounds	O
of	O
selection	O
.	O

Four	O
rounds	O
of	O
selection	O
with	O
the	O
naive	O
library	O
failed	O
to	O
produce	O
any	O
binders	O
with	O
K	O
(	O
d	O
)	O
'	O
s	O
lower	O
than	O
50	O
mu	O
M	O
.	O

These	O
results	O
indicate	O
that	O
protein	O
design	O
simulations	O
can	O
be	O
used	O
to	O
create	O
directed	O
libraries	O
that	O
are	O
enriched	O
in	O
tight	O
binders	O
and	O
that	O
in	O
some	O
cases	O
it	O
is	O
sufficient	O
to	O
computationally	O
screen	O
for	O
well	O
-	O
folded	O
sequences	O
without	O
explicit	O
binding	O
calculations	O
.	O

Involvement	O
of	O
a	O
pertussis	O
toxin	O
-	O
sensitive	O
G	O
protein	O
in	O
the	O
regulation	O
of	O
angiotensinogen	O
production	O
by	O
an	O
angiotensin	B-Protein
II	I-Protein
analog	O
in	O
HepG2	O
cells	O
.	O

The	O
cellular	O
mechanism	O
by	O
which	O
the	O
angiotensin	B-Protein
II	I-Protein
(	O
AII	B-Protein
)	O
agonist	O
,	O
Sar1	O
-	O
AII	O
,	O
inhibits	O
production	O
and	O
release	O
of	O
angiotensinogen	B-Protein
in	O
human	O
hepatoma	O
HepG2	O
cells	O
was	O
examined	O
.	O

Pretreatment	O
of	O
HepG2	O
cells	O
with	O
pertussis	O
toxin	O
attenuated	O
the	O
ability	O
of	O
Sar1	O
-	O
AII	O
to	O
block	O
angiotensinogen	B-Protein
production	O
.	O

This	O
effect	O
could	O
be	O
correlated	O
with	O
the	O
in	O
situ	O
ADP	O
-	O
ribosylation	O
of	O
a	O
protein	O
(	O
s	O
)	O
of	O
apparent	O
molecular	O
weight	O
39	O
,	O
000	O
-	O
41	O
,	O
000	O
on	O
SDS	O
-	O
PAGE	O
,	O
and	O
attenuation	O
of	O
the	O
ability	O
of	O
Sar1	O
-	O
AII	O
to	O
inhibit	O
cAMP	O
accumulation	O
.	O

The	O
role	O
of	O
cAMP	O
in	O
angiotensinogen	B-Protein
production	O
was	O
examined	O
.	O

A	O
transient	O
increase	O
in	O
cAMP	O
accumulation	O
above	O
basal	O
could	O
be	O
evoked	O
by	O
forskolin	O
(	O
8	O
-	O
fold	O
)	O
or	O
by	O
glucagon	B-Protein
(	O
5	O
-	O
fold	O
)	O
using	O
insulin	B-Protein
-	O
deficient	O
media	O
.	O

Although	O
neither	O
forskolin	O
nor	O
glucagon	B-Protein
had	O
a	O
significant	O
effect	O
on	O
angiotensinogen	B-Protein
production	O
agents	O
producing	O
a	O
sustained	O
increase	O
in	O
intracellular	O
cAMP	O
(	O
8	O
-	O
bromo	O
-	O
cAMP	O
,	O
dibutyryl	O
-	O
cAMP	O
,	O
cholera	O
toxin	O
)	O
were	O
able	O
to	O
increase	O
angiotensinogen	B-Protein
production	O
.	O

Although	O
these	O
data	O
indicate	O
that	O
intracellular	O
cAMP	O
is	O
a	O
regulatory	O
factor	O
in	O
angiotensinogen	B-Protein
production	O
other	O
evidence	O
suggests	O
that	O
modulation	O
of	O
intracellular	O
cAMP	O
is	O
not	O
entirely	O
responsible	O
for	O
the	O
effects	O
of	O
Sar1	O
-	O
AII	O
.	O

Evidence	O
for	O
a	O
non	O
-	O
myristoylated	O
pool	O
of	O
the	O
80	O
kDa	O
protein	O
kinase	O
C	O
substrate	O
of	O
rat	O
brain	O
.	O

A	O
protein	O
of	O
80	O
kDa	O
apparent	O
molecular	O
mass	O
was	O
found	O
to	O
be	O
specifically	O
myristolylated	O
in	O
rat	O
brain	O
cytosols	O
derived	O
from	O
either	O
whole	O
brain	O
or	O
synaptosomes	O
.	O

The	O
attachment	O
of	O
the	O
fatty	O
acid	O
took	O
place	O
in	O
the	O
absence	O
of	O
protein	O
synthesis	O
,	O
since	O
the	O
cytosols	O
did	O
not	O
incorporate	O
[	O
14C	O
]	O
lysine	O
into	O
protein	O
,	O
nor	O
did	O
cycloheximide	O
affect	O
the	O
incorporation	O
of	O
the	O
myristic	O
acid	O
into	O
the	O
protein	O
.	O

The	O
fatty	O
acid	O
was	O
incorporated	O
into	O
the	O
protein	O
via	O
an	O
acid	O
-	O
labile	O
/	O
alkali	O
-	O
resistant	O
band	O
,	O
and	O
Pronase	O
digestion	O
of	O
the	O
labelled	O
protein	O
showed	O
that	O
the	O
lipid	O
was	O
covalently	O
linked	O
to	O
a	O
glycine	O
residue	O
.	O

Together	O
,	O
these	O
data	O
suggested	O
that	O
the	O
myristic	O
acid	O
was	O
amide	O
-	O
linked	O
to	O
the	O
N	O
-	O
terminal	O
residue	O
of	O
the	O
protein	O
.	O

The	O
protein	O
was	O
identified	O
as	O
one	O
of	O
the	O
major	O
protein	O
kinase	O
C	O
substrates	O
,	O
the	O
MARCKS	B-Protein
(	O
myristoylated	B-Protein
alanine	I-Protein
-	I-Protein
rich	I-Protein
C	I-Protein
kinase	I-Protein
substrate	I-Protein
)	O
protein	O
,	O
by	O
showing	O
that	O
Ca2	O
+	O
stimulated	O
its	O
phosphorylation	O
,	O
by	O
its	O
heat	O
stability	O
and	O
by	O
immune	O
precipitation	O
(	O
using	O
an	O
antiserum	O
to	O
the	O
MARCKS	B-Protein
protein	O
)	O
.	O

Incorporation	O
of	O
myristic	O
acid	O
into	O
intact	O
protein	O
continued	O
for	O
up	O
to	O
12	O
h	O
,	O
despite	O
the	O
fact	O
that	O
over	O
this	O
period	O
some	O
degradation	O
of	O
the	O
protein	O
could	O
be	O
demonstrated	O
.	O

In	O
pulse	O
-	O
chase	O
experiments	O
,	O
the	O
pattern	O
of	O
loss	O
of	O
the	O
incorporated	O
fatty	O
acid	O
was	O
similar	O
to	O
that	O
of	O
the	O
protein	O
itself	O
,	O
and	O
therefore	O
the	O
loss	O
of	O
radioactivity	O
probably	O
reflects	O
protein	O
degradation	O
rather	O
than	O
specific	O
de	O
-	O
acylation	O
of	O
the	O
protein	O
.	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
there	O
is	O
a	O
pool	O
of	O
unacylated	O
MARCKS	B-Protein
protein	O
in	O
the	O
rat	O
brain	O
.	O

Identification	O
of	O
amino	O
acids	O
in	O
the	O
gamma	O
-	O
carboxylation	O
recognition	O
site	O
on	O
the	O
propeptide	O
of	O
prothrombin	B-Protein
.	O

A	O
gamma	O
-	O
carboxylation	O
recognition	O
site	O
on	O
the	O
propeptide	O
of	O
the	O
vitamin	O
K	O
-	O
dependent	O
blood	O
coagulation	O
proteins	O
directs	O
the	O
carboxylation	O
of	O
glutamic	O
acid	O
residues	O
by	O
binding	O
to	O
the	O
vitamin	B-Protein
K	I-Protein
-	I-Protein
dependent	I-Protein
carboxylase	I-Protein
.	O

To	O
determine	O
residues	O
that	O
define	O
this	O
site	O
,	O
we	O
evaluated	O
the	O
effect	O
of	O
mutation	O
of	O
certain	O
residues	O
in	O
the	O
prothrombin	B-Protein
propeptide	O
on	O
the	O
extent	O
of	O
carboxylation	O
.	O

The	O
prothrombin	B-Protein
cDNA	O
modified	O
by	O
site	O
-	O
specific	O
mutagenesis	O
was	O
expressed	O
in	O
Chinese	O
hamster	O
ovary	O
cells	O
using	O
a	O
system	O
that	O
yields	O
functional	O
fully	O
carboxylated	O
prothrombin	B-Protein
.	O

The	O
cell	O
supernatants	O
containing	O
recombinant	O
prothrombin	B-Protein
were	O
evaluated	O
for	O
the	O
extent	O
of	O
gamma	O
-	O
carboxylation	O
by	O
immunoassay	O
.	O

Conformation	O
-	O
specific	O
anti	O
-	O
prothrombin	B-Protein
:	O
Ca	O
(	O
II	O
)	O
-	O
specific	O
antibodies	O
measure	O
native	O
completely	O
carboxylated	O
prothrombin	B-Protein
;	O
anti	O
-	O
prothrombin	B-Protein
:	O
total	O
antibodies	O
measure	O
all	O
forms	O
of	O
prothrombin	B-Protein
,	O
regardless	O
of	O
gamma	O
-	O
carboxyglutamic	O
acid	O
content	O
.	O

Mutation	O
of	O
His	O
-	O
18	O
to	O
Gly	O
,	O
Val	O
-	O
17	O
to	O
Ser	O
,	O
Leu	O
-	O
15	O
to	O
Gly	O
or	O
Asp	O
,	O
or	O
Ala	O
-	O
10	O
to	O
Asp	O
was	O
associated	O
with	O
a	O
partial	O
(	O
30	O
-	O
65	O
%	O
)	O
inhibition	O
of	O
gamma	O
-	O
carboxylation	O
.	O

Mutation	O
of	O
Ala	O
-	O
14	O
to	O
Ser	O
or	O
Ser	O
-	O
8	O
to	O
Val	O
did	O
not	O
inhibit	O
gamma	O
-	O
carboxylation	O
.	O

From	O
this	O
and	O
earlier	O
work	O
,	O
residues	O
whose	O
mutation	O
leads	O
to	O
a	O
significant	O
impairment	O
of	O
carboxylation	O
include	O
His	O
-	O
18	O
,	O
Val	O
-	O
17	O
,	O
Phe	O
-	O
16	O
,	O
Leu	O
-	O
15	O
,	O
and	O
Ala	O
-	O
10	O
.	O

Residues	O
whose	O
mutation	O
does	O
not	O
alter	O
the	O
carboxylation	O
recognition	O
site	O
include	O
Ala	O
-	O
14	O
,	O
Ser	O
-	O
8	O
,	O
Arg	O
-	O
4	O
,	O
and	O
Arg	O
-	O
1	O
.	O

To	O
determine	O
the	O
size	O
of	O
the	O
recognition	O
site	O
,	O
the	O
in	O
vitro	O
carboxylation	O
of	O
propeptide	O
-	O
containing	O
synthetic	O
peptides	O
was	O
compared	O
.	O

A	O
28	O
-	O
residue	O
peptide	O
,	O
based	O
upon	O
residues	O
-	O
18	O
to	O
+	O
10	O
of	O
prothrombin	B-Protein
,	O
and	O
a	O
54	O
-	O
residue	O
peptide	O
,	O
based	O
upon	O
residues	O
-	O
18	O
to	O
+	O
36	O
of	O
prothrombin	B-Protein
,	O
were	O
carboxylated	O
by	O
partially	O
purified	O
bovine	O
carboxylase	O
with	O
similar	O
Km	O
values	O
of	O
2	O
-	O
5	O
microM	O
.	O

These	O
results	O
indicate	O
that	O
the	O
gamma	O
-	O
carboxyglutamic	O
acid	O
-	O
rich	O
region	O
of	O
prothrombin	B-Protein
makes	O
a	O
minimal	O
contribution	O
to	O
carboxylase	O
binding	O
.	O

A	O
molecular	O
surface	O
of	O
about	O
five	O
amino	O
acids	O
located	O
within	O
the	O
propeptide	O
appears	O
to	O
define	O
the	O
carboxylation	O
recognition	O
site	O
on	O
the	O
precursor	O
forms	O
of	O
the	O
vitamin	O
K	O
-	O
dependent	O
proteins	O
.	O

[	O
Experimental	O
animal	O
research	O
on	O
the	O
thrombolytic	O
effect	O
of	O
acyl	O
-	O
plasmin	B-Protein
]	O
.	O

Plasmin	B-Protein
was	O
acylated	O
by	O
reaction	O
with	O
benzoic	O
acid	O
or	O
p	O
-	O
chlorobenzoic	O
acid	O
p	O
'	O
-	O
amidinophenyl	O
ester	O
.	O

Enzymatically	O
inactive	O
acyl	O
-	O
plasmin	B-Protein
is	O
reactivated	O
in	O
buffer	O
(	O
pH	O
7	O
.	O
5	O
)	O
with	O
a	O
half	O
-	O
life	O
of	O
22	O
min	O
(	O
benzoyl	O
-	O
plasmin	B-Protein
)	O
and	O
9	O
min	O
(	O
p	O
-	O
chlorobenzoyl	O
-	O
plasmin	B-Protein
)	O
,	O
respectively	O
.	O

Plasmin	B-Protein
is	O
rapidly	O
inactivated	O
in	O
plasma	O
by	O
naturally	O
occurring	O
plasma	O
inhibitors	O
so	O
that	O
also	O
upon	O
incubation	O
of	O
acyl	O
-	O
plasmin	B-Protein
in	O
plasma	O
only	O
low	O
enzymatic	O
activity	O
is	O
detectable	O
.	O

Following	O
high	O
doses	O
of	O
plasmin	O
fibrinogenolysis	O
typical	O
of	O
nonspecific	O
proteolysis	O
occurs	O
in	O
vivo	O
but	O
no	O
fibrinolytic	O
effects	O
is	O
demonstrable	O
.	O

On	O
the	O
other	O
hand	O
,	O
acyl	O
-	O
plasmins	B-Protein
are	O
able	O
either	O
to	O
prevent	O
microthrombosis	O
in	O
the	O
lungs	O
induced	O
by	O
infusion	O
of	O
thrombin	B-Protein
or	O
to	O
achieve	O
repatency	O
of	O
the	O
microvasculature	O
after	O
the	O
onset	O
of	O
microthrombosis	O
.	O

Spectroscopic	O
analysis	O
of	O
acylated	O
and	O
deacylated	O
myelin	B-Protein
proteolipid	I-Protein
protein	I-Protein
.	O

The	O
effect	O
of	O
covalently	O
bound	O
fatty	O
acid	O
on	O
the	O
conformation	O
of	O
the	O
myelin	B-Protein
proteolipid	I-Protein
protein	I-Protein
has	O
been	O
studied	O
by	O
ultraviolet	O
and	O
intrinsic	O
fluorescence	O
spectroscopy	O
.	O

With	O
dimethyl	O
sulfoxide	O
used	O
as	O
a	O
perturbant	O
,	O
the	O
exposure	O
of	O
Trp	O
and	O
Tyr	O
residues	O
in	O
various	O
mixtures	O
of	O
chloroform	O
-	O
methanol	O
was	O
evaluated	O
by	O
difference	O
spectroscopy	O
of	O
the	O
proteolipid	B-Protein
protein	I-Protein
(	O
APL	B-Protein
)	O
and	O
its	O
chemically	O
deacylated	O
form	O
(	O
d	O
-	O
APL	B-Protein
)	O
.	O

The	O
fraction	O
of	O
chromophoric	O
groups	O
exposed	O
increased	O
with	O
the	O
proportion	O
of	O
chloroform	O
with	O
25	O
%	O
of	O
the	O
groups	O
exposed	O
in	O
1	O
:	O
2	O
chloroform	O
-	O
methanol	O
and	O
98	O
%	O
in	O
3	O
:	O
1	O
chloroform	O
-	O
methanol	O
.	O

These	O
conformational	O
changes	O
correlate	O
well	O
with	O
changes	O
in	O
intrinsic	O
viscosity	O
.	O

Values	O
for	O
the	O
deacylated	O
form	O
were	O
indistinguishable	O
from	O
those	O
of	O
the	O
acylated	O
protein	O
,	O
suggesting	O
that	O
fatty	O
acids	O
do	O
not	O
affect	O
protein	O
conformation	O
in	O
organic	O
solvents	O
.	O

In	O
water	O
,	O
UV	O
difference	O
spectroscopy	O
indicated	O
that	O
the	O
number	O
of	O
Tyr	O
and	O
Trp	O
groups	O
exposed	O
in	O
both	O
APL	B-Protein
and	O
d	O
-	O
APL	B-Protein
was	O
relatively	O
small	O
and	O
was	O
independent	O
of	O
the	O
molecular	O
size	O
of	O
the	O
perturbant	O
.	O

However	O
,	O
differences	O
in	O
the	O
environment	O
of	O
the	O
Trp	O
groups	O
in	O
the	O
two	O
forms	O
of	O
the	O
protein	O
could	O
be	O
demonstrated	O
by	O
intrinsic	O
fluorescence	O
.	O

When	O
the	O
protein	O
was	O
excited	O
at	O
295	O
nm	O
,	O
the	O
maximum	O
emission	O
wavelength	O
for	O
the	O
acylated	O
protein	O
was	O
330	O
nm	O
,	O
whereas	O
it	O
was	O
335	O
nm	O
for	O
the	O
deacylated	O
form	O
.	O

Furthermore	O
,	O
the	O
Trp	O
groups	O
in	O
d	O
-	O
APL	B-Protein
were	O
more	O
easily	O
quenched	O
by	O
acrylamide	O
than	O
in	O
APL	B-Protein
,	O
indicating	O
that	O
they	O
were	O
more	O
exposed	O
,	O
or	O
in	O
a	O
more	O
hydrophilic	O
environment	O
,	O
following	O
deacylation	O
.	O

Protein	O
aggregation	O
appears	O
to	O
be	O
independent	O
of	O
the	O
presence	O
of	O
fatty	O
acids	O
,	O
suggesting	O
that	O
the	O
fluorescence	O
differences	O
between	O
APL	B-Protein
and	O
d	O
-	O
APL	B-Protein
are	O
related	O
to	O
factors	O
other	O
than	O
aggregation	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Cell	O
-	O
type	O
-	O
specific	O
and	O
site	O
-	O
specific	O
N	O
-	O
glycosylation	O
of	O
type	O
I	O
and	O
type	O
II	O
human	O
tissue	B-Protein
plasminogen	I-Protein
activator	I-Protein
.	O

Tissue	B-Protein
plasminogen	I-Protein
activator	I-Protein
(	O
t	B-Protein
-	I-Protein
PA	I-Protein
)	O
is	O
an	O
important	O
initiator	O
of	O
fibrinolysis	O
.	O

The	O
t	B-Protein
-	I-Protein
PA	I-Protein
polypeptide	O
has	O
four	O
potential	O
N	O
-	O
glycosylation	O
sites	O
of	O
which	O
three	O
are	O
occupied	O
in	O
type	O
I	O
(	O
Asn	O
-	O
117	O
,	O
-	O
184	O
,	O
and	O
-	O
448	O
)	O
and	O
two	O
in	O
type	O
II	O
(	O
Asn	O
-	O
117	O
and	O
-	O
448	O
)	O
.	O

In	O
an	O
effort	O
to	O
elucidate	O
the	O
factors	O
controlling	O
the	O
expression	O
of	O
N	O
-	O
linked	O
oligosaccharides	O
on	O
this	O
polypeptide	O
,	O
we	O
have	O
used	O
a	O
combination	O
of	O
sequential	O
exoglycosidase	O
digestion	O
,	O
methylation	O
analysis	O
,	O
and	O
controlled	O
acetolysis	O
to	O
determine	O
the	O
oligosaccharide	O
structures	O
at	O
each	O
of	O
the	O
N	O
-	O
glycosylation	O
sites	O
of	O
type	O
I	O
and	O
type	O
II	O
t	B-Protein
-	I-Protein
PA	I-Protein
when	O
isolated	O
from	O
a	O
human	O
colon	O
fibroblast	O
cell	O
strain	O
and	O
from	O
a	O
Bowes	O
melanoma	O
cell	O
line	O
.	O

Our	O
results	O
suggest	O
the	O
following	O
:	O
(	O
i	O
)	O
type	O
I	O
and	O
type	O
II	O
t	B-Protein
-	I-Protein
PA	I-Protein
are	O
N	O
-	O
glycosylated	O
in	O
an	O
identical	O
way	O
at	O
Asn	O
-	O
117	O
and	O
Asn	O
-	O
448	O
,	O
when	O
isolated	O
from	O
the	O
same	O
cell	O
line	O
;	O
(	O
ii	O
)	O
Asn	O
-	O
117	O
is	O
predominantly	O
associated	O
with	O
oligomannose	O
-	O
type	O
structures	O
in	O
all	O
cases	O
;	O
(	O
iii	O
)	O
Asn	O
-	O
184	O
and	O
Asn	O
-	O
448	O
are	O
predominantly	O
associated	O
with	O
complex	O
-	O
type	O
structures	O
when	O
t	B-Protein
-	I-Protein
PA	I-Protein
is	O
isolated	O
from	O
fibroblast	O
cells	O
,	O
but	O
with	O
both	O
complex	O
-	O
and	O
oligomannose	O
-	O
type	O
structures	O
when	O
isolated	O
from	O
melanoma	O
cells	O
;	O
(	O
iv	O
)	O
fibroblast	O
cell	O
derived	O
t	B-Protein
-	I-Protein
PA	I-Protein
is	O
associated	O
with	O
both	O
neutral	O
and	O
sialylated	O
oligosaccharides	O
,	O
while	O
melanoma	O
cell	O
derived	O
t	B-Protein
-	I-Protein
PA	I-Protein
is	O
also	O
associated	O
with	O
sulfated	O
oligosaccharides	O
,	O
which	O
are	O
located	O
exclusively	O
at	O
Asn	O
-	O
448	O
of	O
type	O
II	O
t	B-Protein
-	I-Protein
PA	I-Protein
;	O
(	O
v	O
)	O
no	O
complex	O
-	O
type	O
structures	O
occur	O
in	O
common	O
between	O
t	B-Protein
-	I-Protein
PA	I-Protein
from	O
the	O
two	O
cell	O
lines	O
.	O

These	O
results	O
indicate	O
that	O
the	O
t	B-Protein
-	I-Protein
PA	I-Protein
glycoprotein	O
is	O
secreted	O
by	O
each	O
cell	O
line	O
as	O
a	O
set	O
of	O
glycoforms	O
,	O
each	O
glycoform	O
being	O
unique	O
with	O
respect	O
to	O
the	O
nature	O
and	O
disposition	O
of	O
oligosaccharides	O
on	O
a	O
common	O
polypeptide	O
.	O

Further	O
,	O
the	O
two	O
cell	O
lines	O
express	O
no	O
glycoform	O
in	O
common	O
,	O
despite	O
expressing	O
the	O
same	O
t	B-Protein
-	I-Protein
PA	I-Protein
polypeptide	O
.	O

The	O
implications	O
of	O
these	O
results	O
for	O
both	O
the	O
control	O
of	O
oligosaccharide	O
processing	O
in	O
different	O
cell	O
lines	O
and	O
the	O
genetic	O
engineering	O
of	O
mammalian	O
glycoproteins	O
are	O
discussed	O
.	O

Role	O
of	O
variant	O
prealbumin	B-Protein
in	O
the	O
pathogenesis	O
of	O
familial	O
amyloidotic	O
polyneuropathy	O
:	O
fate	O
of	O
normal	O
and	O
variant	O
prealbumin	B-Protein
in	O
the	O
circulation	O
.	O

According	O
to	O
recent	O
studies	O
on	O
protein	O
chemistry	O
and	O
genetic	O
engineering	O
,	O
replacement	O
of	O
the	O
Val30	O
residue	O
of	O
prealbumin	B-Protein
by	O
methionine	O
is	O
believed	O
to	O
play	O
a	O
critical	O
role	O
in	O
the	O
formation	O
of	O
amyloid	B-Protein
deposit	O
and	O
the	O
pathogenesis	O
of	O
familial	O
amyloidotic	O
polyneuropathy	O
(	O
FAP	O
)	O
.	O

However	O
,	O
only	O
limited	O
information	O
is	O
available	O
concerning	O
the	O
behavior	O
of	O
prealbumin	B-Protein
in	O
the	O
circulation	O
.	O

To	O
obtain	O
the	O
molecular	O
insight	O
into	O
the	O
mechanism	O
of	O
amyloid	B-Protein
deposition	O
,	O
it	O
is	O
indispensable	O
to	O
know	O
the	O
fates	O
of	O
normal	O
and	O
variant	O
prealbumin	B-Protein
in	O
vivo	O
.	O

Thus	O
,	O
the	O
fates	O
of	O
prealbumin	B-Protein
samples	O
from	O
normal	O
and	O
FAP	O
patients	O
were	O
studied	O
in	O
normal	O
rats	O
as	O
well	O
as	O
in	O
animals	O
that	O
were	O
challenged	O
with	O
acute	O
inflammation	O
induced	O
by	O
turpentine	O
.	O

The	O
effect	O
of	O
in	O
vitro	O
photooxidation	O
of	O
prealbumin	B-Protein
samples	O
on	O
their	O
behavior	O
was	O
also	O
examined	O
in	O
vivo	O
.	O

Kinetic	O
analysis	O
revealed	O
no	O
appreciable	O
difference	O
between	O
prealbumin	B-Protein
samples	O
from	O
normal	O
and	O
FAP	O
patients	O
.	O

These	O
results	O
suggest	O
that	O
factors	O
other	O
than	O
the	O
rate	O
of	O
transfer	O
of	O
the	O
variant	O
form	O
prealbumin	B-Protein
from	O
plasma	O
to	O
an	O
extravascular	O
compartment	O
may	O
play	O
a	O
critical	O
role	O
in	O
the	O
pathogenesis	O
of	O
amyloid	B-Protein
deposition	O
in	O
FAP	O
patients	O
.	O

Characterization	O
of	O
tyrosylprotein	O
sulfotransferase	O
from	O
rat	O
liver	O
and	O
other	O
tissues	O
.	O

The	O
sulfoconjugation	O
of	O
tyrosyl	O
residues	O
is	O
a	O
widespread	O
post	O
-	O
translational	O
modification	O
of	O
biologically	O
active	O
peptides	O
and	O
proteins	O
.	O

In	O
this	O
paper	O
we	O
describe	O
the	O
characterization	O
of	O
a	O
rat	O
liver	O
tyrosylprotein	O
sulfotransferase	O
that	O
is	O
capable	O
of	O
catalyzing	O
the	O
transfer	O
of	O
a	O
sulfate	O
moiety	O
from	O
3	O
'	O
-	O
phosphoadenosine	O
5	O
'	O
-	O
phosphosulfate	O
(	O
PAPS	O
)	O
to	O
the	O
synthetic	O
polymer	O
,	O
poly	O
-	O
(	O
Glu6	O
,	O
Ala3	O
,	O
Tyr1	O
)	O
(	O
EAY	O
;	O
Mr	O
47	O
,	O
000	O
)	O
using	O
a	O
simple	O
filter	O
paper	O
assay	O
.	O

Following	O
sucrose	O
density	O
gradient	O
centrifugation	O
and	O
comparison	O
with	O
known	O
subcellular	O
marker	O
enzyme	O
activities	O
,	O
rat	O
liver	O
tyrosylprotein	O
sulfotransferase	O
activity	O
was	O
shown	O
to	O
have	O
a	O
distribution	O
similar	O
to	O
the	O
Golgi	O
enzyme	O
,	O
galactosyltransferase	O
.	O

Using	O
the	O
enriched	O
Golgi	O
preparation	O
,	O
rat	O
liver	O
tyrosylprotein	O
sulfotransferase	O
displayed	O
a	O
pH	O
optimum	O
of	O
6	O
.	O
7	O
and	O
required	O
the	O
presence	O
of	O
20	O
mM	O
Mn2	O
+	O
for	O
maximal	O
activity	O
.	O

Co2	O
+	O
(	O
20	O
mM	O
)	O
was	O
able	O
to	O
produce	O
26	O
%	O
of	O
the	O
maximal	O
stimulation	O
observed	O
with	O
Mn2	O
+	O
,	O
whereas	O
other	O
metal	O
ions	O
,	O
such	O
as	O
Mg2	O
+	O
,	O
Ca2	O
+	O
,	O
and	O
Co2	O
+	O
,	O
were	O
not	O
effective	O
in	O
stimulating	O
tyrosylprotein	O
sulfotransferase	O
activity	O
.	O

Whereas	O
tyrosylprotein	O
sulfotransferase	O
activity	O
was	O
observed	O
in	O
the	O
native	O
membrane	O
-	O
bound	O
state	O
,	O
EAY	O
sulfation	O
was	O
maximally	O
enhanced	O
3	O
-	O
fold	O
when	O
assayed	O
in	O
the	O
presence	O
of	O
Lubrol	O
Px	O
.	O

Under	O
the	O
optimal	O
conditions	O
for	O
assaying	O
the	O
sulfation	O
of	O
EAY	O
by	O
a	O
rat	O
liver	O
enriched	O
Golgi	O
fraction	O
,	O
significant	O
degradation	O
of	O
the	O
sulfate	O
donor	O
,	O
PAPS	O
,	O
was	O
observed	O
.	O

The	O
addition	O
of	O
both	O
NaF	O
and	O
5	O
'	O
-	O
AMP	O
to	O
the	O
incubation	O
mixture	O
was	O
found	O
to	O
effectively	O
prevent	O
PAPS	O
degradation	O
and	O
increase	O
the	O
amount	O
of	O
product	O
formed	O
in	O
the	O
assay	O
by	O
10	O
-	O
fold	O
.	O

Using	O
the	O
optimized	O
conditions	O
for	O
the	O
sulfation	O
of	O
EAY	O
by	O
rat	O
liver	O
tyrosylprotein	O
sulfotransferase	O
,	O
membrane	O
-	O
bound	O
sulfotransferase	O
activity	O
was	O
also	O
observed	O
in	O
the	O
crude	O
microsomal	O
pellets	O
of	O
a	O
variety	O
of	O
rat	O
tissues	O
,	O
including	O
lung	O
,	O
pituitary	O
,	O
and	O
cerebellum	O
,	O
as	O
well	O
as	O
in	O
livers	O
from	O
different	O
species	O
.	O

Role	O
of	O
counter	O
ions	O
in	O
trypsin	O
acylation	O
.	O

NaCl	O
effect	O
.	O

The	O
Asp102	O
-	O
carboxylate	O
negative	O
charge	O
of	O
the	O
trypsin	O
catalytic	O
-	O
triad	O
has	O
been	O
substituted	O
in	O
part	O
by	O
Cl	O
-	O
counter	O
-	O
ions	O
.	O

A	O
His57	O
-	O
imidazolium	O
cation	O
and	O
Ser195	O
-	O
tetrahedral	O
oxyanion	O
ionpair	O
generated	O
in	O
the	O
acylation	O
step	O
of	O
catalysis	O
is	O
stabilized	O
by	O
the	O
negative	O
charge	O
of	O
Asp102	O
.	O

The	O
importance	O
of	O
correct	O
location	O
of	O
this	O
negative	O
charge	O
has	O
been	O
investigated	O
by	O
experimental	O
analysis	O
of	O
the	O
NaCl	O
influence	O
on	O
the	O
acylation	O
-	O
rate	O
of	O
trypsin	O
,	O
as	O
well	O
as	O
by	O
electrostatic	O
,	O
potential	O
calculations	O
.	O

The	O
acylation	O
-	O
rate	O
was	O
determined	O
with	O
stopped	O
-	O
flow	O
technique	O
under	O
pseudo	O
-	O
first	O
order	O
conditions	O
,	O
by	O
using	O
4	O
-	O
nitrophenyl	O
-	O
4	O
'	O
-	O
guanidinium	O
benzoate	O
active	O
site	O
titrant	O
at	O
pH	O
4	O
.	O
25	O
+	O
/	O
-	O
0	O
.	O
04	O
,	O
in	O
an	O
unbuffered	O
solution	O
of	O
I	O
=	O
O	O
or	O
0	O
.	O
5	O
M	O
NaCl	O
.	O

The	O
acylation	O
-	O
rate	O
constants	O
,	O
kappa	O
2	O
,	O
are	O
:	O
kappa	O
H2O	O
=	O
0	O
.	O
32	O
+	O
/	O
-	O
0	O
.	O
02	O
s	O
-	O
1	O
and	O
kappa	O
NaCl	O
=	O
3	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
5	O
s	O
-	O
1	O
,	O
and	O
they	O
correlate	O
to	O
beta	B-Protein
-	I-Protein
trypsin	I-Protein
(	O
the	O
most	O
rapid	O
single	O
-	O
chained	O
form	O
of	O
the	O
enzyme	O
)	O
.	O

The	O
rate	O
increasing	O
effect	O
of	O
NaCl	O
,	O
together	O
with	O
the	O
calculated	O
electrostatic	O
energies	O
,	O
indicate	O
that	O
the	O
negative	O
charge	O
contribution	O
of	O
the	O
Asp102	O
-	O
carboxylate	O
to	O
the	O
stabilization	O
of	O
the	O
imidazolium	O
cation	O
and	O
tetrahedral	O
oxyanion	O
intermediate	O
is	O
larger	O
of	O
more	O
orders	O
,	O
than	O
that	O
of	O
the	O
Cl	O
-	O
counter	O
-	O
ion	O
,	O
located	O
in	O
a	O
less	O
favourable	O
position	O
.	O

Effect	O
of	O
oxidation	O
on	O
the	O
stability	O
of	O
tuberculin	O
purified	O
protein	O
derivative	O
(	O
PPD	O
)	O
.	O

The	O
purpose	O
of	O
the	O
present	O
work	O
was	O
two	O
-	O
fold	O
:	O
firstly	O
,	O
to	O
collect	O
data	O
on	O
the	O
effect	O
that	O
air	O
may	O
have	O
on	O
the	O
biological	O
potency	O
of	O
a	O
dilute	O
solution	O
of	O
tuberculin	O
PPD	O
(	O
5	O
TU	O
/	O
dose	O
)	O
,	O
and	O
secondly	O
,	O
to	O
find	O
out	O
whether	O
or	O
not	O
the	O
solubility	O
of	O
a	O
tuberculin	O
PPD	O
preparation	O
stored	O
in	O
powder	O
form	O
would	O
be	O
affected	O
by	O
air	O
over	O
a	O
long	O
period	O
of	O
time	O
.	O

It	O
was	O
shown	O
that	O
the	O
presence	O
of	O
air	O
in	O
the	O
headspace	O
of	O
multidose	O
vials	O
containing	O
a	O
dilute	O
tuberculin	O
PPD	O
solution	O
contributed	O
to	O
the	O
lowering	O
of	O
its	O
potency	O
by	O
approximately	O
50	O
%	O
over	O
a	O
period	O
of	O
4	O
months	O
at	O
5	O
degrees	O
C	O
,	O
and	O
that	O
thereafter	O
the	O
potency	O
remained	O
constant	O
for	O
up	O
to	O
12	O
months	O
.	O

It	O
was	O
also	O
shown	O
that	O
approximately	O
55	O
%	O
of	O
a	O
PPD	O
preparation	O
,	O
stored	O
in	O
powder	O
form	O
over	O
a	O
period	O
of	O
7	O
years	O
at	O
24	O
degrees	O
C	O
in	O
containers	O
closed	O
with	O
non	O
-	O
absorbent	O
cotton	O
plugs	O
,	O
allowing	O
free	O
access	O
of	O
air	O
,	O
became	O
insoluble	O
,	O
whereas	O
when	O
an	O
identical	O
preparation	O
was	O
stored	O
for	O
the	O
same	O
length	O
of	O
time	O
,	O
at	O
24	O
degrees	O
C	O
or	O
for	O
at	O
least	O
14	O
years	O
at	O
5	O
degrees	O
C	O
,	O
in	O
tightly	O
closed	O
containers	O
,	O
it	O
retained	O
its	O
solubility	O
.	O

The	O
partial	O
loss	O
of	O
potency	O
and	O
the	O
loss	O
of	O
some	O
solubility	O
were	O
attributed	O
to	O
the	O
denaturation	O
of	O
PPD	O
through	O
the	O
process	O
of	O
air	O
oxidation	O
.	O

To	O
reduce	O
the	O
loss	O
of	O
potency	O
of	O
tuberculin	O
PPD	O
products	O
through	O
the	O
process	O
of	O
oxidation	O
,	O
it	O
was	O
suggested	O
that	O
:	O
firstly	O
,	O
the	O
vials	O
be	O
filled	O
as	O
fully	O
as	O
possible	O
to	O
minimize	O
the	O
amount	O
of	O
air	O
trapped	O
in	O
the	O
headspace	O
,	O
or	O
the	O
filling	O
of	O
vials	O
be	O
carried	O
out	O
under	O
nitrogen	O
so	O
as	O
to	O
expel	O
any	O
air	O
in	O
the	O
headspace	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Interference	O
of	O
active	O
site	O
specific	O
reagents	O
in	O
plasminogen	B-Protein
-	O
streptokinase	B-Protein
active	O
site	O
formation	O
.	O

We	O
have	O
recently	O
observed	O
slow	O
,	O
non	O
-	O
Michaelis	O
-	O
Menten	O
kinetics	O
of	O
activation	O
of	O
native	O
cat	O
plasminogen	B-Protein
by	O
catalytic	O
concentrations	O
of	O
streptokinase	B-Protein
.	O

In	O
order	O
to	O
understand	O
the	O
reasons	O
for	O
this	O
phenomenon	O
,	O
we	O
undertook	O
to	O
study	O
the	O
formation	O
of	O
the	O
plasminogen	B-Protein
-	O
streptokinase	B-Protein
activator	O
complex	O
under	O
the	O
same	O
plasminogen	B-Protein
activation	O
conditions	O
.	O

The	O
results	O
obtained	O
in	O
this	O
study	O
show	O
that	O
the	O
potential	O
active	O
site	O
in	O
both	O
cat	O
and	O
human	O
plasminogen	B-Protein
is	O
capable	O
of	O
binding	O
strongly	O
the	O
specific	O
substrates	O
(	O
S	O
)	O
p	O
-	O
nitrophenyl	O
p	O
-	O
guanidinobenzoate	O
(	O
NPGB	O
)	O
and	O
H	O
-	O
D	O
-	O
valyl	O
-	O
L	O
-	O
leucyl	O
-	O
L	O
-	O
lysyl	O
-	O
p	O
-	O
nitroanilide	O
,	O
through	O
the	O
active	O
site	O
is	O
incapable	O
of	O
hydrolyzing	O
these	O
substrates	O
.	O

Binding	O
studies	O
support	O
these	O
and	O
the	O
following	O
conclusions	O
.	O

Streptokinase	B-Protein
binds	O
to	O
this	O
zymogen	O
-	O
substrate	O
complex	O
to	O
create	O
the	O
ternary	O
plasminogen	B-Protein
-	O
S	O
-	O
streptokinase	B-Protein
complex	O
,	O
which	O
then	O
slowly	O
converts	O
to	O
an	O
acylated	O
plasminogen	B-Protein
-	O
streptokinase	B-Protein
form	O
.	O

This	O
acylation	O
reaction	O
is	O
550	O
times	O
slower	O
than	O
acylation	O
of	O
the	O
preformed	O
plasminogen	B-Protein
-	O
streptokinase	B-Protein
complex	O
by	O
NPGB	O
.	O

The	O
same	O
reaction	O
also	O
occurs	O
with	O
human	O
plasminogen	B-Protein
,	O
though	O
the	O
acylation	O
reaction	O
is	O
10	O
times	O
faster	O
than	O
when	O
the	O
cat	O
zymogen	O
is	O
used	O
.	O

NPGB	O
binds	O
specifically	O
to	O
plasminogen	B-Protein
but	O
not	O
to	O
streptokinase	B-Protein
.	O

These	O
studies	O
proved	O
that	O
inhibition	O
of	O
cat	O
plasminogen	B-Protein
activation	O
by	O
streptokinase	B-Protein
occurs	O
at	O
the	O
level	O
of	O
activator	O
complex	O
formation	O
.	O

We	O
conclude	O
from	O
our	O
studies	O
that	O
streptokinase	B-Protein
binding	O
to	O
both	O
cat	O
and	O
human	O
plasminogen	B-Protein
occurs	O
at	O
the	O
potential	O
active	O
site	O
of	O
the	O
zymogen	O
.	O

Consequently	O
,	O
it	O
is	O
probable	O
that	O
plasminogen	B-Protein
activation	O
in	O
vivo	O
is	O
inhibited	O
by	O
binding	O
of	O
active	O
site	O
specific	O
inhibitors	O
to	O
plasminogen	B-Protein
.	O

Biosynthesis	O
of	O
GlyCAM	B-Protein
-	I-Protein
1	I-Protein
,	O
a	O
mucin	O
-	O
like	O
ligand	O
for	O
L	B-Protein
-	I-Protein
selectin	I-Protein
.	O

L	B-Protein
-	I-Protein
selectin	I-Protein
,	O
a	O
member	O
of	O
the	O
selectin	O
family	O
of	O
leukocyte	O
-	O
endothelial	O
adhesion	O
proteins	O
,	O
mediates	O
the	O
initial	O
attachment	O
of	O
lymphocytes	O
to	O
lymph	O
node	O
high	O
endothelial	O
venules	O
during	O
lymphocyte	O
recirculation	O
.	O

One	O
of	O
the	O
endothelial	O
-	O
associated	O
ligands	O
for	O
L	B-Protein
-	I-Protein
selectin	I-Protein
is	O
GlyCAM	B-Protein
-	I-Protein
1	I-Protein
,	O
a	O
mucin	O
-	O
like	O
glycoprotein	O
,	O
which	O
presents	O
novel	O
sulfated	O
,	O
sialylated	O
and	O
fucosylated	O
O	O
-	O
glycans	O
.	O

In	O
order	O
to	O
understand	O
the	O
generation	O
of	O
these	O
glycans	O
,	O
we	O
have	O
examined	O
the	O
biosynthesis	O
of	O
GlyCAM	B-Protein
-	I-Protein
1	I-Protein
in	O
lymph	O
node	O
organ	O
culture	O
.	O

Using	O
peptide	O
-	O
specific	O
antibodies	O
,	O
lectins	O
,	O
and	O
recombinant	O
L	B-Protein
-	I-Protein
selectin	I-Protein
,	O
we	O
detected	O
the	O
following	O
species	O
of	O
GlyCAM	B-Protein
-	I-Protein
1	I-Protein
:	O
unglycosylated	O
(	O
<	O
28	O
kDa	O
)	O
;	O
modified	O
with	O
GalNAc	O
only	O
(	O
28	O
-	O
33	O
kDa	O
)	O
;	O
modified	O
with	O
sialic	O
acid	O
,	O
fucose	O
,	O
and	O
sulfate	O
but	O
lacking	O
L	B-Protein
-	I-Protein
selectin	I-Protein
reactivity	O
(	O
40	O
-	O
50	O
kDa	O
)	O
;	O
and	O
mature	O
(	O
L	B-Protein
-	I-Protein
selectin	I-Protein
-	O
reactive	O
)	O
ligand	O
(	O
50	O
-	O
60	O
kDa	O
)	O
.	O

Pulse	O
-	O
chase	O
labeling	O
at	O
15	O
degrees	O
C	O
suggested	O
that	O
GalNAc	O
is	O
added	O
in	O
a	O
pre	O
-	O
Golgi	O
compartment	O
.	O

Treatment	O
with	O
brefeldin	O
A	O
almost	O
completely	O
blocked	O
sulfation	O
,	O
indicating	O
that	O
this	O
modification	O
occurs	O
in	O
the	O
trans	O
-	O
Golgi	O
network	O
.	O

Two	O
distinct	O
sialylation	O
events	O
occurred	O
in	O
the	O
presence	O
of	O
brefeldin	O
A	O
,	O
while	O
fucosylation	O
was	O
partially	O
blocked	O
.	O

We	O
conclude	O
that	O
sialylation	O
precedes	O
both	O
fucosylation	O
and	O
sulfation	O
during	O
biosynthesis	O
.	O

This	O
ordering	O
will	O
help	O
to	O
identify	O
the	O
critical	O
acceptor	O
structures	O
recognized	O
by	O
lymph	O
node	O
glycosyltransferases	O
and	O
sulfotransferases	O
.	O

Properties	O
of	O
type	B-Protein
II	I-Protein
inositol	I-Protein
polyphosphate	I-Protein
5	I-Protein
-	I-Protein
phosphatase	I-Protein
.	O

We	O
have	O
isolated	O
additional	O
cDNA	O
clones	O
encoding	O
type	B-Protein
II	I-Protein
inositol	I-Protein
polyphosphate	I-Protein
5	I-Protein
-	I-Protein
phosphatase	I-Protein
(	O
5	B-Protein
-	I-Protein
phosphatase	I-Protein
II	I-Protein
)	O
resulting	O
in	O
a	O
combined	O
cDNA	O
of	O
3076	O
nucleotides	O
encoding	O
a	O
protein	O
of	O
942	O
amino	O
acids	O
.	O

The	O
5	B-Protein
-	I-Protein
phosphatase	I-Protein
II	I-Protein
hydrolyzed	O
both	O
Ins	O
(	O
1	O
,	O
4	O
,	O
5	O
)	O
P3	O
to	O
Ins	O
(	O
1	O
,	O
4	O
)	O
P2	O
and	O
the	O
phospholipid	O
PtdIns	O
(	O
4	O
,	O
5	O
)	O
P2	O
to	O
PtdIns	O
(	O
4	O
)	O
P	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

There	O
are	O
two	O
motifs	O
highly	O
conserved	O
between	O
types	B-Protein
I	I-Protein
and	O
II	B-Protein
5	I-Protein
-	I-Protein
phosphatase	I-Protein
and	O
several	O
other	O
proteins	O
presumed	O
to	O
be	O
inositol	O
phosphatases	O
suggesting	O
a	O
possible	O
role	O
in	O
catalysis	O
.	O

The	O
type	B-Protein
II	I-Protein
5	I-Protein
-	I-Protein
phosphatase	I-Protein
also	O
contains	O
homology	O
to	O
several	O
GTPase	O
activating	O
proteins	O
although	O
no	O
such	O
activity	O
for	O
5	B-Protein
-	I-Protein
phosphatase	I-Protein
II	I-Protein
was	O
found	O
.	O

The	O
predicted	O
protein	O
ends	O
with	O
the	O
sequence	O
CNPL	O
,	O
suggesting	O
that	O
it	O
is	O
isoprenylated	O
as	O
a	O
mechanism	O
for	O
membrane	O
attachment	O
.	O

We	O
found	O
evidence	O
for	O
isoprenylation	O
by	O
demonstrating	O
incorporation	O
of	O
[	O
3H	O
]	O
mevalonate	O
into	O
native	O
but	O
not	O
C939S	O
mutant	O
5	B-Protein
-	I-Protein
phosphatase	I-Protein
II	I-Protein
expressed	O
in	O
Sf9	O
insect	O
cells	O
.	O

Furthermore	O
,	O
we	O
showed	O
that	O
membrane	O
localization	O
and	O
the	O
activity	O
of	O
5	B-Protein
-	I-Protein
phosphatase	I-Protein
II	I-Protein
toward	O
its	O
lipid	O
substrate	O
PtdIns	O
(	O
4	O
,	O
5	O
)	O
P2	O
is	O
reduced	O
by	O
eliminating	O
5	B-Protein
-	I-Protein
phosphatase	I-Protein
II	I-Protein
isoprenylation	O
in	O
the	O
mutant	O
C939S	O
relative	O
to	O
the	O
native	O
enzyme	O
.	O

Farnesol	O
is	O
utilized	O
for	O
protein	O
isoprenylation	O
and	O
the	O
biosynthesis	O
of	O
cholesterol	O
in	O
mammalian	O
cells	O
.	O

Evidence	O
has	O
been	O
obtained	O
indicating	O
that	O
free	O
farnesol	O
(	O
F	O
-	O
OH	O
)	O
can	O
be	O
utilized	O
for	O
isoprenoid	O
biosynthesis	O
in	O
mammalian	O
cells	O
.	O

When	O
rat	O
C6	O
glial	O
cells	O
and	O
an	O
African	O
green	O
monkey	O
kidney	O
cell	O
line	O
(	O
CV	O
-	O
1	O
)	O
were	O
incubated	O
with	O
[	O
3H	O
]	O
F	O
-	O
OH	O
,	O
radioactivity	O
was	O
incorporated	O
into	O
cholesterol	O
,	O
ubiquinone	O
(	O
CoQ	O
)	O
and	O
isoprenylated	O
proteins	O
.	O

The	O
incorporation	O
of	O
label	O
from	O
[	O
3H	O
]	O
F	O
-	O
OH	O
into	O
cholesterol	O
in	O
C6	O
and	O
CV	O
-	O
1	O
cells	O
was	O
blocked	O
by	O
squalestatin	O
1	O
(	O
SQ	O
)	O
which	O
specifically	O
inhibits	O
the	O
conversion	O
of	O
farnesyl	O
pyrophosphate	O
(	O
F	O
-	O
P	O
-	O
P	O
)	O
to	O
squalene	O
.	O

This	O
result	O
strongly	O
suggests	O
that	O
cholesterol	O
,	O
and	O
probably	O
CoQ	O
and	O
protein	O
,	O
is	O
metabolically	O
labeled	O
via	O
F	O
-	O
P	O
-	O
P	O
.	O

SDS	O
-	O
PAGE	O
analysis	O
of	O
the	O
delipidated	O
protein	O
fractions	O
from	O
C6	O
and	O
CV	O
-	O
1	O
cells	O
revealed	O
several	O
labeled	O
polypeptides	O
.	O

Consistent	O
with	O
these	O
proteins	O
being	O
modified	O
by	O
isoprenylation	O
of	O
cysteine	O
residues	O
.	O

Pronase	O
E	O
digestion	O
released	O
a	O
major	O
labeled	O
product	O
with	O
the	O
chromatographic	O
mobility	O
of	O
[	O
3H	O
]	O
farnesyl	O
-	O
cysteine	O
(	O
F	O
-	O
Cys	O
)	O
.	O

A	O
different	O
set	O
of	O
polypeptides	O
was	O
labeled	O
when	O
C6	O
and	O
CV	O
-	O
1	O
cells	O
were	O
incubated	O
with	O
[	O
3H	O
]	O
geranylgeraniol	O
(	O
GG	O
-	O
OH	O
)	O
.	O

Both	O
sets	O
of	O
proteins	O
appear	O
to	O
be	O
metabolically	O
labeled	O
by	O
[	O
3H	O
]	O
mevalonolactone	O
,	O
and	O
[	O
3H	O
]	O
-	O
labeled	O
F	O
-	O
Cys	O
and	O
geranylgeranyl	O
-	O
cysteine	O
(	O
GG	O
-	O
Cys	O
)	O
were	O
liberated	O
from	O
these	O
proteins	O
by	O
Pronase	O
E	O
treatment	O
.	O

These	O
cellular	O
and	O
biochemical	O
studies	O
indicate	O
that	O
F	O
-	O
OH	O
can	O
be	O
used	O
for	O
isoprenoid	O
biosynthesis	O
and	O
protein	O
isoprenylation	O
in	O
mammalian	O
cells	O
after	O
being	O
converted	O
to	O
F	O
-	O
P	O
-	O
P	O
by	O
phosphorylation	O
reactions	O
that	O
remain	O
to	O
be	O
elucidated	O
.	O

ADP	O
-	O
ribosylation	O
of	O
Rhizobium	O
meliloti	O
glutamine	B-Protein
synthetase	I-Protein
III	I-Protein
in	O
vivo	O
.	O

The	O
control	O
of	O
glutamine	O
synthetase	O
(	O
GS	O
)	O
,	O
the	O
first	O
enzyme	O
in	O
the	O
main	O
pathway	O
used	O
by	O
Rhizobium	O
meliloti	O
to	O
assimilate	O
ammonia	O
,	O
is	O
central	O
to	O
cellular	O
nitrogen	O
metabolism	O
.	O

R	O
.	O
meliloti	O
is	O
unusual	O
in	O
having	O
three	O
distinct	O
types	O
of	O
GS	O
,	O
including	O
a	O
unique	O
GS	O
,	O
GSIII	B-Protein
,	O
that	O
differs	O
considerably	O
from	O
both	O
GSI	B-Protein
,	O
which	O
resembles	O
other	O
bacterial	O
GS	O
proteins	O
and	O
GSII	B-Protein
,	O
which	O
resembles	O
the	O
GS	O
found	O
in	O
eukaryotes	O
.	O

We	O
show	O
here	O
that	O
GSIII	B-Protein
can	O
be	O
post	O
-	O
translationally	O
modified	O
in	O
vivo	O
by	O
ADP	O
-	O
ribosylation	O
at	O
an	O
arginine	O
residue	O
.	O

32PO4	O
attached	O
to	O
GSIII	B-Protein
during	O
bacterial	O
growth	O
as	O
part	O
of	O
the	O
modifying	O
group	O
could	O
be	O
removed	O
by	O
treatment	O
with	O
snake	O
venom	O
phosphodiesterase	O
or	O
by	O
turkey	O
erythrocyte	O
ADP	B-Protein
-	I-Protein
ribosylarginine	I-Protein
hydrolase	I-Protein
.	O

Treatment	O
of	O
modified	O
GSIII	B-Protein
with	O
hydroxylamine	O
at	O
neutral	O
pH	O
releases	O
a	O
chromophore	O
that	O
has	O
the	O
retention	O
time	O
of	O
ADP	O
-	O
ribose	O
when	O
analyzed	O
by	O
reversed	O
-	O
phase	O
high	O
performance	O
liquid	O
chromatography	O
.	O

ADP	O
-	O
ribosylation	O
inhibits	O
GSIII	B-Protein
activity	O
.	O

Recombinant	O
expression	O
and	O
evaluation	O
of	O
the	O
lipoyl	O
domains	O
of	O
the	O
dihydrolipoyl	B-Protein
acetyltransferase	I-Protein
component	I-Protein
of	I-Protein
the	I-Protein
human	I-Protein
pyruvate	I-Protein
dehydrogenase	I-Protein
complex	I-Protein
.	O

The	O
subunits	O
of	O
the	O
dihydrolipoyl	B-Protein
acetyltransferase	I-Protein
(	I-Protein
E2	I-Protein
)	I-Protein
component	I-Protein
of	I-Protein
mammalian	I-Protein
pyruvate	I-Protein
dehydrogenase	I-Protein
complex	I-Protein
(	O
PDC	O
)	O
associate	O
to	O
form	O
a	O
large	O
inner	O
core	O
with	O
a	O
protruding	O
structure	O
composed	O
of	O
three	O
globular	O
domains	O
connected	O
by	O
mobile	O
linker	O
regions	O
.	O

This	O
exterior	O
region	O
of	O
E2	B-Protein
includes	O
two	O
lipoyl	O
domains	O
which	O
engage	O
not	O
only	O
in	O
the	O
intermediate	O
reactions	O
of	O
the	O
complex	O
but	O
also	O
have	O
integral	O
roles	O
in	O
the	O
kinase	O
-	O
phosphatase	O
regulatory	O
interconversion	O
of	O
the	O
pyruvate	O
dehydrogenase	O
(	O
E1	O
)	O
component	O
.	O

To	O
facilitate	O
understanding	O
of	O
these	O
roles	O
,	O
lipoyl	O
domain	O
constructs	O
of	O
the	O
E2	B-Protein
component	I-Protein
of	O
human	O
PDC	O
were	O
expressed	O
as	O
glutathione	B-Protein
S	I-Protein
-	I-Protein
transferase	I-Protein
(	O
GST	B-Protein
)	O
-	O
linked	O
fusion	O
proteins	O
from	O
plasmid	O
inserts	O
prepared	O
by	O
polymerase	O
chain	O
reaction	O
procedures	O
.	O

The	O
NH2	O
-	O
terminal	O
lipoyl	O
domain	O
,	O
E2L1	O
,	O
and	O
the	O
interior	O
lipoyl	O
domain	O
,	O
E2L2	O
,	O
are	O
connected	O
by	O
a	O
30	O
-	O
amino	O
-	O
acid	O
hinge	O
region	O
,	O
H1	O
.	O

Constructs	O
designed	O
and	O
expressed	O
were	O
E2L1	O
(	O
1	O
-	O
98	O
)	O
,	O
E2L1	O
.	O
H1	O
(	O
1	O
-	O
128	O
)	O
,	O
E2L2	O
(	O
120	O
-	O
233	O
)	O
,	O
E2H1	O
.	O
L2	O
(	O
98	O
-	O
233	O
)	O
,	O
and	O
E2L1	O
.	O
H1	O
.	O
L2	O
(	O
1	O
-	O
233	O
)	O
,	O
where	O
numbers	O
in	O
parentheses	O
give	O
the	O
amino	O
acid	O
sequence	O
for	O
the	O
portions	O
of	O
the	O
E2	B-Protein
component	I-Protein
incorporated	O
into	O
a	O
construct	O
.	O

The	O
domains	O
were	O
expressed	O
in	O
Escherichia	O
coli	O
with	O
and	O
without	O
lipoate	O
supplementation	O
.	O

GST	B-Protein
constructs	O
were	O
purified	O
to	O
homogeneity	O
by	O
affinity	O
chromatography	O
and	O
selectively	O
released	O
by	O
thrombin	B-Protein
treatment	O
.	O

Sequencing	O
of	O
insert	O
DNAs	O
and	O
NH2	O
-	O
terminal	O
sequencing	O
confirmed	O
that	O
domains	O
were	O
produced	O
as	O
designed	O
.	O

Measurement	O
of	O
masses	O
by	O
electrospray	O
mass	O
spectrometry	O
indicated	O
that	O
constructs	O
with	O
lipoylated	O
,	O
nonlipoylated	O
,	O
and	O
octanoylated	O
forms	O
were	O
produced	O
when	O
expression	O
was	O
with	O
E	O
.	O
coli	O
grown	O
without	O
lipoate	O
supplementation	O
and	O
that	O
fully	O
lipoylated	O
forms	O
were	O
produced	O
upon	O
lipoate	O
supplementation	O
.	O

The	O
lipoylation	O
status	O
was	O
confirmed	O
,	O
following	O
delipoylation	O
with	O
Enterococcus	O
faecalis	O
lipoamidase	O
,	O
by	O
the	O
expected	O
decrease	O
in	O
mass	O
and	O
by	O
the	O
observation	O
in	O
native	O
gel	O
electrophoresis	O
of	O
a	O
shift	O
to	O
a	O
slower	O
mobility	O
(	O
possibly	O
less	O
compact	O
)	O
form	O
.	O

Constructs	O
were	O
used	O
in	O
E1	O
-	O
catalyzed	O
reductive	O
-	O
acetylation	O
reaction	O
in	O
proportion	O
to	O
their	O
degree	O
of	O
lipoylation	O
and	O
were	O
effective	O
substrates	O
in	O
a	O
NADH	O
-	O
dependent	O
dihydrolipoyl	B-Protein
dehydrogenase	I-Protein
reduction	O
reaction	O
.	O

Thus	O
,	O
we	O
have	O
produced	O
lipoyl	O
domain	O
constructs	O
that	O
can	O
be	O
employed	O
in	O
sorting	O
the	O
specific	O
roles	O
of	O
E2L1	O
and	O
E2L2	O
in	O
facilitating	O
catalytic	O
and	O
regulatory	O
processes	O
.	O

Lipoic	O
acid	O
metabolism	O
in	O
Escherichia	O
coli	O
:	O
the	O
lplA	B-Protein
and	O
lipB	B-Protein
genes	O
define	O
redundant	O
pathways	O
for	O
ligation	O
of	O
lipoyl	O
groups	O
to	O
apoprotein	O
.	O

Lipoic	O
acid	O
is	O
a	O
covalently	O
bound	O
disulfide	O
-	O
containing	O
cofactor	O
required	O
for	O
function	O
of	O
the	O
pyruvate	O
dehydrogenase	O
,	O
alpha	O
-	O
ketoglutarate	O
dehydrogenase	O
,	O
and	O
glycine	O
cleavage	O
enzyme	O
complexes	O
of	O
Escherichia	O
coli	O
.	O

Recently	O
we	O
described	O
the	O
isolation	O
of	O
the	O
lplA	B-Protein
locus	O
,	O
the	O
first	O
gene	O
known	O
to	O
encode	O
a	O
lipoyl	O
-	O
protein	O
ligase	O
for	O
the	O
attachment	O
of	O
lipoyl	O
groups	O
to	O
lipoate	O
-	O
dependent	O
apoenzymes	O
(	O
T	O
.	O
W	O
.	O
Morris	O
,	O
K	O
.	O
E	O
.	O
Reed	O
,	O
and	O
J	O
.	O
E	O
.	O
Cronan	O
,	O
Jr	O
.	O
,	O
J	O
.	O
Biol	O
.	O
Chem	O
.	O
269	O
:	O
16091	O
-	O
16100	O
,	O
1994	O
)	O
.	O

Here	O
,	O
we	O
report	O
an	O
unexpected	O
redundancy	O
between	O
the	O
functions	O
of	O
lplA	B-Protein
and	O
lipB	B-Protein
,	O
a	O
gene	O
previously	O
identified	O
as	O
a	O
putative	O
lipoate	O
biosynthetic	O
locus	O
.	O

First	O
,	O
analysis	O
of	O
lplA	B-Protein
null	O
mutants	O
revealed	O
the	O
existence	O
of	O
a	O
second	O
lipoyl	O
ligase	O
enzyme	O
.	O

We	O
found	O
that	O
lplA	B-Protein
null	O
mutants	O
displayed	O
no	O
growth	O
defects	O
unless	O
combined	O
with	O
lipA	B-Protein
(	O
lipoate	O
synthesis	O
)	O
or	O
lipB	B-Protein
mutations	O
and	O
that	O
overexpression	O
of	O
wild	O
-	O
type	O
LplA	B-Protein
suppressed	O
lipB	B-Protein
null	O
mutations	O
.	O

Assays	O
of	O
growth	O
,	O
transport	O
,	O
lipoyl	O
-	O
protein	O
content	O
,	O
and	O
apoprotein	O
modification	O
demonstrated	O
that	O
lplA	B-Protein
encoded	O
a	O
ligase	O
for	O
the	O
incorporation	O
of	O
exogenously	O
supplied	O
lipoate	O
,	O
whereas	O
lipB	B-Protein
was	O
required	O
for	O
function	O
of	O
the	O
second	O
lipoyl	O
ligase	O
,	O
which	O
utilizes	O
lipoyl	O
groups	O
generated	O
via	O
endogenous	O
(	O
lipA	B-Protein
-	O
mediated	O
)	O
biosynthesis	O
.	O

The	O
lipB	B-Protein
-	O
dependent	O
ligase	O
was	O
further	O
shown	O
to	O
cause	O
the	O
accumulation	O
of	O
aberrantly	O
modified	O
octanoyl	O
-	O
proteins	O
in	O
lipoate	O
-	O
deficient	O
cells	O
.	O

Lipoate	O
uptake	O
assays	O
of	O
strains	O
that	O
overproduced	O
lipoate	O
-	O
accepting	O
apoproteins	O
also	O
demonstrated	O
coupling	O
between	O
transport	O
and	O
the	O
subsequent	O
ligation	O
of	O
lipoate	O
to	O
apoprotein	O
by	O
the	O
LplA	B-Protein
enzyme	O
.	O

Although	O
mutations	O
in	O
two	O
genes	O
(	O
fadD	B-Protein
and	O
fadL	B-Protein
)	O
involved	O
in	O
fatty	O
acid	O
failed	O
to	O
affect	O
lipoate	O
utilization	O
,	O
disruption	O
of	O
the	O
smp	B-Protein
gene	O
severely	O
decreased	O
lipoate	O
utilization	O
.	O

DNA	O
sequencing	O
of	O
the	O
previously	O
identified	O
slr1	B-Protein
selenolipoate	O
resistance	O
mutation	O
(	O
K	O
.	O
E	O
.	O
Reed	O
,	O
T	O
.	O
W	O
.	O
Morris	O
,	O
and	O
J	O
.	O
E	O
.	O
Cronan	O
,	O
Jr	O
.	O
,	O
Proc	O
.	O
Natl	O
.	O
Acad	O
.	O
Sci	O
.	O
USA	O
91	O
:	O
3720	O
-	O
3724	O
,	O
1994	O
)	O
showed	O
this	O
mutation	O
(	O
now	O
called	O
lplA1	B-Protein
)	O
to	O
be	O
a	O
G76S	O
substitution	O
in	O
the	O
LplA	B-Protein
ligase	O
.	O

When	O
compared	O
with	O
the	O
wild	O
-	O
type	O
allele	O
,	O
the	O
cloned	O
lplA1	B-Protein
allele	O
conferred	O
a	O
threefold	O
increase	O
in	O
the	O
ability	O
to	O
discriminate	O
against	O
the	O
selenium	O
-	O
containing	O
analog	O
.	O

These	O
results	O
support	O
a	O
two	O
-	O
pathway	O
/	O
two	O
-	O
ligase	O
model	O
of	O
lipoate	O
metabolism	O
in	O
E	O
.	O
coli	O
.	O

Regulation	O
of	O
Na	O
+	O
/	O
glucose	O
cotransport	O
in	O
LLC	O
-	O
PK1	O
cells	O
by	O
glucose	O
in	O
culture	O
medium	O
:	O
involvement	O
of	O
Gi	O
protein	O
.	O

The	O
reduction	O
of	O
the	O
glucose	O
concentrations	O
in	O
the	O
culture	O
medium	O
results	O
in	O
an	O
increase	O
in	O
Na	O
+	O
/	O
glucose	O
cotransport	O
activity	O
in	O
the	O
epithelial	O
cells	O
.	O

To	O
study	O
this	O
regulation	O
of	O
Na	O
+	O
/	O
glucose	O
cotransport	O
in	O
LLC	O
-	O
PK1	O
cells	O
,	O
we	O
have	O
attempted	O
to	O
examine	O
the	O
involvement	O
of	O
Gi	O
protein	O
.	O

The	O
immunoblotting	O
with	O
an	O
antibody	O
for	O
the	O
carboxy	O
-	O
terminal	O
of	O
alpha	O
subunit	O
of	O
Gi	O
protein	O
(	O
Gi	O
alpha	O
)	O
revealed	O
no	O
significant	O
change	O
in	O
the	O
level	O
of	O
Gi	O
alpha	O
in	O
cells	O
cultured	O
with	O
low	O
(	O
5	O
mM	O
)	O
or	O
high	O
(	O
25	O
mM	O
)	O
glucose	O
concentrations	O
.	O

In	O
contrast	O
,	O
the	O
cultured	O
with	O
low	O
glucose	O
concentrations	O
induced	O
the	O
increases	O
of	O
both	O
islet	O
activating	O
protein	O
(	O
IAP	O
)	O
-	O
catalyzed	O
ADP	O
-	O
ribosylation	O
of	O
Gi	O
alpha	O
and	O
Na	O
+	O
/	O
glucose	O
cotransport	O
activity	O
.	O

Furthermore	O
,	O
this	O
increase	O
in	O
the	O
transport	O
activity	O
was	O
blocked	O
by	O
the	O
presence	O
of	O
IAP	O
in	O
a	O
dose	O
dependent	O
manner	O
.	O

These	O
results	O
suggest	O
that	O
there	O
is	O
a	O
close	O
relationship	O
between	O
the	O
concentration	O
of	O
the	O
heterotrimeric	O
form	O
of	O
Gi	O
protein	O
(	O
Gi	O
alpha	O
beta	O
gamma	O
)	O
and	O
the	O
activity	O
of	O
Na	O
+	O
/	O
glucose	O
cotransport	O
in	O
LLC	O
-	O
PK1	O
cells	O
.	O

Posttranslational	O
modification	O
of	O
nitrogenase	O
.	O

Differences	O
between	O
the	O
purple	O
bacterium	O
Rhodospirillum	O
rubrum	O
and	O
the	O
cyanobacterium	O
Anabaena	O
variabilis	O
.	O

In	O
the	O
photosynthetic	O
bacteria	O
Rhodospirillum	O
rubrum	O
and	O
Rhodopseudomonas	O
capsulatus	O
post	O
-	O
translational	O
regulation	O
of	O
nitrogenase	O
is	O
due	O
to	O
ADP	O
-	O
ribosylation	O
of	O
the	O
Fe	O
-	O
protein	O
,	O
the	O
dinitrogenase	B-Protein
reductase	I-Protein
[	O
Burris	O
,	O
R	O
.	O
H	O
.	O
(	O
1991	O
)	O
J	O
.	O
Biol	O
.	O
Chem	O
.	O
266	O
,	O
9339	O
-	O
9342	O
]	O
.	O

This	O
mechanism	O
has	O
been	O
assumed	O
to	O
be	O
responsible	O
for	O
nitrogenase	O
modification	O
in	O
a	O
variety	O
of	O
organisms	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
examined	O
whether	O
ADP	O
-	O
ribosylation	O
holds	O
true	O
for	O
the	O
filamentous	O
cyanobacterium	O
Anabaena	O
variabilis	O
.	O

Genes	O
coding	O
for	O
the	O
nitrogenase	O
-	O
modifying	O
enzymes	O
dinitrogenase	B-Protein
reductase	I-Protein
-	I-Protein
activating	I-Protein
glycohydrolase	I-Protein
(	O
DRAG	B-Protein
)	O
and	O
dinitrogenase	B-Protein
reductase	I-Protein
ADP	I-Protein
-	I-Protein
ribosyl	I-Protein
transferase	I-Protein
(	O
DRAT	B-Protein
)	O
from	O
R	O
.	O
rubrum	O
have	O
been	O
subcloned	O
and	O
overexpressed	O
in	O
Escherichia	O
coli	O
.	O

After	O
isolation	O
under	O
anaerobic	O
conditions	O
,	O
both	O
proteins	O
were	O
functional	O
as	O
determined	O
by	O
in	O
-	O
vitro	O
assays	O
using	O
nitrogenase	O
from	O
R	O
.	O
rubrum	O
as	O
substrate	O
.	O

In	O
contrast	O
to	O
the	O
R	O
.	O
rubrum	O
enzyme	O
,	O
nitrogenase	O
from	O
A	O
.	O
variabilis	O
was	O
not	O
affected	O
by	O
DRAG	B-Protein
or	O
DRAT	B-Protein
.	O

Neither	O
could	O
inactive	O
nitrogenase	O
be	O
restored	O
by	O
DRAG	B-Protein
,	O
nor	O
nitrogenase	O
activity	O
suppressed	O
by	O
DRAT	B-Protein
.	O

Using	O
specific	O
antibodies	O
against	O
arginine	O
-	O
bound	O
ADP	O
-	O
ribose	O
[	O
Meyer	O
,	O
T	O
.	O
&	O
Hilz	O
,	O
H	O
.	O
(	O
1986	O
)	O
Eur	O
.	O
J	O
.	O
Biochem	O
.	O
155	O
,	O
157	O
-	O
165	O
]	O
,	O
immunoblotting	O
of	O
the	O
inactive	O
,	O
modified	O
form	O
of	O
the	O
Fe	O
-	O
protein	O
from	O
R	O
.	O
rubrum	O
but	O
not	O
that	O
from	O
A	O
.	O
variabilis	O
showed	O
a	O
strong	O
cross	O
reaction	O
.	O

Furthermore	O
,	O
differently	O
to	O
R	O
.	O
rubrum	O
no	O
ADP	O
-	O
ribosylated	O
proteins	O
could	O
be	O
detected	O
at	O
all	O
,	O
indicating	O
the	O
absence	O
of	O
this	O
posttranslational	O
modification	O
in	O
A	O
.	O
variabilis	O
.	O

Molecular	O
cloning	O
and	O
characterization	O
of	O
an	O
isoprenylated	O
67	O
kDa	O
protein	O
.	O

The	O
cDNA	O
coding	O
for	O
a	O
67	O
kDa	O
protein	O
(	O
p67	B-Protein
)	O
was	O
isolated	O
from	O
a	O
rat	O
Schwann	O
cell	O
library	O
.	O

A	O
recombinant	O
form	O
of	O
p67	B-Protein
expressed	O
in	O
bacteria	O
was	O
used	O
to	O
produce	O
polyclonal	O
anti	O
-	O
p67	B-Protein
antibodies	O
.	O

By	O
immunoblot	O
analysis	O
p67	B-Protein
was	O
found	O
to	O
be	O
expressed	O
in	O
most	O
tissues	O
and	O
cell	O
lines	O
examined	O
.	O

Inspection	O
of	O
the	O
deduced	O
amino	O
acid	O
sequence	O
revealed	O
a	O
COOH	O
-	O
terminal	O
consensus	O
sequence	O
for	O
isoprenylation	O
.	O

Consistent	O
with	O
this	O
finding	O
,	O
p67	B-Protein
was	O
a	O
substrate	O
for	O
isoprenylation	O
in	O
vitro	O
by	O
geranylgeranylpyrophosphate	O
.	O

p67	B-Protein
was	O
associated	O
predominantly	O
with	O
the	O
particulate	O
fraction	O
of	O
rat	O
smooth	O
muscle	O
cells	O
.	O

The	O
rat	O
p67	B-Protein
sequence	O
was	O
highly	O
homologous	O
to	O
a	O
family	O
of	O
recently	O
described	O
human	O
and	O
mouse	O
gamma	B-Protein
-	I-Protein
interferon	I-Protein
inducible	O
,	O
guanine	O
nucleotide	O
binding	O
proteins	O
.	O

The	O
use	O
of	O
active	O
centre	O
acylation	O
to	O
control	O
the	O
pharmacokinetic	O
profile	O
of	O
a	O
recombinant	O
chimaeric	O
plasminogen	B-Protein
activator	O
.	O

Recombinant	O
hybrid	O
plasminogen	B-Protein
activators	O
consisting	O
of	O
the	O
"	O
A	O
"	O
chain	O
of	O
plasminogen	B-Protein
linked	O
to	O
the	O
"	O
B	O
"	O
chain	O
of	O
t	B-Protein
-	I-Protein
PA	I-Protein
that	O
are	O
inhibited	O
rapidly	O
by	O
plasma	O
protease	O
inhibitors	O
have	O
recently	O
been	O
described	O
(	O
Robinson	O
et	O
al	O
.	O
Circulation	O
1992	O
;	O
86	O
:	O
548	O
-	O
552	O
)	O
.	O

We	O
have	O
now	O
shown	O
that	O
following	O
bolus	O
administration	O
of	O
native	O
hybrid	O
to	O
guinea	O
pigs	O
,	O
fibrinolytic	O
activity	O
was	O
cleared	O
rapidly	O
from	O
the	O
circulation	O
.	O

Active	O
centre	O
acylation	O
appeared	O
to	O
protect	O
the	O
hybrid	O
from	O
inhibition	O
and	O
allowed	O
material	O
to	O
circulate	O
as	O
potentially	O
active	O
species	O
for	O
prolonged	O
periods	O
.	O

Clearance	O
rates	O
of	O
a	O
range	O
of	O
acyl	O
derivatives	O
of	O
the	O
hybrid	O
were	O
7	O
-	O
35	O
-	O
fold	O
slower	O
than	O
for	O
native	O
hybrid	O
and	O
20	O
-	O
100	O
-	O
fold	O
slower	O
than	O
for	O
t	B-Protein
-	I-Protein
PA	I-Protein
.	O

Clearance	O
rates	O
were	O
influenced	O
markedly	O
by	O
deacylation	O
rate	O
,	O
such	O
that	O
clearance	O
half	O
-	O
life	O
correlated	O
well	O
with	O
deacylation	O
half	O
-	O
life	O
.	O

We	O
have	O
thus	O
shown	O
that	O
it	O
is	O
feasible	O
to	O
control	O
the	O
pharmacokinetic	O
profile	O
of	O
a	O
recombinant	O
hybrid	O
plasminogen	B-Protein
activator	O
over	O
a	O
wide	O
range	O
by	O
selection	O
of	O
an	O
appropriate	O
acyl	O
group	O
for	O
attachment	O
to	O
the	O
active	O
site	O
.	O

Such	O
control	O
is	O
not	O
possible	O
with	O
plasminogen	B-Protein
activators	O
that	O
are	O
cleared	O
predominantly	O
by	O
mechanisms	O
other	O
than	O
inhibition	O
.	O

The	O
31	O
-	O
kDa	O
precursor	O
of	O
interleukin	B-Protein
1	I-Protein
alpha	I-Protein
is	O
myristoylated	O
on	O
specific	O
lysines	O
within	O
the	O
16	O
-	O
kDa	O
N	O
-	O
terminal	O
propiece	O
.	O

The	O
cytokine	O
interleukin	B-Protein
1	I-Protein
alpha	I-Protein
(	O
IL	B-Protein
-	I-Protein
1	I-Protein
alpha	I-Protein
)	O
is	O
a	O
critical	O
mediator	O
of	O
the	O
immune	O
and	O
inflammatory	O
responses	O
.	O

A	O
unique	O
determinant	O
of	O
its	O
activity	O
as	O
compared	O
with	O
IL	B-Protein
-	I-Protein
1	I-Protein
beta	I-Protein
may	O
be	O
its	O
association	O
with	O
the	O
plasma	O
membrane	O
.	O

While	O
the	O
biologic	O
activity	O
of	O
"	O
membrane	O
IL	O
-	O
1	O
"	O
has	O
been	O
extensively	O
reported	O
,	O
the	O
mechanism	O
of	O
membrane	O
binding	O
remains	O
unclear	O
.	O

We	O
report	O
that	O
the	O
N	O
terminus	O
of	O
the	O
31	O
-	O
kDa	O
IL	B-Protein
-	I-Protein
1	I-Protein
alpha	I-Protein
precursor	O
is	O
myristoylated	O
on	O
specific	O
internal	O
lysine	O
residues	O
.	O

Immunoprecipitation	O
of	O
[	O
3H	O
]	O
myristic	O
acid	O
-	O
radiolabeled	O
human	O
monocyte	O
lysates	O
with	O
IgG	O
antibodies	O
to	O
the	O
31	O
-	O
kDa	O
IL	B-Protein
-	I-Protein
1	I-Protein
alpha	I-Protein
precursor	O
recovered	O
a	O
protein	O
with	O
the	O
physicochemical	O
properties	O
of	O
the	O
IL	B-Protein
-	I-Protein
1	I-Protein
alpha	I-Protein
N	O
-	O
terminal	O
propiece	O
(	O
16	O
kDa	O
,	O
pI	O
4	O
.	O
45	O
)	O
.	O

Glycyl	O
N	O
-	O
myristoylation	O
of	O
this	O
protein	O
is	O
precluded	O
by	O
the	O
absence	O
of	O
a	O
glycine	O
residue	O
at	O
position	O
2	O
,	O
suggesting	O
that	O
the	O
propiece	O
is	O
myristoylated	O
on	O
epsilon	O
-	O
amino	O
groups	O
of	O
lysine	O
.	O

To	O
determine	O
which	O
lysine	O
(	O
s	O
)	O
are	O
acylated	O
,	O
a	O
series	O
of	O
synthetic	O
peptides	O
containing	O
all	O
lysines	O
found	O
in	O
the	O
IL	B-Protein
-	I-Protein
1	I-Protein
alpha	I-Protein
N	O
-	O
terminal	O
propiece	O
were	O
used	O
in	O
an	O
in	O
vitro	O
myristoylation	O
assay	O
containing	O
peptide	O
,	O
myristoyl	O
-	O
CoA	O
,	O
and	O
monocyte	O
lysate	O
as	O
enzyme	O
source	O
.	O

Analysis	O
of	O
the	O
reaction	O
products	O
by	O
reverse	O
-	O
phase	O
HPLC	O
and	O
gas	O
-	O
phase	O
sequencing	O
demonstrated	O
the	O
specific	O
myristoylation	O
of	O
Lys	O
-	O
82	O
and	O
Lys	O
-	O
83	O
,	O
yielding	O
predominantly	O
monoacylated	O
product	O
.	O

A	O
conserved	O
sequence	O
in	O
the	O
IL	B-Protein
-	I-Protein
1	I-Protein
beta	I-Protein
propiece	O
was	O
myristoylated	O
with	O
at	O
least	O
8	O
-	O
fold	O
less	O
efficiency	O
.	O

Acylation	O
of	O
the	O
IL	B-Protein
-	I-Protein
1	I-Protein
alpha	I-Protein
precursor	O
by	O
a	O
previously	O
unrecognized	O
lysyl	O
epsilon	O
-	O
amino	O
N	O
-	O
myristoyl	O
-	O
transferase	O
activity	O
may	O
facilitate	O
its	O
specific	O
membrane	O
targeting	O
.	O

Nerve	B-Protein
growth	I-Protein
factor	I-Protein
induces	O
a	O
succession	O
of	O
increases	O
in	O
isoprenylated	O
methylated	O
small	O
GTP	O
-	O
binding	O
proteins	O
of	O
PC	O
-	O
12	O
pheochromocytoma	O
cells	O
.	O

Pheochromocytoma	O
(	O
PC	O
-	O
12	O
)	O
cells	O
exposed	O
to	O
nerve	B-Protein
growth	I-Protein
factor	I-Protein
(	O
NGF	B-Protein
)	O
acquire	O
a	O
sympathetic	O
neuron	O
-	O
like	O
phenotype	O
.	O

This	O
NGF	B-Protein
-	O
response	O
is	O
blocked	O
by	O
methylation	O
inhibitors	O
and	O
can	O
be	O
mimicked	O
by	O
the	O
farnesylated	O
methylated	O
small	O
GTP	O
-	O
binding	O
protein	O
p21ras	B-Protein
.	O

The	O
implicated	O
involvement	O
of	O
prenylation	O
,	O
methylation	O
and	O
a	O
small	O
GTP	O
-	O
binding	O
protein	O
in	O
the	O
NGF	B-Protein
-	O
response	O
has	O
been	O
studied	O
by	O
directly	O
measuring	O
3H	O
-	O
mevalonic	O
acid	O
(	O
MVA	O
)	O
-	O
metabolites	O
incorporated	O
into	O
proteins	O
,	O
protein	O
carboxy	O
[	O
methyl	O
-	O
3H	O
]	O
ester	O
formation	O
and	O
levels	O
of	O
[	O
alpha	O
-	O
32P	O
]	O
GTP	O
-	O
binding	O
proteins	O
in	O
NGF	B-Protein
-	O
induced	O
PC	O
-	O
12	O
cells	O
.	O

We	O
demonstrate	O
that	O
NGF	B-Protein
induces	O
a	O
2	O
-	O
3	O
-	O
fold	O
increase	O
in	O
21	O
-	O
24	O
kDa	O
methylated	O
membrane	O
proteins	O
that	O
incorporate	O
3H	O
-	O
MVA	O
-	O
metabolites	O
,	O
and	O
bind	O
GTP	O
.	O

Levels	O
of	O
[	O
alpha	O
-	O
32P	O
]	O
GTP	O
-	O
binding	O
in	O
these	O
proteins	O
were	O
increased	O
by	O
2	O
-	O
3	O
-	O
fold	O
.	O

Methylation	O
and	O
membrane	O
association	O
of	O
the	O
small	O
GTP	O
-	O
binding	O
proteins	O
were	O
blocked	O
by	O
lovastatin	O
,	O
an	O
inhibitor	O
of	O
3	B-Protein
-	I-Protein
hydroxy	I-Protein
-	I-Protein
3	I-Protein
-	I-Protein
methylglutaryl	I-Protein
-	I-Protein
CoA	I-Protein
(	I-Protein
HMG	I-Protein
-	I-Protein
CoA	I-Protein
)	I-Protein
reductase	I-Protein
,	O
which	O
also	O
enhanced	O
their	O
labeling	O
by	O
3H	O
-	O
MVA	O
-	O
metabolites	O
.	O

Cycloheximide	O
reduced	O
the	O
levels	O
of	O
[	O
methyl	O
-	O
3H	O
]	O
labeled	O
21	O
-	O
24	O
kDa	O
proteins	O
and	O
of	O
the	O
overlapping	O
[	O
alpha	O
-	O
32P	O
]	O
GTP	O
binding	O
-	O
proteins	O
.	O

About	O
70	O
%	O
of	O
the	O
[	O
methyl	O
-	O
3H	O
]	O
-	O
groups	O
found	O
in	O
these	O
proteins	O
were	O
recovered	O
from	O
two	O
dimensional	O
gel	O
blots	O
in	O
nine	O
distinct	O
spots	O
of	O
[	O
alpha	O
-	O
32P	O
]	O
GTP	O
-	O
binding	O
proteins	O
.	O

Taken	O
together	O
these	O
results	O
strongly	O
suggest	O
that	O
in	O
PC	O
-	O
12	O
cells	O
,	O
NGF	B-Protein
induces	O
an	O
increase	O
in	O
the	O
synthesis	O
of	O
prenylated	O
methylated	O
small	O
GTP	O
-	O
binding	O
proteins	O
.	O

The	O
efficacy	O
of	O
lovastatin	O
blockage	O
of	O
protein	O
methylation	O
and	O
enhancement	O
of	O
3H	O
-	O
MVA	O
-	O
metabolites	O
incorporation	O
into	O
GTP	O
-	O
binding	O
proteins	O
was	O
lower	O
in	O
NGF	B-Protein
-	O
induced	O
cells	O
than	O
in	O
controls	O
.	O

This	O
suggests	O
that	O
NGF	B-Protein
also	O
induces	O
an	O
increase	O
in	O
HMG	B-Protein
-	I-Protein
CoA	I-Protein
reductase	I-Protein
activity	O
.	O

At	O
the	O
early	O
phase	O
of	O
the	O
NGF	B-Protein
response	O
in	O
PC	O
-	O
12	O
cells	O
(	O
15	O
min	O
-	O
1	O
h	O
)	O
,	O
the	O
levels	O
of	O
two	O
small	O
GTP	O
-	O
binding	O
proteins	O
(	O
molecular	O
mass	O
of	O
21	O
-	O
22	O
kDa	O
and	O
23	O
-	O
24	O
kDa	O
)	O
were	O
increased	O
.	O

Thus	O
,	O
at	O
least	O
two	O
proteins	O
,	O
of	O
which	O
one	O
but	O
not	O
the	O
other	O
may	O
be	O
p21ras	B-Protein
,	O
appear	O
to	O
be	O
involved	O
in	O
the	O
early	O
response	O
.	O

After	O
a	O
lag	O
period	O
of	O
24	O
h	O
with	O
NGF	B-Protein
,	O
a	O
second	O
more	O
robust	O
phase	O
of	O
increase	O
in	O
methylated	O
small	O
GTP	O
-	O
binding	O
proteins	O
was	O
apparent	O
.	O

This	O
relatively	O
late	O
response	O
,	O
which	O
was	O
almost	O
completed	O
within	O
24	O
h	O
,	O
may	O
reflect	O
involvement	O
of	O
small	O
GTP	O
-	O
binding	O
proteins	O
in	O
neurite	O
-	O
outgrowth	O
and	O
in	O
the	O
functional	O
activity	O
of	O
the	O
differentiated	O
cells	O
.	O

Many	O
small	O
GTP	O
-	O
binding	O
proteins	O
were	O
increased	O
during	O
the	O
second	O
phase	O
,	O
precluding	O
electrophoretic	O
separation	O
of	O
all	O
of	O
them	O
.	O

3	O
proteins	O
,	O
however	O
,	O
were	O
well	O
separated	O
(	O
one	O
23	O
-	O
24	O
kDa	O
protein	O
and	O
two	O
21	O
-	O
22	O
kDa	O
proteins	O
)	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

Posttranslational	O
regulation	O
of	O
nitrogenase	O
in	O
Rhodobacter	O
capsulatus	O
:	O
existence	O
of	O
two	O
independent	O
regulatory	O
effects	O
of	O
ammonium	O
.	O

In	O
the	O
photosynthetic	O
bacterium	O
Rhodobacter	O
capsulatus	O
,	O
nitrogenase	O
activity	O
is	O
regulated	O
by	O
ADP	O
-	O
ribosylation	O
of	O
component	B-Protein
II	I-Protein
in	O
response	O
to	O
the	O
addition	O
of	O
ammonium	O
to	O
cultures	O
or	O
to	O
the	O
removal	O
of	O
light	O
.	O

The	O
ammonium	O
stimulus	O
results	O
in	O
a	O
fast	O
and	O
almost	O
complete	O
inhibition	O
of	O
the	O
in	O
vivo	O
acetylene	O
reduction	O
activity	O
,	O
termed	O
switch	O
-	O
off	O
,	O
which	O
is	O
reversed	O
after	O
the	O
ammonium	O
is	O
exhausted	O
.	O

In	O
the	O
present	O
study	O
of	O
the	O
response	O
of	O
cells	O
to	O
ammonium	O
,	O
ADP	O
-	O
ribosylation	O
of	O
component	B-Protein
II	I-Protein
occurred	O
but	O
could	O
not	O
account	O
for	O
the	O
extent	O
and	O
timing	O
of	O
the	O
inhibition	O
of	O
activity	O
.	O

The	O
presence	O
of	O
an	O
additional	O
response	O
was	O
confirmed	O
with	O
strains	O
expressing	O
mutant	O
component	B-Protein
II	I-Protein
proteins	O
;	O
although	O
these	O
proteins	O
are	O
not	O
a	O
substrate	O
for	O
ADP	O
-	O
ribosylation	O
,	O
the	O
strains	O
continued	O
to	O
exhibit	O
a	O
switch	O
-	O
off	O
response	O
to	O
ammonium	O
.	O

This	O
second	O
regulatory	O
response	O
of	O
nitrogenase	O
to	O
ammonium	O
was	O
found	O
to	O
be	O
synchronous	O
with	O
ADP	O
-	O
ribosylation	O
and	O
was	O
responsible	O
for	O
the	O
bulk	O
of	O
the	O
observed	O
effects	O
on	O
nitrogenase	O
activity	O
.	O

In	O
comparison	O
,	O
ADP	O
-	O
ribosylation	O
in	O
R	O
.	O
capsulatus	O
was	O
found	O
to	O
be	O
relatively	O
slow	O
and	O
incomplete	O
but	O
responded	O
independently	O
to	O
both	O
known	O
stimuli	O
,	O
darkness	O
and	O
ammonium	O
.	O

Based	O
on	O
the	O
in	O
vitro	O
nitrogenase	O
activity	O
of	O
both	O
the	O
wild	O
type	O
and	O
strains	O
whose	O
component	B-Protein
II	I-Protein
proteins	O
cannot	O
be	O
ADP	O
-	O
ribosylated	O
,	O
it	O
seems	O
likely	O
that	O
the	O
second	O
response	O
blocks	O
either	O
the	O
ATP	O
or	O
the	O
electron	O
supply	O
to	O
nitrogenase	O
.	O

In	O
vitro	O
and	O
in	O
vivo	O
functional	O
characterization	O
of	O
bovine	O
vitamin	B-Protein
K	I-Protein
-	I-Protein
dependent	I-Protein
gamma	I-Protein
-	I-Protein
carboxylase	I-Protein
expressed	O
in	O
Chinese	O
hamster	O
ovary	O
cells	O
.	O

Coagulation	B-Protein
factor	I-Protein
IX	I-Protein
is	O
a	O
serine	O
protease	O
for	O
which	O
high	O
-	O
level	O
expression	O
of	O
biologically	O
active	O
protein	O
in	O
heterologous	O
cells	O
is	O
limited	O
due	O
to	O
inefficient	O
proteolytic	O
removal	O
of	O
the	O
propeptide	O
as	O
well	O
as	O
vitamin	O
K	O
-	O
dependent	O
carboxylation	O
of	O
multiple	O
amino	O
-	O
terminal	O
glutamic	O
acid	O
residues	O
.	O

We	O
have	O
overexpressed	O
the	O
vitamin	B-Protein
K	I-Protein
-	I-Protein
dependent	I-Protein
gamma	I-Protein
-	I-Protein
carboxylase	I-Protein
cDNA	O
and	O
monitored	O
its	O
ability	O
to	O
improve	O
factor	B-Protein
IX	I-Protein
processing	O
in	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	O
)	O
cells	O
.	O

From	O
amino	O
acid	O
sequence	O
analysis	O
of	O
bovine	O
liver	O
vitamin	B-Protein
K	I-Protein
-	I-Protein
dependent	I-Protein
gamma	I-Protein
-	I-Protein
carboxylase	I-Protein
,	O
degenerate	O
oligonucleotides	O
were	O
used	O
to	O
isolate	O
a	O
3	O
.	O
5	O
-	O
kbp	O
bovine	O
cDNA	O
that	O
encoded	O
a	O
758	O
-	O
residue	O
open	O
reading	O
frame	O
.	O

Expression	O
of	O
the	O
cDNA	O
in	O
COS	O
-	O
1	O
and	O
CHO	O
cells	O
yielded	O
17	O
-	O
and	O
16	O
-	O
fold	O
increases	O
in	O
the	O
in	O
vitro	O
gamma	O
-	O
carboxylase	O
activity	O
of	O
microsomal	O
preparations	O
,	O
respectively	O
.	O

Anti	O
-	O
serum	O
raised	O
against	O
a	O
predicted	O
peptide	O
sequence	O
reacted	O
with	O
a	O
94	O
-	O
kDa	O
polypeptide	O
in	O
the	O
partially	O
purified	O
bovine	O
liver	O
preparation	O
as	O
well	O
as	O
in	O
stably	O
transfected	O
CHO	O
cells	O
.	O

The	O
amount	O
of	O
antibody	O
reactivity	O
correlated	O
with	O
the	O
increased	O
ability	O
to	O
carboxylate	O
a	O
peptide	O
substrate	O
in	O
vitro	O
.	O

These	O
results	O
strongly	O
support	O
the	O
conclusion	O
that	O
the	O
cDNA	O
encodes	O
the	O
vitamin	B-Protein
K	I-Protein
-	I-Protein
dependent	I-Protein
gamma	I-Protein
-	I-Protein
carboxylase	I-Protein
.	O

Transient	O
transfection	O
of	O
the	O
gamma	B-Protein
-	I-Protein
carboxylase	I-Protein
expression	O
vector	O
into	O
factor	B-Protein
IX	I-Protein
-	O
expressing	O
CHO	O
cells	O
did	O
not	O
improve	O
the	O
specific	O
procoagulant	O
activity	O
of	O
secreted	O
factor	B-Protein
IX	I-Protein
.	O

In	O
contrast	O
,	O
transfection	O
of	O
an	O
expression	O
vector	O
encoding	O
the	O
propeptide	O
processing	O
enzyme	O
PACE	B-Protein
(	O
paired	B-Protein
basic	I-Protein
amino	I-Protein
acid	I-Protein
cleaving	I-Protein
enzyme	I-Protein
)	O
did	O
improve	O
the	O
specific	O
activity	O
of	O
secreted	O
factor	B-Protein
IX	I-Protein
by	O
3	O
-	O
fold	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
ability	O
of	O
CHO	O
cells	O
to	O
modify	O
glutamic	O
acid	O
residues	O
to	O
gamma	O
-	O
carboxyglutamic	O
acid	O
in	O
secreted	O
factor	B-Protein
IX	I-Protein
is	O
not	O
limited	O
by	O
the	O
expression	O
of	O
the	O
vitamin	B-Protein
K	I-Protein
-	I-Protein
dependent	I-Protein
gamma	I-Protein
-	I-Protein
carboxylase	I-Protein
alone	O
.	O

Processive	O
post	O
-	O
translational	O
modification	O
.	O

Vitamin	O
K	O
-	O
dependent	O
carboxylation	O
of	O
a	O
peptide	O
substrate	O
.	O

Mass	O
spectrometry	O
has	O
been	O
used	O
to	O
demonstrate	O
that	O
vitamin	O
K	O
-	O
dependent	O
carboxylation	O
is	O
a	O
processive	O
post	O
-	O
translational	O
modification	O
(	O
i	O
.	O
e	O
.	O
multiple	O
carboxylations	O
occur	O
during	O
a	O
single	O
association	O
between	O
enzyme	O
and	O
substrate	O
)	O
.	O

Purified	O
vitamin	B-Protein
K	I-Protein
-	I-Protein
dependent	I-Protein
carboxylase	I-Protein
can	O
carboxylate	O
as	O
many	O
as	O
12	O
glutamate	O
residues	O
in	O
FIXQ	O
/	O
S	O
,	O
a	O
peptide	O
substrate	O
based	O
on	O
amino	O
acids	O
-	O
18	O
to	O
41	O
of	O
the	O
human	O
blood	O
clotting	O
enzyme	O
factor	B-Protein
IX	I-Protein
.	O

Mass	O
spectrometry	O
was	O
used	O
to	O
determine	O
the	O
number	O
of	O
gamma	O
-	O
carboxyl	O
groups	O
added	O
to	O
FIXQ	O
/	O
S	O
by	O
the	O
carboxylase	O
during	O
an	O
in	O
vitro	O
reaction	O
.	O

Despite	O
the	O
fact	O
that	O
most	O
substrate	O
molecules	O
in	O
a	O
reaction	O
were	O
uncarboxylated	O
,	O
almost	O
all	O
carboxylated	O
FIXQ	O
/	O
S	O
molecules	O
were	O
carboxylated	O
many	O
times	O
.	O

This	O
observation	O
can	O
only	O
be	O
explained	O
by	O
two	O
types	O
of	O
mechanisms	O
.	O

In	O
a	O
processive	O
mechanism	O
,	O
multiple	O
carboxylations	O
could	O
occur	O
during	O
a	O
single	O
substrate	O
binding	O
event	O
.	O

Alternatively	O
,	O
a	O
distributive	O
mechanism	O
could	O
result	O
in	O
the	O
observed	O
behavior	O
if	O
the	O
initial	O
carboxylation	O
event	O
results	O
in	O
a	O
substrate	O
that	O
is	O
additionally	O
carboxylated	O
far	O
more	O
efficiently	O
than	O
the	O
uncarboxylated	O
FIXQ	O
/	O
S	O
.	O

Kinetic	O
experiments	O
and	O
arguments	O
were	O
used	O
to	O
show	O
that	O
the	O
vitamin	B-Protein
K	I-Protein
-	I-Protein
dependent	I-Protein
carboxylase	I-Protein
is	O
not	O
distributive	O
but	O
rather	O
is	O
one	O
of	O
the	O
first	O
well	O
documented	O
examples	O
of	O
an	O
enzyme	O
that	O
catalyzes	O
a	O
processive	O
post	O
-	O
translation	O
modification	O
.	O

Size	O
variations	O
in	O
the	O
mucin	O
-	O
type	O
domain	O
of	O
hamster	O
oviductin	B-Protein
:	O
identification	O
of	O
the	O
polypeptide	O
precursors	O
and	O
characterization	O
of	O
their	O
biosynthetic	O
maturation	O
.	O

The	O
recent	O
sequencing	O
of	O
a	O
cDNA	O
clone	O
for	O
hamster	O
oviductin	B-Protein
revealed	O
that	O
this	O
zona	O
pellucida	O
-	O
associated	O
glycoprotein	O
is	O
a	O
particularly	O
intriguing	O
chimeric	O
molecule	O
because	O
it	O
encloses	O
regions	O
of	O
significant	O
similarity	O
with	O
chitinase	O
-	O
related	O
proteins	O
as	O
well	O
as	O
a	O
carboxyterminal	O
mucin	O
-	O
type	O
domain	O
.	O

This	O
domain	O
contains	O
contiguous	O
Ser	O
/	O
Thr	O
-	O
rich	O
repeated	O
stretches	O
of	O
15	O
amino	O
acids	O
;	O
similar	O
units	O
are	O
also	O
found	O
in	O
the	O
deduced	O
sequence	O
of	O
human	O
oviductin	O
.	O

Such	O
structural	O
domains	O
constitute	O
a	O
central	O
feature	O
of	O
mucins	O
.	O

We	O
amplified	O
this	O
region	O
from	O
16	O
hamster	O
oviductin	B-Protein
cDNA	O
clones	O
and	O
identified	O
three	O
length	O
variants	O
.	O

In	O
order	O
to	O
elucidate	O
the	O
biosynthetic	O
maturation	O
of	O
the	O
glycoprotein	O
,	O
a	O
high	O
-	O
titer	O
antiserum	O
against	O
synthetic	O
peptides	O
derived	O
from	O
internal	O
sequences	O
of	O
hamster	O
oviductin	B-Protein
was	O
produced	O
and	O
used	O
in	O
pulse	O
-	O
chase	O
experiments	O
.	O

Two	O
major	O
and	O
one	O
minor	O
polypeptide	O
precursors	O
were	O
identified	O
from	O
tunicamycin	O
-	O
treated	O
cell	O
lysates	O
and	O
in	O
vitro	O
translated	O
products	O
from	O
oviductal	O
poly	O
(	O
A	O
)	O
+	O
RNA	O
.	O

Their	O
apparent	O
molecular	O
masses	O
correlate	O
with	O
the	O
predicted	O
lengths	O
of	O
the	O
three	O
size	O
variants	O
identified	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
amplification	O
.	O

Using	O
glycosylation	O
and	O
transport	O
inhibitors	O
,	O
we	O
sought	O
to	O
dissect	O
the	O
posttranslational	O
sequential	O
steps	O
leading	O
to	O
the	O
final	O
maturation	O
of	O
hamster	O
oviductin	B-Protein
and	O
proposed	O
a	O
compartmental	O
model	O
for	O
its	O
biosynthesis	O
.	O

The	O
polypeptide	O
precursors	O
are	O
rapidly	O
converted	O
in	O
the	O
endoplasmic	O
reticulum	O
into	O
an	O
N	O
-	O
and	O
O	O
-	O
glycosylated	O
premature	O
form	O
of	O
80	O
-	O
90	O
kDa	O
(	O
time	O
<	O
20	O
min	O
)	O
,	O
which	O
is	O
further	O
O	O
-	O
glycosylated	O
and	O
sulfated	O
in	O
the	O
trans	O
-	O
Golgi	O
network	O
,	O
giving	O
rise	O
to	O
the	O
secreted	O
species	O
of	O
160	O
-	O
350	O
kDa	O
.	O

The	O
polymorphism	O
in	O
the	O
heavily	O
O	O
-	O
glycosylated	O
region	O
of	O
hamster	O
oviductin	B-Protein
is	O
predicted	O
to	O
increase	O
the	O
heterogeneity	O
of	O
the	O
glycoprotein	O
.	O

Such	O
changes	O
may	O
alter	O
the	O
putative	O
biological	O
function	O
of	O
the	O
different	O
variants	O
mediated	O
by	O
their	O
mucin	O
-	O
type	O
domain	O
,	O
such	O
as	O
protection	O
of	O
the	O
embryo	O
and	O
/	O
or	O
adhesion	O
-	O
related	O
phenomena	O
.	O

Design	O
and	O
synthesis	O
of	O
non	O
-	O
peptide	O
Ras	O
CAAX	O
mimetics	O
as	O
potent	O
farnesyltransferase	O
inhibitors	O
.	O

Cysteine	O
farnesylation	O
of	O
the	O
ras	O
oncogene	O
product	O
Ras	O
is	O
required	O
for	O
its	O
transforming	O
activity	O
and	O
is	O
catalyzed	O
by	O
farnesyltransferase	O
(	O
FTase	O
)	O
.	O

The	O
Ras	O
carboxyl	O
terminal	O
tetrapeptide	O
CAAX	O
(	O
C	O
is	O
cysteine	O
,	O
A	O
is	O
any	O
aliphatic	O
amino	O
acid	O
,	O
X	O
is	O
methionine	O
or	O
serine	O
)	O
is	O
the	O
minimum	O
sequence	O
for	O
FTase	O
recognition	O
.	O

We	O
report	O
here	O
the	O
design	O
,	O
synthesis	O
,	O
and	O
biological	O
characterization	O
of	O
Ras	O
CAAX	O
non	O
-	O
peptide	O
mimetics	O
in	O
which	O
the	O
cysteine	O
is	O
linked	O
through	O
a	O
reduced	O
pseudopeptide	O
bond	O
to	O
4	O
-	O
amino	O
-	O
3	O
'	O
-	O
carboxybiphenyl	O
.	O

These	O
non	O
-	O
peptide	O
mimetics	O
are	O
potent	O
inhibitors	O
of	O
FTase	O
(	O
IC50	O
=	O
40	O
nM	O
for	O
the	O
most	O
potent	O
inhibitor	O
)	O
and	O
are	O
highly	O
selective	O
for	O
FTase	O
over	O
GGTase	O
I	O
(	O
geranylgeranyltransferase	O
I	O
)	O
.	O

They	O
are	O
not	O
substrates	O
for	O
farnesylation	O
,	O
do	O
not	O
have	O
peptidic	O
features	O
,	O
and	O
have	O
no	O
hydrolyzable	O
bonds	O
.	O

Structure	O
-	O
activity	O
studies	O
reveal	O
the	O
importance	O
of	O
the	O
position	O
of	O
the	O
carboxylic	O
acid	O
on	O
the	O
aryl	O
ring	O
as	O
well	O
as	O
the	O
reduction	O
of	O
the	O
cysteine	O
amide	O
bond	O
.	O

Substitution	O
at	O
the	O
2	O
-	O
position	O
of	O
4	O
-	O
amino	O
-	O
3	O
'	O
-	O
carboxybiphenyl	O
increases	O
inhibitory	O
potency	O
,	O
while	O
the	O
removal	O
of	O
the	O
carboxylic	O
acid	O
results	O
in	O
a	O
10	O
-	O
fold	O
loss	O
of	O
inhibitory	O
activity	O
.	O

Multiple	O
palmitoylation	O
of	O
synaptotagmin	O
and	O
the	O
t	O
-	O
SNARE	O
SNAP	B-Protein
-	I-Protein
25	I-Protein
.	O

Synaptotagmin	O
,	O
a	O
likely	O
calcium	O
sensor	O
for	O
synaptic	O
transmission	O
,	O
and	O
SNAP	B-Protein
-	I-Protein
25	I-Protein
,	O
a	O
t	O
-	O
SNARE	O
of	O
the	O
presynaptic	O
plasma	O
membrane	O
,	O
are	O
key	O
proteins	O
for	O
the	O
docking	O
and	O
fusion	O
of	O
synaptic	O
and	O
other	O
vesicles	O
.	O

We	O
report	O
that	O
both	O
synaptotagmin	O
and	O
SNAP	B-Protein
-	I-Protein
25	I-Protein
are	O
palmitoylated	O
with	O
their	O
fatty	O
acids	O
attached	O
in	O
a	O
labile	O
thioester	O
-	O
type	O
bond	O
.	O

A	O
SNAP	B-Protein
-	I-Protein
25	I-Protein
mutant	O
with	O
deleted	O
palmitoylation	O
sites	O
is	O
found	O
exclusively	O
in	O
the	O
cytosol	O
after	O
cell	O
fractionation	O
,	O
whereas	O
the	O
palmitoylated	O
form	O
of	O
SNAP	B-Protein
-	I-Protein
25	I-Protein
is	O
membrane	O
-	O
bound	O
,	O
establishing	O
that	O
SNAP	B-Protein
-	I-Protein
25	I-Protein
is	O
membrane	O
-	O
anchored	O
via	O
covalently	O
linked	O
palmitate	O
.	O

Rate	O
limitations	O
in	O
posttranslational	O
processing	O
by	O
the	O
mammary	O
gland	O
of	O
transgenic	O
animals	O
.	O

Our	O
studies	O
in	O
transgenic	O
animal	O
bioreactors	O
sought	O
to	O
determine	O
the	O
rate	O
limitations	O
in	O
posttranslational	O
processing	O
of	O
recombinant	O
human	O
protein	B-Protein
C	I-Protein
(	O
rhPC	B-Protein
)	O
made	O
in	O
mammary	O
gland	O
of	O
mice	O
and	O
pigs	O
.	O

Human	O
protein	B-Protein
C	I-Protein
(	O
hPC	B-Protein
)	O
is	O
a	O
complex	O
plasma	O
protein	O
containing	O
nine	O
gamma	O
-	O
carboxylated	O
glutamic	O
acid	O
(	O
gla	O
)	O
residues	O
that	O
bind	O
calcium	O
at	O
about	O
1	O
to	O
3	O
mM	O
.	O

Gamma	O
carboxylation	O
is	O
a	O
vitamin	O
K	O
-	O
dependent	O
posttranslational	O
modification	O
.	O

The	O
effect	O
of	O
rhPC	B-Protein
synthesis	O
rate	O
on	O
the	O
extent	O
of	O
gamma	O
-	O
carboxylation	O
of	O
glutamic	O
acid	O
was	O
studied	O
.	O

We	O
have	O
perturbed	O
the	O
biosynthesis	O
of	O
rhPC	B-Protein
by	O
using	O
two	O
different	O
transgenes	O
to	O
direct	O
mammary	O
gland	O
-	O
specific	O
expression	O
.	O

Promoter	O
elements	O
of	O
the	O
murine	O
whey	B-Protein
acid	I-Protein
protein	I-Protein
(	O
mWAP	B-Protein
)	O
gene	O
were	O
used	O
to	O
drive	O
the	O
expression	O
of	O
hPC	B-Protein
-	O
cDNA	O
and	O
hPC	B-Protein
-	O
genomic	O
transgenes	O
.	O

Transgenic	O
mice	O
with	O
hPC	B-Protein
-	O
cDNA	O
and	O
hPC	B-Protein
-	O
genomic	O
sequences	O
gave	O
expression	O
levels	O
of	O
11	O
+	O
/	O
-	O
4	O
micrograms	O
rhPC	B-Protein
/	O
ml	O
of	O
milk	O
and	O
895	O
+	O
/	O
-	O
21	O
micrograms	O
rhPC	B-Protein
/	O
ml	O
of	O
milk	O
,	O
respectively	O
.	O

Transgenic	O
pigs	O
with	O
hPC	B-Protein
-	O
cDNA	O
and	O
hPC	B-Protein
-	O
genomic	O
sequences	O
gave	O
expression	O
levels	O
of	O
100	O
to	O
500	O
micrograms	O
rhPC	B-Protein
/	O
ml	O
of	O
milk	O
and	O
800	O
to	O
2000	O
micrograms	O
rhPC	B-Protein
/	O
ml	O
of	O
milk	O
,	O
respectively	O
.	O

A	O
monoclonal	O
antibody	O
(	O
7D7B10	O
-	O
mAb	O
)	O
that	O
binds	O
an	O
epitope	O
in	O
the	O
gla	O
domain	O
of	O
hPC	B-Protein
in	O
the	O
absence	O
of	O
calcium	O
was	O
used	O
to	O
study	O
the	O
conformational	O
behavior	O
of	O
immunopurified	O
rhPC	B-Protein
.	O

Immunopurified	O
rhPC	B-Protein
from	O
lower	O
expressing	O
mice	O
and	O
pigs	O
gave	O
a	O
calcium	O
-	O
dependent	O
binding	O
inhibition	O
by	O
7D7B10	O
-	O
mAb	O
similar	O
to	O
that	O
of	O
hPC	B-Protein
.	O

Immunopurified	O
rhPC	B-Protein
from	O
higher	O
expressing	O
mice	O
and	O
pigs	O
gave	O
a	O
less	O
calcium	O
-	O
dependent	O
response	O
.	O

This	O
study	O
suggests	O
that	O
a	O
rate	O
limitation	O
in	O
gamma	O
-	O
carboxylation	O
by	O
the	O
mammary	O
gland	O
occurs	O
at	O
expression	O
levels	O
about	O
>	O
20	O
micrograms	O
/	O
ml	O
in	O
mice	O
and	O
>	O
500	O
micrograms	O
/	O
ml	O
in	O
pigs	O
.	O

Identification	O
and	O
isoprenylation	O
of	O
plant	O
GTP	O
-	O
binding	O
proteins	O
.	O

To	O
identify	O
isoprenylated	O
plant	O
GTP	O
-	O
binding	O
proteins	O
,	O
Arabidopsis	O
thaliana	O
and	O
Nicotiana	O
tabacum	O
cDNA	O
expression	O
libraries	O
were	O
screened	O
for	O
cDNA	O
-	O
encoded	O
proteins	O
capable	O
of	O
binding	O
[	O
32P	O
]	O
GTP	O
in	O
vitro	O
.	O

ATGB2	B-Protein
,	O
an	O
Arabidopsis	O
homologue	O
of	O
the	O
GTP	O
-	O
binding	O
protein	O
Rab2	B-Protein
,	O
was	O
found	O
to	O
bind	O
GTP	O
in	O
vitro	O
and	O
to	O
be	O
a	O
substrate	O
for	O
a	O
geranylgeranyl	O
:	O
protein	O
transferase	O
(	O
GGTase	O
)	O
present	O
in	O
plant	O
extracts	O
.	O

The	O
carboxyl	O
terminus	O
of	O
this	O
protein	O
contains	O
a	O
-	O
GCCG	O
sequence	O
,	O
which	O
has	O
not	O
previously	O
been	O
shown	O
to	O
be	O
recognized	O
by	O
any	O
prenyl	O
:	O
protein	O
transferase	O
(	O
PTase	O
)	O
,	O
but	O
which	O
most	O
closely	O
resembles	O
that	O
isoprenylated	O
by	O
the	O
type	O
II	O
GGTase	O
(	O
-	O
XXCC	O
,	O
-	O
XCXC	O
,	O
or	O
-	O
CCXX	O
)	O
.	O

In	O
vitro	O
geranylgeranylation	O
of	O
an	O
Arabidopsis	O
Rab1	B-Protein
protein	O
containing	O
a	O
carboxyl	O
-	O
terminal	O
-	O
CCGQ	O
sequence	O
confirmed	O
the	O
presence	O
of	O
a	O
type	O
II	O
GGTase	O
-	O
like	O
activity	O
in	O
plant	O
extracts	O
.	O

Several	O
other	O
proteins	O
were	O
also	O
identified	O
by	O
in	O
vitro	O
GTP	O
binding	O
,	O
including	O
Arabidopsis	O
and	O
tobacco	O
homologues	O
of	O
Rab11	B-Protein
,	O
ARF	O
(	O
ADP	O
-	O
ribosylation	O
factor	O
)	O
and	O
Sar	O
proteins	O
,	O
as	O
well	O
as	O
a	O
novel	O
22	O
kDa	O
Arabidopsis	O
protein	O
(	O
ATG81	B-Protein
)	O
.	O

This	O
22	O
kDa	O
protein	O
had	O
consensus	O
GTP	O
-	O
binding	O
motifs	O
and	O
bound	O
GTP	O
with	O
high	O
specificity	O
,	O
but	O
its	O
structure	O
was	O
not	O
closely	O
related	O
to	O
that	O
of	O
any	O
known	O
GTP	O
-	O
binding	O
protein	O
(	O
it	O
most	O
resembled	O
proteins	O
within	O
the	O
ARF	O
/	O
Sar	O
and	O
G	O
protein	O
alpha	O
-	O
subunit	O
superfamilies	O
)	O
.	O

Molecular	O
cloning	O
and	O
characterization	O
of	O
nlpH	B-Protein
,	O
encoding	O
a	O
novel	O
,	O
surface	O
-	O
exposed	O
,	O
polymorphic	O
,	O
plasmid	O
-	O
encoded	O
33	O
-	O
kilodalton	O
lipoprotein	O
of	O
Borrelia	O
afzelii	O
.	O

Borrelia	O
burgdorferi	O
sensu	O
lato	O
organisms	O
,	O
comprising	O
B	O
.	O
burgdorferi	O
sensu	O
stricto	O
,	O
Borrelia	O
afzelii	O
,	O
and	O
Borrelia	O
garinii	O
,	O
are	O
tick	O
-	O
borne	O
pathogens	O
causing	O
Lyme	O
borreliosis	O
in	O
humans	O
.	O

To	O
identify	O
putative	O
virulence	O
determinants	O
,	O
a	O
B	O
.	O
afzelii	O
DNA	O
library	O
was	O
screened	O
for	O
Congo	O
red	O
dye	O
binding	O
,	O
a	O
property	O
associated	O
with	O
virulence	O
in	O
pathogenic	O
bacteria	O
.	O

One	O
clone	O
was	O
found	O
to	O
carry	O
a	O
663	O
-	O
nucleotide	O
-	O
long	O
open	O
reading	O
frame	O
encoding	O
a	O
Congo	O
red	O
dye	O
-	O
binding	O
protein	O
with	O
a	O
calculated	O
molecular	O
mass	O
of	O
25	O
,	O
660	O
Da	O
.	O

The	O
amino	O
acid	O
sequence	O
deduced	O
from	O
its	O
nucleotide	O
sequence	O
was	O
found	O
to	O
include	O
a	O
consensus	O
bacterial	O
lipidation	O
site	O
present	O
at	O
residues	O
15	O
to	O
18	O
(	O
Leu	O
-	O
Ser	O
-	O
Gly	O
-	O
Cys	O
)	O
.	O

The	O
lipoprotein	O
nature	O
was	O
demonstrated	O
by	O
incorporation	O
of	O
radioactive	O
palmitate	O
;	O
hence	O
,	O
this	O
protein	O
has	O
been	O
termed	O
NlpH	B-Protein
,	O
for	O
new	O
lipoprotein	O
H	O
.	O

NlpH	B-Protein
is	O
located	O
on	O
the	O
surface	O
of	O
B	O
.	O
afzelii	O
,	O
and	O
the	O
nlpH	B-Protein
gene	O
is	O
found	O
on	O
a	O
circular	O
plasmid	O
.	O

The	O
nlpH	B-Protein
gene	O
is	O
also	O
found	O
in	O
B	O
.	O
burgdorferi	O
sensu	O
stricto	O
and	O
B	O
.	O
garinii	O
.	O

Immediately	O
upstream	O
of	O
nlpH	B-Protein
is	O
located	O
a	O
smaller	O
reading	O
frame	O
encoding	O
a	O
polypeptide	O
containing	O
the	O
casein	O
kinase	O
II	O
phosphorylation	O
recognition	O
sequence	O
,	O
(	O
Ser	O
/	O
Thr	O
)	O
-	O
X	O
-	O
Y	O
-	O
(	O
Glu	O
/	O
Asp	O
)	O
,	O
repeated	O
10	O
times	O
.	O

Fatty	O
acylation	O
of	O
the	O
rat	O
and	O
human	O
asialoglycoprotein	O
receptors	O
.	O

A	O
conserved	O
cytoplasmic	O
cysteine	O
residue	O
is	O
acylated	O
in	O
all	O
receptor	O
subunits	O
.	O

Functional	O
rat	O
or	O
human	O
asialoglycoprotein	O
receptors	O
(	O
ASGP	O
-	O
Rs	O
)	O
are	O
hetero	O
-	O
oligomeric	O
integral	O
membrane	O
glycoproteins	O
.	O

Rat	O
ASGP	O
-	O
R	O
contains	O
three	O
subunits	O
,	O
designated	O
rat	O
hepatic	B-Protein
lectins	I-Protein
(	I-Protein
RHL	I-Protein
)	I-Protein
1	I-Protein
,	O
2	B-Protein
,	O
and	O
3	B-Protein
;	O
human	O
ASGP	O
-	O
R	O
contains	O
two	O
subunits	O
,	O
HHL1	B-Protein
and	O
HHL2	B-Protein
.	O

Both	O
receptors	O
are	O
covalently	O
modified	O
by	O
fatty	O
acylation	O
(	O
Zeng	O
,	O
F	O
.	O
-	O
Y	O
.	O
,	O
Kaphalia	O
,	O
B	O
.	O
S	O
.	O
,	O
Ansari	O
,	O
G	O
.	O
A	O
.	O
S	O
.	O
,	O
and	O
Weigel	O
,	O
P	O
.	O
H	O
.	O
(	O
1995	O
)	O
J	O
.	O
Biol	O
.	O
Chem	O
.	O
270	O
,	O
21382	O
-	O
21387	O
;	O
Zeng	O
,	O
F	O
.	O
-	O
Y	O
.	O
,	O
Oka	O
,	O
J	O
.	O
A	O
.	O
,	O
and	O
Weigel	O
,	O
P	O
.	O
H	O
.	O
(	O
1996	O
)	O
Biochem	O
.	O
Biophys	O
.	O
Res	O
.	O
Commun	O
.	O
218	O
,	O
325	O
-	O
330	O
)	O
.	O

We	O
report	O
here	O
that	O
the	O
single	O
Cys	O
residue	O
in	O
the	O
cytoplasmic	O
domain	O
of	O
each	O
RHL	O
or	O
HHL	O
subunit	O
is	O
fatty	O
acylated	O
.	O

The	O
degree	O
of	O
acylation	O
is	O
>	O
/	O
=	O
90	O
%	O
per	O
subunit	O
.	O

Deacylation	O
of	O
affinity	O
-	O
purified	O
ASGP	O
-	O
Rs	O
with	O
hydroxylamine	O
results	O
in	O
the	O
spontaneous	O
formation	O
of	O
dimers	O
through	O
reversible	O
disulfide	O
bonds	O
,	O
indicating	O
that	O
deacylation	O
concomitantly	O
generates	O
free	O
thiol	O
groups	O
.	O

Reaction	O
of	O
hydroxylamine	O
-	O
treated	O
ASGP	O
-	O
R	O
with	O
[	O
14C	O
]	O
iodoacetamide	O
resulted	O
in	O
the	O
specific	O
incorporation	O
of	O
radioactivity	O
into	O
all	O
RHL	O
and	O
HHL	O
subunits	O
,	O
verifying	O
that	O
fatty	O
acids	O
are	O
attached	O
via	O
thioester	O
linkages	O
.	O

To	O
identify	O
the	O
Cys	O
residue	O
involved	O
in	O
the	O
thioester	O
linkages	O
,	O
14C	O
-	O
carboxyamidomethylated	O
RHL	O
subunits	O
were	O
separated	O
by	O
SDS	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
and	O
digested	O
in	O
-	O
gel	O
with	O
trypsin	O
,	O
and	O
the	O
resulting	O
peptides	O
were	O
separated	O
by	O
reverse	O
-	O
phase	O
high	O
performance	O
liquid	O
chromatography	O
.	O

Amino	O
acid	O
sequence	O
of	O
radioactive	O
peptides	O
revealed	O
that	O
Cys35	O
in	O
RHL1	B-Protein
and	O
Cys54	O
in	O
RHL2	B-Protein
and	O
RHL3	B-Protein
were	O
radiolabeled	O
and	O
,	O
therefore	O
,	O
are	O
fatty	O
acylation	O
sites	O
.	O

Fatty	O
acylation	O
of	O
HHL	O
subunits	O
was	O
analyzed	O
by	O
site	O
-	O
directed	O
mutagenesis	O
.	O

Metabolic	O
labeling	O
of	O
Cos7	O
cells	O
transfected	O
with	O
wild	O
type	O
HHL1	B-Protein
cDNA	O
resulted	O
in	O
substantial	O
incorporation	O
of	O
[	O
3H	O
]	O
palmitate	O
into	O
purified	O
HHL1	B-Protein
.	O

Incorporation	O
of	O
[	O
3H	O
]	O
palmitate	O
into	O
a	O
C36S	O
mutant	O
of	O
HHL1	B-Protein
was	O
negligible	O
(	O
approximately	O
1	O
%	O
)	O
compared	O
with	O
wild	O
type	O
.	O

This	O
result	O
also	O
shows	O
that	O
Cys57	O
within	O
the	O
transmembrane	O
domain	O
of	O
HHL1	B-Protein
is	O
not	O
normally	O
palmitoylated	O
.	O

We	O
conclude	O
that	O
Cys35	O
in	O
RHL1	B-Protein
,	O
Cys54	O
in	O
RHL2	B-Protein
and	O
RHL3	B-Protein
,	O
and	O
Cys36	O
in	O
HHL1	B-Protein
are	O
fatty	O
acylated	O
.	O

Cys57	O
in	O
HHL1	B-Protein
and	O
probably	O
Cys56	O
in	O
RHL1	B-Protein
are	O
not	O
palmitoylated	O
.	O

HSDJ	B-Protein
,	O
a	O
human	O
homolog	O
of	O
DnaJ	B-Protein
,	O
is	O
farnesylated	O
and	O
is	O
involved	O
in	O
protein	O
import	O
into	O
mitochondria	O
.	O

The	O
role	O
of	O
HSDJ	B-Protein
,	O
a	O
human	O
homolog	O
of	O
bacterial	O
DnaJ	B-Protein
and	O
yeast	O
YDJ1p	B-Protein
/	O
MAS5	B-Protein
,	O
in	O
mitochondrial	O
protein	O
import	O
was	O
examined	O
.	O

Recombinant	O
HSDJ	B-Protein
was	O
purified	O
and	O
an	O
antibody	O
was	O
prepared	O
.	O

HSDJ	B-Protein
mRNA	O
was	O
heat	O
-	O
induced	O
in	O
cultured	O
cells	O
.	O

In	O
pulse	O
-	O
labeling	O
and	O
chase	O
experiments	O
using	O
COS	O
-	O
7	O
cells	O
,	O
the	O
endogenous	O
HSDJ	B-Protein
homolog	O
was	O
prenylated	O
.	O

Transiently	O
expressed	O
HSDJ	B-Protein
was	O
also	O
prenylated	O
,	O
whereas	O
its	O
mutant	O
C394S	O
in	O
which	O
cysteine	O
of	O
the	O
"	O
CaaX	O
box	O
"	O
was	O
mutated	O
to	O
serine	O
,	O
was	O
not	O
.	O

HSDJ	B-Protein
,	O
but	O
not	O
C394S	O
,	O
synthesized	O
in	O
rabbit	O
reticulocyte	O
lysate	O
was	O
farnesylated	O
.	O

The	O
HSDJ	B-Protein
antibody	O
inhibited	O
import	O
of	O
ornithine	B-Protein
transcarbamylase	I-Protein
precursor	O
(	O
pOTC	B-Protein
)	O
into	O
isolated	O
mitochondria	O
when	O
added	O
prior	O
to	O
pOTC	B-Protein
synthesis	O
,	O
but	O
not	O
when	O
added	O
prior	O
to	O
import	O
assay	O
.	O

In	O
transient	O
expression	O
of	O
pOTC	B-Protein
in	O
COS	O
-	O
7	O
cells	O
,	O
pOTC	B-Protein
was	O
synthesized	O
and	O
processed	O
to	O
the	O
mature	O
form	O
with	O
an	O
apparent	O
half	O
-	O
life	O
of	O
2	O
-	O
3	O
min	O
.	O

Coexpression	O
of	O
HSDJ	B-Protein
or	O
C394S	O
resulted	O
in	O
slight	O
retardation	O
of	O
the	O
pOTC	B-Protein
processing	O
.	O

These	O
results	O
indicate	O
that	O
HSDJ	B-Protein
is	O
involved	O
in	O
an	O
early	O
step	O
(	O
s	O
)	O
of	O
protein	O
import	O
into	O
mitochondria	O
.	O

Farnesyl	O
:	O
proteintransferase	O
inhibitors	O
as	O
agents	O
to	O
inhibit	O
tumor	O
growth	O
.	O

Ras	O
,	O
a	O
signal	O
-	O
transducing	O
protein	O
involved	O
in	O
mediating	O
growth	O
factor	O
-	O
stimulated	O
proliferation	O
,	O
is	O
mutationally	O
activated	O
in	O
over	O
30	O
%	O
of	O
human	O
tumors	O
.	O

To	O
be	O
functional	O
Ras	O
must	O
bind	O
to	O
the	O
inner	O
surface	O
of	O
the	O
plasma	O
membrane	O
,	O
with	O
post	O
-	O
translational	O
lipid	O
modifications	O
being	O
necessary	O
for	O
this	O
localization	O
.	O

The	O
essential	O
,	O
first	O
modification	O
of	O
Ras	O
is	O
farnesylation	O
catalyzed	O
by	O
the	O
enzyme	O
farnesyl	O
:	O
proteintransferase	O
(	O
FPTase	O
)	O
.	O

Inhibitors	O
of	O
FPTase	O
(	O
FTIs	O
)	O
are	O
currently	O
being	O
tested	O
to	O
determine	O
if	O
they	O
are	O
capable	O
of	O
tumor	O
growth	O
inhibition	O
.	O

Here	O
we	O
describe	O
our	O
efforts	O
,	O
along	O
with	O
those	O
of	O
other	O
groups	O
,	O
in	O
testing	O
the	O
biological	O
and	O
biochemical	O
effects	O
of	O
FTIs	O
.	O

Long	O
-	O
term	O
alcohol	O
effects	O
on	O
hepatic	O
phosphoglucomutase	B-Protein
activities	O
in	O
relation	O
to	O
posttranslational	O
modification	O
of	O
the	O
protein	O
.	O

ADP	O
-	O
ribosylation	O
is	O
a	O
posttranslational	O
protein	O
modification	O
catalyzed	O
by	O
two	O
classes	O
of	O
enzymes	O
:	O
mono	O
-	O
ADP	O
-	O
ribosyltransferase	O
and	O
poly	O
-	O
ADP	O
-	O
ribose	O
polymerases	O
.	O

We	O
previously	O
demonstrated	O
that	O
long	O
-	O
term	O
alcohol	O
intake	O
remarkably	O
enhanced	O
an	O
endogenous	O
ADP	O
-	O
ribosylation	O
of	O
a	O
58	O
kDa	O
protein	O
in	O
rat	O
liver	O
and	O
also	O
identified	O
the	O
58	O
kDa	O
protein	O
as	O
phosphoglucomutase	B-Protein
(	O
PGM	B-Protein
)	O
.	O

To	O
assess	O
biological	O
significance	O
of	O
this	O
phenomenon	O
,	O
we	O
tested	O
the	O
effects	O
of	O
long	O
-	O
term	O
alcohol	O
intake	O
on	O
PGM	B-Protein
activities	O
in	O
connection	O
with	O
posttranslational	O
modification	O
of	O
the	O
protein	O
.	O

ADP	O
-	O
ribosylation	O
of	O
PGM	B-Protein
was	O
mono	O
-	O
rather	O
than	O
poly	O
-	O
ADP	O
-	O
ribosylation	O
.	O

Also	O
,	O
nonenzymatic	O
binding	O
of	O
ADP	O
-	O
ribose	O
was	O
excluded	O
.	O

It	O
was	O
of	O
note	O
that	O
ADP	O
-	O
ribosylation	O
of	O
exogenous	O
PGM	B-Protein
was	O
remarkably	O
increased	O
by	O
adding	O
rat	O
liver	O
plasma	O
membranes	O
,	O
and	O
that	O
the	O
extent	O
of	O
the	O
increase	O
was	O
greater	O
in	O
alcohol	O
-	O
fed	O
rats	O
than	O
in	O
pair	O
-	O
fed	O
controls	O
.	O

Furthermore	O
,	O
PGM	B-Protein
activities	O
were	O
significantly	O
increased	O
after	O
long	O
-	O
term	O
alcohol	O
intake	O
concomitant	O
with	O
increased	O
ADP	O
-	O
ribosyltransferase	O
activities	O
toward	O
PGM	B-Protein
.	O

In	O
view	O
of	O
the	O
variety	O
of	O
roles	O
of	O
PGM	B-Protein
in	O
the	O
liver	O
,	O
such	O
as	O
carbohydrate	O
metabolism	O
and	O
Ca2	O
+	O
homeostasis	O
,	O
it	O
is	O
tempting	O
to	O
speculate	O
that	O
increased	O
ADP	O
-	O
ribosylation	O
of	O
PGM	B-Protein
may	O
play	O
a	O
role	O
in	O
long	O
-	O
term	O
alcohol	O
effects	O
on	O
hepatocytes	O
.	O

Specific	O
isoprenyl	O
group	O
linked	O
to	O
transducin	B-Protein
gamma	I-Protein
-	O
subunit	O
is	O
a	O
determinant	O
of	O
its	O
unique	O
signaling	O
properties	O
among	O
G	O
-	O
proteins	O
.	O

Among	O
11	O
subtypes	O
of	O
heterotrimeric	O
G	O
-	O
protein	O
gamma	O
-	O
subunit	O
,	O
gamma1	B-Protein
(	O
rod	O
)	O
,	O
gamma8	B-Protein
(	O
cone	O
)	O
and	O
gamma11	B-Protein
are	O
modified	O
with	O
farnesyl	O
while	O
the	O
others	O
are	O
modified	O
with	O
geranylgeranyl	O
at	O
the	O
C	O
-	O
terminus	O
.	O

To	O
understand	O
the	O
role	O
of	O
specific	O
isoprenylation	O
(	O
farnesylation	O
)	O
of	O
retinal	O
transducin	O
,	O
we	O
examined	O
how	O
and	O
to	O
what	O
extent	O
the	O
type	O
of	O
isoprenyl	O
group	O
affects	O
transducin	O
-	O
beta	O
gamma	B-Protein
(	O
beta1	B-Protein
gamma1	B-Protein
)	O
functions	O
such	O
as	O
interactions	O
with	O
membranes	O
,	O
Galpha	O
/	O
receptor	O
,	O
and	O
effectors	O
.	O

To	O
this	O
end	O
,	O
the	O
C	O
-	O
terminal	O
farnesylation	O
signal	O
sequence	O
(	O
CVIS	O
)	O
of	O
gamma1	B-Protein
was	O
replaced	O
by	O
a	O
geranylgeranylation	O
signal	O
(	O
CVIL	O
)	O
,	O
and	O
the	O
resultant	O
mutant	O
(	O
S74L	O
)	O
or	O
wild	O
-	O
type	O
(	O
WT	O
)	O
gamma1	B-Protein
was	O
coexpressed	O
with	O
beta1	B-Protein
in	O
the	O
baculovirus	O
-	O
Tn5	O
insect	O
cell	O
system	O
.	O

Both	O
gamma1WT	B-Protein
and	O
gamma1S74L	B-Protein
expressed	O
as	O
a	O
beta	O
gamma	O
complex	O
were	O
mixtures	O
modified	O
with	O
farnesyl	O
and	O
geranylgeranyl	O
groups	O
.	O

The	O
ratio	O
of	O
farnesyl	O
to	O
geranylgeranyl	O
in	O
preparations	O
of	O
beta1	B-Protein
gamma1WT	B-Protein
and	O
beta1	B-Protein
gamma1S74L	B-Protein
purified	O
from	O
the	O
Tn5	O
cell	O
membrane	O
fraction	O
was	O
about	O
1	O
:	O
2	O
and	O
1	O
:	O
6	O
,	O
respectively	O
.	O

These	O
two	O
forms	O
of	O
recombinant	O
beta1	B-Protein
gamma1	B-Protein
and	O
retinal	O
beta1	B-Protein
gamma1	B-Protein
were	O
different	O
in	O
their	O
abilities	O
to	O
associate	O
with	O
rod	O
outer	O
segment	O
membranes	O
with	O
the	O
following	O
rank	O
order	O
:	O
beta1	B-Protein
gamma1S74L	B-Protein
>	O
beta1	B-Protein
gamma1WT	B-Protein
>	O
retinal	O
beta1	B-Protein
gamma1	B-Protein
.	O

Functionally	O
,	O
beta1	B-Protein
gamma1S74L	B-Protein
was	O
the	O
most	O
potent	O
to	O
promote	O
pertussis	O
toxin	O
-	O
catalyzed	O
ADP	O
ribosylation	O
of	O
transducin	O
-	O
alpha	O
(	O
Talpha	O
)	O
,	O
to	O
stimulate	O
metarhodopsin	B-Protein
II	I-Protein
-	O
catalyzed	O
GTPgammaS	O
-	O
binding	O
reaction	O
to	O
Talpha	O
and	O
to	O
modulate	O
adenylyl	O
cyclase	O
and	O
phospholipase	O
C	O
activities	O
.	O

All	O
of	O
the	O
beta1	B-Protein
gamma1	B-Protein
functions	O
absolutely	O
required	O
the	O
isoprenylation	O
of	O
the	O
gamma	O
-	O
subunit	O
.	O

As	O
for	O
the	O
interaction	O
with	O
Goalpha	B-Protein
and	O
adenylyl	O
cyclase	O
,	O
predominantly	O
geranylgeranylated	O
beta1	B-Protein
gamma1S74L	B-Protein
was	O
less	O
effective	O
than	O
geranylgeranylated	O
beta1	B-Protein
gamma2	B-Protein
purified	O
from	O
bovine	O
brain	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
properties	O
of	O
Gbeta	O
gamma	O
are	O
strongly	O
affected	O
by	O
the	O
type	O
of	O
functionally	O
indispensable	O
isoprenylation	O
in	O
addition	O
to	O
the	O
amino	O
acid	O
sequence	O
of	O
Ggamma	O
.	O

The	O
relative	O
contribution	O
of	O
the	O
two	O
factors	O
depends	O
on	O
proteins	O
with	O
which	O
Gbeta	O
gamma	O
interacts	O
.	O

What	O
does	O
insulin	B-Protein
do	O
to	O
Ras	O
?	O

The	O
Ras	O
pathway	O
lies	O
in	O
the	O
center	O
of	O
signalling	O
cascades	O
of	O
numerous	O
growth	O
-	O
promoting	O
factors	O
.	O

The	O
Ras	O
pathway	O
appears	O
to	O
connect	O
signalling	O
events	O
that	O
begin	O
at	O
the	O
plasma	O
membrane	O
with	O
nuclear	O
events	O
.	O

Insulin	B-Protein
is	O
one	O
of	O
the	O
major	O
stimulants	O
of	O
the	O
Ras	O
signalling	O
pathway	O
.	O

The	O
influence	O
of	O
insulin	B-Protein
on	O
this	O
pathway	O
consists	O
of	O
five	O
important	O
events	O
:	O
(	O
1	O
)	O
p21Ras	B-Protein
activation	O
is	O
promoted	O
by	O
insulin	B-Protein
stimulation	O
of	O
the	O
guanine	O
nucleotide	O
exchange	O
factor	O
,	O
Sos	O
,	O
resulting	O
in	O
increased	O
GTP	O
-	O
loading	O
of	O
p21Ras	B-Protein
;	O
(	O
2	O
)	O
p21Ras	B-Protein
deactivation	O
involves	O
the	O
hyperphosphorylation	O
of	O
Sos	O
;	O
(	O
3	O
)	O
insulin	B-Protein
increases	O
farnesyltransferase	O
(	O
FTase	O
)	O
activity	O
that	O
farnesylates	O
p21Ras	B-Protein
;	O
(	O
4	O
)	O
increased	O
amounts	O
of	O
farnesylated	O
p21Ras	B-Protein
translocate	O
to	O
the	O
plasma	O
membrane	O
where	O
they	O
can	O
be	O
activated	O
by	O
other	O
growth	O
-	O
promoting	O
agents	O
;	O
and	O
(	O
5	O
)	O
cellular	O
responses	O
to	O
other	O
growth	O
factors	O
are	O
potentiated	O
by	O
insulin	B-Protein
-	O
stimulated	O
pre	O
-	O
loading	O
of	O
the	O
plasma	O
membrane	O
with	O
farnesylated	O
p21Ras	B-Protein
.	O

3	O
-	O
Hydroxy	O
-	O
3	O
-	O
methylglutaryl	O
coenzyme	O
A	O
reductase	O
inhibitors	O
increase	O
fibrinolytic	O
activity	O
in	O
rat	O
aortic	O
endothelial	O
cells	O
.	O

Role	O
of	O
geranylgeranylation	O
and	O
Rho	O
proteins	O
.	O

3	O
-	O
Hydroxy	O
-	O
3	O
-	O
methylglutaryl	O
coenzyme	O
A	O
(	O
HMG	O
CoA	O
)	O
reductase	O
inhibitors	O
(	O
HRIs	O
)	O
have	O
been	O
recently	O
shown	O
to	O
prevent	O
atherosclerosis	O
progression	O
.	O

Clinical	O
benefit	O
results	O
from	O
combined	O
actions	O
on	O
various	O
components	O
of	O
the	O
atherosclerotic	O
lesion	O
.	O

This	O
study	O
was	O
designed	O
to	O
identify	O
the	O
effects	O
of	O
HRI	O
on	O
one	O
of	O
these	O
components	O
,	O
the	O
endothelial	O
fibrinolytic	O
system	O
.	O

Aortas	O
isolated	O
from	O
rats	O
treated	O
for	O
2	O
days	O
with	O
lovastatin	O
(	O
4	O
mg	O
/	O
kg	O
body	O
wt	O
per	O
day	O
)	O
showed	O
a	O
3	O
-	O
fold	O
increase	O
in	O
tissue	B-Protein
plasminogen	I-Protein
activator	I-Protein
(	O
tPA	B-Protein
)	O
activity	O
.	O

In	O
a	O
rat	O
aortic	O
endothelial	O
cell	O
line	O
(	O
SVARECs	O
)	O
and	O
in	O
human	O
nontransformed	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
,	O
HRI	O
induced	O
an	O
increase	O
in	O
tPA	B-Protein
activity	O
and	O
antigen	O
in	O
a	O
time	O
-	O
and	O
concentration	O
-	O
dependent	O
manner	O
.	O

In	O
SVARECs	O
,	O
the	O
maximal	O
response	O
was	O
observed	O
when	O
cells	O
were	O
incubated	O
for	O
48	O
hours	O
with	O
50	O
micromol	O
/	O
L	O
HRI	O
.	O

An	O
increase	O
of	O
tPA	B-Protein
mRNA	O
was	O
also	O
in	O
evidence	O
.	O

In	O
contrast	O
,	O
HRI	O
inhibited	O
plasminogen	B-Protein
activator	I-Protein
inhibitor	I-Protein
-	I-Protein
1	I-Protein
activity	O
and	O
mRNA	O
.	O

The	O
effects	O
of	O
HRI	O
were	O
reversed	O
by	O
mevalonate	O
and	O
geranylgeranyl	O
pyrophosphate	O
,	O
but	O
not	O
by	O
LDL	O
cholesterol	O
and	O
farnesyl	O
pyrophosphate	O
,	O
and	O
were	O
not	O
induced	O
by	O
alpha	O
-	O
hydroxyfarnesyl	O
phosphonic	O
acid	O
,	O
an	O
inhibitor	O
of	O
protein	O
farnesyl	O
transferase	O
.	O

C3	B-Protein
exoenzyme	I-Protein
,	O
an	O
inhibitor	O
of	O
the	O
geranylgeranylated	O
-	O
activated	O
Rho	O
protein	O
,	O
reproduced	O
the	O
effect	O
of	O
lovastatin	O
on	O
tPA	B-Protein
and	O
plasminogen	B-Protein
activator	I-Protein
inhibitor	I-Protein
-	I-Protein
1	I-Protein
activity	O
and	O
blocked	O
its	O
reversal	O
by	O
geranylgeranyl	O
pyrophosphate	O
.	O

The	O
effect	O
of	O
HRI	O
was	O
associated	O
with	O
a	O
disruption	O
of	O
cellular	O
actin	O
filaments	O
without	O
modification	O
of	O
microtubules	O
.	O

A	O
disrupter	O
of	O
actin	O
filaments	O
,	O
cytochalasin	O
D	O
,	O
induced	O
the	O
same	O
effect	O
as	O
lovastatin	O
on	O
tPA	B-Protein
,	O
whereas	O
a	O
disrupter	O
of	O
microtubules	O
,	O
nocodazole	O
,	O
did	O
not	O
.	O

In	O
conclusion	O
,	O
HRI	O
can	O
modify	O
the	O
fibrinolytic	O
potential	O
of	O
endothelial	O
cells	O
,	O
likely	O
via	O
inhibition	O
of	O
geranylgeranylated	O
Rho	O
protein	O
and	O
disruption	O
of	O
the	O
actin	O
filaments	O
.	O

The	O
resulting	O
increase	O
of	O
fibrinolytic	O
activity	O
of	O
endothelial	O
cells	O
may	O
contribute	O
to	O
the	O
beneficial	O
effects	O
of	O
HRI	O
in	O
the	O
progression	O
of	O
atherosclerosis	O
.	O

Cleavage	O
of	O
the	O
C	O
-	O
terminus	O
of	O
NEDD8	B-Protein
by	O
UCH	B-Protein
-	I-Protein
L3	I-Protein
.	O

NEDD8	B-Protein
is	O
a	O
novel	O
ubiquitin	B-Protein
-	O
like	O
protein	O
that	O
has	O
been	O
shown	O
to	O
conjugate	O
to	O
nuclear	O
proteins	O
in	O
a	O
manner	O
analogous	O
to	O
ubiquitination	O
and	O
sentrinization	O
.	O

To	O
identify	O
proteins	O
that	O
are	O
involved	O
in	O
the	O
NEDD8	B-Protein
-	O
conjugation	O
and	O
de	O
-	O
conjugation	O
pathway	O
,	O
the	O
yeast	O
two	O
-	O
hybrid	O
system	O
was	O
used	O
to	O
screen	O
a	O
human	O
heart	O
cDNA	O
library	O
using	O
NEDD8	B-Protein
as	O
a	O
bait	O
.	O

Seven	O
strongly	O
positive	O
clones	O
were	O
found	O
to	O
contain	O
a	O
cDNA	O
insert	O
encoding	O
the	O
ubiquitin	O
C	O
-	O
terminal	O
hydrolase	O
,	O
UCH	B-Protein
-	I-Protein
L3	I-Protein
.	O

In	O
vitro	O
GST	O
pull	O
-	O
down	O
assay	O
demonstrated	O
that	O
UCH	B-Protein
-	I-Protein
L3	I-Protein
bound	O
to	O
both	O
NEDD8	B-Protein
and	O
ubiquitin	B-Protein
.	O

In	O
contrast	O
,	O
UCH	B-Protein
-	I-Protein
L3	I-Protein
did	O
not	O
bind	O
to	O
sentrin	B-Protein
-	I-Protein
1	I-Protein
,	O
sentrin	B-Protein
-	I-Protein
2	I-Protein
,	O
or	O
sentrin	B-Protein
-	I-Protein
3	I-Protein
.	O

Recombinant	O
UCH	B-Protein
-	I-Protein
L3	I-Protein
,	O
but	O
not	O
UCH	B-Protein
-	I-Protein
L1	I-Protein
,	O
was	O
able	O
to	O
cleave	O
the	O
C	O
-	O
terminus	O
of	O
NEDD8	B-Protein
.	O

Thus	O
,	O
UCH	B-Protein
-	I-Protein
L3	I-Protein
can	O
function	O
as	O
a	O
C	O
-	O
terminal	O
hydrolase	O
for	O
both	O
NEDD8	B-Protein
and	O
ubiquitin	B-Protein
.	O

UCH	B-Protein
-	I-Protein
L3	I-Protein
may	O
play	O
a	O
physiologically	O
significant	O
role	O
in	O
the	O
cleavage	O
of	O
the	O
C	O
-	O
terminus	O
of	O
NEDD8	B-Protein
,	O
which	O
is	O
required	O
for	O
NEDD8	B-Protein
to	O
conjugate	O
to	O
target	O
proteins	O
.	O

Crm1p	B-Protein
mediates	O
regulated	O
nuclear	O
export	O
of	O
a	O
yeast	O
AP	O
-	O
1	O
-	O
like	O
transcription	O
factor	O
.	O

The	O
yeast	O
AP	O
-	O
1	O
-	O
like	O
transcription	O
factor	O
,	O
Yap1p	B-Protein
,	O
activates	O
genes	O
required	O
for	O
the	O
response	O
to	O
oxidative	O
stress	O
.	O

Yap1p	B-Protein
is	O
normally	O
cytoplasmic	O
and	O
inactive	O
,	O
but	O
will	O
activate	O
by	O
nuclear	O
translocation	O
if	O
cells	O
are	O
placed	O
in	O
an	O
oxidative	O
environment	O
.	O

Here	O
we	O
show	O
that	O
Yap1p	B-Protein
is	O
a	O
target	O
of	O
the	O
beta	O
-	O
karyopherin	O
-	O
like	O
nuclear	O
exporter	O
,	O
Crm1p	B-Protein
.	O

Yap1p	B-Protein
is	O
constitutively	O
nuclear	O
in	O
a	O
crm1	B-Protein
mutant	O
,	O
and	O
Crm1p	B-Protein
binds	O
to	O
a	O
nuclear	O
export	O
sequence	O
(	O
NES	O
)	O
-	O
like	O
sequence	O
in	O
Yap1p	B-Protein
in	O
the	O
presence	O
of	O
RanGTP	B-Protein
.	O

Recognition	O
of	O
Yap1p	B-Protein
by	O
Crm1p	B-Protein
is	O
inhibited	O
by	O
oxidation	O
,	O
and	O
this	O
inhibition	O
requires	O
at	O
least	O
one	O
of	O
the	O
three	O
cysteine	O
residues	O
flanking	O
the	O
NES	O
.	O

These	O
results	O
suggest	O
that	O
Yap1p	B-Protein
localization	O
is	O
largely	O
regulated	O
at	O
the	O
level	O
of	O
nuclear	O
export	O
,	O
and	O
that	O
the	O
oxidation	O
state	O
affects	O
the	O
accessibility	O
of	O
the	O
Yap1p	B-Protein
NES	O
to	O
Crm1p	B-Protein
directly	O
.	O

We	O
also	O
show	O
that	O
a	O
mutation	O
in	O
RanGAP	B-Protein
(	O
rna1	B-Protein
-	I-Protein
1	I-Protein
)	O
is	O
synthetically	O
lethal	O
with	O
crm1	B-Protein
mutants	O
.	O

Yap1p	B-Protein
export	O
is	O
inhibited	O
in	O
both	O
rna1	B-Protein
-	I-Protein
1	I-Protein
and	O
prp20	B-Protein
(	O
RanGNRF	B-Protein
)	O
mutant	O
strains	O
,	O
but	O
Yap1p	B-Protein
rapidly	O
accumulates	O
at	O
the	O
nuclear	O
periphery	O
after	O
shifting	O
rna1	B-Protein
-	I-Protein
1	I-Protein
,	O
but	O
not	O
other	O
mutant	O
cells	O
to	O
the	O
non	O
-	O
permissive	O
temperature	O
.	O

Thus	O
,	O
disassembly	O
of	O
export	O
complexes	O
in	O
response	O
to	O
RanGTP	B-Protein
hydrolysis	O
may	O
be	O
required	O
for	O
release	O
of	O
substrate	O
from	O
a	O
terminal	O
binding	O
site	O
at	O
the	O
nuclear	O
pore	O
complex	O
(	O
NPC	O
)	O
.	O

The	O
dynamic	O
role	O
of	O
GRP78	B-Protein
/	O
BiP	B-Protein
in	O
the	O
coordination	O
of	O
mRNA	O
translation	O
with	O
protein	O
processing	O
.	O

The	O
role	O
of	O
GRP78	B-Protein
/	O
BiP	B-Protein
in	O
coordinating	O
endoplasmic	O
reticular	O
(	O
ER	O
)	O
protein	O
processing	O
with	O
mRNA	O
translation	O
was	O
examined	O
in	O
GH3	O
pituitary	O
cells	O
.	O

ADP	O
-	O
ribosylation	O
of	O
GRP78	B-Protein
and	O
eukaryotic	B-Protein
initiation	I-Protein
factor	I-Protein
(	I-Protein
eIF	I-Protein
)	I-Protein
-	I-Protein
2alpha	I-Protein
phosphorylation	O
were	O
assessed	O
,	O
respectively	O
,	O
as	O
indices	O
of	O
chaperone	O
inactivation	O
and	O
the	O
inhibition	O
of	O
translational	O
initiation	O
.	O

Inhibition	O
of	O
protein	O
processing	O
by	O
ER	O
stress	O
(	O
ionomycin	O
and	O
dithiothreitol	O
)	O
resulted	O
in	O
GRP78	B-Protein
deribosylation	O
and	O
eIF	O
-	O
2	O
phosphorylation	O
.	O

Suppression	O
of	O
translation	O
relative	O
to	O
ER	O
protein	O
processing	O
(	O
cycloheximide	O
)	O
produced	O
approximately	O
50	O
%	O
ADP	O
-	O
ribosylation	O
of	O
GRP78	B-Protein
within	O
90	O
min	O
without	O
eIF	O
-	O
2	O
phosphorylation	O
.	O

ADP	O
-	O
ribosylation	O
was	O
reversed	O
in	O
90	O
min	O
by	O
cycloheximide	O
removal	O
in	O
a	O
manner	O
accelerated	O
by	O
ER	O
stressors	O
.	O

Cycloheximide	O
sharply	O
reduced	O
eIF	O
-	O
2	O
phosphorylation	O
in	O
response	O
to	O
ER	O
stressors	O
for	O
about	O
30	O
min	O
;	O
sensitivity	O
returned	O
as	O
GRP78	B-Protein
became	O
increasingly	O
ADP	O
-	O
ribosylated	O
.	O

Reduced	O
sensitivity	O
of	O
eIF	O
-	O
2	O
to	O
phosphorylation	O
appeared	O
to	O
derive	O
from	O
the	O
accumulation	O
of	O
free	O
,	O
unmodified	O
chaperone	O
as	O
proteins	O
completed	O
processing	O
without	O
replacements	O
.	O

Prolonged	O
(	O
24	O
h	O
)	O
incubations	O
with	O
cycloheximide	O
resulted	O
in	O
the	O
selective	O
loss	O
of	O
the	O
ADP	O
-	O
ribosylated	O
form	O
of	O
GRP78	B-Protein
and	O
increased	O
sensitivity	O
of	O
eIF	O
-	O
2	O
phosphorylation	O
in	O
response	O
to	O
ER	O
stressors	O
.	O

Brefeldin	O
A	O
decreased	O
ADP	O
-	O
ribosylation	O
of	O
GRP78	B-Protein
in	O
parallel	O
with	O
increased	O
eIF	O
-	O
2	O
phosphorylation	O
.	O

The	O
cytoplasmic	O
stressor	O
,	O
arsenite	O
,	O
which	O
inhibits	O
translational	O
initiation	O
through	O
eIF	O
-	O
2	O
phosphorylation	O
without	O
affecting	O
the	O
ER	O
,	O
also	O
produced	O
ADP	O
-	O
ribosylation	O
of	O
GRP78	B-Protein
.	O

